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Abstract 
Although numerous transcription factors (TFs) are expressed by oligodendrocytes 
(OGs), the role(s) of most of these TFs in oligodendrogenesis remains to be elucidated.  
One such TF is Hoxa2, which was recently shown to be expressed by O4-positive (+) pro-
OGs.  Hence, the main objectives of this thesis were to determine the expression profile 
and function(s) of Hoxa2 during OG development.  Immunocytochemical analysis of 
primary mixed glial cultures demonstrated that Hoxa2 is expressed throughout 
oligodendrogenesis, diminishing only with the acquisition of a myelinating phenotype.  
Subsequently, immunohistochemical analysis suggested that Hoxa2 is expressed by 
migratory oligodendroglial cells in the embryonic spinal cord.  However, double 
immunofluorescent analysis of Hoxa2 transgenic knockout mice showed that OG 
specification and early maturation proceed normally in the absence of Hoxa2 in the spinal 
cord.  
As Hoxa2 is one of 39 murine Hox genes, which exhibit extensive overlapping 
expression profiles in the spinal cord, we decided to examine the expression of an 
additional Hox TF, Hoxb4, during OG development.  Immunocytochemical analysis of 
primary mixed glial cultures demonstrated that Hoxb4 is also expressed throughout OG 
development.  Furthermore, comparison of the expression profiles of Hoxb4 and Olig2 
suggested that Hoxb4 is expressed by oligodendroglial cells in the spinal cord.  Hence, 
Hoxb4, as well as other Hox TFs could compensate for Hoxa2 in the spinal cord in its 
absence.  
 As the anterior boundary of most Hox genes has been found to be in the 
hindbrain or spinal cord, we decided to look at the telencephalon which would be less 
likely to have compensatory mechanisms.  Our results showed that similar to the spinal 
cord, Hoxa2 is expressed by oligodendroglial cells in the telencephalon.  Subsequently, it 
was found that over-expressing Hoxa2 in CG4 cells, an oligodendroglial cell line derived 
from the perinatal rat cerebral cortex, impairs their differentiation.  In an attempt to 
determine the mechanism by which it accomplishes this, we examined the expression of 
polysialylated neural cell adhesion molecule (PSA-NCAM), which has been implicated in 
this process.  Contrary to our expectations, however, it was found that over-expressing 
Hoxa2 in CG4 cells results in significantly fewer PSA-NCAM+ cells.  Hence, the results 
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suggest that Hoxa2’s effect on OG differentiation is independent of its effect on PSA-
NCAM expression. 
The expression of Hox genes is enhanced by retinoic acid (RA), which, in turn, 
both inhibits, as well as promotes OG differentiation.  Although the reason for these 
opposing roles is uncertain, examination of the experimental protocols utilized by 
different research groups reveals disparities in age, CNS region, as well as RA 
concentration.  As a result, RA’s effect on oligodendrogenesis could be stage- and/or 
concentration-dependent.  In order to determine which of these factors could impact RA’s 
effect on OG differentiation we treated CG4 cells with two different concentrations of 
RA at two distinct time points.  The results showed that both factors (concentration and 
time/stage) can impact RA’s effect on CG4 cell differentiation.  In an attempt to 
determine the mechanism by which it accomplishes this, we examined the expression of 
PSA-NCAM.  Contrary to our expectations, the results suggest that RA’s effect on CG4 
differentiation is independent of its effect on PSA-NCAM expression.  The results of this 
thesis suggest that Hoxa2 and RA could play multiple roles in OG development.  
Although these roles appear to be similar, further research will be needed to determine 
whether Hoxa2 acts a downstream effector in the RA signaling pathway in 
oligodendroglial cells.  
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1.0 GENERAL INTRODUCTION 
 
Oligodendrocytes (OGs) are the cells possessing the ability to assemble a myelin 
sheath around axons in the central nervous system (CNS) (Southwood et al. 2004).  In 
vitro OG development progresses through a number of distinct stages characterized by 
specific antigenic phenotypes.  In particular, during early stages of oligodendrogenesis, 
A2B5+ oligodendrocyte precursor cells (OPCs) and O4+ pro-OGs actively proliferate 
(Fok-Seang and Miller 1994) and migrate (Noble et al. 1988).  Subsequently, loss of 
these traits and the emergence of galactocerebroside (GalC) expression (Fok-Seang and 
Miller 1994; Noble et al. 1988) signal terminal differentiation into pre-myelinating OGs.  
Progression to the mature myelinating phenotype occurs when the cells synthesize myelin 
proteins and elaborate sheet-like membranes (Duchala et al. 1995).  
Oligodendroglial cells express a dynamic combination of transcription factors 
(TFs) as they progress from precursors to mature myelinating cells.  Researchers have 
elucidated the roles of some of these TFs with the aid of transgenic knockout mice and/or 
transfection assays; however, the function(s) of most of these TFs remains to be 
determined.  One such TF is Hoxa2, which is one of 39 mouse and human Hox genes that 
are organized into four clusters (Hox A, B, C, D) located on different chromosomes 
(Favier and Dollé 1997; Santagati and Rijli 2003; Scott 1992).  These genes are 
characterized by a 180 base pair homeobox which encodes a 60 amino acid 
homeodomain (McGinnis et al. 1984a; McGinnis et al. 1984b).  Through this 
homeodomain Hox TFs can regulate the expression of downstream effector genes by 
binding to specific nucleotide sequences (Akin and Nazarali 2005; Hirsch et al. 1990; 
Hoey and Levine 1988). 
Hox gene expression, in turn, is enhanced by retinoic acid (RA), an active 
metabolite of vitamin A (Maden 2002).  Interestingly, RA can either inhibit (Laeng et al. 
1994; Noll and Miller 1994) or promote (Barres et al. 1994; Givogri et al. 2001; Pombo 
et al. 1999) OG differentiation.  The reason for these opposing roles is uncertain; 
however, examination of the experimental protocols utilized by the individual research 
groups reveals differences in age, CNS region, as well as RA concentration.  Therefore, 
RA’s effect on oligodendrogenesis may be stage- and/or concentration-dependent.  
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How RA can inhibit or enhance OG differentiation is unknown; however, its 
inhibitory effect may be due to its ability to enhance the expression of polysialylated 
neural cell adhesion molecule (PSA-NCAM) (Husmann et al. 1989), a cell surface 
glycoprotein implicated in inhibiting OG differentiation (Decker et al. 2000).  In 
particular, in carcinoma cell lines RA enhances the activity of sialyltransferase, which 
adds sialic acid residues to the NCAM protein, in a concentration-dependent manner 
(Deutsch and Lotan 1983).  As this effect is first evident one day after RA treatment 
(Deutsch and Lotan 1983), downstream targets of RA, such as Hox TFs (Simeone et al. 
1990), may be involved.  Interestingly, several Hox TFs have been implicated in the 
regulation of NCAM expression (Jones et al. 1993; Jones et al. 1992).  Therefore, RA 
may inhibit OG differentiation via enhancing the expression of PSA-NCAM, potentially 
with the aid of downstream effectors, such as Hox TFs.  
 Therefore, the aim of this thesis is threefold: to fully characterize Hoxa2 
expression during OG development; to determine its role in this process, as well as its 
effect on PSA-NCAM expression; and, finally, to examine RA’s effect on OG 
differentiation in relation to PSA-NCAM.    
 
1.1 Objectives 
1. To examine the expression of Hoxa2 during OG development. 
2. To determine Hoxa2’s role in oligodendrogenesis. 
3. To examine the role of RA in OG development in relation to PSA-NCAM. 
 
1.2 Hypotheses 
1. Hoxa2 inhibits OG differentiation via enhancing the expression of PSA-NCAM. 
2. RA inhibits OG differentiation via enhancing PSA-NCAM expression. 
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2.0 LITERATURE REVIEW 
 
2.1 Introduction to oligodendrocyte development and its regulation 
2.1.1 Specification 
OGs are the myelinating cells of the CNS (Southwood et al. 2004).  In the 
developing embryo, OPCs arise in multiple distinct foci located in various regions of the 
CNS.  For example, in the developing murine spinal cord (Cai et al. 2005; Fogarty et al. 
2005; Fu et al. 2002; Vallstedt et al. 2005), hindbrain (Vallstedt et al. 2005), and 
telencephalon (Kessaris et al. 2006) OPCs arise in both ventral and dorsal neuroepithelial 
domains [Figure 2.1; Table 2.1].  Subsequently, the OPCs must migrate out from these 
domains in order to populate specific CNS regions (Fogarty et al. 2005; Kessaris et al. 
2006).  Hence, the regulation of OG specification in these regions is critical for normal 
CNS functioning.  As such, the purpose of this section of the literature review is to 
describe the regulation of OG specification, highlighting, when possible, any similarities 
or differences that exist in the ventral and/or dorsal regions of the spinal cord, hindbrain, 
and telencephalon.   
2.1.1.1 Spinal cord 
In the spinal cord, OPCs, which are characterized by platelet-derived growth 
factor alpha-receptor (PDGFαR) expression, initially arise in a distinct region of the 
embryonic ventral ventricular zone (vVZ) (Sun et al. 1998).  This region is known as the 
motor neuron progenitor (pMN) domain [Figure 2.1A], since it gives rise to motor 
neurons (MNs) at earlier stages of embryonic development (Fu et al. 2002).  The pMN 
domain, in turn, is one of five ventral progenitor domains formed in response to graded 
sonic hedgehog (Shh) concentrations (Briscoe et al. 2000; Gritli-Linde et al. 2001).  In 
particular, Shh, which is expressed and secreted by cells of the notochord and floor plate 
(FP) (Echelard et al. 1993; Marti et al. 1995), initially regulates the expression of the TFs 
that define the boundaries of these progenitor domains (Briscoe et al. 2000; Ericson et al. 
1997; Lu et al. 2000; Pierani et al. 1999).  This includes regulating the expression of 
Nkx2.2 and Pax6 (Ericson et al. 1997), as well as Olig2 (Lu et al. 2000) and Irx3  
(Briscoe et al. 2000), which define the ventral (Briscoe et al. 2000) and dorsal (Novitch et 
al. 2001) boundaries, respectively, of the pMN domain [Figure 2.2].  Subsequently, cross-
repressive interactions between these TFs maintain and refine these boundaries 
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Figure 2.1 Oligodendrocyte precursor cells arise from both ventral (pink) and 
dorsal (orange) neuroepithelial domains in the spinal cord (A), hindbrain (B), and 
telencephalon (C).  
 
(A) Illustration of a transverse section of the embryonic spinal cord showing the 
various progenitor domains, as well as the FP and roof plate (RP).  PDGFαR+ 
OPCs initially arise from the pMN domain, which is specifically demarcated by 
the TF Olig2.  Most of the information regarding the transcriptional control of 
OG specification pertains to this domain.  However, OPCs also arise from other 
ventral progenitor domains in the rat, including p3 at embryonic age (E) 11.5 and 
p0-p2 at E16.5.  In addition, OPCs also arise from three dorsal progenitor (dp) 
domains (shown in orange). (Some of the TFs involved in the dorsal-ventral 
patterning of the spinal cord are shown on the right.) 
(B) Illustration of a transverse section of the embryonic hindbrain which shows 
where ventral (pink) and dorsal (orange) OPCs arise.  To the right of the 
illustration are some TFs that are involved in the patterning of the ventral 
hindbrain.  It is important to note that the domain from which ventral OPCs arise 
varies depending upon the anterior-posterior location, with OPCs arising from the 
visceral MN progenitor (pMNv) domain in the anterior hindbrain and the pMN 
domain in the posterior hindbrain.  (The dorsal hindbrain is not shown due to lack 
of sufficient information regarding exactly where OPCs arise in this region.) 
(C) Illustration of a coronal section of the embryonic telencephalon depicting where 
ventral (pink) and dorsal (orange) OPCs arise.  The specific regions from which 
they arise are shown on the right along with some of the TFs known to pattern 
these regions.     
 
Abbreviations: dVZ-dorsal ventricular zone; MGE-medial ganglionic eminence; LGE-
lateral ganglionic eminence 
 
 
 
 
 
 
 
 
 
 
 
                                        
 5
                                                                             
                           
                                                                                     
 6
Table 2.1 Oligodendrocyte precursor cells arise in ventral and dorsal regions of the 
spinal cord, hindbrain, and telencephalon.  
CNS region Ventral/ 
Dorsal 
Age 
arise*  
Region 
arise 
Final destination Reference 
E11.5 
(rat) 
p3 Spinal cord Sugimori et 
al. (2007) 
E12.5 pMN Spinal cord Fu et al. 
(2002); Lu et 
al. (2000)  
 
Ventral 
E16.5 
(rat) 
p0-p2 Spinal cord Sugimori et 
al. (2007) 
Spinal cord 
Dorsal ~E15 dp3-5 Lateral funiculus 
(rare in the dorsal 
or ventral funiculi) 
Cai et al. 
(2005); 
Fogarty et al. 
(2005); 
Vallstedt et al. 
(2005)  
 
Ventral pMN,pMNvHindbrain 
Dorsal 
~E13.5 
 
Hindbrain Vallstedt et al. 
(2005)  
~E12.5 MGE/AEP Ventral 
~E15 LGE/CGE 
Preoptic area,  
corpus callosum, 
Anterior 
commissure,  
Lateral Olfactory 
Tract,  
Motor cortex 
Ivanova et al. 
(2003); 
Kessaris et al. 
(2006)  
Telencephalon 
Dorsal ~P0 dVZ Corpus callosum, 
Fimbria, Motor 
cortex 
Gorski et al. 
(2002); 
Kessaris et al. 
(2006)  
 
*listed as murine age unless otherwise stated 
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Figure 2.2 Sonic hedgehog signaling directs the formation of ventral progenitor 
domains, such as the pMN domain, which gives rise to motor neurons and 
subsequently oligodendrocytes.    
 
Shh, which exhibits a ventral to dorsal decreasing expression gradient in the spinal cord, 
enhances (→) or represses (⊥) the expression of the TFs that define the boundaries of the 
pMN domain.  These boundaries are further maintained and refined by repressive 
interactions between these TFs.  (*: effect is only evident during early stages of 
development)    
 
 
 
 
 
 
 
 
 
 
 pMN 
p3 
p2 
Pax6
Nkx2.2
Irx3
Olig2
Shh
1st MNs 
then OGs 
 
*
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(Briscoe et al. 2000; Novitch et al. 2001).   
Of the TFs that define the boundaries of the pMN domain only Olig2, which 
specifically demarcates this region (Fu et al. 2002; Novitch et al. 2001), is critical for OG 
specification in the ventral spinal cord.  In fact, in its absence, the expression of PDGFαR 
is undetectable throughout the murine spinal cord (Lu et al. 2002).  An additional Olig 
gene, Olig1, is also expressed in the pMN domain of rodents (Zhou et al. 2000); however, 
it is not critical for OG specification in this region since PDGFαR expression appears on 
schedule in its absence (Lu et al. 2002).   
The function of Irx3, which defines the dorsal boundary of the pMN domain 
along with Olig2 (Fu et al. 2002; Novitch et al. 2001), is currently unknown.  However, it 
is likely to be important in spatial aspects of OG specification since it maintains and 
refines this boundary through cross-repressive interactions with Olig2 (Novitch et al. 
2001).  As such, it would be expected that in the absence of Irx3 there would be a dorsal 
expansion of Olig2 expression and, therefore, OG specification.  Furthermore, as early 
development appears to proceed from ventral to dorsal in the spinal cord (Altman and 
Bayer 1984), the predicted dorsal expansion of the Olig2+ pMN domain could result in 
prolonged OG specification.  Interestingly, recent research findings suggest that Irx3 may 
be indirectly enhanced by bone morphogenetic proteins (BMPs) (Meyer and Roelink 
2003), which are dorsalizing signals expressed and secreted by the epidermal ectoderm 
and RP (Lee et al. 2000; Liem Jr. et al. 1997; Liem Jr. et al. 1995).  This proposed Irx3 
enhancement, in turn, may explain how BMPs are able to inhibit Olig2 expression and, 
hence, OG development in the ventral spinal cord (Mekki-Dauriac et al. 2002).  
Obviously, confirmation of these speculations will require further research. 
Nkx2.2 and Pax6, which define the ventral boundary of the pMN domain (Briscoe 
et al. 2000), are important in temporal and/or spatial aspects of OG specification.  In 
particular, Pax6-deficient mice exhibit a dorsal shift and a delay of one day in the 
appearance of PDGFαR+ cells (Sun et al. 1998).  As Pax6 and Nkx2.2 cross-repress one 
another (Briscoe et al. 2000), it is not surprising that these mice also display a dorsal 
expansion in the Nkx2.2+ domain (Ericson et al. 1997).  In fact, this dorsal expansion 
may explain the OG anomalies seen in the Pax6-deficient mice, since Nkx2.2 represses 
Olig2 expression at early stages of spinal cord development (Novitch et al. 2001; Zhou et 
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al. 2001).  Support for this statement comes from the finding that both PDGFαR and 
Olig2 expression are lost in the pMN domain at E13.5 in Nkx6.1;Nkx6.2 double mutant 
mice, which also exhibit a dorsal expansion in the Nkx2.2+ domain (Vallstedt et al. 
2005).  Furthermore, a ventral expansion in Olig2 expression, as well as an increased 
number of PDGFαR+ cells occurs in the absence of Nkx2.2 (Qi et al. 2001).  This ventral 
expansion of the Olig2+ pMN domain also appears to occur in Ngn3 mutant mice, which 
lack Nkx2.2 expression in the spinal cord at E13.5 (Lee et al. 2003).   
Nkx2.2’s repression of Olig2 expression appears to be only a transient event.  In 
particular, although Nkx2.2 and Olig2 are initially expressed in adjacent non-overlapping 
domains, Nkx2.2 expression subsequently expands dorsally such that it partially overlaps 
with that of Olig2 during oligodendrogenesis (Agius et al. 2004; Fu et al. 2002; Zhou et 
al. 2001).  Recent research findings implicate Shh in this re-patterning, as well as 
maintaining the expression of Olig2.  In particular, blocking hedgehog signaling in E4 
chick spinal cord explants abolishes Olig2 expression and reduces the size of the Nkx2.2+ 
domain (Agius et al. 2004).  Interestingly, evidence also exists supporting a role for Shh 
signaling in the switch from MN to OG development.  In particular, a delay of one day in 
the onset of PDGFαR expression occurs in the absence of Gli2, a downstream effector in 
the Shh signaling pathway (Qi et al. 2003).  A similar finding is also seen in mice lacking 
both Shh and Gli3 (Oh et al. 2005); Gli3 acts as a repressor of ventral fates in the absence 
of Shh (Litingtung and Chiang 2000).  In turn, these Shh-/-;Gli3-/- mice exhibit an 
increase in the number of newly generated neurons, as well as a delay in the down-
regulation of Ngn2 expression in the pMN domain (Oh et al. 2005).  In comparison, over-
expressing Shh in E1.5 chick neural tubes via electroporation results not only in a dorsal 
expansion in the Nkx2.2+ domain but also a dorsal shift in Ngn2 expression.  This, in 
turn, is accompanied by an earlier onset of OG development at the expense of MNs 
(Danesin et al. 2006).  However, it is unknown whether the switch from neurogenesis to 
oligodendrogenesis elicited by Shh is actually due to the dorsal expansion of the Nkx2.2+ 
domain or whether other factors are involved.  Current data seems to favors the latter 
since down-regulation of Ngn1 and Ngn2 expression in the Olig2+ pMN domain precedes 
the overlap with Nkx2.2 expression (Zhou et al. 2001).  In turn, this down-regulation of 
Ngn1/2 is critical for OG specification to occur, since electroporation of chick embryonic 
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spinal cords with Olig2 fails to promote ectopic OG specification unless Ngn1 and Ngn2 
expression is repressed (Zhou et al. 2001).  Furthermore, a significant increase in the 
number of PDGFαR+ cells occurs in the spinal cords of E12.5 Ngn1;Ngn2 double mutant 
mice (Sugimori et al. 2007).   
As there is only a transient delay in OG specification in Gli2-/- (Qi et al. 2003) 
and Shh-/-;Gli3-/- (Oh et al. 2005) mice, other signaling pathways and/or TFs may 
compensate for Shh signaling in these mice.  Evidence does support a role for Notch 
signaling in the switch from MN to OG development.  In particular, constitutive Notch 
signaling activity during early stages of zebrafish embryonic development results in 
excess OPCs being found in the spinal cord at the expense of neurons (Park and Appel 
2003).  Conversely, reduced Notch signaling activity leads to a large excess of neurons 
and a loss of OPCs in zebrafish embryonic spinal cords (Park and Appel 2003).  
Interestingly, a similar phenotype is seen in the spinal cords of chick embryos that 
undergo in ovo electroporation with short interfering RNAs (siRNAs) directed against the 
NFIA (Deneen et al. 2006).  Indeed, NFIA is required to maintain the expression of Hes5 
(Deneen et al. 2006), which is a downstream target in the Notch signaling pathway 
(Wang et al. 1998).  How Notch signaling favors OG development is uncertain; however, 
it may involve its ability to repress the expression of Ngn1 and Ngn2 (Zhou et al. 2001).   
Evidence also exists supporting a role for Sox9, a class E Sox TF, in the switch 
from neurogenesis to oligodendrogenesis.  Specific ablation of Sox9 expression in nestin-
positive neural stem cells (NSCs) results in a significant transient increase in the number 
of MNs.  This, in turn, is accompanied by a significant reduction in the number of OPCs 
that partially recovers with continued embryonic development (Stolt et al. 2003).  Other 
class E Sox TFs appear to partially compensate for Sox9 in its absence, since OPC 
numbers are more severely reduced in the spinal cords of Sox8;Sox9- and Sox9;Sox10-
double deficient mice (Stolt et al. 2003; Stolt et al. 2005).  Further research will be 
required, however, to determine whether these SoxE TFs favor OG development via 
down-regulating Ngn1/2 expression or whether other mechanisms are involved. 
Recent research suggests that the SoxD TFs, Sox5 and Sox6, may interfere with 
SoxE function in the spinal cord via competing for binding sites and/or interaction 
partners (Stolt et al. 2006).  This, in turn, may explain why OPCs arise earlier and are 
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transiently increased in the spinal cords of Sox5;Sox6 double-deficient mice.  However, 
as the number of MNs is not altered in these mutant mice (Stolt et al. 2006), further 
research will be needed in order to clarify the exact roles of SoxE and SoxD TFs in OG 
specification, as well as how they relate to one another.   
In addition to the pMN domain, OPCs also appear to arise from the ventral 
progenitor domains p3, as well as p0-p2 (Sugimori et al. 2007) [Figure 2.1A, Table 2.1].  
The OPCs derived from the Nkx2.2+ p3 domain appear to arise earlier than the 
oligodendroglial precursors in the Olig2+ pMN domain, and can be distinguished from 
them until E16.5 in the rat.  At this time OPCs also appear to arise from the Pax6+ p0-p2 
domains, although these cells do not express Pax6.  In fact, the down-regulation of Pax6 
in these cells appears to be important for the onset of OG development in this region 
since oligodendroglial cells arise earlier in the p0-p2 domains in Pax6 mutant mice 
(Sugimori et al. 2007). 
Olig2+ OPCs can also arise from a distinct region of the neuroepithelium in the 
dorsal spinal cord at approximately E15 (Cai et al. 2005; Vallstedt et al. 2005).  This 
region appears to correspond to dp3-5, since a proportion of the Olig2+ cells are closely 
associated with Pax7- and Mash1-neuroepthelial expression, which overlaps in these 
progenitor domains.  Furthermore,  Olig2+ cells are found immediately dorsal to the 
Dbx2+ domain, which delineates the dp5/dp6 boundary (Cai et al. 2005) [Figure 2.1A].  
However, as new research suggests that OG specification in the dorsal spinal cord may be 
more extensive than this (Battiste et al. 2007), further investigations will be needed. 
In contrast to its ventral counterpart, OG specification in the dorsal spinal cord 
seems to occur independently of Shh signaling since Olig2+ cells are found in this region 
in E14.5 Shh mutant mice (Cai et al. 2005).  Instead, OG development in this region is 
believed to occur when BMP signaling is sufficiently reduced with continued embryonic 
development.  Accordingly, treatment of dorsal spinal cord explants with BMP7 inhibits 
Olig2 expression (Vallstedt et al. 2005), which is critical for OG development throughout 
the spinal cord (Lu et al. 2002).  
2.1.1.2 Hindbrain 
In the ventral hindbrain, OPCs arise in one of two specific progenitor domains 
depending upon the anterior-posterior location.  In the most posterior hindbrain, OPCs 
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arise in the Olig2+ pMN domain similar to that seen in the ventral spinal cord (Vallstedt 
et al. 2005).  In contrast, in the anterior hindbrain, which lacks a pMN domain (Pattyn et 
al. 2003), OPCs arise in the Nkx2.2+ pMNv domain located just dorsal to the FP 
(Vallstedt et al. 2005) [Figure 2.1B].     
The regulation of OG specification in the ventral hindbrain differs from that of the 
spinal cord in several respects, which may or may not be domain specific.  For instance, 
unlike the spinal cord, Olig2 is not critical for OG specification in the murine hindbrain 
since early stages of OG development occur largely unaltered in its absence (Lu et al. 
2002).  Instead, Olig1 appears to compensate for Olig2 in this region, since PDGFαR 
expression is absent in the hindbrains of Olig1;Olig2 double knockout mice (Zhou and 
Anderson 2002).  Although the OG anomalies seen in these mutant mice do not appear to 
be domain specific, further research will be needed to verify this.   
In comparison, evidence does suggest that Nkx2.2 differentially affects OG 
specification depending upon the anterior-posterior region of the hindbrain and, hence, 
the specific ventral progenitor domain.  Similar to the spinal cord, a dorsal expansion of 
the Nkx2.2+ domain is accompanied by a loss of PDGFαR+ cells in the posterior 
hindbrain of Nkx6.1;Nkx6.2 mutant mice (Pattyn et al. 2003; Vallstedt et al. 2005).  In 
contrast, in the anterior hindbrain of these mutant mice, this dorsal expansion corresponds 
with extensive ectopic PDGFαR expression (Vallstedt et al. 2005).  Hence, unlike the 
spinal cord and posterior hindbrain, Nkx2.2 appears to promote OG specification in the 
anterior hindbrain, where OPCs arise from the unique pMNv domain.   
With the exception of rhombomere (r) 1, dorsal Olig1+ OPCs arise at E13.5 in a 
region of the hindbrain neuroepithelium immediately dorsal to the Dbx2+ domain.  
Although very little is known regarding the regulation of OG specification in the dorsal 
hindbrain, it appears to be similar to that of the dorsal spinal cord (Vallstedt et al. 2005). 
2.1.1.3 Telencephalon 
In the ventral telencephalon, OPCs arise in two distinct waves: first, from the 
MGE, as well as the anterior entopenduncular area (AEP) and, then, subsequently from 
the LGE and/or caudal ganglionic eminence (CGE) (Kessaris et al. 2006) [Figure 2.1C].  
Like the ventral spinal cord, OG specification in this region is Shh-dependent, since 
blocking hedgehog signaling strongly inhibits OG development in ventral forebrain 
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cultures (Tekki-Kessaris et al. 2001).  Furthermore, PDGFαR expression is absent in the 
forebrain of 13.5 days post coitum (dpc) Shh mutant mice (Alberta et al. 2001).   
Despite this similarity, however, several differences have been identified 
regarding the regulation of OG specification in this region.  For example, unlike the 
spinal cord, Olig2 does not appear to be critical for OG specification in a focal region of 
the ventral forebrain, since PDGFαR expression is evident in its absence (Lu et al. 2002).  
Instead, Olig1 appears to compensate for Olig2 in this region, as evident by the fact that 
all examined brain regions lack PDGFαR+ cells in Olig1;Olig2 double knockout mice 
(Zhou and Anderson 2002).   
The neuroepithelium of the ventral telencephalon, unlike the pMN domain, 
expresses a number of distinct TFs, including Nkx2.1, Gsh2 (Corbin et al. 2003; Kessaris 
et al. 2006), and Mash1 (Corbin et al. 2003; Porteus et al. 1994) [Figure 2.1C].  
Interestingly, evidence suggests that each of these TFs affects OG specification in this 
region.  In particular, Nkx2.1 appears to promote OG specification in the ventral 
telencephalon since a transient delay in the appearance of PDGFαR expression occurs in 
its absence (Nery et al. 2001; Tekki-Kessaris et al. 2001).  Whether its effect is direct or 
indirect is unknown; however, current evidence favors the latter since Shh expression is 
largely absent in the ventral telencephalon of Nkx2.1 mutant mice (Sussel et al. 1999; 
Tekki-Kessaris et al. 2001).  Recent research also suggests that Mash1 is important for 
OG specification in the MGE/AEP since in its absence a dramatic transient decrease in 
PDGFαR expression is observed in the ventral telencephalon at E12.5 and E13.5 (Parras 
et al. 2007).  In contrast, Gsh2 appears to inhibit OG specification, at least in certain 
ventral telencephalic regions, since in its absence ectopic PDGFαR expression is found 
in the neuroepithelium of the MGE, as well as in the ventral-most LGE (Corbin et al. 
2003).  Although the reason for this ectopic OG development is unknown, it may be 
associated with patterning defects seen in the ventral telencephalon of these mutant mice 
(Corbin et al. 2003).  
In the dorsal telencephalon, OPCs arise from the neuroepithelium, which is 
characterized by the expression of the TF Emx1 (Kessaris et al. 2006).  OG specification 
in this area, like several other CNS regions, appears to be inhibited by BMP signaling 
since treatment of E16 rat cortical cultures with BMP2 significantly decreases the number 
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of oligodendroglial cells (Mabie et al. 1999).  In comparison, Shh signaling appears to 
promote OG development in this region since blocking hedgehog signaling in E15.5 
cortical explants strongly inhibits oligodendrogenesis (Tekki-Kessaris et al. 2001).  In 
contrast, Olig2 does not appear to be critical for OG specification in the dorsal 
telencephalon since PDGFαR+ cells are found when Olig2 expression is specifically 
ablated in cortical progenitors (Yue et al. 2006).  Although it is currently unknown 
whether Olig1 could compensate for Olig2 in this region, it appears to be a distinct 
possibility since the percentage of OPCs is greatly increased when cortical cultures are 
infected with an Olig1-containing adenovirus (Alberta et al. 2001; Lu et al. 2000).     
2.1.1.4 Conclusion 
Over the past decade enormous strides have been made in our understanding of 
the regulation of oligodendrogenesis, especially in the ventral spinal cord.  In this region 
OG specification is largely the result of the interplay between Shh, BMP, and Notch 
signaling pathways.  In turn, these pathways regulate the expression of the TFs that 
dictate the spatial and/or temporal aspects of oligodendrogenesis [Figure 2.3].  Although 
much less is known regarding the regulation of OG specification in other ventral and/or 
dorsal regions of the spinal cord, hindbrain, and telencephalon, several similarities, as 
well as differences have been identified.  Interestingly, the differences appear to be 
partially related to the TFs involved in patterning these distinct progenitor domains.  
Hence, identifying other TFs and signaling pathways in these neuroepithelial domains 
may greatly expedite research into the regulation of OG specification in these CNS 
regions.  Ultimately, understanding similarities, as well as differences regarding the 
transcriptional control of oligodendrogenesis in specific CNS regions will aid in the 
development of therapeutic treatments for demyelinating diseases, such as multiple 
sclerosis (MS).     
2.1.2 Differentiation 
Following specification, OG development in vitro progresses through four distinct 
stages characterized by unique antigenic and morphological phenotypes [Figure 2.4].  In 
particular, during the first stage of oligodendrogenesis, known as the OPC stage, the cells 
are bipolar and express a complex ganglioside on their surface that is recognized by the 
monoclonal antibody A2B5 (Abney et al. 1983; Eisenbarth et al. 1979; Wang et al. 1998).                             
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Figure 2.3 Basic transcriptional cascade of oligodendrocyte specification in the pMN 
domain. 
 
Many TFs (eg.Olig2, Nkx2.2, Pax6) and signaling pathways (BMP, Notch, Shh) are 
important for OG specification in the pMN domain.  Interestingly, many of these factors 
are involved in the dorsal-ventral patterning of the spinal cord.  For instance, Shh directs 
the formation of five ventral progenitor domains, including the pMN domain, via 
regulating the expression of TFs in the vVZ.  This includes regulating the expression of 
Nkx2.2 and Pax6, as well as Olig2 and Irx3, which define the ventral and dorsal 
boundaries, respectively, of the pMN domain.  Subsequently, cross-repressive 
interactions between these TFs maintain and refine these boundaries.  Of these TFs only 
Olig2 is critical for OG specification in this region; however, it cannot promote OG 
development unless Ngn1/2 expression is down-regulated such as via Notch signaling.  
 
Abbreviations: ?- speculated; *-transient effect; →- enhance; ┬-repress; →-maintain  
 
 
Shh 
BMP? 
Irx3 
OPC Ngn1/2 Olig2 
Hes5 
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Figure 2.4 Expression profiles of various transcription factors during 
oligodendrocyte development.  
 
(top) OGs progress through four distinct stages characterized by unique morphological 
and antigenic phenotypes.  (myelin.: myelinating) 
 
(bottom) Speculated expression profiles of the TFs expressed by cells of the 
oligodendroglial lineage.  Profiles for individual TFs were determined via an analysis of 
published data that utilized immunocytochemical, immunohistochemical, RT-PCR, in 
situ hybridization, and Northern blot analyses. (See Table 2.2 for references).  If not 
stated otherwise, expression was assumed to be nuclear.  In cases where the overall 
expression profiles of two or more TFs appeared to be similar, these TFs were grouped 
together (ex. Hes5 and Id4).  Variations in line thickness illustrate either changes in the 
percentage of cells expressing the TF(s) or the intensity of the TF(s) expression. 
 
 (   ) nuclear expression; (   ) cytoplasmic expression; POU III: Brn-1,2 and SCIP;*later 
stages of OG development were not analyzed; # expression profile may vary depending 
on CNS region or cell line. 
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Progression of these cells to the pro-OG stage occurs when they become multipolar and 
express surface epitopes recognized by the O4 monoclonal antibody (Bansal et al. 1989; 
Gard and Pfeiffer 1989).  Subsequently, terminal differentiation into pre-myelinating 
OGs is signified by the emergence of GalC expression (Fok-Seang and Miller 1994; 
Noble et al. 1988).  Progression to the mature myelinating phenotype occurs when the 
cells begin to synthesize myelin proteins, such as myelin basic protein (MBP) and 
proteolipid protein (PLP), and elaborate sheet-like membranes (Duchala et al. 1995; Gard 
and Pfeiffer 1989).   
In the developing embryo, OPCs initially arise in multiple distinct foci located in 
various regions of the CNS (Cai et al. 2005; Perez Villegas et al. 1999; Pringle and 
Richardson 1993; Spassky et al. 1998).  Subsequently, these cells must proliferate and 
migrate out of these foci in order to populate specific CNS regions (Ono et al. 1997; 
Pringle and Richardson 1993; Spassky et al. 1998; Tekki-Kessaris et al. 2001).  As pre-
myelinating OGs do not actively proliferate (Fok-Seang and Miller 1994) or migrate 
(Noble et al. 1988), the proper progression of oligodendroglial cells through the various 
stages of development is critical to ensure normal myelination and, hence, CNS 
functioning.    
As the oligodendroglial cells progress from precursor to mature myelinating cells 
they express a dynamic combination of TFs [Figure 2.4].  Whereas some TFs, such as 
Sox10 (Stolt et al. 2002), are expressed throughout OG development, the expression of 
many TFs, such as SCIP (Collarini et al. 1992) and Krox24 (Sock et al. 1997), is 
transient.  In most cases their expression decreases with differentiation (Collarini et al. 
1992; Schreiber et al. 1997); however, Nkx6.2 and Zfp488 expression increase in time 
with that of myelin protein genes (Awatramani et al. 1997; Wang et al. 2006).   
Over the last decade the role(s) of some of these TFs has been elucidated utilizing 
transgenic knockout mice, as well as transfection assays [Table 2.2].  Most of these TFs 
are known downstream targets/effectors of the Shh, BMP or Notch signaling pathways.  
Therefore, the purpose of this section of the literature review is to describe signaling 
pathways and TFs that inhibit and/or promote this process.  As OG differentiation 
appears to be regulated similarly in the brain and spinal cord (Genoud et al. 2002; Xin et 
al. 2005), its regulation in these regions will be examined in unison.   
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Table 2.2 Transcription factors expressed by cells of the oligodendrocyte lineage. 
Family Class/ 
Group 
Transcription 
Factor 
Role in OG 
Differentiation 
Additional CNS Expressing 
Cells  
E2A36 I 
HEB36 
  
Mash112,39  Neural precursor18 
Ngn317 +17 Neural precursor17 
Olig14,21 +20,40 Neural precursor21 
II 
Olig24,8 +8 Neural precursor21,26 
Id239 Neural precursor, neuron11,22, 
astrocyte37  
V 
Id413 
-13,39 
Neural precursor, neuron11 
HLH 
VI Hes512 -12 Neural precursor, neuron1 
A Hoxa29,23 -^41 Neuron9,23, astrocyte9 Hox 
B Hoxb424  Neuron24 
Nkx2.2*27 +27 Neural precursor27 Nkx  
Nkx6.2*5 Myelin (u)31 Neural precursor, neuron31 
Brn-128  Neural precursor2, neuron10 
Brn-228  Neural precursor2, neuron10 
POU III 
SCIP7,28  Neural precursor, neuron2 
Sox415  Neural precursor, neuron6 C 
Sox1115  Neural precursor, neuron6,15 
Sox532 -32 Neural precursor , neuron, 
radial glia32 
D 
Sox632 -32 Neural precursor , neuron, 
radial glia32 
Sox8*33 +33  
Sox934  Neural precursor, radial glia, 
astrocyte34, Bergmann glia14 
Sox 
E 
Sox1016*35 +35  
 F Sox1730 +30 Neuron, astrocyte30 
Krox2429   
MyTI3*25 +25 Neural precursor, neuron3 
rKr219  Neural precursor,neuron19 
Zinc 
Finger 
 
Zfp48838 +38  
Abbreviations:  HLH: helix-loop-helix; +: promote; -: inhibit; *: TF binding sites found 
in the promoters of myelin protein genes; (u): ultrastructure; ^: data obtained from CG4 
cells 
 
References:  1Akazawa et al. (1992) , 2Alvarez-Bolado et al. (1995), 3Armstrong et al. 
(1995), 4Arnett et al. (2004), 5Awatramani et al. (1997), 6Cheung et al. (2000), 7Collarini 
et al. (1992), 8 Fu et al. (2002), 9Hao et al. (1999), 10He et al. (1989), 11Jen et al. (1996), 
12Kondo and Raff (2000a), 13Kondo and Raff (2000b), 14Kordes et al. (2005),15Kuhlbrodt 
et al. (1998a), 16Kuhlbrodt et al. (1998b), 17Lee et al. (2003), 18Lo et al. (1991), 19Lovas et 
al. (2001), 20Lu et al. (2002), 21 Lu et al. (2000), 22Neuman et al. (1993)  23Nicolay et al. 
(2004a), 24 Nicolay et al. (2004b), 25Nielsen et al. (2004), 26Novitch et al. (2001), 27Qi et 
al. (2001), 28Schreiber et al. (1997), 29Sock et al. (1997), 30Sohn et al. (2006), 
31Southwood et al. (2004), 32Stolt et al. (2006), 33Stolt et al. (2004), 34Stolt et al. (2003), 
35Stolt et al. (2002), 36Sussman et al. (2002), 37Tzeng and De Vellis (1998), 38Wang et al. 
(2006), 39Wang et al. (2001), 40Xin et al. (2005), 41 Section 6.3.3, pg. 90 
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2.1.2.1 Inhibitory factors 
Following specification, OPCs must migrate out from their neuroepithelial 
domains in order to populate specific CNS regions.  As a result, their differentiation must 
be inhibited until they reach their final destination.  A number of signaling pathways have 
been implicated in this inhibition including Notch and BMP.  Most of the evidence 
supporting the role of Notch signaling in this process has resulted from manipulating one 
specific Notch receptor, Notch1.  In particular, activation of the Notch signaling pathway 
in purified OPC cultures, either by exposure to standard Notch ligands or by transfection 
with a vector encoding a constitutively active form of Notch1, results in a large 
proportion of these cells failing to differentiate (Wang et al. 1998).  Similarly, induction 
of a constitutively active form of zebrafish Notch1a following OG specification greatly 
reduces the number of spinal cord oligodendroglial cells that progress to the plp1/dm20+ 
stage (Park and Appel 2003).  In contrast, the expression of PLP and MBP is transiently 
increased in numerous brain regions of Notch1-deficient mice (Givogri et al. 2002).  
Furthermore, specific ablation of Notch1 in oligodendroglial cells results in premature 
differentiation in the murine spinal cord and cerebrum (Genoud et al. 2002).  The 
mechanism by which Notch signaling inhibits OG differentiation has not been 
determined; however, it may involve its ability to enhance the expression of Hes5 (Wang 
et al. 1998).  Indeed, over-expression of Hes5 in purified OPCs results in most cells 
failing to differentiate (Kondo and Raff 2000a).  
Hes5 appears to inhibit OG differentiation via multiple mechanisms.  In 
particular, it can directly repress the expression of Sox10, which is important in this 
process.  In addition, it can repress MBP promoter activity in Oli-neu cells (Liu et al. 
2006); this effect is most likely indirect since Hes5 binding to the MBP promoter is not 
required for its repression of promoter activity.  The mechanism by which Hes5 represses 
MBP expression is unknown but may involve its sequestration of Sox10 and/or Mash1 
(Liu et al. 2006), two TFs known to activate the MBP promoter in Oli-neu cells (Gokhan 
et al. 2005).  Binding of Hes5 to Sox10 and/or Mash1 may interfere with their ability to 
enhance MBP expression.  This, in turn, may explain why Hes5 is only able to repress 
MBP promoter activity when Sox10 is expressed at low levels (Liu et al. 2006).  Sox10 
expression levels appear to increase after primary oligodendroglial cells are induced to 
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differentiate in vitro (Dugas et al. 2006; Wei et al. 2004).  As a result, Hes5’s ability to 
interfere with Sox10’s function should be limited to early stages of oligodendrogenesis. 
Evidence also suggests that BMP signaling inhibits OG differentiation.  
Placement of BMP4-soaked beads at the ventral midline of murine cervical spinal 
cord/hindbrain explants results in a dramatic decrease in PLP+ and myelin associated 
glycoprotein (MAG)+ cells in the area around the beads (See et al. 2004).  The 
mechanism by which BMP signaling accomplishes this inhibitory effect is unknown, but 
may involve its ability to induce the expression of the TFs Id2 and Id4 (Samanta and 
Kessler 2004).  Accordingly, over-expression of Id2 (Wang et al. 2001) or Id4 (Kondo 
and Raff 2000b) in purified OPCs results in most cells failing to differentiate into GalC+ 
OGs.  Although the reason for their inhibitory effect is unknown, it may be due to their 
proposed ability to prevent heterodimerization of Olig TFs with E proteins (Samanta and 
Kessler 2004), which, in turn, are believed to mediate Olig TF effects (Sussman et al. 
2002), such as promoting OG differentiation (Lu et al. 2002; Xin et al. 2005).  
The Sox D TFs, Sox5 and Sox6, are also important for inhibiting OG 
differentiation since a significant increase in the number of MBP- and PLP-expressing 
cells is evident in the spinal cords of 18.5 dpc Sox5;Sox6 conditional-double deficient 
mice (Stolt et al. 2006).  It appears that these TFs inhibit OG differentiation via 
interfering with the function of Sox10.  In particular, Sox5 and Sox6 can block Sox10-
directed activation of the MBP promoter in oligodendroglial cell lines.  As these TFs can 
recognize Sox10-binding sites and interaction partners (Stolt et al. 2006), they may block 
Sox10 function via multiple mechanisms.   
2.1.2.2 Promoting factors 
Various TFs, including Olig1, Olig2, Nkx2.2 and MyTI, favor OG differentiation.  
For example, in Olig1 mutant mice, PLP/DM20 and MBP expression is markedly 
reduced in the postnatal day (P) 0 (Lu et al. 2002) and P14 (Xin et al. 2005) spinal cord 
and undetectable in the P14 corpus callosum, neocortex and striatum (Xin et al. 2005).  
Similarly, the number of GalC+ and PLP+ OGs is significantly reduced in spinal cord 
cultures following Olig2-antisense treatment (Fu et al. 2002).  Olig1 and Olig2 may 
promote OG differentiation by regulating the expression of other TFs.  One such TF is 
Zfp488, which is a potential downstream target of Olig1.  Olig1 mutant mice lack Zfp488 
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expression in the spinal cord, optic nerves, cerebellum, and corpus callosum.  In turn, 
down-regulating Zfp488 expression in the oligodendroglial cell line CG4 results in a 
reduction in MBP and 2′,3′-cyclic nucleotide 3′-phosphodiesterase (CNP) gene 
expression (Wang et al. 2006).  Interestingly, Zfp488’s transcription appears to be 
specifically regulated by Olig1 since only Olig1, not Olig2, can significantly enhance 
luciferase reporter activity driven by its putative promoter.  Olig2 does appear to interact 
with Zfp488 at the protein level (Wang et al. 2006); however, further research will be 
needed to determine if this interaction is required for their function.   
Although Olig2 does not appear to regulate Zfp488 expression, evidence suggests 
that it can affect Sox10 expression.  Ectopically expressing Olig2 in chick embryonic 
spinal cords via in ovo electroporation induces Sox10 expression (Liu et al. 2007).  In 
contrast, Sox10 mRNA is undetectable throughout the spinal cord in the absence of Olig2 
(Lu et al. 2002).  In comparison, Olig1, whose expression reappears after Sox10 in the 
rodent embryonic spinal cord (Zhou et al. 2000), may be important in the maintenance of 
Sox10 expression since Olig1 mutant mice exhibit a decrease in the number of Sox10+ 
cells (Lu et al. 2002; Xin et al. 2005).  As researchers have yet to find a chick Olig1 
ortholog (Zhou et al. 2001), this may explain why strong expression of Sox10 is seen 
much earlier in rodents (Zhou et al. 2000) than in the chick (Zhou et al. 2001).  
Sox10 is important in OG differentiation since there is a delay and a dramatic 
decrease in PLP and MBP expression in the spinal cords of Sox10-deficient mice (Stolt et 
al. 2002).  Furthermore, transplantation of Sox10-deficient NSCs into 3 to 9 day old 
mouse retinas fails to myelinate the host nerve fiber layer (Stolt et al. 2002).  More 
recently, Dugas et al. (2006) used siRNA to knockdown Sox10 expression in OPCs in 
vitro and found a significant reduction in the number of cells that differentiate into MBP-
expressing OGs. 
In comparison, over-expressing Sox10 in embryonic chick spinal cords via in ovo 
electroporation induces the expression of Nkx2.2, Olig2, MBP, PLP and MAG (Liu et al. 
2007).  As some of the MAG+ cells co-express Nkx2.2 or Olig2 (Liu et al. 2007), it 
suggests that Sox10 may indirectly enhance myelin protein gene expression through these 
TFs.  However, as a proportion of the MAG+ cells do not express Nkx2.2 or Olig2 (Liu et 
al. 2007), Sox10 may also induce myelin protein gene expression directly.  Indeed, Sox10 
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does appear to directly regulate MBP expression since it can bind to three distinct sites in 
MBP’s proximal promoter.  In turn, Sox10-directed activation of this proximal promoter 
is reduced or almost completely blocked by mutating the three sites individually or all 
together, respectively (Stolt et al. 2002).   
Sox10 also appears to regulate the transcription of two gap junction proteins, 
connexin47 (Schlierf et al. 2006) and connexin32 (Bondurand et al. 2001; Schlierf et al. 
2006), which are important for normal CNS myelination (Menichella et al. 2003).  In 
particular, Sox10 activates the connexin32 promoter (Bondurand et al. 2001; Schlierf et 
al. 2006), as well as the connexin47 promoter 1b (Schlierf et al. 2006) in luciferase 
reporter gene assays.  This activation appears to be direct since it is dramatically reduced 
by mutations in either the Sox10 DNA-binding domain or binding sites (Bondurand et al. 
2001; Schlierf et al. 2006).  In turn, these connexin proteins are important for normal 
CNS myelination since connexin32;connexin47 double knockout mice exhibit profound 
CNS myelin abnormalities, such as thin, vacuolated, or absent myelin sheaths 
(Menichella et al. 2003).  
Since Sox10 is a poor transcriptional effector on its own (Kuhlbrodt et al. 1998b), 
other TFs are likely implicated in this process.  One potential candidate is the TF SCIP 
which is expressed by oligodendroglial cells (Collarini et al. 1992) and functions 
synergistically with Sox10 (Kuhlbrodt et al. 1998b).  However, myelination occurs 
normally in the spinal cords of SCIP mutant mice (Bermingham Jr. et al. 1996).  In 
contrast, mice lacking the ligand-dependent TF COUP-TFI, which is a potential upstream 
regulator of SCIP, exhibit CNS hypomyelination and dysmyelination (Yamaguchi et al. 
2004).  The reason for the disparity in these mutant phenotypes is unknown but may 
reflect the fact that two additional class III POU TFs, Brn-1 and Brn-2, which could be 
regulated by COUP-TFI, are expressed by oligodendroglial cells (Schreiber et al. 1997) 
and, hence, could compensate for SCIP in its absence.  Interestingly, oligodendroglial 
cells express two additional Sox genes, Sox4 and Sox11, which function synergistically 
with Brn-1 and/or Brn-2 (Kuhlbrodt et al. 1998a).   
Two additional TFs that appear to function synergistically with Sox10 are Olig2 
and Sp1.  When Olig2 and its heterodimerization partner E47 are co-transfected with 
Sox10 in Oli-neu cells there is a synergistic increase in MBP promoter activity (Gokhan 
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et al. 2005).  As Sox10 can interact with Olig2 at the protein level (Stolt et al. 2006), this 
synergistic activation may depend on the formation of a transcriptional complex.  Like 
Olig2, a synergistic activation of the MBP promoter is also seen when NIH 3T3 cells are 
co-transfected with Sox10 and Sp1 (Wei et al. 2004); however, it is unknown whether 
these TFs interact at the protein level. 
Sox8, another group E Sox TF, also plays a role in OG differentiation since a 
transient reduction occurs in the number of MBP+ and PLP+ cells in the spinal cords of 
Sox8-deficient mice (Stolt et al. 2004).  Hence, the myelin protein expression seen in 
Sox10-deficient mice may be due to the compensatory effects of Sox8 and vice versa.  In 
fact, Sox8 appears to have a limited ability to compensate for Sox10 since a dramatic 
decrease in MBP and PLP expression is found in the spinal cords of P7 transgenic mice 
in which Sox10 is replaced by Sox8 (Kellerer et al. 2006). 
In addition to Sox10, Olig2 also appears to regulate the expression of Nkx2.2.  In 
particular, ectopic Nkx2.2 expression is found five days following in ovo electroporation 
of E2 chick spinal cords with an Olig2-expressing vector (Liu et al. 2007).  Nkx2.2 is 
important in promoting OG differentiation since a delay and a dramatic decrease in 
PLP/DM20 and MBP expression is evident in the spinal cords of Nkx2.2 mutant mice (Qi 
et al. 2001).  Furthermore, in its absence, MBP expression is reduced or lost in the E17.5 
medulla and P7 forebrain, respectively (Qi et al. 2001).  Correspondingly, Ngn3 mutant 
mice, which lack Nkx2.2 expression in the E13.5 spinal cord, display a dramatic 
reduction in PLP and MBP expression at P0 (Lee et al. 2003).   
How Nkx2.2 promotes OG differentiation is not clear, but it appears to involve its 
ability to regulate the expression of certain myelin protein genes.  In particular, over-
expressing Nkx2.2 in NIH 3T3 cells can induce green fluorescent protein expression 
driven by a portion of the PLP promoter (Qi et al. 2001).  This induction may be direct 
since consensus Nkx2.2-binding sites are found in the PLP promoter (Qi et al. 2001).  
The MBP promoter also contains Nkx2.2-binding sites (Qi et al. 2001).  In contrast to 
PLP, however, Nkx2.2 represses MBP promoter activity either on its own (Wei et al. 
2005) or that directed by certain other TFs, including Sox10 (Gokhan et al. 2005).  
Although these results appear to contradict the transgenic knockout data, they may reflect 
a cell line- or CNS region-specific effect.  In particular, these transient transfection assays 
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were conducted utilizing two oligodendroglial cell lines, CG4 (Wei et al. 2005) and Oli-
neu (Gokhan et al. 2005).  The CG4 and Oli-neu cell lines were established from primary 
oligodendroglial cultures obtained from either the perinatal rat cerebral cortex (Louis et 
al. 1992) or E15 murine brains (Jung et al. 1995), respectively.  Interestingly, Nkx2.2’s 
expression profile during OG development appears to vary not only between these two 
cell lines, but also with that of primary cultures obtained from the embryonic murine 
spinal cord (Fu et al. 2002; Gokhan et al. 2005; Qi et al. 2001; Wei et al. 2005).  
Resolution of this issue will have to await further research. 
Another Nkx gene, Nkx6.2, exhibits an expression profile similar to that of MBP 
and PLP (Awatramani et al. 1997).  Although the MBP and PLP promoters contain 
multiple Nkx6.2-binding sites (Awatramani et al. 1997), MBP is similarly expressed in 
the spinal cord, forebrain, and cerebellum of both wild-type (WT) and Nkx6.2 mutant 
mice (Cai et al. 2001).  However, Nkx6.2 is required for normal myelin ultrastructure 
(Southwood et al. 2004). 
Evidence suggests that the TF MyTI may also promote OG differentiation.  
Oligodendroglial cells co-transfected with a plasmid expressing the seven zinc-finger 
isoform of MyTI and a CNP-luciferase reporter results in a 6.7-fold induction in reporter 
activity compared to the empty vector (Nielsen et al. 2004).  Furthermore, infection of rat 
OPC cultures with a retrovirus containing a truncated MyTI, which is designed to 
interfere with endogenous MyTI function, results in a significant reduction in the 
differentiation of oligodendroglial cells (Nielsen et al. 2004). 
Sox17, a Sox F TF, is also important in OG differentiation (Sohn et al. 2006).  
Down-regulation of Sox17 expression in purified OPCs with siRNAs results in a 
significant increase or decrease in the percentage of A2B5+ and O4+ cells, respectively.  
Not only are these findings reversed in OPCs which over-express Sox17, but these cells 
also display increased RNA levels of MBP, MAG, and CNP.  In turn, Sox17 may promote 
OG differentiation via several mechanisms.  For instance, over-expression of Sox17 in 
purified OPCs results in a significant decrease in the percentage of proliferative cells, 
which suggests that it could promote cell cycle exit.  In addition, Sox17 may regulate the 
transcription of particular myelin protein genes.  It can enhance luciferase activity driven 
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by the MBP promoter (Sohn et al. 2006); however, whether this effect is direct or indirect 
will require further research. 
Surprisingly, recent research suggests that Notch signaling also promotes OG 
differentiation (Cui et al. 2004; Hu et al. 2003).  Although unexpected given the previous 
information [Section 2.1.2.1, pg.18], it could reflect a ligand-, receptor-, and/or 
downstream effector-dependent event.  Indeed, evidence suggests that it could be ligand-
dependent.  Whereas activation of Notch signaling via the standard Notch ligands, 
Jagged1 or Delta1, results in most OPCs failing to differentiate (Hu et al. 2003; Wang et 
al. 1998), treatment of purified OPCs with the novel Notch ligands, F3 or NB-3, 
promotes their maturation into CNP+ OGs (Cui et al. 2004; Hu et al. 2003).  In contrast, 
current data does not support a receptor-dependent effect since Notch1 appears to be 
important for inhibiting (Genoud et al. 2002; Givogri et al. 2002), as well as promoting 
(Cui et al. 2004; Hu et al. 2003) OG differentiation.  However, as Notch2 and/or Notch3 
are expressed in similar areas as Notch1 in the embryonic and postnatal CNS (Irvin et al. 
2001; Lindsell et al. 1996), further research will be needed to clarify which receptors are 
involved in each process.  In comparison, there is evidence to support a downstream 
effector-dependent event.  In particular, the Delta1/Notch signaling pathway in OPCs 
appears to utilize CBF1 (Wang et al. 1998), whereas the F3,NB-3/Notch signaling 
pathway in the same cells requires Deltex1 (Cui et al. 2004; Hu et al. 2003).  
Interestingly, these Notch signaling pathways also appear to activate distinct target genes 
since exposing oligodendroglial cells to Delta1 or F3/NB-3 enhances the mRNA 
expression of Hes5 (Wang et al. 1998) or MAG (Cui et al. 2004; Hu et al. 2003), 
respectively.  Hence, various factors may dictate what effect Notch signaling has on OG 
differentiation. 
2.1.2.3 Conclusion 
Over the past decade researchers have made significant contributions to our 
understanding of the transcriptional control of OG differentiation [Table 2.2].  In most 
cases, the TFs and signaling pathways identified either inhibit or promote this process; 
however, instances exist where the effect of a particular signaling pathway may depend 
upon such factors as the ligand and/or downstream effector.  Intriguingly, many of the 
signaling pathways and TFs appear to act, in part, via affecting the expression and/or 
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function of other TFs [Figure 2.5].  In addition, many appear to play similar roles 
throughout the CNS.  However, it should be kept in mind that some of this information 
was obtained utilizing in vitro assays (Barres et al. 1994; Cui et al. 2004; Hu et al. 2003; 
Laeng et al. 1994; Nielsen et al. 2004; Noll and Miller 1994; See et al. 2004; Sohn et al. 
2006) and, hence, will have to be verified in vivo.  In addition, further research will be 
required to clarify where particular TFs play a role in OG differentiation since most 
researchers have only examined the expression of myelin proteins.  Furthermore, it 
remains to be determined how the transcriptional control of OG differentiation compares 
between ventral and dorsal progenitors.  Although this is a huge undertaking, it will be 
aided by the vast knowledge already accumulated regarding the expression of TFs in the 
CNS [Table 2.3].  The importance of obtaining this information is evident from the 
findings that although ventral and dorsal OPCs appear to be able to compensate for each 
other if one progenitor type is ablated (Cai et al. 2005; Kessaris et al. 2006), this 
compensation appears to be limited if the OPCs are present but their maturation is 
defective (Yue et al. 2006).  Ultimately, identifying the molecular mechanisms regulating 
OG development will be critical to the establishment of therapeutic strategies for 
demyelinating diseases, such as MS.   
2.2 Introduction to Hox genes in the central nervous system: Hoxa2  
Hox genes, which exhibit sequence homology to Drosophila homeotic complex 
genes, can be identified by the presence of a 180 base pair homeobox that encodes a 60 
amino acid homeodomain (McGinnis et al. 1984a; McGinnis et al. 1984b).  Through their 
homeodomain Hox TFs can bind to specific nucleotide sequences and affect the 
expression of downstream effector genes (Akin and Nazarali 2005; Hirsch et al. 1990; 
Hoey and Levine 1988; Jones et al. 1992).  In turn, the binding specificity of Hox TFs in 
vivo often depends upon the presence of co-factors, such as Pbx and Prep/Meis (Moens 
and Selleri 2006). 
In mice and humans, 39 Hox/HOX genes have been identified that can be 
arranged into four clusters (Hox A, B, C, D) found on different chromosomes (Akin and 
Nazarali 2005; Favier and Dollé 1997; Santagati and Rijli 2003; Scott 1992) [Figure 2.6].  
The location of a particular Hox gene within a cluster determines its anterior limit of  
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Figure 2.5 Transcriptional network of oligodendrocyte differentiation. 
 
Several TFs (eg. Olig2, Sox10, Olig1, Hes5) and signaling pathways (BMP, Notch) affect 
OG differentiation.  Most of these factors appear to act, in part, via modulating the 
expression and/or function of other factors.  For example, Olig1 may promote OG 
differentiation by maintaining and inducing the expression of Sox10 and Zfp488, 
respectively.  In contrast, Hes5 may impair this process via inhibiting the expression 
and/or function of Sox10, which promotes OG differentiation.   
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Table 2.3 Expression profiles of PDGFαR (♣), PLP/DM20 (♦), and transcription 
factors implicated in oligodendrocyte development in the central nervous system. 
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N.B. Although TFs and/or OG markers are expressed in the same CNS region, the 
expression profiles may or may not overlap.  For the purpose of this table information 
was standardized utilizing the Carnegie (C)/Theiler (T) staging system.  Utilizing this 
staging system the day of vaginal plug is considered E1; therefore, the days were adjusted 
accordingly so as to have consistent expression data.  In cases where the staging 
information was not given1,4,10,16,17,20,25,26,29-31,37,38,41 the indicated age in the manuscript 
was utilized.  The E listed is for mice; the corresponding rat E is 1.5 days older. Most 
references utilized in situ hybridization, whereas some references also utilized 
immunohistochemistry3,4,7,14,15,16,21,22,28-31,33,37,39.  
 
Abbreviations: POU: Brn-1,2 and SCIP; SoxC: Sox4 and 11; SoxE: Sox8, 9, and 10  
References:  1Akazawa et al. (1992), 2Alvarez-Bolado et al. (1995), 3Armstrong et al. 
(1995), 4Cai et al. (2005), 5Casarosa et al. (1999), 6Cheung et al. (2000), 7Hao et al. 
(1999), 8He et al. (1989), 9Jen et al. (1996), 10Komuro et al. (1993), 11Kordes et al. (2005), 
12Kuhlbrodt et al. (1998a), 13Kuhlbrodt et al. (1998b), 14Lee et al. (2003), 15Lo et al. 
(1991), 16Lovas et al. (2001), 17Lu et al. (2002), 18Lu et al. (2000), 19Nery et al. (2001), 
20Neuman et al. (1993), 21Nicolay et al. (2004a), 22Nicolay et al. (2004b), 23Price et al. 
(1992), 24Pringle and Richardson (1993), 25Pringle et al. (1992), 26Qi et al. (2001), 
27Ravassard et al. (1997), 28Sohn et al. (2006), 29Stolt et al. (2006), 30Stolt et al. (2004), 
31Stolt et al. (2003), 32Suzuki et al. (1990), 33Takebayashi et al. (2000), 34Tekki-Kessaris 
et al. (2001), 35Timsit et al. (1995), 36Tzeng and De Vellis (1998), 37Vallstedt et al. 
(2005), 38Wang et al. (2006), 39Wolf et al. (2001), 40Zhou & Anderson (2002), 41Zhou et 
al. (2000). 
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Figure 2.6 There are 39 mouse and human Hox/HOX genes which are organized into 
four clusters located on different chromosomes. 
 
The genes are shown in the order in which they are found on the chromosomes.  Genes 
located at the same position in different chromosomes are known as paralogs.  There are 
13 paralogous groups in total; however, not all groups contain a full complement of 
genes.  For example, paralog group 2 has only two members: Hoxa2, which is the gene 
our laboratory is interested in (star), and Hoxb2.  Furthermore, Hox genes located at the 3' 
end of the chromosomes exhibit a more anterior limit of expression than those located at 
more 5' positions. [Adapted from Scott (1992) and Santagati and Rijli (2003)] 
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expression with 3′ genes exhibiting more anterior limits than 5′ genes (Duboule and Dollé 
1989; Graham et al. 1989).  In turn, Hox genes located at the same position in different 
clusters are called paralogs.  There are 13 paralogous groups in total; however, not all 
groups contain a full complement of genes (Scott 1992).  Genes within each paralogous 
group exhibit similarities in sequence (Nazarali et al. 1992; Tan et al. 1992), as well as 
expression profiles (Gaunt et al. 1989; Hunt et al. 1991).   
  As our laboratory is interested in elucidating the role of one specific Hox TF, 
Hoxa2, in OG development, this section of the literature review will describe the 
expression, regulation, and function of Hoxa2 during embryonic development with 
specific emphasis on the CNS.  
2.2.1 Hoxa2 mRNA and protein expression 
Paralog group 2, which exhibits sequence homology with the Drosophila gene 
proboscipedia (Cribbs et al. 1992), consists of only two members: Hoxa2 and Hoxb2 
(Akin and Nazarali 2005; Hunt et al. 1991; Nazarali et al. 1992).  The murine Hoxa2 
gene, which resides on chromosome 6, encodes a 41kD, 372 amino acid protein (Tan et 
al. 1992).  Initially, Northern blot analysis at different embryonic ages found that Hoxa2 
expression was most abundant in 12 dpc mice, progressively decreasing with further 
embryonic development (Tan et al. 1992).  Subsequently, it was found to be expressed in 
multiple regions including the VII and VIII cranial ganglia (Hunt et al. 1991; Tan et al. 
1992), the mesenchyme of the second and third branchial arches (Hunt et al. 1991), as 
well as the spinal ganglia, larynx, lungs, vertebrae, sternum, intestine (Tan et al. 1992), 
and CNS (Hao et al. 1999; Nicolay et al. 2004a; Tan et al. 1992; Wolf et al. 2001). 
In the CNS, Hoxa2 mRNA and protein is expressed in the embryonic 
telencephalon (Tan et al. 1992), diencephalon (Wolf et al. 2001), hindbrain (Davenne et 
al. 1999; Nonchev et al. 1996; Tan et al. 1992), and spinal cord (Hao et al. 1999; Nicolay 
et al. 2004a; Tan et al. 1992).  In fact, at the 12-somite stage Hoxa2 is the most anteriorly 
expressed Hox gene with its anterior limit of expression located at the boundary between 
r1 and r2 (Nonchev et al. 1996).  Although it is found in all rhombomeres posterior to this 
boundary, its expression is higher in r3 and r5 (Hunt et al. 1991; Nonchev et al. 1996).  
Expression analysis along the dorsal-ventral axis shows that Hoxa2 is found primarily in 
the dorsal regions of the hindbrain (Davenne et al. 1999).  In comparison, Hoxa2 protein 
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expression in the spinal cord is evident at E10 in two distinct ventrolateral regions of the 
neural tube that correspond to the future ventral horns (Hao et al. 1999).  In this region 
Hoxa2 exhibits an overlapping expression profile with Islet1, a marker for MNs.  Hence, 
this suggests MNs express Hoxa2 in the E10 spinal cord.  At E14 Hoxa2-immunoreactive 
cells are also evident in the dorsal horns of the spinal cord, and by E18 more cells are 
stained in the dorsal horns than in their ventral counterparts (Hao et al. 1999).  In the 
diencephalon, Hoxa2 is expressed in the thalamus and hypothalamus at E12.5 (Wolf et al. 
2001).  In the telencephalon, it is expressed in the neuroepithelium of the MGE, as well 
as the dorsal telencephalon at E12.5 and E14 (Tan et al. 1992; Wolf et al. 2001).  In glial 
cultures obtained from the telencephalon Hoxa2 is expressed by glial fibrillary acidic 
protein (GFAP)+ astrocytes and O4+ pro-OGs (Hao et al. 1999).  
2.2.2 Factors regulating Hoxa2 expression  
Multiple factors affect the expression of Hoxa2, particularly in the hindbrain 
[Figure 2.7].  For instance, its lack of expression in r1 appears to be due to the repressive 
activity of fibroblast growth factor 8 (FGF8), which is a signaling molecule expressed in 
the organizing center located at the midbrain-hindbrain boundary known as the isthmus 
(Irving and Mason 2000).  In comparison, Hoxa2 expression in specific rhombomeres 
posterior to r1 is under the control of several distinct enhancers.  For example, its 
expression in r2 appears to be directed by an enhancer that overlaps with the 3′ end of the 
Hoxa2 gene (Frasch et al. 1995).  As transfection of Hoxa2, along with its co-factor genes 
Pbx1a and Prep1, is sufficient to activate a reporter gene driven by this enhancer (Lampe 
et al. 2004), it suggests that an auto-regulatory loop may be involved in maintaining 
Hoxa2 expression in r2.  Auto- and cross-regulatory Hox TF loops may also affect Hoxa2 
expression in r4.  In particular, researchers have revealed potential Hox/Pbx and 
Prep/Meis binding sites within the r4 enhancer located in the Hoxa2 intron.  These sites 
are important for the enhancer’s activity since a mutation in one or more of these sites 
results in a reduction in reporter gene expression in r4.  Furthermore, ectopic expression 
of either HOXB1 or Hoxa2 in the hindbrain is able to induce r4 enhancer activity  
(Tümpel et al. 2007). 
An enhancer directing Hoxa2 expression in r3 and r5 is located in the intergenic 
region between Hoxa2 and Hoxa3 (Nonchev et al. 1996).  This enhancer region contains 
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Figure 2.7 Hoxa2 expression in the hindbrain is regulated by numerous factors. 
During early embryonic development the hindbrain is divided into eight units known as 
rhombomeres (r1 is the most anterior whereas r8 is the most posterior).  At the 12-somite 
stage Hoxa2 is expressed up to the r1/r2 boundary.  Although it is expressed in all 
rhombomeres posterior to this boundary, it is more intense in r3 and r5 (illustrated by 
darker orange color).  Various factors appear to affect the expression of Hoxa2 in a 
rhombomere specific fashion.  Please refer to the text [Section 2.2.2, pg. 32] for more 
details. (*-effect does not appear to be limited to r5)    
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two Krox20-binding sites.  These sites are important for this enhancer activity since 
reporter gene expression is absent in both rhombomeres in transgenic mice carrying a 
single point mutation in each of these binding sites (Nonchev et al. 1996).  In the absence 
of Krox20, however, the reporter gene expression driven by this enhancer is only reduced 
or lost in r3 but not in r5 (Maconochie et al. 2001).  Although the reason for this disparity 
is unknown, the mutations in the Krox20-binding sites may affect the ability of other 
related TFs to bind to the enhancer and, hence, affect r5 expression.  Interestingly, recent 
research suggests that additional elements outside of this enhancer region can impact 
Hoxa2 expression in r5.  In particular, a mutation in the RA response element (RARE), 
located 3′ of the Hoxa1 gene (Frasch et al. 1995; Langston and Gudas 1992), results in a 
reduction in Hoxa2’s expression in r5 (Dupé et al. 1997).  RA’s ability to enhance Hoxa2 
expression, however, does not appear to be limited to this rhombomere since implantation 
of RA-soaked beads close to or at the level of the isthmus results in the anterior limit of 
Hoxa2’s expression domain expanding up to and sometimes within the mesencephalon 
(Plant et al. 2000).  Furthermore, HOXA2 is induced by RA in human embryonal 
carcinoma cell lines (Simeone et al. 1991).   
2.2.3 Developmental abnormalities found in Hoxa2 mutant mice 
Hoxa2-/- mice, which can be identified via the absence of the pinna of the 
external ear (Rijli et al. 1993), exhibit several distinct defects.  Most of the mutant mice 
display a wide cleft of the secondary palate (Gendron-Maguire et al. 1993; Rijli et al. 
1993), as well as a malformation of the tongue (Rijli et al. 1993).  These defects may 
explain why the mutant pups do not suckle and, hence, die within the first day (Gendron-
Maguire et al. 1993; Rijli et al. 1993).  The mutant mice also exhibit a homeotic 
transformation of the second arch neural crest-derived skeletal elements into first arch 
derivatives (Gendron-Maguire et al. 1993; Rijli et al. 1993).   
In the CNS, Hoxa2 mutant mice exhibit anomalies in anterior-posterior 
patterning.  In particular, the absence of Hoxa2 results in an apparent loss or compromise 
of the r1/r2 and r2/r3 boundaries, respectively, as well as a posterior expansion of r1 
(Gavalas et al. 1997).  As the cerebellum appears to be derived from r1 (Wingate and 
Hatten 1999), it is not surprising that these mutant mice exhibit an enlarged cerebellum at 
18.5 dpc (Gavalas et al. 1997).  This enlargement, in turn, may be explained by the fact 
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that the external granule cell layer (EGL) is thickened in specific areas of the cerebellum 
(Gavalas et al. 1997).  Indeed, there is a variable reduction in the size of the cerebellum 
with a concomitant loss of cells in the EGL following early global over-expression of 
Hoxa2 in chick embryos (Eddison et al. 2004).   
Hoxa2 mutant mice also display anomalies in TF patterning along the dorsal-
ventral axis of the hindbrain.  In particular, a ventral shift in the Pax3+ expression domain 
occurs in r2 and r3 in the absence of Hoxa2.  These mutant mice also display a down-
regulation of Pax6 expression in both of these rhombomeres.  However, Hoxb2 appears 
to partially compensate for Hoxa2 in r3, since these expression anomalies are more 
severe in Hoxa2;Hoxb2 double knockout mice (Davenne et al. 1999).     
As different types of neuronal precursors arise from distinct dorsal-ventral regions 
of the neural tube, the patterning defects found in Hoxa2 mutant mice suggest that the 
development of certain precursors may be affected.  Indeed, researchers have found that 
Lbx1-expressing somatic sensory interneuron precursors, which arise in dp domains 
(Gross et al. 2002), are lost in r2 and dramatically reduced in r3 in Hoxa2 mutant mice 
(Gaufo et al. 2004).  As Hoxa2 is expressed in the dorsal hindbrain (Davenne et al. 1999), 
its effect on Lbx1 may be direct, however, further research will be needed to verify this.   
Similar to Lbx1, the expression of Evx1, which selectively labels interneurons 
arising from the p0 domain (Moran-Rivard et al. 2001), is completely absent in r2 and 
partly in r3 of Hoxa2-/- mice (Davenne et al. 1999).  The reason for the loss of these 
interneurons  is unknown, but it is likely indirect due to the fact that Hoxa2 is expressed 
dorsally in the hindbrain (Davenne et al. 1999).  However, it does not appear that the 
anomalies in Pax3 and Pax6 expression found in these mutant mice can account for this.  
In particular, although Pax6 is expressed in the p0 domain (Moran-Rivard et al. 2001), 
Evx1 expression is present in Pax6-deficient mice (Burrill et al. 1997) suggesting that it is 
not required for their development.  Similarly, the Evx1+ expression domain is not 
affected in the absence of both Pax3 and Pax7 (Mansouri and Gruss 1998).  Hence, 
further research will be needed to elucidate whether the anomalies in dorsal-ventral 
patterning are responsible for the loss of Evx1+ interneurons in Hoxa2 mutant mice.   
Evidence also suggests Hoxa2’s potential involvement in MN development; 
however, its exact role is debatable.  In particular, trigeminal branchiomotor neurons, 
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which arise from the Nkx2.2+ pMNv domain (Briscoe et al. 1999), develop in r2 in the 
absence of Hoxa2 (Gaufo et al. 2004), therefore, suggesting that it is not required for the 
development of these neurons.  Instead, r2 and r3 trigeminal MNs exhibit errors in axonal 
pathfinding in the hindbrains of Hoxa2 mutant mice (Gavalas et al. 1997).  However, 
other researchers have found that the ventral column of Phox2b expression, which 
corresponds to the pMNv domain (Pattyn et al. 1997; Pattyn et al. 2003), exhibits a dorsal 
expansion in r2 (Davenne et al. 1999).  This, in turn, is accompanied by an abnormal 
distribution of MNs in r2 with their cell bodies being found in more dorsal locations 
(Davenne et al. 1999).  Furthermore, infection of embryonic chick neural tubes with a 
Hoxa2-expressing retrovirus leads to the development of ectopic trigeminal 
branchiomotoneurons in infected areas of r1 (Jungbluth et al. 1999).  Obviously, 
resolution of this issue will require further research.    
2.2.4 Conclusion 
Hoxa2 is expressed in multiple regions of the CNS, as well as by several distinct 
cell types.  Currently, research regarding its regulation and function has primarily focused 
on the hindbrain.  In this CNS region, multiple factors regulate Hoxa2 expression in a 
rhombomere-specific fashion.  In turn, Hoxa2 is important in anterior-posterior and 
dorsal-ventral patterning, as well as neuronal development in the hindbrain.  Further 
research is needed, however, to elucidate its function at later stages of embryonic 
development, such as during oligodendrogenesis.  
2.3 Introduction to NCAM and oligodendrocyte development 
 2.3.1 NCAM and its isoforms 
NCAM, a cell surface glycoprotein, exists as three prominent protein isoforms 
(120, 140, 180 kD), encoded by four predominant transcripts arising from alternative 
splicing and polyadenylation sites of a single gene (Barbas et al. 1988).  NCAMs undergo 
a variety of post-translational modifications, including glycosylation by enzymes, such as 
sialyltransferase (Breen et al. 1987; Breen and Regan 1988; Finne et al. 1983; Rothbard 
et al. 1982).  As the activity of this enzyme is developmentally regulated (Breen et al. 
1987; Breen and Regan 1988), NCAMs can vary in their sialic acid content with the 
highest evident in PSA-NCAM (Breen et al. 1987; Breen and Regan 1988; Finne et al. 
1983; Rothbard et al. 1982).  In turn, sialic acid content is inversely related to NCAM 
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homophilic binding properties, such as adhesion and rate of aggregation (Hoffman and 
Edelman 1983; Sadoul et al. 1983).   
 2.3.2 NCAMs and oligodendrocyte development 
The stage of development determines the form of NCAM expressed by an 
oligodendroglial cell.  In particular, PSA-NCAM is expressed primarily by A2B5+ OPCs.  
Subsequently, its expression is dramatically down-regulated such that less than 5% of 
O4+ pro-OGs express PSA-NCAM (Trotter et al. 1989).  Instead, with continued 
development oligodendroglial cells express predominantly NCAM-120 (Bhat and 
Silberberg 1988; Trotter et al. 1989) and to a lesser extent NCAM-140 (Trotter et al. 
1989).  
Expression profiles of PSA-NCAM and NCAM suggest that they could play 
distinct roles during OG development.  PSA-NCAM’s expression profile, as well as its 
anti-adhesive properties suggests that it could play a role in OPC migration.  Indeed, 
removing the polysialic acid units from the NCAM molecule, using the enzyme 
endoneuraminidase (endoN), in explant cultures blocks OPC migration from the explant 
(Wang et al. 1994).  Further clarification of its role in OPC migration comes from a study 
by Barral-Moran and colleagues who found that after the removal of polysialic acid units 
the cells are still motile but exhibit aberrant movements (Barral-Moran et al. 2003).  
More recent research suggests that PSA-NCAM is important in PDGF-directed migration 
of oligodendroglial cells (Zhang et al. 2004).   
Research also suggests that PSA-NCAM could play a role in inhibiting OG 
differentiation since endoN treatment increases the number of O4+ cells, particularly 
those maintained in a serum free medium (Decker et al. 2000).  In addition, PSA-NCAM 
appears to indirectly affect myelination.  Axonal PSA-NCAM expression has been shown 
to decrease with a time frame that parallels myelination (Nait-Oumesmar et al. 1995).  In 
turn, researchers have found that endoN treatment in vitro, as well as in vivo results in an 
increase in the number of myelinated internodes (Charles et al. 2000).   
In comparison to its embryonic form, the expression and adhesive properties of 
NCAM suggest that it could also be involved in myelination.  Although this has not been 
examined directly there is some circumstantial evidence to support this.  In particular, 
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growing oligodendroglial cells on a NCAM substrate results in an increase in the cells’ 
surface areas compared to control (Gard et al. 1996).  
 2.3.3 Conclusion  
Various isoforms of the cell surface glycoprotein NCAM are expressed by 
oligodendroglial cells in vitro.  However, current knowledge regarding the function of 
NCAM is limited to the embryonic isoform, PSA-NCAM.   
2.4 Introduction to retinoic acid and oligodendrocyte development 
Over the last 15 years there has been a wealth of information reported in the 
literature regarding OG development and RA, which is an active metabolite of vitamin A.  
Therefore, the purpose of this section of the literature review is to highlight what is 
currently known about RA signaling in oligodendroglial cells, as well as its potential 
role(s) in OG specification and differentiation.  
2.4.1 Retinoic acid signaling during oligodendrocyte development 
In order for RA to play a role in oligodendrogenesis it has to be synthesized either 
by the oligodendroglial cells themselves or by cells/tissue within their vicinity.   RA 
synthesis is a two step enzymatic process (Maden 2002) during which retinol (vitamin A) 
is first converted to retinal by retinol/alcohol dehydrogenases and then, subsequently, to 
RA via retinaldehyde dehydrogenases (Raldhs).  Current information regarding the 
expression profiles of Raldhs suggests that the ability of oligodendroglial cells to 
synthesize RA is stage-dependent.  The three currently known Raldhs― Raldh1, Raldh2, 
and Raldh3― are expressed in specific regions of the CNS (Berggren et al. 1999; Li et al. 
2000; Niederreither et al. 2002).  Although these regions do not correspond to the 
neuroepithelial domains from which OPCs are known to arise (Cai et al. 2005; Fu et al. 
2002; Kessaris et al. 2006), they are within their vicinity.  For example, in the embryonic 
chick spinal cord Raldh2 is expressed by MNs in the ventral horns from stages 17 to 29.  
In addition, intense Raldh2 expression is found in the RP of the spinal cord from stage 16 
through to stage 27, as well as in the meninges (Berggren et al. 1999).  As Raldh2 is the 
only Raldh known to be expressed in this CNS region, these results suggest that OPCs, 
which arise in the embryonic chick spinal cord at stage 26 (Novitch et al. 2001), are 
unable to synthesize RA themselves and, hence, must rely on its secretion by other cells, 
such as MNs.  In contrast to OPCs, evidence suggests that differentiated OGs can 
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synthesize RA.  Raldh2 is expressed by CNP+ OGs in the adult rat spinal cord (Mey et al. 
2005).  Furthermore, when the OG cell line OLN-93 is directed to differentiate it also 
expresses Raldh2 and can synthesize RA in the presence of retinal (Mey and 
Hammelmann 2000).   
RA exists as two isomers, all-trans and 9-cis, both of which affect OG 
development in vitro (Barres et al. 1994; Laeng et al. 1994; Noll and Miller 1994; Pombo 
et al. 1999).  However, little is known regarding which isomer(s) oligodendroglial cells 
are exposed to during their development in vivo.  The only research group that has tried to 
address this issue is Mey and Hammelman (2000) who found that differentiated OLN-93 
cells are only able to synthesize all-trans RA.  As it is not known how this relates to OG 
development in vivo, further research will be required. 
In addition to its synthesis, the level of RA in a cell is also affected by its 
metabolism.  RA is metabolized to 4-oxo RA and 4-hydroxy RA by CYP26 (White et al. 
1996).  Although CYP26 is expressed by OLN-93 cells (Mey and Henkes 2002), it is not 
known whether it is expressed by primary oligodendroglial cells.  Hence, more research 
is needed to determine if the ability of oligodendroglial cells to metabolize RA is also 
stage-dependent. 
In order to affect OG development RA must enter the oligodendroglial cell’s 
nucleus and bind to RA receptors (RARs) and retinoid X receptors (RXRs), which exist 
as multiple isoforms.  9-cis RA can bind to both RARs and RXRs, whereas all-trans RA 
can only bind to the former (Allenby et al. 1993).  These receptors, in turn, bind primarily 
as heterodimers, to cis-acting RAREs on DNA and, hence, can alter the expression of 
downstream effector genes.  However, little information is known regarding RAR and 
RXR expression by oligodendroglial cells.  For instance, RARα is the only receptor 
currently known to be expressed by OPCs (Laeng et al. 1994).  In addition, the only 
receptors that are known to be expressed by CNP+ OGs in the adult rat spinal cord are 
RARα, RXRα, and RXRγ (Schrage et al. 2006).  OLN-93 cells are known to express 
RARα, RARβ, and RARγ, as well as RXRα and RXRβ (Mey and Henkes 2002).  However, 
a more detailed expression analysis is needed to determine whether the complement of 
receptors changes as the oligodendroglial cells progress from precursors to mature 
myelinating cells.   
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2.4.2 Retinoic acid and oligodendrocyte specification 
Although RA’s role in OG specification has not been addressed directly, research 
suggests that it could be involved in this process, at least in the spinal cord.  In the spinal 
cord, PDGFαR+ OPCs initially arise in a distinct region of the embryonic vVZ (Sun et al. 
1998).  This region is known as the pMN domain, since it gives rise to MNs at earlier 
stages of embryonic development (Fu et al. 2002).  In turn, the pMN domain, which is 
specifically demarcated by the expression of the bHLH TF Olig2, is one of five ventral 
progenitor domains formed in response to graded Shh concentrations (Briscoe et al. 2000; 
Gritli-Linde et al. 2001).  In particular, Shh, which is expressed and secreted by cells of 
the notochord and FP (Echelard et al. 1993; Marti et al. 1995), initially regulates the 
expression of the TFs that define the boundaries of these progenitor domains (Briscoe et 
al. 2000; Ericson et al. 1997; Lu et al. 2000; Pierani et al. 1999).  This includes regulating 
the expression of Nkx2.2 and Pax6 (Ericson et al. 1997), as well as Olig2 (Lu et al. 2000) 
and Irx3 (Briscoe et al. 2000), which define the ventral (Briscoe et al. 2000) and dorsal 
(Novitch et al. 2001) boundaries, respectively, of the pMN domain.   
Interestingly, researchers have found that Shh alone cannot fully recapitulate the 
TF expression profiles found in the pMN domain.  In particular, Nkx2.2 expression, 
which is excluded from this region during neurogenesis (Fu et al. 2002), is found in 
neural plate explants treated with Shh concentrations known to give rise to predominantly 
MNs (Ericson et al. 1997).  As Nkx2.2 represses Olig2 expression at early stages of 
spinal cord development (Novitch et al. 2001; Zhou et al. 2001), an additional factor must 
be required to ensure proper establishment of the pMN domain.  Recent research has 
suggested that this factor could be RA since it blocks Shh-induced Nkx2.2 expression in 
neural plate explants (Novitch et al. 2003).  How it is able to accomplish this is uncertain 
but could involve its ability to enhance the expression of Pax6 (Novitch et al. 2003), 
which maintains and refines the ventral boundary of the pMN domain through cross-
repressive interactions with Nkx2.2 (Briscoe et al. 2000).  Hence, RA appears to 
collaborate with Shh to ensure the correct patterning of the pMN domain.  Indeed, Shh’s 
ability to induce Olig2 expression is dramatically reduced when retinoid signaling is 
blocked (Novitch et al. 2003).  As Olig2 is critical for OG development in the spinal cord 
(Lu et al. 2002), RA may be required for this process to occur normally.  
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In addition to ensuring the proper patterning of the pMN domain, evidence also 
exists suggesting that RA could be involved in the switch from neurogenesis to 
gliogenesis in the spinal cord.  In particular, activation of two different RAR isoforms, 
RARα and RARβ, results in most neural progenitor cells differentiating into glial cells or 
MNs, respectively (Goncalves et al. 2005).  Hence, OG specification in the ventral spinal 
cord could be dependent upon changes in the expression profiles of RARs in the pMN 
domain.  Circumstantial support for this statement comes from the finding that OPCs 
express RARα but not RARβ (Laeng et al., 1994).      
2.4.3 Retinoic acid and oligodendrocyte differentiation 
Research examining RA’s role in OG differentiation suggests that it can inhibit 
(Laeng et al. 1994; Noll and Miller 1994), as well as promote (Barres et al. 1994; Givogri 
et al. 2001; Pombo et al. 1999) this process.  Although the reason for these differential 
effects is currently unknown, there is evidence to suggest that it could depend on the 
stage of oligodendrogenesis, the RA concentration, and/or the receptor.  In particular, RA 
treatment of spinal cord cultures, obtained from either E14, E16, or E18 rats, inhibits OG 
differentiation with the effect being most evident in cultures obtained from the E14 rats 
(Noll and Miller 1994).  As O4+ pro-OGs and GalC+ pre-myelinating OGs are known to 
first arise in the spinal cord at E16 and E18, respectively (Fok-Seang and Miller 1994), it 
could be postulated that RA inhibits OG differentiation at the OPC stage.  This, in turn, 
may explain why Laeng et al. (1994) and Givogri et al. (2001) report opposing research 
findings.  Both of these research groups used cultures obtained from the cerebral 
hemispheres of neonatal rats.  However, as Laeng et al (1994) purified their cultures for 
OPCs prior to RA treatment their cells would be expected to be more immature than 
those used by Givogri et al. (2001).  Alternatively, the contradictory findings could 
reflect a concentration-dependent effect since these two groups also utilized different RA 
concentrations.  There is also evidence to suggest that RA’s effect on OG differentiation 
could be receptor dependent.  This is due to the fact that although all-trans RA enhances 
MBP expression (Givogri et al. 2001), it is unable to induce MBP promoter activity in C6 
cells co-transfected with RARα and the MBP-promoter construct (Pombo et al. 1999).  
Hence, different receptors could be responsible for RA’s opposing effects on OG 
differentiation. 
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How RA is able to inhibit OG differentiation is unknown but it may involve its 
ability to enhance the expression of PSA-NCAM (Husmann et al. 1989), which is 
implicated in inhibiting OG differentiation (Decker et al. 2000).  In particular, in 
carcinoma cell lines, RA enhances the activity of sialyltransferase, which adds sialic acid 
residues to the NCAM protein, in a concentration-dependent manner (Deutsch and Lotan 
1983).  As this effect is first evident one day after RA treatment (Deutsch and Lotan 
1983), downstream targets of RA, such as Hox and Krox TFs (Conlon and Rossant 1992), 
may be involved.  In turn, Hox TFs have been implicated in the regulation of NCAM 
expression (Jones et al. 1992).  Furthermore, Hoxa2 (Hao et al. 1999; Nicolay et al. 
2004a) [Section 3.3.1, pg. 52] and Hoxb4 (Nicolay et al. 2004b) [Section 4.3, pg. 72] 
have been shown to be expressed by cells of the OG lineage.  Therefore, RA may inhibit 
OG differentiation via enhancing the expression of PSA-NCAM, potentially with the aid 
of downstream effectors, such as Hox TFs.    
In comparison, there could be multiple mechanisms by which RA promotes OG 
differentiation.  For example, in the oligodendroglial cell line OLN-93, RA enhances the 
expression of leukemia inhibitory factor (LIF) (Mey and Henkes 2002).  LIF, in turn, 
promotes terminal differentiation of purified OPCs when it is added daily for six days at a 
concentration of 4 ng/ml (Ibarrola et al. 1996).  RA also enhances the expression of the 
myelin protein genes PLP (López-Barahona et al. 1993) and MBP (Givogri et al. 2001; 
Pombo et al. 1999).  Interestingly, the mechanism by which it brings about these effects 
appears to be different.  Whereas RA enhances the activity of the MBP promoter (Pombo 
et al. 1999), it increases PLP expression via enhancing PLP’s mRNA stability, which 
results in an increase in PLP’s half life (López-Barahona et al. 1993).  Another potential 
mechanism by which RA could promote differentiation is via raising the intracellular pH 
(pHi) of oligodendroglial cells (Bernard et al. 2006), which increases with OG 
differentiation (Boussouf and Gaillard 2000).  The level of OG differentiation is 
dependent on the pHi, with the highest level of differentiation evident around pHi 7.15 
(Bernard et al. 2006).  RA could also promote OG differentiation via affecting the 
expression of cell cycle regulators.  For instance, in the presence of RA, the RAR can 
repress the promoter activity of the TF E2F-1 (Nygård et al. 2003), which induces the 
expression of genes involved in DNA replication or mitosis (Polager et al. 2002).  This 
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repression, in turn, could lead to cell cycle withdrawal and, subsequently, OG maturation.  
RA’s ability to promote differentiation also appears to depend upon members of the p53 
TF family since RA-induced differentiation is blocked when purified OPCs are infected 
with dominant-negative forms of p53 or p73 (Billon et al. 2004).  How p53 and p73 
promote OG differentiation is not known, but it may involve their ability to induce the 
gene expression of two cyclin-dependent kinase inhibitors, p21 and p27 (Fontemaggi et 
al. 2002).  Accordingly, over-expressing p27 in CG4 cells enhances MBP promoter 
activity (Wei et al. 2003; Wei et al. 2004) via increasing Sp1 binding to the MBP 
promoter (Wei et al. 2003).  In comparison, there is a dramatic decrease in MBP 
expression in the cerebellum of p21-/- mice at P4 and P6 (Zezula et al. 2001).  
2.4.4 Conclusion 
Oligodendroglial cells express various components of the RA signaling pathway; 
however, further research is needed to determine if the components of this pathway 
change as the cells progress from precursors to mature myelinating cells.  Current 
evidence suggests that RA plays multiple roles in OG development.  However, as most of 
this information was obtained utilizing in vitro assays, it will need to be confirmed in 
vivo.  
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Preamble to Chapter 3  
The objectives of this chapter are to examine the expression of Hoxa2 during the early 
stages of OG development, as well as to determine whether Hoxa2 is required for the 
specification and/or early maturation of OGs.  
 
(Manuscript published, Appendix C) 
Nicolay DJ, Doucette JR, Nazarali AJ. 2004a. Early stages of oligodendrocyte 
development in the embryonic murine spinal cord proceed normally in the absence of 
Hoxa2. Glia 48:14-26. 
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3.0 EARLY STAGES OF OLIGODENDROCYTE DEVELOPMENT IN THE 
EMBRYONIC MURINE SPINAL CORD PROCEED NORMALLY IN THE 
ABSENCE OF Hoxa2 (Manuscript published). 
 
3.1 Summary 
Recent discoveries have enhanced our knowledge of the transcriptional control of 
OG development.  In particular, the TFs Olig2, Pax6, and Nkx2.2 have been shown to be 
important in the specification and/or maturation of the OG lineage.  Although numerous 
other TFs are expressed by OGs, little is known regarding their role(s) in 
oligodendrogenesis.  One such TF is Hoxa2, which was recently shown to be expressed 
by O4+ pro-OGs.  The objectives of this study are to examine the expression of Hoxa2 
during the early stages of OG development, as well as to determine whether Hoxa2 is 
required for specification and/or early maturation of OGs.  Immunocytochemical analysis 
of primary mixed glial cultures demonstrated that Hoxa2 is expressed throughout 
oligodendrogenesis, diminishing only with the acquisition of a myelinating phenotype.  
Serial transverse spinal cord sections from E12.5, E14.25, E16, and E18 Hoxa2+/+, 
Hoxa2+/-, and Hoxa2-/- mice were subjected to single and double immunohistochemical 
analysis in order to examine Hoxa2, Olig2, Nkx2.2, and Pax6 expression profiles.  
Results obtained from Hoxa2+/+ and Hoxa2+/- mice suggest that Hoxa2 is expressed by 
migratory oligodendroglial cells.  In addition, comparison of spinal cord sections 
obtained from Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- mice suggest that specification and 
early maturation of OGs proceeds normally in the absence of Hoxa2, since there are no 
obvious alterations in the expression patterns of Olig2, Nkx2.2, and/or Pax6.  Hence, 
although Hoxa2 is expressed throughout OG development, it does not appear to be 
critical for early stages of oligodendrogenesis in the murine spinal cord. 
3.2 Introduction 
OPCs, which are characterized by PDGFαR expression, first appear in the murine 
spinal cord at E12.5 in a distinct region of the vVZ (Sun et al. 1998).  This region has 
been shown to correspond to the pMN domain, which is one of five ventral progenitor 
domains formed in response to graded Shh concentrations (Briscoe et al. 2000; Ericson et 
al. 1997; Fu et al. 2002; Novitch et al. 2001).  In particular, Shh, which is expressed and 
secreted by cells of the notochord and FP, initially regulates the expression of the TFs 
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that define the ventral (Nkx2.2/Pax6) and dorsal (Olig2/Irx3) boundaries of the pMN 
domain (Briscoe et al. 2000; Bumcrot et al. 1995; Echelard et al. 1993; Ericson et al. 
1997; Marti et al. 1995; Novitch et al. 2001) [Figure 3.1].  Subsequently, repressive 
interactions between these TFs maintain and refine these boundaries (Briscoe et al. 2000; 
Novitch et al. 2001).   
Olig2, Pax6, and Nkx2.2 have been shown to be important in OG specification 
and/or maturation, since mutations of these genes lead to anomalies in these processes 
(Lu et al. 2002; Qi et al. 2001; Sun et al. 1998).  Olig2, which specifically demarcates the 
pMN domain and is expressed throughout OG development, is critical for spinal cord 
oligodendrogenesis since, in its absence, expression of PDGFαR, Sox10, MBP, and 
PLP/DM20 are undetectable (Lu et al. 2002).  Mice deficient in Pax6 exhibit a delay of 1 
day and a dorsal shift in the appearance of PDGFαR+ cells (Sun et al. 1998).  Nkx2.2 is 
important in the spatial aspect of PDGFαR+ OPC specification, as demonstrated by a 
ventral expansion, as well as an increased number of Olig2+ cells (Qi et al. 2001).  It has 
also been hypothesized that a separate OPC lineage arises from the Nkx2.2+ p3 domain.  
In addition, Nkx2.2 is important in OG maturation due to the fact that Nkx2.2 mutant 
mice display not only a delay and reduction in MBP and PLP/DM20 expression in the 
white matter but also an absence of these markers in the gray matter (Qi et al. 2001). 
Although numerous other TFs are expressed by cells of the OG lineage, 
researchers have been unable to define where they ultimately lay in the transcriptional 
control of oligodendrogenesis.  One TF that has been shown to be expressed by O4+ pro-
OGs is Hoxa2 (Hao et al. 1999).  Hoxa2 is one of 39 mouse and human Hox/HOX genes 
that are organized into four clusters (Hox A, B, C, D) located on different chromosomes 
(Favier and Dollé 1997; Santagati and Rijli 2003; Scott 1992).  These genes are 
characterized by a 180 base pair homeobox, which encodes a 60 amino acid 
homeodomain (McGinnis et al. 1984a; McGinnis et al. 1984b).  Hox TFs can regulate the 
expression of downstream effector genes by binding to specific nucleotide sequences 
through the homeodomain (Hirsch et al. 1990; Hoey and Levine 1988; Jones et al. 1993; 
Jones et al. 1992).  We have further investigated Hoxa2 expression, as well as its 
potential role(s) in OG development.  Our results suggest that although Hoxa2 is express- 
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Figure 3.1 PDGFαR+ oligodendrocyte precursor cells originate from the pMN 
domain. 
 
Shh, which appears to exhibit a ventral to dorsal decreasing concentration gradient, 
represses (┴) and enhances (→) the expression of class I (Pax6 and Irx3) and II (Nkx2.2 
and Olig2) TFs, respectively, that define the boundaries of the pMN domain.  These 
boundaries are further maintained and refined by repressive interactions between these 
TFs (Briscoe et al. 2000; Echelard et al. 1993; Ericson et al. 1997; Fu et al. 2002; Novitch 
et al. 2001; Timsit et al. 1995). N, Notochord. 
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ed by cells of the OG lineage, it does not appear to be critical for the specification or 
early maturation of these cells in the murine spinal cord. 
3.3 Materials and Methods 
3.3.1 Primary glial cultures and immunocytochemistry 
Cerebral hemispheres from newborn mice were dissected in Dulbecco’s modified 
Eagle’s medium/ F12/10% fetal bovine serum (DMEM/F12/10% FBS).  Subsequently, 
single cell suspensions, obtained by forcing diced tissue through a 75 µm Nitex mesh, 
were plated in DMEM/F12/10% FBS for 4 days to allow adherence of the cells.  They 
were then cultured for two 1-week periods, respectively, in a B104 conditioned medium 
and a low serum-containing (0.3%) growth medium (GP medium) [described previously 
by Gard and Pfeiffer (1990) and Doucette and Devon (1994)] supplemented with 10 
ng/ml basic FGF.  Culture medium was changed every 4 days.   
The following primary antibodies were used for immunocytochemical detection: 
anti-Hoxa2 (1:800; Hao et al. 1999), A2B5 (1:10, hybridoma; American Type Cell 
Culture [ATCC]), O4 (1:10, hybridoma; Sommer and Schachner 1981), anti-GalC (1:20, 
hybridoma; Ranscht et al. 1982), and anti-MBP (1:800; Sternberger Monoclonals, 
Lutherville, MD).  A2B5, O4, GalC, and MBP are used to mark cells at different stages 
of OG development [Figure 3.2].  In particular, the monoclonal antibody A2B5 is used to 
recognize a complex ganglioside expressed on the surface of OPCs (Abney et al. 1983; 
Eisenbarth et al. 1979).  The monoclonal antibody O4 recognizes surface epitopes 
expressed by pro-OGs (Bansal et al. 1989).  GalC, the major galactosphingolipid of 
myelin, marks pre-myelinating OGs (Ranscht et al. 1982).  Finally, expression of myelin 
proteins, such as MBP, marks mature myelinating OGs.  Double labeling cells for Hoxa2 
and A2B5, O4, or GalC was conducted using a procedure previously described by  
Doucette and Devon (1994) with the following modifications: live cells were incubated 
for 30 min at 37°C in A2B5, O4, or anti-GalC monoclonal antibodies diluted in 
phosphate-buffered saline (PBS); the blocking and permeabilization steps were combined 
with a 30-min incubation in 3% skim milk powder solution containing 0.1% Triton X 
(3% SM/0.1% TX); and cells were incubated for 4 h at room temperature (RT) in anti-
Hoxa2 diluted in 1% SM/0.03% TX.  The secondary antibodies used included goat anti- 
mouse IgM fluorescein isothiocyanate (FITC) (1:100, A2B5/ O4; Sigma, Oakville, ON),   
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Figure 3.2 Oligodendrocytes progress through four distinct stages in vitro, 
characterized by unique morphological and antigenic phenotypes (Abney et al. 1983; 
Asou et al. 1995; Bansal et al. 1989; Duchala et al. 1995; Fok-Seang and Miller 1994; 
Miller 1996; Noble et al. 1988; Raff et al. 1985; Raff et al. 1983; Sommer and Schachner 
1981). 
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donkey anti-mouse IgG FITC (1:50, GalC; BIO/CAN Scientific, Mississauga, ON), and 
goat anti-rabbit IgG CY3 (1:200, Hoxa2; BIO/CAN Scientific).  Between incubations, 
cultures were washed twice for 5 min in PBS.  Double immunostaining Hoxa2 with MBP 
was done using a procedure previously described by Doucette and Devon (1994), with 
two modifications: (1) cells were incubated in anti-MBP and then anti-Hoxa2 for 30 min 
and 4 h, respectively; (2) between anti-MBP and anti-Hoxa2 incubations, cells were 
rinsed in PBS and were then incubated for 30 min in 3% SM/0.1% TX.  The nuclei in all 
cell cultures were stained using Hoechst dye (Sigma, ON).  The percentage of OGs (O4+, 
GalC+, and MBP+ cells) that expressed Hoxa2 was calculated from 2 coverslips in which 
100–200 cells were counted.  
3.3.2 Hoxa2 transgenic mice and immunohistochemistry 
Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- C57 black mice (Gendron-Maguire et al. 
1993) were obtained by timed heterozygous matings.  They were staged according to the 
Carnegie (Butler and Juurlink 1987) and Theiler (1972) staging systems [Appendix A].  
The E and corresponding C/T stages used were as follows: E12.5 (C16/T19), E14.25 
(C19+/T21), E16 (C23/T23), and E18 (T25); the Carnegie staging system does not go 
beyond stage 23.  Although Hoxa2-/- mice could be identified by pinna deformities at 
later stages of embryonic development (i.e., E14+), genotypes were confirmed by 
polymerase chain reaction (PCR) analysis (Gendron-Maguire et al. 1993). 
Mouse embryos were fixed by immersion in 4% formaldehyde at 4°C for 24–48 h 
depending on their age.  Embryos were then rinsed and stored in 20% sucrose until they 
were processed.  Serial cryostat sections (8 μm) were collected on gelatin-coated 
coverslips and allowed to dry for ~1 h prior to staining.  The following primary 
antibodies were used: anti-Olig2 [gift of Dr. Hirohide Takebayashi (Takebayashi et al. 
2000); E12.5, 1:4,000; rest, 1:2,000], anti-Nkx2.2 (hybridoma; Developmental Studies 
Hybridoma Bank; E12.5, 1:4; rest, 1:2), anti-Hoxa2 (Hao et al. 1999; E12.5, 1:3,000; rest, 
1:1,500), and anti-Pax6 (Developmental Studies Hybridoma Bank; E12.5, 1:1,000; rest, 
1:500).  Immunohistochemical analysis of Hoxa2 and Olig2 was performed with a 
procedure previously described by Hao et al. (1999).  The following modifications were 
made with regard to time intervals: PBS washes were 8 min instead of 10 min; 3% 
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SM/0.1% TX blocks/permeabilizations were 20 min versus 30–60 min; and incubation in 
the secondary antibody was 30 min versus 45 min.  
Immunohistochemical analysis of Nkx2.2 and Pax6 used a modified Mouse on 
Mouse (MOM)™ (Vector Laboratories, Burlingame, CA) staining procedure.  Briefly, 
sections were washed twice in PBS for 8 min, followed by a 20-min 
permeabilizing/blocking period in 3% SM/0.1% TX.  After two 2-min washes in PBS, 
sections were incubated for 1 h in MOM Mouse Ig blocking solution.  Following a 5-min 
block in MOM diluent, sections were incubated at RT for 30 min and 10 min in primary 
and secondary antibodies, respectively.  Two 2-min PBS washes were done between 
incubations.  Endogenous peroxidase activity was then blocked by a 8-min incubation in 
a 0.3% hydrogen peroxide solution.  After two 4-min PBS washes, sections were 
incubated in avidin-biotin complex (Vectastain® Elite ABC; Vector) for 20 min at RT.  
The sections were subsequently washed for 8 min in PBS and then 0.175 M sodium 
acetate, respectively.  For diaminobenzidine tetrahydrochloride (DAB) staining, a 2-min 
incubation was performed as described previously by Hao et al. (1999).  Sections were 
then washed in PBS, dehydrated, and mounted in Permount® (Fisher Scientific, Nepean, 
ON).   
For immunofluorescent double labeling, sections were washed twice in PBS for 8 
min, followed by a 20-min block/permeabilization in 3% SM/0.1% TX.  They were then 
incubated overnight in primary antibodies [anti-Hoxa2 (1:200), anti-Olig2 (1:2,000), anti-
Pax6 (1:100), anti-Nkx2.2 (concentrate), anti-Islet1 (Developmental Studies Hybridoma 
Bank, 1:3,000), and anti-β-tubulin (1:8,000)] diluted in 1% SM/0.03% TX.  After two 8-
min PBS washes, sections were incubated for 3 h in Alexa 594 and 488 secondary 
antibodies (Molecular Probes, Eugene, OR).  Finally, sections were rinsed in PBS and 
were mounted in Citifluor® (Merivac, Montreal, QC).  (When sections were stained for 
β-tubulin an additional 8-min incubation in Hoechst dye was performed to identify 
nuclei.) 
3.4 Results 
3.4.1 Hoxa2 is expressed throughout oligodendrocyte development in 
vitro 
Immunocytochemical analysis of primary mixed neopallial glial cell cultures 
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demonstrates that Hoxa2 is expressed throughout OG development, diminishing only 
with the acquisition of a myelinating phenotype [Figure 3.3].  In particular, greater than 
95% of O4+ pro-OGs and GalC+ pre-myelinating OGs express Hoxa2 [Figure 3.3E,H].  
As OGs mature to the MBP+ myelinating phenotype, the percentage of Hoxa2-expressing 
cells drops to 56% [Figure 3.3K].  The location of immunoreactivity is primarily nuclear; 
however, at the pre-myelinating stage cytoplasmic staining is also observed.  Although 
Hoxa2 is expressed in most cells in the OG lineage, its expression in these mixed glial 
cell cultures is not limited to OGs.  This is demonstrated by the expression of Hoxa2 in 
cells that are A2B5, O4, GalC, and MBP-negative [Figure 3.3B,E,H,K]. 
3.4.2 Hoxa2 expression is not required for oligodendrocyte 
specification in the murine spinal cord  
At E12.5 (C16/T19) Hoxa2 is expressed predominantly in the ventral horns 
[Figure 3.4A].  In contrast, Nkx2.2 and Olig2, which may mark separate OPC lineages, 
are expressed in distinct regions of the vVZ in Hoxa2+/+ and Hoxa2+/- mice [Figure 
3.4B,C].  In particular, Nkx2.2 is expressed in the p3 domain, which is adjacent to the FP.  
Olig2 is expressed just dorsal to the Nkx2.2+ p3 domain in the pMN domain.  Although 
Olig2 expression is restricted to the vVZ, some Nkx2.2+ cells are found in the adjacent 
mantle layer [Figure 3.4B].  Double immunofluorescent staining demonstrated that some 
of the Nkx2.2+ cells located in the mantle layer co-express Hoxa2 [Appendix B].  Many 
Islet1+ MNs in the mantle layer also co-express Hoxa2 [Figure 3.4I,J].  
At E14.25 (C19+/T21), Hoxa2 is expressed throughout the mantle layer [Figure 
3.4E].  Although at E14.25, Nkx2.2 and Olig2 continue to be expressed in the vVZ, 
Nkx2.2+ and Olig2+ cells are also found in the mantle layer [Figure 3.4F,G].  
Occasionally, Olig2-immunoreactive cells are observed in the marginal layer at this stage 
of development [Appendix B].  Double immunofluorescent staining demonstrated that 
few if any cells co-express Nkx2.2 and Olig2 at E14.25 (C19+/T21) [Appendix B].  
However, most Nkx2.2+ cells located in the mantle layer express Hoxa2 [Figure 3.4K,L].  
The absence of Hoxa2 expression in the vVZ during OG specification would suggest that 
it may not be critical for this process in the spinal cord.  To test this directly, 
immunohistochemical analysis of Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- spinal cord 
sections were conducted to determine whether Nkx2.2, Pax6, and/or Olig2 expression 
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Figure 3.3 Hoxa2 is expressed throughout oligodendrocyte development.  
 
Primary mixed glial cell cultures from neonatal murine cerebral hemispheres were grown 
in culture for 18 days.  Double immunofluorescent staining was conducted with each of 
the four OG markers [A2B5 (A), O4 (D), GalC (G), and MBP (J)] and Hoxa2 (B, E, H, 
K).  Cells were visualized using nuclear fluorescent Hoechst counterstain (C, F, I, L). 
Each row illustrates micrographs obtained from individual filters [fluorescein (A, D, G, 
J), rhodamine (B, E, H, K), and DAPI (C, F, I, L)] of the same field.  Arrows demarcate 
representative Hoxa2-immunoreactive cells.  Arrowheads demarcate a Hoxa2-MBP+ cell.  
The insets at the top right corner of the rhodamine micrograph (E,H,K) show the 
percentage of O4+, GalC+, and MBP+ cells that are immunoreactive for Hoxa2, 
respectively. [Percentages depict averages calculated from two coverslips in which 100-
200 OGs were counted.  The percentage of A2B5+Hoxa2+ cells was not determined 
because the monoclonal A2B5 antibody binds to cell surface antigens on O-2A precursor 
cells, which can give rise to either OGs or type 2 astrocytes depending on culture 
conditions (Abney et al. 1983; Raff et al. 1983) and, therefore, is not specific to the OG 
lineage.] Scale bar = 100μm.   
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Figure 3.4 Transcription factor expression during oligodendrocyte specification in 
the spinal cords of Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- mice. 
 
(Top two rows) Transverse thoracic spinal cord sections from E12.5 (C16/T19) (A-D) and 
E14.25 (C19+/T21) (E-H) Hoxa2+/+ and Hoxa2+/- mice were immunolabeled with anti-
Hoxa2 (A,E), anti-Nkx2.2 (B,F), anti-Olig2 (C,G) and anti-Pax6 (D,H) as described in 
Materials and Methods.  Initially Hoxa2 expression was localized to the ventral horns 
(vh) at E12.5 (A), after which it was expressed throughout the mantle layer (ml) (E).  
Nkx2.2+ and Olig2+ cells, which were initially localized to distinct domains in the vVZ at 
E12.5 (B,C) had begun to migrate into the ml by E14.25 (F,G). Pax6 was expressed in the 
ventricular zone (vz) at both stages (D,H), with occasional immunoreactive cells found in 
the ml by E14.25 (H).   
 
(Middle row) Transverse thoracic spinal cord sections from E12.5 (I,J) and E14.25 (K,L) 
Hoxa2+/+ and Hoxa2 +/- mice were double immunolabeled with anti-Hoxa2 (I,K) and 
anti-Islet1(Isl1) (J) or anti-Nkx2.2 (L), respectively.  Each fluorescent image illustrates 
micrographs obtained from individual filters [fluorescein (I,K) and rhodamine (J,L)] of 
the same field.  Hoxa2 was co-expressed by Islet1 (Isl1)+ MNs at E12.5 (I,J).  At E14.25 
Hoxa2+Nkx2.2+ cells were demonstrated in the mantle layer (K,L).   
 
(Bottom two rows) Transverse thoracic spinal cord sections from E12.5 (M-O) and 
E14.25 (P-R) Hoxa2-/- mice were immunolabeled with anti-Nkx2.2 (M,P), anti-Olig2 
(N,Q), and anti-Pax6 (O,R).  Expression profiles of Nkx2.2, Olig2, and Pax6 were similar 
in the presence (B-D, F-H) and absence (M-R) of Hoxa2.  Analyses were conducted with 
spinal cord sections from at least three embryos at each stage of development in both the 
presence and absence of Hoxa2.  Significant discrepancies were not observed and any 
inconsistencies were primarily due to the way the sections were cut, in particular, the 
location (C,Q) and shape (H,R) of the central canal varied between some sections. Scale 
bar = 100μm.    
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profiles are altered in the absence of Hoxa2.  Hoxa2+/+ and Hoxa2+/- mice were used 
interchangeably to represent the presence of Hoxa2, since expression profiles were 
similar in both genotypes.  Single immunohistochemical analysis of Hoxa2+/+ mice 
demonstrated that at E12.5 (C16/T19) Olig2 is expressed in an adjacent non-overlapping 
domain with Nkx2.2, whereas Pax6 is expressed dorsal to the Nkx2.2+ domain [Figure 
3.4B–D].  Comparison of these expression profiles with those obtained from Hoxa2-/- 
mice demonstrated that they are maintained in the absence of Hoxa2 [Figure 3.4M-O].  
At E14.25 (C19+/T21), when immunoreactive cells are still evident in the vVZ, 
expression profiles of Nkx2.2, Olig2, and Pax6 are similar regardless of genotype [Figure 
3.4F–H,P–R].  Double immunofluorescent staining of Nkx2.2 and Olig2 or Pax6 at E12.5 
(C16/T19) confirmed that the expression profiles are maintained in the absence of Hoxa2 
[Figure 3.5].   
3.4.3 Hoxa2 is not required for early maturation of oligodendrocytes 
in the murine spinal cord 
At E16 (C23/T23) and E18 (T25), Hoxa2 is expressed throughout the mantle 
layer, with occasional immunoreactive cells also observed in the marginal layer [Figure 
3.6A,E,I–K].  Nkx2.2+ and Olig2+ cells continue to migrate into the mantle layer, and 
eventually these cells begin to accumulate in the marginal layer of Hoxa2+/+ and 
Hoxa2+/- mice.  This migration is accompanied by a reduction and the eventual 
disappearance of Nkx2.2- and Olig2- immunoreactive cells in the vVZ at E16 (C23/T23) 
and E18 (T25), respectively [Figure 3.6B,C,F,G].  Comparisons of Nkx2.2 and Olig2 
expression profiles from Hoxa2+/+ and Hoxa2+/- mice with that of Hoxa2-/- mice failed 
to reveal any consistent changes in expression profiles [Figure 3.6B–D,F–H,L–Q].  
Double labeling immunohistochemical analysis of Olig2 and Nkx2.2 expression in 
Hoxa2+/+ and Hoxa2+/- mice demonstrated that with continued maturation, co- 
expression of these TFs becomes evident, especially in the marginal layer [Figure 
3.7A,B].  Comparison of these co-expression profiles with those obtained from Hoxa2-/- 
mice show no detectable alterations [Figure 3.7C,D].  In addition, comparisons of 
Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- mice demonstrated that the accumulation of Olig2+ 
cells in the marginal layer of the developing spinal cord proceed similarly regardless of 
genotype [Figure 3.7E–H].  Thus, the early maturation of OGs proceeds  
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Figure 3.5 Oligodendrocyte specification occurs normally in the absence of Hoxa2.   
 
Transverse thoracic E12.5 (C16/T19) Hoxa2+/+ and Hoxa2-/- spinal cord sections were 
subjected to double immunofluorescent labeling with anti-Nkx2.2 and anti-Olig2 (A-D) 
or anti-Nkx2.2 and anti-Pax6 (E-H) antibodies.  Each row illustrates micrographs 
obtained from individual filters [fluorescein (A, C, E, G) and rhodamine (B, D, F, H)] of 
the same field.  Nkx2.2 and Olig2 exhibit adjacent non-overlapping expression domains 
in both WT (A,B) and mutant (C,D) mice.  Nkx2.2 and Pax6 also exhibit similar 
expression domains in both WT (E,F) and mutant (G,H) mice. Scale bar = 100μm. 
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Figure 3.6 Transcription factor expression during oligodendrocyte maturation in 
the spinal cords of Hoxa2+/+, Hoxa2+/- and Hoxa2-/- mice.  
 
(Top two rows) Transverse thoracic spinal cord sections from E16 (C23/T23) (A-D) and 
E18 (T25) (E-H) Hoxa2+/+ and Hoxa2+/- mice were immunolabeled with anti-Hoxa2 
(A,E), anti-Nkx2.2 (B,F), anti-Olig2 (C,G), and anti-Pax6 (D,H) as described in Materials 
and Methods.  At these stages Hoxa2 was expressed predominantly in the ml (A,E).  
Nkx2.2+ and Olig2+ cells continued to migrate into the ml and eventually accumulated in 
the mal (B,C,F,G).  Pax6 expression was concentrated in the ventricular zone at these 
stages, with occasional immunoreactive cells found in the ml (D,H). 
 
(Middle row) Transverse thoracic spinal cord section from an E16 (I-K) Hoxa2+/- mouse 
was double immunolabeled with anti-Hoxa2 (I) and anti-β-tubulin (J). β-tubulin staining 
was used to demarcate the mal, which is populated primarily by glial cells.  Cells were 
visualized using nuclear fluorescent Hoechst counterstain (K).  Each fluorescent image 
illustrates micrographs obtained from individual filters [fluorescein (I), rhodamine (J), 
and DAPI (K)] of the same field.  At later stages of development occasional Hoxa2+ cells 
(arrows) were found in the glial-rich mal. 
 
(Bottom two rows) Transverse thoracic spinal cord sections from E16 (L–N) and E18 (O–
Q) Hoxa2-/- mice were immunolabeled with anti-Nkx2.2 (L,O), anti-Olig2 (M,P), and 
anti-Pax6 (N,Q). Expression profiles of Nkx2.2, Olig2, and Pax6 were similar in both the 
presence (B–D,F–H) and absence (L–Q) of Hoxa2. Scale bars=100 μm. 
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Figure 3.7 Early oligodendrocyte maturation proceeds normally in the absence of 
Hoxa2. 
 
Transverse thoracic E16 (C23/T23) Hoxa2+/- and Hoxa2-/- spinal cord sections were 
subjected to double immunofluorescent labeling with anti-Nkx2.2 and anti-Olig2 (A-D) 
or anti-Olig2 and anti-β-tubulin (E-H) as described in Materials and Methods. Each row 
illustrates micrographs obtained from individual filters [fluorescein (A, C, E, G) and 
rhodamine (B, D, F, H)] of the same field.  With continued maturation, cells began to co-
express Olig2 and Nkx2.2 (arrows) in both heterozygous (A, B) and mutant (C, D) mice.  
Furthermore, the migratory pattern of Olig2+ cells was similar in both the heterozygous 
(E, F) and mutant (G, H) mice, as demonstrated by the accumulation of immunoreactive 
cells in the marginal layer (mal). Scale bar = 100μm. 
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normally in the absence of the Hoxa2 gene. 
3.5 Discussion 
OG development in vitro progresses through a number of distinct stages, which 
are characterized by specific antigenic phenotypes [Figure 3.2].  During the early stages 
of oligodendrogenesis, OPCs and pro-OGs, which are characterized by A2B5 and/or O4 
staining, actively proliferate and migrate.  Subsequently, loss of these traits and the 
emergence of GalC expression signal terminal differentiation into pre-myelinating OGs. 
 Finally, progression to the mature myelinating phenotype occurs with the production of 
myelin proteins and the elaboration of sheet-like membranes (Abney et al. 1983; Duchala 
et al. 1995; Fok-Seang and Miller 1994; Miller 1996; Noble et al. 1988; Raff et al. 1985). 
Although in situ hybridization and immunohistochemical analysis have shown 
that Hoxa2 is expressed in regions of the CNS, including the myelencephalon, 
diencephalon, and spinal cord (Tan et al. 1992; Wolf et al. 2001), Hao et al. (1999) were 
the first to demonstrate the expression of Hoxa2 by cells of the OG lineage.  In particular, 
Hao et al. (1999) demonstrated that O4+ pro-OGs, obtained from E15 murine cerebral 
hemispheres, expressed Hoxa2.  To confirm these findings, as well as further investigate 
Hoxa2 expression in cells of the OG lineage, an immunocytochemical analysis was 
performed on primary mixed glial cultures obtained from the cerebral hemispheres of 
newborn mice.  These cultures consisted of oligodendroglia that developed on top of an 
astrocytic monolayer.  The results showed that although Hoxa2 is expressed throughout 
OG development [Figure 3.3], the location of immunoreactivity, as well as the number of  
Hoxa2+ OGs changes with maturation.  In particular, Hoxa2 expression by OGs is 
primarily nuclear [Figure 3.3B,E], however, cytoplasmic staining is also observed at the 
pre-myelinating stage [Figure 3.3H].  The reason for this cytoplasmic staining is 
unknown, but it has been demonstrated with several other TFs (Armstrong et al. 1995; 
Wang et al. 2001).  Subsequently, there is a reduction in the number of Hoxa2+ 
myelinating OGs in comparison to Hoxa2+ pre-myelinating OGs [Figure 3.3H,K].   
Researchers recently identified a subfamily of bHLH TFs known as the Olig 
genes, whose members include Olig1, Olig2, and Olig3 (Lu et al. 2000; Takebayashi et al. 
2000; Zhou et al. 2000).  Olig1 and Olig2 are co-expressed by cells in the pMN domain 
of the developing spinal cord prior to PDGFαR (Lu et al. 2000; Zhou et al. 2000).  In 
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contrast, Olig3, which is transiently expressed in the embryonic CNS, is not co-expressed 
with Olig2 (Takebayashi et al. 2002).  Olig1+ and Olig2+ cells disperse throughout the 
spinal cord in a ventral to dorsal manner similar to that of PDGFαR+ cells (Zhou et al. 
2000).  Furthermore, double in situ hybridization histochemical analysis has also 
demonstrated that PDGFαR+ cells co-express Olig1 and Olig2 (Lu et al. 2000; Zhou et al. 
2000).  Hence, they are believed to be the earliest known markers of the OG lineage.  In 
addition, Olig1 and Olig2 continue to be expressed in OGs into adulthood (Lu et al. 2000; 
Takebayashi et al. 2000) 
In the present study, Olig2 was used to identify cells of the PDGFαR+ OPC 
lineage.  Although Olig2 initially specifies MN precursors at the early stages of spinal 
cord development, it is down-regulated as the cells differentiate (Novitch et al. 2001).  In 
addition, its mRNA is not expressed by GFAP+ astrocytes (Takebayashi et al. 2000), 
which are also found in the CNS.  These findings suggest that during periods of 
oligodendrogenesis in the spinal cord, Olig2 is specific to the OG lineage.  Olig2 was 
used as our OG marker instead of Olig1 for two reasons.  First, whereas the number of 
Olig2+ cells has been shown to be similar to that of PDGFαR+ cells, Olig1+ cells appear 
to out-number PDGFαR+ cells (Zhou et al. 2000).  Second, Olig2 has been shown to be 
critical for OG development in the spinal cord since OPCs and mature OGs fail to 
develop in its absence.  In contrast, PDGFαR+ cells appear on schedule in the absence of 
Olig1; however, there is a delay in the appearance of Sox10, MBP, and PLP/DM20 
expression in the white matter of the spinal cord (Lu et al. 2002). 
Research on OG development in the chick has led to the hypothesis that a separate 
OPC lineage may also arise from the Nkx2.2+ p3 domain.  Although all migratory Olig2+ 
cells co-express Nkx2.2 in the chick spinal cord, Nkx2.2+ cells that are weak or negative 
for Olig2 expression are found, and a portion of these cells express O4 (Fu et al. 2002; 
Zhou et al. 2001).  In addition, ~33% of A2B5+ glial restricted precursor cells, which 
were immunopurified from ~E13.5 rat spinal cords, have been shown to be 
immunoreactive for Nkx2.2.  These Nkx2.2+ cells are believed to be OGs because few β-
tubulin+ neurons and GFAP+ astrocytes express Nkx2.2 (Qi et al. 2001). 
In our study, immunohistochemical analyses were initiated at E12.5 (C16/T19) 
since Olig2 expression would be down-regulated in postmitotic MNs at this time.  In 
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addition, it corresponds to the emergence of PDGFαR expression in the vVZ (Sun et al. 
1998).  At this stage, Hoxa2 is expressed predominantly in the presumptive ventral horns 
[Figure 3.4A], which is in direct contrast to Nkx2.2 and Olig2, which are expressed in the 
vVZ [Figure 3.4B,C] of Hoxa2+/+ and Hoxa2+/- mice.  Hence, our results suggest that 
Hoxa2 expression in OPCs occurs following specification.  At later stages, overlapping 
expression profiles of Hoxa2 with Nkx2.2 and Olig2 in the mantle layer suggest that 
Hoxa2 is expressed by migratory OG cells.  Unfortunately, we were unable to 
conclusively show double labeling of Hoxa2 and Olig2 because both antibodies are rabbit 
polyclonals.  However, we were able to demonstrate co-expression of Hoxa2 by Nkx2.2+ 
cells [Figure 3.4K,L], which have been hypothesized to represent a separate population of 
OPCs (Fu et al. 2002), as well as co-expression of Nkx2.2 and Olig2 [Figure 3.7A–D].  
With continued maturation Hoxa2 expression in OGs appears to diminish as 
suggested by the finding that Nkx2.2+ and Olig2+ cells greatly out-number Hoxa2+ cells 
in the marginal layer [Figure 3.6A–C,E–G].  In contrast, Hoxa2+ cells out-number 
Nkx2.2+ and Olig2+ cells in the mantle layer, which supports the in vitro finding that cells 
in addition to OGs also express Hoxa2 [Figure 3.6A–C,E–G].  For example, Hoxa2 has 
been shown to be expressed by Islet1+ MNs and GFAP+ astrocytes (Hao et al. 1999) 
[Figure 3.4I,J].  Although Hoxa2 is not specific to the OG lineage, no TFs have been 
shown to be expressed exclusively by OGs. 
As most research regarding OG development has involved the analysis of the 
rodent spinal cord, we decided to focus our study on this area of the CNS.  Although Shh 
dependence and the ventral origin of OPCs are similar in the spinal cord and brain 
(Alberta et al. 2001; Hall et al. 1996; Ono et al. 1995; Orentas et al. 1999; Pringle and 
Richardson 1993; Tekki-Kessaris et al. 2001; Woodruff et al. 2001), differences in OG 
development in these regions have emerged.  For example, Nkx2.2+/Olig2+ cells are 
found in the vVZ of the chick spinal cord prior to emigration (Fu et al. 2002; Zhou et al. 
2001).  In contrast, in the chick hindbrain only Nkx2.2+ cells are found in the vVZ at the 
onset of oligodendrogenesis with Olig2 expression only evident in migratory cells (Fu et 
al. 2002).  Takebayashi et al. (2000) have also shown discrepancies in Olig1 and Olig2 
expression in the murine embryonic brain versus spinal cord.  In particular, in the murine 
embryonic brain Olig2 displays a broader expression domain than Olig1.  In addition, it 
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was shown that in certain brain regions numerous Olig2+ cells are found, few of which 
co-express Olig1 or CNP (Takebayashi et al. 2000), the latter being a myelinating glial 
cell specific enzyme.  Takebayashi et al. (2000) concluded that Olig2 may not be limited 
to OGs in the brain and, hence, may play a role in this region distinct from Olig1.  This 
conclusion is supported by the study of Lu et al. (2002), who found that in the hindbrain 
and areas of the forebrain, the early stages of OG development proceed largely unaltered 
in the absence of Olig2.  Hence, Olig2 does not appear to play a critical role in OG 
development in certain brain regions.  These discrepancies may be partially due to 
differing expression profiles of regulatory TFs by cells of the OG lineage along the 
anterior-posterior axis, such as the Hox genes. 
One potential role for Hoxa2 in OG development may be via its transcriptional 
regulation of NCAM.  NCAM, a cell surface glycoprotein, exists as three prominent 
protein isoforms (120, 140, 180 kD), which are encoded by four predominant transcripts 
arising from alternative splicing and polyadenylation sites of a single gene (Barbas et al. 
1988).  Examination of the 5′ end of the NCAM gene has revealed two homeodomain 
binding sites (HBSs: I and II) that have the potential to be regulated by Hox genes 
(Hirsch et al. 1990; Jones et al. 1993; Jones et al. 1992).  Hoxc6 (Hox3.3) and Hoxb9 
(Hox2.5) have previously been shown to significantly enhance chloramphenicol 
acetyltransferase (CAT) activity via NCAM HBS (Jones et al. 1993; Jones et al. 1992).  
In contrast, Hoxb8 (Hox2.4) decreases HBS-I+/ HBS-II+- directed CAT activity, as well 
as Hoxb9-enhanced activity (Jones et al. 1992).  Hence, NCAM promoter activity may be 
the result of the combined actions of numerous Hox genes.  Furthermore, mutations in 
NCAM HBSs results in alterations in β-galactosidase reporter gene expression patterns in 
the embryonic spinal cord in vivo (Wang et al. 1996). 
NCAMs undergo a variety of post-translational modifications, including 
glycosylation by enzymes such as sialyltransferase (Breen et al. 1987; Breen and Regan 
1988; Finne et al. 1983; Rothbard et al. 1982); the activity of this enzyme is 
developmentally regulated (Breen et al. 1987; Breen and Regan 1988).  As a result, 
NCAMs vary in their sialic acid content, with the highest evident in PSA-NCAM (Breen 
et al. 1987; Breen and Regan 1988; Finne et al. 1983; Rothbard et al. 1982).  Sialic acid 
content has been demonstrated to be inversely related to NCAM homophilic binding 
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properties, such as adhesion and rate of aggregation (Hoffman and Edelman 1983; Sadoul 
et al. 1983).  Hence, Hoxa2 could potentially enhance or repress transcription of the 
NCAM gene, which would subsequently give rise to embryonic or adult forms, depending 
on the activity of sialyltransferase.  The expression of either the embryonic or adult form 
of NCAM by oligodendroglial cells may affect their motility and maturation (Gard et al. 
1996; Wang et al. 1994). 
Comparison of Nkx2.2, Olig2, and Pax6 expression profiles obtained from spinal 
cord sections of at least three E12.5, E14.25, E16, and E18 mice in both the presence 
(Hoxa2+/+ and Hoxa2+/-), and the absence of Hoxa2 (Hoxa2-/-) failed to reveal major 
differences.  These results suggest that Hoxa2 does not appear to be critical for the OG 
specification and early maturation in the murine spinal cord.  One potential reason for this 
could be that other Hox genes may compensate for the loss of Hoxa2 in the developing 
spinal cord.  Analyzing OG development in the more anterior regions of the CNS in 
Hoxa2-/- mice, where Hox gene compensation is less likely, should demonstrate whether 
discrepancies in early stages of OG development exist in the absence of the Hoxa2 gene. 
The regulatory mechanisms controlling oligodendrogenesis, once elucidated, will 
guide the development of therapeutic approaches to treating demyelinating diseases such 
as MS.  MS is an inflammatory disease of the CNS characterized by focal areas of 
demyelination that appear to be immune driven (Lucchinetti et al. 1999; Ozawa et al. 
1994; Prineas et al. 1993a; Prineas et al. 1993b; Raine 1997a; Raine 1997b; Storch et al. 
1998).  The OG progenitors are the most motile of the OG lineage cells (Gansmuller et al. 
1991) that are recruited to areas of demyelination over only a very limited area (Franklin 
and Blakemore 1997).  There are three potential sources of remyelinating OGs: adult 
progenitors endogenous to or adjacent to the lesion, or mature OGs that have survived the 
demyelinating event (Levine et al. 2001).  Remyelination, which is characterized by 
axons exhibiting thin myelin sheaths, fails with disease progression (Brück et al. 1994; 
Ozawa et al. 1994; Prineas et al. 1993a; Prineas et al. 1993b; Prineas et al. 1989; Raine 
and Wu 1993).  The reason that remyelination fails remains unknown, but it may include 
errors in migration or maturation.  PSA-NCAM is one of several molecules that appear to 
be important for the migratory ability of OG progenitor cells (Barral-Moran et al. 2003).  
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Hence, elucidation of the transcriptional control by Hox genes of molecules involved in 
these processes, such as NCAMs, will help determine ways to enhance remyelination. 
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Preamble to Chapter 4 
The purpose of this chapter is to determine if other Hox TFs could potentially 
compensate for Hoxa2 in the spinal cord in its absence.  Given the fact that Hoxa2 is one 
of 39 murine Hox genes, which exhibit extensive overlapping expression profiles in the 
spinal cord, I decided to examine the expression of an additional Hox TF, Hoxb4, during 
OG development.   
 
(Manuscript published, Appendix C) 
Nicolay DJ, Doucette JR, Nazarali AJ. 2004b. Hoxb4 in oligodendrogenesis. Cell Mol 
Neurobiol 24:357-366. 
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4.0 Hoxb4 IN OLIGODENDROGENESIS (Manuscript published) 
 
 4.1 Summary 
1. Although recent advances have provided insight into the transcriptional control of 
OG development, little information exists on the role of clustered Hox genes in 
this process.  The aim of this study is to examine the expression profile of Hoxb4 
in the oligodendroglial lineage. 
2. Immunocytochemical analysis of primary mixed glial cultures demonstrated that 
Hoxb4 is expressed throughout OG development, being co-expressed with 
oligodendroglial markers, A2B5, O4 (97%), GalC (91%), and MBP (93%). 
3. Immunohistochemical analysis of transverse spinal cord sections demonstrated 
diffuse expression of Hoxb4 throughout the spinal cord at E12.5 (C16/T19), after 
which expression is confined primarily to the presumptive gray matter. 
4. At E14.25 (C19C/T21), Olig2+ cells begin to migrate out from the vVZ into the 
presumptive gray matter. These results suggest that Olig2+ cells may co-express 
Hoxb4 since it is expressed throughout this region. 
5. The expression of Hoxb4 by cells of the OG lineage indicates that it could play a 
role in OG maturation. 
4.2 Introduction 
OGs are myelinating cells of the CNS.  In the murine spinal cord PDGFαR+ OPCs 
first appear at approximately E12.5 in a distinct region of the vVZ (Sun et al. 1998).  This 
region has been shown to correspond to the pMN domain, which is defined by the 
expression of the bHLH gene Olig2 (Novitch et al. 2001; Zhou et al. 2000).  Although 
Olig2 initially specifies MN precursors at early stages of spinal cord development, it is 
down-regulated as these precursor cells differentiate into MNs (Mizuguchi et al. 2001; 
Novitch et al. 2001; Zhou et al. 2000).  Olig2 expression that persists in the pMN domain 
after MNs are generated specifies cells of the OG lineage (Lu et al. 2000; Zhou et al. 
2000).  Initially only a few OPCs are found on each side of the central canal but these 
cells subsequently proliferate and migrate first laterally then dorsally to populate the 
entire cross-sectional area of the spinal cord (Lu et al. 2000; Zhou et al. 2000). 
Analysis of glial cell differentiation in vitro has shown that OG development  
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progresses through a number of distinct stages, which are characterized by the expression 
of specific cell surface markers [Figure 4.1].  During early stages of differentiation, 
characterized by A2B5 and/or O4 staining, cells are actively proliferating and migratory. 
 Loss of these traits signals terminal differentiation of the OG lineage, which is 
characterized by the expression of GalC and, subsequently, the expression of myelin 
proteins (Abney et al. 1983; Asou et al. 1995; Bansal et al. 1989; Duchala et al. 1995; 
Fok-Seang and Miller 1994; Miller 1996; Noble et al. 1988; Raff et al. 1985; Raff et al. 
1983; Sommer and Schachner 1981). 
The timing of OG differentiation is believed to be dependent on an intrinsic clock 
that counts cell divisions driven by mitogens, such as platelet-derived growth factor 
(PDGF) (Raff et al. 1985; Raff et al. 1988).  Differentiation is further modified by 
hydrophobic signals, such as RA or thyroid hormone (Barres et al. 1994; Ibarrola et al. 
1996; Noll and Miller 1994).  Potential downstream targets of RA signaling are the Hox 
genes, which are characterized by a 180 base pair homeobox (Gould et al. 1998; 
McGinnis et al. 1984a; McGinnis et al. 1984b).  This nucleotide sequence encodes a 60 
amino acid homeodomain that contains a helix-turn-helix motif (Kissinger et al. 1990; 
McGinnis et al. 1984a; McGinnis et al. 1984b). Hence, Hox TFs can regulate the 
expression of downstream effector genes by binding to specific nucleotide sequences 
through the homeodomain (Han et al. 1989; Hoey and Levine 1988; Kissinger et al. 
1990).  Hoxb4 is one of 39 mouse and human Hox/HOX genes that are organized into 
four clusters (Hox A, B, C, D) located on different chromosomes (Favier and Dollé 1997; 
Graham et al. 1989; Scott 1992).  In situ hybridization histochemistry conducted by 
Gaunt et al. (1989) and Graham et al. (1988, 1989) demonstrated that Hoxb4 mRNA is 
expressed in numerous tissues, including the CNS with the anterior limit of expression 
extending into the myelencephalon.  We have analyzed Hoxb4 expression patterns during 
murine OG development in cell cultures and in spinal cord sections.  Our results 
demonstrate that Hoxb4 is expressed by cells of the OG lineage. 
4.3 Materials and Methods 
4.3.1 Primary glial cultures 
Cerebral hemispheres from newborn mice were dissected in DMEM/F12/10% 
FBS.  Single cell suspensions, obtained by forcing diced tissue through a 75 μm Nitex 
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Figure 4.1 Illustration depicting oligodendrocyte development. Oligodendrocytes 
progress through four distinct stages which are characterized by unique 
morphological and antigenic phenotypes 
 
(Abney et al. 1983; Asou et al. 1995; Bansal et al. 1989; Duchala et al. 1995; Fok-Seang 
and Miller 1994; Miller 1996; Noble et al. 1988; Raff et al. 1985; Raff et al. 1983; 
Sommer and Schachner 1981) 
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mesh, were plated in DMEM/F12/10% FBS for 4 days to allow adherence of the cells.  
They were then cultured for two 1-week periods, respectively, in a B104 conditioned 
medium and a low serum-containing (0.3% FBS) growth medium (GP medium) used 
previously by Gard and Pfeiffer (1990) and by Doucette and Devon (1994); this OG 
growth medium was supplemented with 10 ng/ml basic FGF.  The growth medium was 
changed every 4 days. 
4.3.2 Immunocytochemistry 
The following primary antibodies were utilized for immunocytochemistry: anti-
Hoxb4 (BabCO, CA; 1:500), A2B5 (ATCC; 1:10), O4 (hybridoma; Sommer and 
Schachner, 1981; 1:10), anti-GalC (BRD1 hybridoma; Ranscht et al. 1982; 1:20), and 
anti-MBP (Sternberger Monoclonals; 1:800).  The cell cultures were double 
immunostained with Hoxb4 and A2B5, O4, or GalC using the live staining method 
described by Doucette and Devon (1994) and Hao et al. (1999) but with an incubation 
period of 30 min at 37°C for A2B5, O4, and anti-GalC.  The secondary antibodies used 
included a goat anti-mouse IgM FITC (Sigma, ON; 1:100); a donkey anti-mouse IgG 
FITC (BIO/CAN Scientific, ON; 1:50); and a goat anti-rabbit IgG CY3 (BIO/CAN 
Scientific, ON; 1:200).  Between incubations cultures were washed two times for 5 min 
each in PBS.  Double immunostaining for Hoxb4 and MBP was done using the procedure 
described in Doucette and Devon (1994) with two modifications: (1) permeabilization 
and blocking were combined with a 30 min incubation in 3% SM/0.1% TX; (2) the 
primary antibodies were diluted in 1% SM/0.03% TX.  The nuclei in all cell cultures 
were stained using HOECHST dye. 
4.3.3 Immunohistochemistry 
C57 black mouse embryos were staged according to the Carnegie (Butler and 
Juurlink 1987) and Theiler (1972) staging systems.  The E and corresponding C/T stages 
utilized were E12.5 (C16/T19), E14.25 (C19+/T21), E16 (C23/T23), and E18 (T25); the 
Carnegie staging system does not go higher than stage 23.  Once the embryos were staged, 
they were fixed by immersion in 4% formaldehyde at 4°C for 24–48 h depending on their 
age, and cryostat sections (8 μm) were cut through the upper thoracic level as described 
by Hao et al. (1999).  The following primary antibodies were used: polyclonal anti-Olig2 
(E12.5, 1:4000; rest of stages, 1:2000, gift of Dr Hirohide Takebayashi) and anti-Hoxb4 
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(E12.5, 1:3000; rest of the stages, 1:2000).  Immunohistochemical staining was 
performed using the procedure described by Hao et al. (1999), with the following 
modifications: PBS washes were 8 min instead of 10 min; 3% SM/0.1% TX 
block/permeabilizations were 20 min versus 30–60 min; and incubation in the secondary 
antibody was 30 min versus 45 min. 
4.4 Results and Discussion 
Immunocytochemistry was conducted in this study as it allowed for a thorough 
investigation of Hoxb4 expression throughout OG development.  The cerebral 
hemisphere cultures analyzed consisted of oligodendroglia that developed on top of an 
astrocytic monolayer.  Although the anterior limit of Hoxb4 expression has been shown 
to be the mid-myelencephalon (Gaunt et al. 1989; Graham et al. 1989; Graham et al. 
1988), Hoxb4 is expressed by cells obtained from murine cerebral hemispheres.  Similar 
findings have been observed with Hoxa2 where its expression was subsequently shown to 
extend to the forebrain (Hao et al. 1999; Tan et al. 1992; Wolf et al. 2001).  Furthermore 
our laboratory has previously demonstrated that Hoxa2 is expressed by O4+ pro-OGs 
obtained from E15 mouse cerebral hemispheres (Hao et al. 1999). 
Hoxb4 is expressed by the majority of cells throughout OG development.  Greater 
than 90% of the cells that express O4 (97%), GalC (91%), and MBP (93%) also co-
express Hoxb4 [Figure 4.2].  The percentage of A2B5+/Hoxb4+ cells was not determined 
because A2B5 labels O-2A precursor cells, which can give rise to either OGs or type 2 
astrocytes depending on culture conditions (Raff et al. 1983) and, therefore is not specific 
to the OG lineage.  Expression of Hoxb4, which is a TF, is primarily nuclear [Figure 4.2B, 
E, K], however, weak cytoplasmic staining is observed occasionally in GalC+ cells 
[Figure 4.2H].  The reason for this is unknown but similar observations have been 
reported with several other TFs (Armstrong et al. 1995; Wang et al. 2001). 
Although Hoxb4 is expressed throughout OG development, it is not specific to the 
OG lineage. This is demonstrated by the fact that the number of Hoxb4+ cells is greater 
than that of OG markers in primary mixed glial cultures [Figure 4.2].  Furthermore, 
Hoxb4 RNA has been shown to be expressed in various embryonic tissues, including 
hindbrain, spinal cord, stomach, lung, kidneys, and prevertebra (Gaunt et al.1989; 
Graham et al. 1988). 
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Figure 4.2 Hoxb4 expression pattern throughout oligodendrocyte development. 
 
Primary glial cell cultures from neonatal murine brain were grown in culture for 
18 days. Double immunofluorescent staining was conducted with each of the four OG 
markers [A2B5 (A), O4 (D), GalC (G), and MBP (J)] and Hoxb4 (B, E,H, K). Cells were 
visualized utilizing nuclear fluorescent HOESCHT counterstain. Each row illustrates 
micrographs obtained from individual filters [fluorescein (A, D, G, J), rhodamine (B, E, 
H, K), and DAPI (C, F, I, L)] of the same field. Arrows demarcate representative Hoxb4 
immunoreactive cells. The insets at the top right corner of the rhodamine micrographs (E, 
H, L) show the percentage of O4+, GalC+, and MBP+ cells that are immunoreactive for 
Hoxb4, respectively. [Percentages depict averages calculated from 2 to 3 coverslips in 
which 100–150 OGs were counted.] Bar = 100 μm for Fig. (A)–(L). 
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Hoxb4 expression was investigated in transverse spinal cord sections at stages 
E12.5 (C16/T19) to E18 (T25).  At E12.5 (C16/T19) expression is diffuse being slightly 
more intense in the presumptive ventral horns [Figure 4.3A].  At later stages of 
development (E14.25–E18) Hoxb4 is also found in the presumptive dorsal horns [Figure 
4.3C, E, G].  Previously, Graham et al. (1988, 1991) and Gaunt et al. (1989), had 
determined by in situ hybridization histochemistry the expression patterns of Hoxb4.  
Although only one micrograph of a 12.5 dpc transverse spinal cord section illustrated 
Hoxb4 expression, it has been stated to exhibit a dorsal-ventral expression pattern similar 
to that of the other Hoxb genes (Graham et al. 1991; Graham et al. 1988).  At 10.5 dpc, 
the expression of Hoxb genes is dispersed throughout the entire spinal cord (Graham et al. 
1991; Graham et al. 1988).  In our immunohistochemical analysis, immunoreactivity 
appears to be slightly greater in the presumptive ventral horns [Figure 4.3A].  In situ 
hybridization histochemistry has also shown that Hoxb genes exhibit strong expression in 
the dorsal spinal cord at 12.5 dpc after which expression appears in the ventral spinal 
cord at 14.5 dpc (Graham et al. 1991).  In our study, Hoxb4 is found to be expressed 
throughout the presumptive gray matter at E14.25 (C19+/T21) [Figure 4.3C].  The Hoxb4 
gene has been shown to give rise to multiple transcripts (Graham et al. 1988); it is not 
known if all yield a translated product.  The probe utilized by Graham et al. (1991) did 
not distinguish between them; therefore, differences in expression patterns may exist for 
the individual transcripts. 
There are currently very few immunohistochemical markers available for studying 
OG development in vivo.  Therefore, OG development in the spinal cord was followed by 
analyzing Hoxb4 expression in relation to that of Olig2.  Evidence that supports the use 
of Olig2 as an OG marker is threefold.  First, Olig2+ cells, which are initially found in 
pMN domain, disperse throughout the spinal cord as previously described for PDGFαR 
(Lu et al. 2000; Zhou et al. 2000).  Furthermore, it has been shown that the number of 
Olig2+ cells is similar to that of PDGFαR+ cells (Zhou et al. 2000).  Second, Olig2 is not 
co-expressed with the astrocytic marker GFAP (Takebayashi et al. 2000).  Finally, Olig2 
appears to be critical for OG development since in its absence OPCs and differentiated 
OGs fail to develop in the spinal cord (Lu et al. 2002).  Therefore, Olig2 is the earliest 
known marker of OG development since its expression precedes that of PDGFαR by 
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Figure 4.3 Expression of Hoxb4 in the embryonic spinal cord in relation to the 
oligodendrocyte marker Olig2. 
 
Transverse sections of the thoracic spinal cord at E12.5 (C16/T19), E14.25 (C19C/T21), 
E16 (C23/T23), and E18 (T25) were immunolabeled with Hoxb4 (A, C, E, G) and Olig2 
(B, D, F, H).  At E12.5 when Olig2+ OPCs (B) were localized to the vVZ Hoxb4 (A) was 
diffusely expressed throughout the spinal cord, being slightly more intense in the ventral 
horns. Also at later stages of embryonic development Hoxb4’s expression pattern (C, E, 
G) displayed domains of overlap with Olig2 (D, F, H). The micrographs are 
representative of sections obtained from approximately four embryos from at least two 
different litters. Bar = 100 μm for Fig. (A)–(H). 
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approximately 1–1.5 days (Zhou et al. 2000).  Immunohistochemical analysis in this 
report has focused primarily on the ventral spinal cord due to the predominant expression 
of Olig2 in this region during embryonic development.  We were unable to demonstrate 
co-expression of Hoxb4 with Olig2 since both antibodies are rabbit polyclonals. 
Immunohistochemical analyses were initiated at E12.5 (C16/T19) since at this 
stage Olig2 expression has been down-regulated in differentiated MNs and PDGFαR+ 
OPCs have arisen in the vVZ.  Unlike Olig2, which is localized to the vVZ [Figure 4.3B], 
Hoxb4 stained nuclei are diffusely distributed at this stage, with immunoreactivity 
slightly more intense in the presumptive ventral horns [Figure 4.3A].  The Hoxb4+ cells 
in the ventral horns are most likely neurons because neuron-specific β-tubulin is also 
expressed in these areas [Appendix B].  However, the results suggest that Hoxb4 may be 
expressed by OPCs in vivo since Hoxb4 stained nuclei are diffusely distributed 
throughout the ventricular zone.  From E14.25 (C19+/T21) onward, Hoxb4 is expressed 
throughout the presumptive gray matter [Figure 4.3C,E,G].  Beginning at E16 (C23/T23), 
some Hoxb4+ cells are also observed in the presumptive white matter, increasing 
somewhat in numbers at E18 (T25) [Figure 4.3E,G].  Olig2+ cells begin to accumulate in 
the presumptive gray matter at ~E14.25 (C19+/T21) with occasional immunoreactive 
cells found in the presumptive white matter [Figure 4.3D].  This migratory pattern 
continues at later stages with an increasing number of immunoreactive cells accumulating 
in the presumptive white matter [Figure 4.3F,H].  Therefore, these results suggest that a 
population of Olig2+ cells may co-express Hoxb4.  However, the Olig2+ cells out-number 
Hoxb4+ cells in the presumptive white matter [Figure 4.3G,H].  In addition, the number 
of Hoxb4+ cells in transverse spinal cord sections is greater than that of the Olig2+ cells, 
which lends support to our cell culture findings that cells other than OGs express this Hox 
protein.  
One potential role of Hoxb4 in OG development may be as a downstream effector 
in the RA pathway.  The role of RA in OG development has previously been described.  
In particular, Noll and Miller (1994), utilizing E14–18 rat spinal cord cultures, found that 
RA (1 μM) inhibits maturation of OPCs.  Interestingly, Barres et al. (1994) showed that 
low concentrations of RA (10 nM) applied to P8 rat optic nerve cultures promotes 
differentiation.  Although these results initially appear to be contradictory it could be 
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hypothesized that they represent ends of the same developmental pattern.  Hence, high 
concentrations of RA early on in development could inhibit OG differentiation, allowing 
OPC distribution throughout the spinal cord (Noll and Miller 1994).  Then as OG 
development proceeds and RA levels diminish, cells could be facilitated to differentiate.  
Since RA has been shown to regulate Hoxb4 expression in hindbrain (Gould et al. 1998), 
it has the potential to affect expression in OGs.  Now that it has been demonstrated that 
Hoxb4 is expressed by cells of the OG lineage it will be interesting to determine whether 
RA exerts its effects on OG development via Hox genes, such as Hoxb4. 
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Preamble to Chapter 5 
As the anterior boundary of most Hox genes is found in the hindbrain or spinal cord, it 
was decided to look at a more anterior region which would be less likely to have 
compensatory mechanisms at play.  Hoxa2 is expressed in the telencephalon, which 
exhibits several similarities to the spinal cord in regards to the transcriptional control of 
oligodendrogenesis.  Therefore, I investigated Hoxa2 expression, as well as its potential 
role(s) in OG development in this CNS region. 
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5.0 ROLE OF Hoxa2 IN TELENCEPHALIC MYELINATING GLIAL CELLS 
 
5.1 Summary 
Oligodendroglial cells express a dynamic combination of TFs as they progress 
through the various stages of development.  Although the TF Hoxa2 is known to be 
expressed throughout OG development in vitro [Section 3.4.1, pg. 51], its role in this glial 
cell is currently unknown.  Therefore, the aim of this study was to examine Hoxa2 
expression and function in oligodendroglial cells in the telencephalon.  Hoxa2 is 
expressed by oligodendroglial cells in this region; however, it does not appear to be 
required for OG specification or early maturation in the telencephalon.  
Immunocytochemical analysis was conducted on WT and Hoxa2-over-expressing CG4 
cells to determine Hoxa2’s effect on oligodendroglia differentiation.  The results show 
that after four days CG4 cultures over-expressing Hoxa2 contain significantly fewer O4+ 
and GalC+ cells than WT CG4 cultures.  In order to determine the mechanism by which 
Hoxa2 could affect CG4 cell differentiation, we examined the expression of PSA-NCAM, 
which may impair this process.  Contrary to our expectation, however, the results show 
that Hoxa2-Sense (Hoxa2-S) CG4 cultures contain significantly fewer PSA-NCAM+ cells 
compared to WT.  This finding suggests that Hoxa2’s effect on CG4 cell differentiation is 
independent of PSA-NCAM.  However, as PSA-NCAM is known to affect other aspects 
of OG development, such as migration, this result suggests that Hoxa2 could also play 
other roles in oligodendroglia development.        
5.2 Introduction 
In the developing telencephalon, OPCs arise in three distinct waves: first from the 
MGE/AEP, and then, subsequently, from the LGE/CGE, and, finally, from the dorsal 
telencephalon (Kessaris et al. 2006).  OPCs must proliferate and migrate out from these 
domains in order to populate specific telencephalic regions (Kessaris et al. 2006) [Table 
2.1].  In addition, they must progress through three subsequent stages of 
development―the pro-OG, pre-myelinating OG, and mature myelinating OG stages 
[Figure 2.4]― in order to myelinate axons in this region.  As pre-myelinating OGs do not 
actively proliferate (Fok-Seang and Miller 1994) or migrate (Noble et al. 1988), the 
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proper progression of oligodendroglial cells through the various stages of development is 
critical to ensure normal myelination and, hence, CNS function.   
Oligodendroglial cells express a dynamic combination of TFs as they progress 
through the various stages of oligodendrogenesis [Figure 2.4].  However, the function(s) 
of most of these TFs remains to be elucidated.  One such TF is Hoxa2, which is one of 39 
mouse and human Hox/HOX genes that are organized into four clusters (Hox A, B, C, D) 
located on different chromosomes (Akin and Nazarali 2005; Favier and Dollé 1997; 
Santagati and Rijli 2003; Scott 1992).  Our initial attempts to elucidate Hoxa2’s role in 
oligodendrogenesis in the embryonic spinal cord failed to reveal any noticeable 
differences in OG specification [Section 3.4.2, pg.52] or early maturation [Section 3.4.3, 
pg. 56] in Hoxa2 transgenic knockout mice (Nicolay et al. 2004a).  However, as Hoxa2 is 
one of 39 murine Hox genes, which exhibit extensive overlapping expression profiles in 
the spinal cord (Akin and Nazarali 2005), other Hox genes could compensate for Hoxa2 
in this CNS region in its absence.  As a result, in the present study, we have investigated 
Hoxa2’s expression and function during oligodendrogenesis in the telencephalon.    This 
region was chosen based on the fact that Hoxa2 mRNA and protein is expressed in the 
telencephalon (Tan et al. 1992; Wolf et al. 2001), as well as by oligodendroglial cells 
found in primary mixed glial cultures obtained from this region (Hao et al. 1999; Nicolay 
et al. 2004a) [Section 3.4.1, pg. 51].  Furthermore, as the expression limit of most Hox 
genes is in the spinal cord or hindbrain (Akin and Nazarali 2005), the likelihood of 
compensatory effects by other Hox genes should be minimal in this CNS region.  In turn, 
the telencephalon exhibits several similarities with the spinal cord in regards to the 
transcriptional control of oligodendrogenesis.  The results of this study confirm that 
Hoxa2 is expressed by early oligodendroglial cells in the embryonic telencephalon.  In 
addition, they suggest that Hoxa2 may affect multiple aspects of OG development, 
including differentiation.  
5.3 Materials and Methods 
 5.3.1 Hoxa2 transgenic and CD1 mice 
Hoxa2+/+, Hoxa2+/-, and Hoxa2-/- C57 black mice (Gendron-Maguire et al., 
1993) were acquired by timed heterozygous matings. Swiss CD1 and C57 black mice 
were staged according to the Carnegie (Butler and Juurlink, 1987) and Theiler (1972) 
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staging systems.  The E and corresponding C/T stages used were as follows: E13.5 
(C18/T20), E14.25 (C19+/T21) and E18 (T25); the Carnegie staging system does not go 
beyond stage 23. Although Hoxa2-/- embryos can be identified by external ear 
deformities at E14.25 (C19+/T21) onward, genotypes were confirmed by PCR analysis 
(Gendron-Maguire et al., 1993).  The E13.5 (C18/T20) and E14.25 (C19+/T21) mouse 
embryos were fixed by immersion in 4% formaldehyde, which was made from 
paraformaldehyde, at 4°C.  The E18 (T25) mouse embryos were perfused with 4% 
formaldehyde and subsequently post-fixed for 1 day.  All embryos were then rinsed and 
stored in 20% sucrose until they were sectioned.  Cryostat sections (8μm) were collected 
on gelatin-coated coverslips and allowed to dry for at least 1 h prior to staining.  In the 
case of the E18 (T25) mice, the sections were stored at -20°C until they were processed 
via immunohistochemistry.  
 5.3.2 In situ hybridization histochemistry and immunohistochemistry 
For in situ hybridization histochemistry (conducted by a former PhD student 
Louise Wolf), Swiss CD1 mice were fixed with 4% formaldehyde, embedded in OCT, 
and sectioned utilizing a cryostat.  The sections (8 μm) were subsequently hybridized 
with Hoxa2 and Hoxd1 probes as described in Hao et al. (1999) and Wolf et al. (2001).   
For immunohistochemical analysis the following primary antibodies were used: 
anti-Olig2 (a kind gift from Dr. Hirohide Takebayashi (Takebayashi et al., 2000); 
1:6000), anti-Hoxa2 (Hao et al., 1999; 1:1000), anti-Pax6 (Developmental Studies 
Hybridoma Bank; 1:400) and anti-PDGFαR (BD Pharminigen™; 1:100).  The protocol 
utilized for double labeling sections for Olig2 and Pax6 was previously described in 
Nicolay et al. (2004a) [Section 3.3.2, pg. 50].  For immunofluorescent double labeling of 
Hoxa2 with PDGFαR, sections were washed twice in PBS for 8 min, followed by a 2 min 
incubation in Digest-All (Zymed, San Francisco, CA).  Subsequently, the sections were 
washed for 5 min in PBS and then blocked/permeabilized in 3% SM/0.1% TX for 20 min.  
They were then incubated overnight in primary antibodies diluted in 1% SM/0.03% TX.  
After two 8-min PBS washes, sections were incubated for 3 h in secondary antibodies 
(goat anti-rat IgG Alexa 594 (1:400) and goat anti-rabbit IgG Alexa 488 (1:200) 
[Invitrogen, Burlington, ON]), which were also diluted in 1% SM/0.03% TX.  This was 
followed by an 8-min incubation in Hoechst fluorescent nuclear dye.  Following these 
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incubations the sections were washed twice for 8 min each in PBS.  Finally, the 
sections/coverslips were mounted with Prolong® Gold antifade reagent. 
 5.3.3 Plasmid construction and transfection  
The protocol described below was conducted by a former MSc student Ms. 
Monica Wang (MSc Thesis 2007).  
The sense cDNA of Hoxa2 was amplified from the pRSV-Hoxa2 vector via PCR 
utilizing the Hoxa2 primers listed in Table 5.1.  The PCR product was then double 
digested with SalI and ClaI and cloned into the SalI/ClaI site of the pTRE-2hyg2-Myc 
vector (Clontech, Mountain View, CA).  The construct was confirmed by DNA sequence 
analysis. 
All plasmids used for transfection were purified utilizing the EndoFree Plasmid Maxi Kit 
(Qiagen, Mississauga, ON).  After purification, 30 μg of the pTet-off vector (kind gift of 
Dr. Peter Dickie, University of Alberta) was linearized with HindIII, followed by phenol 
extraction and ethanol precipitation.  Linearized plasmid (10 μg) was then added to 30 μl 
of 2.5 M CaCl2 and made up to a total volume of 150 μl with sterile water.  The DNA-
Ca3(PO4)2 precipitate was prepared by adding the above mixture dropwise to an equal 
volume of 2x HEPES-buffered saline while vortexing.  After 15 min, this mixture was 
then slowly added to the growth medium [DMEM supplemented with 50 µg/ml apo-
transferrin, 10 pg/ml D-biotin, 50 ng/ml sodium selenite, 5 µg/ml insulin, 1% 
antibiotic/antimycotic and 30% B104 conditioned medium] in a 60 mm dish, which had 
been plated the previous day with CG4 cells and was 80% confluent.  The cells were 
incubated with the DNA precipitate in a humidified incubator in 5% CO2 at 37°C for 12 
h.  The cells were then rinsed with PUCKs [0.1% glucose, 0.8% sodium chloride, 0.04% 
potassium chloride, 0.006% potassium phosphate, 0.005% sodium phosphate and 0.002% 
phenol red in triple distilled water] and maintained in growth medium for two days.  
Subsequently, stable CG4-tTA clones were selected in the presence of 300 μg/ml G418 
(Sigma) in 100 mm dishes.  The isolated clones were then examined for their ability to 
induce gene expression via transiently transfecting the cells with the control vector 
pTRE-2hyg2-Myc-Luc (Clontech, Mountain View, CA) utilizing the calcium phosphate 
precipitate method.  The clone exhibiting the highest luciferase activity was chosen for 
the subsequent transfection.  As such, the CG4-tTA cells were plated onto 100 mm dishes 
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Table 5.1 Primers utilized for PCR analysis 
Gene Forward Primer  Reverse Primer 
β-actina 5′-ATTGTAACCAACTGGGACG-3′ 5′-TTGCCGATAGTGATGACCT-3′ 
Hoxa2d 5′-ATCGATAGAAGGCCATGAATTACG-3′ 5′-TCGTCGACTTAGTAATTCAGATGC-3′ 
Hoxa2* 5′-CTGGATGAAGGAGAAGAAGGC-3′ 5′-CGGTTCTGAAACCACACTTTC-3′ 
MBPb 5′-CTATAAATCGGCTCACAAGG-3′ 5′-AGGCGGTTATATTAAGAAGC-3′ 
PSTc 5′-ACTGAGGAGCACCAAGAGACGC-3′ 5′-CCATGAAGGCAGGAATCCAAAGG-3′ 
 
a Hu et al. (2004) 
b www.hcnr.med.harvard.edu/programs/atrc/reagent_details/MBP%20Rat.pdf 
c Soares et al. (2000); PST-Polysialyltransferase 
d Tan et al. (1992) 
* designed by Dr. Shaoping Ji; utilized for RT-PCR analysis, Appendix B   
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at a density of 8 x 105 cells/dish two days prior to the transfection.   The cells were 
transfected with the recombinant plasmid pTRE-2hyg2-Myc-Hoxa2-S via 
electroporation, which was carried out using the Gene Pulser and a 0.4 cm electroporation 
cuvette (Bio-Rad Laboratories, Hercules, CA).  The cells were harvested and collected in 
electroporation medium [1:1 HEPES-buffered saline and growth medium containing 
twice the concentration of insulin] at a concentration of 5 x 106 cells/ml.  Subsequently, 
20 μg of DNA was diluted in 20 μl of sterile water and added to 0.78 ml of cell 
suspension.  Electroporation was performed at RT with a charge of 0.34 kV at a 
capacitance of 250 μF.  Following electroporation the cells were allowed to sit for 10 min 
prior to plating them in recovery medium [DMEM supplemented with 2 mM sodium 
pyruvate, 5% FBS, 5 µg/ml insulin, and 1% antibiotic/antimycotic] onto poly-D-lysine-
coated culture dishes.  After 2 h the medium was then changed to growth medium.  
Subsequently, stable clones were selected in the presence of 200 μg/ml Hygromycin B 
(Sigma, ON) and 100 μg/ml G418.    
  5.3.4 CG4 cells 
Hoxa2-S and WT CG4 cells were initially expanded in growth medium.  
Subculturing involved rinsing the cells first with PUCKs [Section 5.3.3, pg. 82] followed 
by an approximately 20 min incubation in harvesting medium [EDTA and PUCKs  (1:1) 
supplemented with 25 mM glucose, 2 mM sodium pyruvate, 10 mM HEPES, 1.25 μg/ml 
insulin, and 1% antibiotic/antimycotic].  The cells were then collected and centrifuged at 
800 rpm for 10 min.  Subsequently, they were resuspended and plated in recovery 
medium.  At the beginning of the trial, both Hoxa2-S and WT CG4 cells were plated at a 
density of 100,000 cells/well onto poly-D-lysine-coated wells or coverslips in separate 
24-well plates.  Following cell attachment, the recovery medium was changed to a 
differentiation medium.  This medium was formulated similar to the growth medium 
[Section 5.3.3, pg. 82] except that it lacked B104 conditioned medium and, instead, 
contained 2% FBS.  Subsequently, the cells were maintained in culture for either one or 
four days, at which time a portion of the wells containing Hoxa2-S and WT CG4 cells 
were processed.  
  5.3.5 Immunocytochemistry 
Immunocytochemistry was conducted utilizing the following primary antibodies: 
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 A2B5 (1:100, hybridoma; ATCC), O4 (1:1000, Cedarlane Laboratories Ltd, Burlington, 
ON), anti-GalC (1:100, Ranscht et al., 1982), anti-GFAP (1:800, Dako Canada Inc., 
Mississauga, ON), anti-PSA-NCAM (1:100, concentrate, Developmental Studies 
Hybridoma Bank), and anti-bromodeoxyuridine (BrdU) (1:400, Sigma-Aldrich, Oakville, 
ON).  Cells were labeled for either A2B5/GalC or O4 utilizing the same protocol.  These 
markers are used to identify cells at different stages of OG development [Figure 2.4].  
The monoclonal antibody A2B5 is used to recognize a complex ganglioside expressed on 
the surface of OPCs (Abney et al. 1983; Eisenbarth et al. 1979).  The monoclonal 
antibody O4 recognizes surface epitopes expressed by pro-OGs (Bansal et al. 1989).  
GalC, the major galactosphingolipid of myelin, marks pre-myelinating OGs (Ranscht et 
al. 1982).  The cells were first fixed for 10 min with 4% formaldehyde after which they 
were washed two times for 5 min each with PBS.  This was followed by two 30-min 
incubations: first in the primary antibodies and then in the secondary antibodies [goat 
anti-mouse IgM μ-chain specific Alexa 594 (1:400, A2B5/O4; Invitrogen, Burlington, 
ON) and goat anti-mouse IgG γ-chain specific FITC (1:50, GalC/MOG; BIO/CAN 
Scientific, Mississauga, ON)].  The nuclei of all cells were then stained with a 10-min 
incubation in Hoechst dye (Sigma-Aldrich, Oakville, ON).  Following these incubations 
the cells were washed twice with PBS for 5 min each.  Finally, the cells/coverslips were 
mounted utilizing ProLong® Gold antifade reagent (Invitrogen, Burlington, ON).   
Double labeling cultures for PSA-NCAM/GFAP was conducted as described 
above with a few modifications.  First, the cells were initially stained for PSA-NCAM 
and then GFAP.  Second, the anti-GFAP antibody was diluted in 1% SM/0.03% TX 
instead of PBS.  Finally, the secondary antibodies utilized were goat anti-mouse IgM μ-
chain specific Alexa 594 (1:400, PSA; Invitrogen, Burlington, ON) and goat anti-rabbit 
IgG Alexa 488 (1:200, GFAP; Invitrogen, Burlington, ON).   
For staining proliferative cells, BrdU (Sigma-Aldrich, Oakville, ON) at a final 
concentration of 1 μM was added to the culture medium 1.5 h prior to processing.  
Subsequently, the cells were fixed with 4% formaldehyde for 10 min followed by two 5 
min washes with PBS.  The cells were then incubated at 37ºC for 30 min in 2N HCl.  
This was followed by two 5 min PBS washes and a 10 min block/permeabilization in 3% 
SM/0.1% TX.  The cells were then incubated for 1 h in primary antibody, 30 min in the 
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secondary antibody (goat anti-mouse IgG γ-chain specific FITC [1:50, BIO/CAN, 
Mississauga, ON]), and finally 20 min in a nuclear fluorescent Hoechst counterstain.  
Two 5 min PBS washes were done between, as well as following these incubations.  The 
cells/coverslips were subsequently mounted in ProLong® Gold antifade reagent. 
The percentage of cells that were stained with a particular antibody was 
determined by counting the immunoreactive and Hoechst+ cells on micrographs taken 
from every third field at a magnification of 20 X for a total of 25 fields utilizing the 
ImagePro® Express 5.1 software (Olympus Canada Inc., Markham, ON).  Most of this 
data were then subjected to statistical analysis utilizing a two-way analysis of variance 
(ANOVA) to determine the significant main effects and a Bonferroni’s post hoc test to 
determine statistical significance (p<0.05).  In the case of BrdU, the statistical analysis 
utilized was the Mann-Whitney test. 
5.3.6 Reverse transcriptase-polymerase chain reaction 
Samples were collected for RNA isolation via aspirating the culture medium and 
subsequently lysing the cells with 350 µl of Buffer RLT.  Lysed cells were collected in 
1.5 ml Eppendorf tubes, vortexed for 1 min, and then stored at -80ºC until they were 
processed.  Total RNA was extracted utilizing the RNeasy® Mini kit (Qiagen Inc., 
Mississauga, ON) as per manufacturer’s instructions.  cDNA was subsequently obtained 
utilizing SuperScript™ Reverse Transcriptase (Invitrogen, Burlington, ON) according to 
the manufacturer’s instructions with the following modification: after the addition and 
gentle mixing of SuperScript™ Reverse Transcriptase the tubes were incubated at 25ºC 
for 10 min, 37ºC for 1.5 h, and finally 70ºC for 15 min.  The EconoTAQ™ DNA 
Polymerase (VWR, West Chester, PA) kit was subsequently utilized for PCR analysis.  
As such, the following chemicals were added to the PCR tube: 2 µl cDNA, 5 µl 10X 
Buffer, 1.5 µl primer 1 and 2 (10 µM), 1 µl of each dNTP, 1 µl TAQ polymerase, sterile 
distilled water to 50 µl.  The oligonucleotide DNA primers utilized are listed in Table 5.1.  
PCR was performed in a PTC-100™ thermal cycler.  After an initial denaturation step for 
1.5 min at 94°C, 30 cycles were carried out with each cycle consisting of a denaturation 
(45 s at 94°C), annealing (1 min at 55°C) and elongation (1 min at 72°C) step.  This was 
followed by a further elongation step for 4 min at 72°C.  PCR products were analyzed by 
electrophoresis on 1% agarose gels using 1xTAE as the running buffer.  The resulting 
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bands, which were visualized with ethidium bromide, were photographed with the 
AlphaImager™ Gel Imaging System.  
5.3.7 Western blot analysis 
Culture medium was aspirated from individual wells after which 200 μl of RIPA 
buffer [150 mM NaCl, 0.5 ml TX, 0.01% SDS, 0.1% sodium deoxycholate, 10 mM Tris, 
5 mM EDTA in triple distilled water] was added to lyse the cells.  Cell lysate was 
subsequently collected in 1.5 ml Eppendorf tubes and stored at -80°C until they were 
processed.  Protein quantification was conducted utilizing the DC Protein Assay (Bio-
Rad Laboratories Ltd., Mississauga ON) as per manufacturer’s instructions.  
Subsequently, equal amounts of protein for each sample were separated on a 10% 
polyacrylamide-SDS gel and transferred to a PolyScreen® PDVF membrane 
(PerkinElmer, Boston, MA).  The membrane was subsequently incubated in 3% SM in 
PBS overnight in order to block non-specific binding.  This was followed by two 1 h 
incubations, first in primary antibody (anti-actin-1:1000, Developmental Studies 
Hybridoma Bank; anti-Hoxa2- 1:1000, Hao et al. (1999); or anti-NCAM- 1:1500, kind 
gift of ENKAM Pharmaceuticals A/S, University of Copenhagen, Denmark) and then, 
subsequently, in secondary antibody (goat anti-mouse IgM horseradish peroxidase 
conjugate-1:750, Cedarlane Laboratories Ltd., Burlington ON; or goat anti-rabbit IgM 
horseradish peroxidase conjugate- 1:1500,  Bio-Rad Laboratories Ltd., Mississauga ON).  
Following these incubations, the membrane was washed three times for 20-30 min each 
with 0.08% Tween-20 in PBS.  Subsequently, the membrane was treated briefly with a 
chemiluminescence agent (PerkinElmer) and then exposed to X-ray film.  The resulting 
bands were subsequently visualized on X-ray film.   
5.4 Results 
5.4.1 Hoxa2 is expressed in multiple regions of the embryonic 
telencephalon 
To examine Hoxa2 expression in the telencephalon, in situ hybridization 
histochemical analysis was conducted on E13.5 (C18/T20) transverse brain sections.  The 
results show that Hoxa2 is expressed in the ventricular zone of the MGE, LGE, and  
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Figure 5.1 Hoxa2 and Hoxd1 are expressed in the embryonic murine telencephalon. 
 
Transverse sections of E13.5 (C18/T20) CD1 murine brains were subjected to in situ 
hybridization histochemical analysis for Hoxa2 (A,B) [figure (B) is a higher 
magnification of figure (A)] and Hoxd1 (C).  Hoxa2 mRNA expression is evident 
throughout the telencephalon, being more intense in the dorsal telencephalon (P) and the 
LGE than in the MGE (A,B).  Similar to Hoxa2, Hoxd1 is expressed throughout the 
E13.5 (C18/T20) telencephalon (C). Abbreviations: SVZ-subventricular zone, VZ-
ventricular zone.  Bar = 100 μm except for (A) where bar = 200 μm. [taken from Louise 
Wolf’s PhD Thesis 2004] 
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dorsal telencephalon, as well as the subventricular zone of the LGE [Figure 5.1A,B].  As 
Hoxd1 exhibits a similar expression profile to Hoxa2 in the diencephalon (Wolf et al. 
2001), its expression was also examined in this region.  Similar to Hoxa2, Hoxd1 mRNA 
is expressed throughout the E13.5 (C18/T20) telencephalon [Figure 5.1C].     
5.4.2 Olig2 and Pax6 telencephalic expression profiles are not altered 
in the absence of Hoxa2 
Hoxa2+/+, Hoxa2+/- and Hoxa2-/- telencephalic sections were analyzed for the 
expression of Olig2 and Pax6, two TFs whose expression profiles are limited to either the 
ventral or dorsal telencephalon, respectively.  Hoxa2+/- and Hoxa2+/+ mice were used 
interchangeably to represent the presence of Hoxa2, since Olig2 and Pax6 expression 
profiles were found to be similar in both genotypes.  The results of this analysis show that 
Olig2 is primarily expressed in the neuroepithelium of the MGE and LGE in both the 
presence and absence of Hoxa2 [Figure 5.2A,B].  Similarly, regardless of genotype, Pax6 
is expressed in the neuroepithelium of the dorsal telencephalon [Figure 5.2C,D].        
5.4.3 Telencephalic PDGFαR expression is unaltered in the absence of 
Hoxa2   
In order to determine if Hoxa2 is expressed by OPCs in the telencephalon, double 
immunofluorescent analysis was conducted on E18 (T25) coronal telencephalic sections.  
This analysis revealed that Hoxa2 is expressed by PDGFαR+ OPCs in the corpus 
callosum [Figure 5.3A-C] and cerebral cortex [Figure 5.3F-H].  Although its expression 
is more abundant in the cerebral cortex, only a small subset of the PDGFαR+ cells express 
Hoxa2 in both regions.  In turn, Hoxa2’s expression in the telencephalon is not limited to 
OGs as evident by the fact that it is expressed by cortical cells that are PDGFαR- [Figure 
5.3].  Subsequently, immunofluorescent analysis was conducted to determine whether 
PDGFαR expression is affected in either of these areas in the absence of Hoxa2.  The 
results showed that PDGFαR+ cells are evident in both the cerebral cortex [Figure 5.3I,J] 
and the corpus callosum [Figure 5.3D,E] regardless of genotype.   
5.4.4 There are significantly fewer O4+ and GalC+ cells in CG4 cells 
over-expressing Hoxa2 
In order to examine Hoxa2’s role in OG differentiation, CG4 cells, established 
from perinatal rat cortical OPCs (Louis et al. 1992), were stably transfected with a Tet-off  
 90
 
Figure 5.2 Olig2 and Pax6 exhibit similar expression profiles in Hoxa2+/+ and 
Hoxa2-/- mice. 
 
E14.25 (C19+/T21) coronal telencephalic sections were immunolabeled for Olig2 (A,B) 
and Pax6 (C,D) as described in Materials and Methods.  The expression profiles of these 
TFs were found to be similar both in the presence (A,C) and absence (B,D) of Hoxa2.  
Scale bars = 100μm. 
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Figure 5.3 PDGFαR expression in the telencephalon of E18 (T25) Hoxa2+/- and 
Hoxa2-/- mice. 
 
Coronal telencephalic sections from E18 (T25) Hoxa2+/- (A-D, F-I) and Hoxa2-/- (E, J) 
mice were immunolabeled for Hoxa2 (A, F) and/or PDGFαR (B,D,E,G,I,J) as described 
in Materials and Methods.  A small population of PDGFαR+ cells was found to express 
Hoxa2 (arrows) in both the corpus callosum (A-C) and cerebral cortex (F-H).  The 
arrowhead in (H) demarcates a Hoxa2+/ PDGFαR- cell.  [The first two micrographs in the 
first and third rows (A,B and F,G) represent individual filters (fluorescein- A,F; 
rhodamine-B,G) of the same region, whereas the third micrograph (C,H) represents a 
merging of these filters.]  The expression profile of PDGFαR in these telencephalic 
regions was found to be similar in the presence (D,I) and absence (E, J) of Hoxa2. 
Analyses were conducted on sections obtained from two Hoxa2+/- and Hoxa2-/- 
embryos.  Scale bar = 100μm. 
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vector containing a Hoxa2-S construct.  Subsequently, both WT and Hoxa2-S CG4 cells 
were grown in differentiation medium for either one or four days, at which point they 
were processed via immunocytochemistry for the following OG markers: A2B5, O4, and 
GalC.  The data obtained from this experiment were then subjected to a two-way 
ANOVA with the data from each OG marker being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were then performed utilizing Bonferroni’s 
multiple comparison post-test.  The two-way ANOVA revealed significant main effects 
of culture type [A2B5: F(1,8)=14.01, p=0.0057; O4: F(1,8)=20.40, p=0.0020; GalC: 
F(1,8)=18.04, p=0.0028] and time [A2B5: F(1,8)=20.25, p=0.0020; O4: F(1,8)=22.23, 
p=0.0015; GalC: F(1,8)=8.93, p=0.0174] for all three OG markers.  However, regardless 
of the marker, it failed to reveal a significant interaction between these factors [A2B5: 
F(1,8)=1.469, p>0.05; O4: F(1,8)=1.565, p>0.05; GalC: F(1,8)=2.234, p>0.05].  
Subsequently, Bonferroni’s post-test revealed that at one day in culture, significantly 
more A2B5+ cells are found in the Hoxa2-S cultures in comparison to WT.  It also 
revealed that the Hoxa2-S cultures contain significantly more A2B5+ cells at one day 
compared to four days in culture [Figure 5.4A].  An additional finding was that after four 
days in culture the percentage of O4+ and GalC+ cells is significantly lower in the cells 
over-expressing Hoxa2 in comparison to WT CG4 cells [Figure 5.4B,C].  In agreement 
with this data, RT-PCR analysis suggests that MBP expression is lower in Hoxa2-S 
cultures when compared to WT [Figure 5.4D].    
5.4.5 The median percentage of BrdU+ cells is similar in Hoxa2-S and 
wild-type cultures  
In order to determine if Hoxa2 over-expression affects CG4 cell proliferation, 
immunocytochemical analysis for BrdU was conducted on WT and Hoxa2-S CG4 cells at 
one day.  The results of this analysis failed to reveal a significant difference [p>0.05] 
between WT CG4 cells and those over-expressing Hoxa2 with regards to the median 
percentage of BrdU-immunoreactive cells [Table 5.2].   
5.4.6 Over-expression of Hoxa2 in CG4 cells results in significantly 
fewer PSA-NCAM+ cells 
PSA-NCAM was examined as a potential downstream target of Hoxa2 in CG4 
cells via conducting immunocytochemical analysis on Hoxa2-S and WT CG4 cells at  
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Figure 5.4 Over-expression of Hoxa2 in CG4 cells results in significantly fewer pro-
oligodendrocytes and pre-myelinating oligodendrocytes.   
 
(A-C) After either one (1d) or four days (4d) in culture, both Hoxa2-S and WT CG4 cells 
were processed via immunocytochemistry for A2B5, O4, and GalC as described in 
Materials and Methods.  The histogram bars represent the mean of the percentages 
obtained from three individual coverslips, which were treated identically.  The error bars 
represent the standard error of the mean.  Post hoc comparisons were performed with 
Bonferroni’s multiple comparison post-test.  This post-test revealed that the percentage of 
A2B5+ cells is significantly higher (p<0.05; bracket) in the Hoxa2-S cultures than WT at 
1 day.  In addition, a significant decrease (p<0.05; bracket) in the percentage of A2B5-
immunoreactive cells is seen between 1d and 4d (A).  In comparison to A2B5, the 
percentage of O4+ (B) and GalC+ (C) cells is significantly lower (p<0.05; bracket) in the 
Hoxa2-S cultures compared to WT at four days.  As would be expected with 
differentiating cultures, the percentage of O4-immunoreactive cells is significantly higher 
(p<0.05; bracket) in the 4d WT cultures in comparison to the 1d (B). 
 
(D) After four days in culture, a subset of the cells were collected and processed via RT-
PCR for MBP and β-actin as described in Materials and Methods.  Given similar amounts 
of cDNA, as shown by β-actin, MBP mRNA expression appears to be weaker in Hoxa2-S 
cultures in comparison to WT.  
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Table 5.2 The median percentage of proliferating cells is similar in Hoxa2-S and 
wild-type CG4 cultures.  
 Median % 
Coverslip #1 
Median % 
Coverslip #2 
Median %  
Coverslip #3 
WT CG4 40.7 47.1 43.8 
Hoxa2-S CG4 45.9 45.9 37.8 
 
WT and Hoxa2-S CG4 cells were grown in differentiation medium for one day at which 
point they were processed via immunocytochemistry for BrdU as described in Materials 
and Methods.  Statistical significance was determined utilizing a Mann-Whitney test.  
The median percentage of BrdU+ cells was found to be similar regardless of the culture 
type [p>0.05]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 97
both one and four days in culture.  The data obtained from this experiment were then 
subjected to a two-way ANOVA, as well as a Bonferroni’s multiple comparison post-test.  
The two-way ANOVA revealed significant main effects of culture type [F(1,8)=406.4, 
p<0.0001] and time [F(1,8)=106.8, p<0.0001], as well as a significant interaction 
between these factors [F(1,8)=48.78, p=0.0001].  Subsequently, Bonferroni’s post-test 
showed that there are significantly fewer PSA-NCAM-immunoreactive cells in Hoxa2-S 
cultures compared to WT, regardless of the time in vitro.  In addition, it showed that the 
percentage of PSA-NCAM+ cells is significantly increased in WT CG4 cells at four days 
versus one day in culture [Figure 5.5].  
As PSA-NCAM is a post-translational modification of the NCAM molecule, 
western blot analysis was conducted on the cultures at four days to determine if NCAM 
expression is also reduced in CG4 cells over-expressing Hoxa2.  Furthermore, RT-PCR 
analysis was also conducted to determine whether the expression of PST, which is the 
enzyme responsible for adding polysialic acid units to the NCAM molecule in 
oligodendroglial cells (Stoykova et al. 2001), is affected in the Hoxa2-S cultures.  The 
results suggest that both NCAM and PST expression is reduced in Hoxa2-S cultures 
compared to WT [Figure 5.6].   
5.5 Discussion 
The TF Hoxa2 is expressed in various regions and cell types in the CNS (Hao et 
al. 1999; Nicolay et al. 2004a; Tan et al. 1992; Wolf et al. 2001).  However, current 
knowledge regarding its function in the CNS is limited to early stages of development, 
such as dorsal-ventral and anterior-posterior patterning, as well as neuronal development 
(Davenne et al. 1999; Gavalas et al. 1997).  Our laboratory is interested in investigating 
Hoxa2’s function at later stages of CNS development, specifically during 
oligodendrogenesis.   
In the present study, we have investigated the expression and function of Hoxa2 
in the telencephalon.  Expression analysis of Hoxa2 in the E13.5 telencephalon revealed 
that it was expressed in three regions known to give rise to OPCs [Figure 5.1A,B].  
Hence, this suggested that it could play a role in OG specification in one or more of these 
regions.  As there are no known markers that can distinguish between the OPCs arising 
from these distinct telencephalic domains, we could not address this issue directly.   
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Figure 5.5 The percentage of PSA-NCAM+ cells is significantly reduced in the 
Hoxa2-S CG4 cultures in comparison to wild-type.  
 
WT and Hoxa2-S CG4 cells were grown in differentiation medium for one day at which 
point they were processed via immunocytochemistry for PSA-NCAM.  The top row (A) 
contains representative micrographs illustrating PSA-NCAM expression in WT and 
Hoxa2-S cultures at 4d [Scale bar = 100 μm].  The histogram bars represent the mean of 
the percentages obtained from three individual coverslips, which were treated identically.  
In addition, the error bars represent the standard error of the mean.  Post hoc comparisons 
were performed with Bonferroni’s multiple comparison post-test.  This post-test revealed 
that the percentage of PSA-NCAM+ cells is significantly lower (p<0.05; brackets) in 
Hoxa2-S cultures in comparison to WT at both 1d and 4d.  Furthermore, whereas there is 
a significant increase (p<0.05; bracket) in the percentage of immunoreactive cells in the 
WT cultures between 1d and 4d, the same is not found in the Hoxa2-S cultures. 
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Instead, we examined OG specification in the ventral telencephalon of Hoxa2 transgenic 
knockout mice via analyzing the expression of the TF Olig2.  This TF, which is expressed 
in the ganglionic eminences (Takebayashi et al. 2000), was chosen based on the finding 
that in Olig2 mutant mice OPCs are largely absent in the forebrain except for a focal 
region in the cortex (Lu et al. 2002).  As the results of our analysis failed to reveal any 
differences in Olig2’s expression profile [Figure 5.2], it suggests that OG specification in 
the ventral telencephalon occurs normally in the absence of Hoxa2.  However, as there is 
a focal region of the telencephalon that still contains OPCs in Olig2 mutant mice (Lu et 
al. 2002), further research will need to be conducted as more information becomes known 
regarding the regulation of ventral and dorsal OG specification in this region.   
In comparison to its ventral counterpart, information regarding the transcriptional 
control of OG specification in the dorsal telencephalon is currently lacking.  However, 
there is evidence to suggest that it is regulated differently than that of the ventral 
telencephalon.  Although Olig2 is expressed by dorsal OPCs in the telencephalon, it is 
not required for their specification (Yue et al. 2006).  As a result, it was decided to 
analyze the expression of Pax6 in the telencephalon of Hoxa2 transgenic knockout mice 
in order to determine if dorsal telencephalic patterning and, hence, development was 
affected in the absence of Hoxa2.  This TF was chosen because its mRNA expression is 
predominantly found in the neuroepithelium of the dorsal telencephalon (Puelles et al. 
1999; Walther and Gruss 1991).  Furthermore, recent research indicates that Pax6 
functions in dorsal telencephalic development via repressing the expression of TFs 
normally found in the ventral telencephalon, as well as preventing premature 
differentiation and depletion of the cortical progenitor pool (Quinn et al. 2007).  The 
results of this analysis revealed that Pax6 is expressed similarly regardless of genotype 
[Figure 5.2].  Therefore, this suggests that dorsal telencephalic development and, hence, 
oligodendrogenesis occurs normally in the absence of Hoxa2.  This, however, will have 
to be verified as more information is obtained regarding the transcriptional regulation of 
OG specification in this region.   
Subsequent double immunofluorescent analysis of Hoxa2 with PDGFαR showed 
that Hoxa2 is expressed by PDGFαR+ OPCs in the embryonic telencephalon [Figure 5.3].  
These results support our previous immunocytochemical analysis which showed that 
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Hoxa2 is expressed by A2B5-immunoreactive cells in primary mixed glial cultures 
obtained from newborn cerebral hemispheres (Nicolay et al. 2004a) [Section 3.4.1, pg. 
51].  Interestingly, Hoxa2’s expression profile during OG development in vitro is 
reminiscent of that seen with several other TFs, such as Sox5 and Sox6, which have been 
shown to inhibit OG differentiation (Stolt et al. 2006).  Based on this information we 
postulated that Hoxa2 could play a role in this process.  As our Hoxa2 transgenic 
knockout mice die shortly after birth, which is before GalC+ OGs are known to arise in 
the telencephalon, we could not examine OG differentiation in these mice in vivo (Gard 
and Pfeiffer 1989).  Furthermore, as several additional Hox TFs have been shown to be 
expressed by oligodendroglial cells in primary mixed glial cultures obtained from the 
cerebral hemispheres of newborn mice (Nicolay et al. 2004b) [Section 4.4, pg. 72; 
Appendix B],  these TFs could compensate for Hoxa2 in its absence.  As a result, it was 
decided to over-express Hoxa2 in the CG4 oligodendroglial cell line in order to determine 
if Hoxa2 could play a role in their differentiation.  The reason we chose to utilize a cell 
line instead of primary cultures was due to its advantages regarding accessibility and 
increased rate of differentiation.  This cell line was established from primary cultures of 
oligodendroglial cells obtained from the perinatal rat cerebral cortex (Louis et al. 1992).  
These cells not only display numerous characteristics of normal oligodendroglial cells 
including morphological and antigenic phenotypes [Appendix B], but they also respond 
to similar mitogens (Louis et al. 1992).    
In this experiment WT and Hoxa2-S CG4 cells were grown in differentiation 
medium for either one or 4 days at which point immunocytochemical analysis was 
conducted to determine what stage of development the cells were at.  The results show 
that at one day the only significant difference between the cultures was in regards to the 
percentage of A2B5+ cells, being significantly higher in Hoxa2-S cultures compared to 
WT [Figure 5.4A].  The reason for this effect is uncertain; however, it could be due to 
several factors.  For instance, it could be due to the fact that Hoxa2-over-expression 
affects CG4 proliferation.  However, as the median percentage of BrdU+ is similar in both 
Hoxa2-S and WT cultures [Table 5.2], this is unlikely.  As CG4 cells can give rise to both 
OGs and type 2 astrocytes, which both express A2B5, the higher percentage of A2B5+ 
cells at one day in the Hoxa2-S cultures could reflect an enhancement of astrocyte 
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development in these cultures compared to WT.  However, as the expression of the 
astrocytic marker GFAP is negligible in all cultures regardless of time, this appears 
unlikely.  
The results also showed that the percentage of A2B5+ cells is significantly 
reduced in Hoxa2-S cultures at 4 days in comparison to one day [Figure 5.4A].  This 
finding would suggest that the cells are progressing through to later stages of 
development.  It was somewhat surprising, therefore, to find that there are significantly 
fewer O4- and GalC-immunoreactive cells in the Hoxa2-S cultures at four days [Figure 
5.4B,C].  These findings leave us with the question of why A2B5 expression is decreased 
in these Hoxa2 over-expressing cells.  As A2B5+ cells may also co-express O4 the 
decrease could be due, in part, to the decrease in the percentage of O4+ cells. 
In an attempt to identify potential mechanisms by which Hoxa2 could affect OG 
differentiation, we conducted a literature search in hopes of discovering downstream 
targets of Hox TFs that are expressed by OGs.  Based on this search we decided to focus 
on the cell surface glycoprotein NCAM.  This molecule exists as three prominent protein 
isoforms (Barbas et al. 1988), which can undergo a variety of post-translational 
modifications.  One such modification, glycosylation, can lead to the formation of the 
embryonic form of NCAM, known as PSA-NCAM (Rothbard et al. 1982).  Interestingly, 
PSA-NCAM, which is expressed primarily by A2B5+ cells (Trotter et al. 1989), has been 
implicated in inhibiting OG differentiation (Decker et al. 2000).  As a result, PSA-NCAM 
expression was examined in WT and Hoxa2-S CG4 cultures after one and four days in 
differentiation medium to see if it was up-regulated in the Hoxa2-S cultures.  However, 
contrary to our hypothesis, we find that the percentage of PSA-NCAM+ cells is 
significantly lower in Hoxa2-S cultures when compared to WT regardless of the time in 
culture [Figure 5.5B].  This is somewhat surprising based on the findings of Decker et al. 
(2000), who report an increase in the percentage O4+ cells following removal of the 
polysialic acid residue with endoN.  Closer examination of their data, however, reveals 
that this effect is only evident under certain in vitro conditions (Decker et al. 2000).  
Furthermore, a similar experiment conducted by a different research group failed to 
reveal any differences in the percentage of GalC+ cells in endoN-treated and control 
cultures (Zhang et al. 2004).  Based on this information, as well as our results, it appears 
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that Hoxa2’s effect on CG4 cell differentiation is independent of its effect on PSA-
NCAM expression.  Although Hoxa2’s effect on PSA-NCAM expression is opposite to 
what was expected, distinct Hox genes are known to differentially affect NCAM 
promoter activity (Jones et al. 1993; Jones et al. 1992).  Based on our western blot 
analysis, Hoxa2 appears to negatively affect PSA-NCAM expression, in part, via 
regulating NCAM expression.    
In order to properly interpret these findings it should be kept in mind that the 
overall effect of Hoxa2 over-expression in CG4 cells can be impacted by several factors.  
In particular, the degree of the effect may be limited by the availability of the co-factors 
Pbx and/or Prep/Meis.  Furthermore, as Hox genes are known to undergo auto- and cross-
regulation (Lampe et al. 2004; Tümpel et al. 2007), over-expressing Hoxa2 in CG4 cells 
could impact its expression, as well as other Hox genes.  Finally, the environmental 
factors at play in these cultures may impact the effect of Hoxa2 over-expression on CG4 
development.  For example, as downstream effectors of the BMP signaling pathway can 
modulate the transcriptional activities of Hox TFs, Hoxa2’s effect on CG4 development 
could be impacted by the presence or absence of BMPs (Li et al. 2006).  
One additional finding from our experiment is that in WT cultures the percentage 
of PSA-NCAM+ and A2B5+ cells is increased and decreased, respectively, over time 
[Figure 5.4A, 5.5B].  Furthermore, examination of the morphology of the PSA-NCAM-
immunoreactive cells revealed multipolar cells indicative of later stages of OG 
development [Figure 5.5A].  Hence, these findings contradict a previous study which 
found that PSA-NCAM is expressed primarily by OPCs (Trotter et al. 1989).  The reason 
for this disparity is unknown; however, it could reflect differences between primary 
cultures and CG4 cells.  Alternatively, it could reflect differences in PSA-NCAM 
expression in specific CNS regions, as the primary cultures utilized by Trotter et al. 
(1989) were obtained from the cerebellum whereas the CG4 cell line was established 
from the cerebral cortex (Louis et al. 1992).  Further research will be needed to resolve 
this difference. 
In addition to being implicated in OG differentiation, PSA-NCAM has been 
shown to be important in PDGF-directed OPC migration (Zhang et al. 2004).  Hence, this 
suggests that Hoxa2 could negatively impact this trait in OPCs.  Although 
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immunohistochemical analysis of E18 coronal telencephalic sections failed to reveal any 
noticeable differences in PDGFαR expression [Figure 5.3], other Hox TFs are found in 
the telencephalon which could potentially compensate for Hoxa2 in its absence.  Hence, 
further research will be needed to address this issue. 
In conclusion, our results support a role for Hoxa2 in OG differentiation.  
Furthermore, they suggest that Hoxa2 may affect additional aspects of OG development, 
since PSA-NCAM is involved in PDGF-directed OPC migration (Zhang et al. 2004).  
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Preamble to Chapter 6 
The expression of Hox genes is enhanced by RA, which, in turn, can either inhibit or 
promote OG differentiation.  Although the reason for these opposing roles is uncertain, 
examination of the experimental protocols utilized by different research groups reveals 
differences in age, CNS region, as well as RA concentration.  As a result, RA’s effect on 
oligodendrogenesis could be time- and/or concentration-dependent.  This chapter is 
focused on determining which of these factors can impact RA’s effect on 
oligodendroglial differentiation. 
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6.0 RETINOIC ACID’S EFFECT ON THE DIFFERENTIATION OF 
MYELINATING GLIAL CELLS IS IMPACTED BY CONCENTRATION AND 
TIME 
 
6.1 Summary 
1. RA can either inhibit or promote OG differentiation.  Although the factors that 
dictate what effect RA has on OG differentiation is uncertain, they may include 
RA concentration and/or treatment time. 
2. RA was added to CG4 cells at two different concentrations (10 nM and 1 μM) at 
two distinct time points (4h or 1d).  The cultures were subsequently grown in 
differentiation medium for a total of four days after which they were processed 
via immunocytochemistry for A2B5, O4, GalC, and MOG.  The data collected 
regarding the individual markers were subjected to a two-way ANOVA, as well as 
a Bonferroni’s multiple comparison post-test. 
3. Statistical analysis revealed that significantly more GalC+ cells are found in 
cultures treated with 1 μM RA at 1d than those treated with either 10nM RA at 1d 
or 1 μM RA at 4h. 
4. Examination of the expression of PSA-NCAM, a potential downstream target of 
RA in oligodendroglial cells, revealed that significantly fewer PSA-NCAM+ cells 
are found in cultures treated with either 1 μM RA at 4h or 10 nM RA at 1d than 
those treated with 10 nM RA at 4h. 
5. The results of this experiment suggest that both RA concentration and treatment 
time can impact RA’s effect on OG development.       
6.2 Introduction 
Oligodendroglial cells in vivo arise in multiple distinct foci (Cai et al. 2005; 
Kessaris et al. 2006; Vallstedt et al. 2005) and, therefore, must proliferate and migrate in 
order to populate specific CNS regions.  In addition, these oligodendroglial cells must 
progress through four stages of development ― OPCs, pro-OGs, pre-myelinating OGs, 
and mature myelinating OGs ― [Figure 2.4] in order to myelinate axons in these regions.  
As pre-myelinating OGs do not actively proliferate (Fok-Seang and Miller 1994) or 
migrate (Noble et al. 1988), the terminal differentiation of these cells has to be delayed 
until they reach their final destination.  Indeed, numerous TFs and signaling pathways 
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inhibit OG differentiation (Kondo and Raff 2000a; Kondo and Raff 2000b; Laeng et al. 
1994; Noll and Miller 1994; Wang et al. 2001; Wang et al. 1998).  Two of these signaling 
pathways (Notch and RA) also promote (Barres et al. 1994; Cui et al. 2004; Givogri et al. 
2001; Hu et al. 2003; Pombo et al. 1999) this process.  How these signaling pathways 
inhibit, as well as promote OG differentiation is uncertain, however, in the case of Notch 
it appears to be ligand-dependent.  Activation of the Notch signaling pathway in purified 
OPCs by the standard Notch ligands, Jagged1 or Delta1, inhibits OG differentiation 
(Wang et al. 1998).  In contrast, treatment of OPCs with F3 or NB-3, which represent a 
novel group of Notch ligands, promotes OG differentiation (Cui et al. 2004; Hu et al. 
2003).   
Although the reason for the differential effects of RA on OG differentiation is 
currently unknown, analysis of the experimental protocols utilized by different research 
groups [Table 6.1] suggests that it could be due to a stage- and/or concentration-
dependent effect(s).  Researchers have found that RA treatment of spinal cord cultures, 
which were obtained from either E14, E16, or E18 rats, inhibits OG differentiation with 
the effect being most dramatic in cultures obtained from the E14 rats (Noll and Miller 
1994).  As O4+ pro-OGs and GalC+ pre-myelinating OGs are known to first arise in the 
spinal cord at E16 and E18, respectively (Fok-Seang and Miller 1994), it could be 
hypothesized that RA inhibits OG differentiation at the A2B5+ OPC stage.  This, in turn, 
may explain why Laeng et al. (1994) and Givogri et al. (2001) report contradictory 
research findings.  Although both research groups utilized cultures obtained from the 
cerebral hemispheres of neonatal rats, Laeng et al (1994) purified the cultures for OPCs 
prior to RA treatment whereas Givogri et al. (2001) did not.  As a result, the cells utilized 
by Laeng et al (1994) would be expected to be more immature than those used by the 
other research group.  However, as these two groups also utilized different concentrations 
of RA, the contradictory findings could also reflect a concentration-dependent effect.  In 
order to determine which factors could impact RA’s effect on OG differentiation we 
treated the oligodendroglial cell line CG4 with two different concentrations of RA at two 
distinct time points.  The results show that both concentration and time can impact RA’s 
effect on the differentiation of CG4 cells.   
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Table 6.1 Comparison of studies analyzing the effect of retinoic acid on 
oligodendrocyte differentiation  
Study Age Source of 
OGs 
[RA] Differentiation 
Barres et al. 
(1994)  
P8 Optic nerve* 10nM all-trans/9-
cis 
+ 
Givogri et al. 
(2001)  
P0-3 
(7DIV) 
Cerebral 
Hemispheres 
1μM all-trans + 
Laeng et al. 
(1994)  
P0 Cerebral 
Hemispheres*
8µM all-trans - 
Noll and 
Miller (1994)  
E14, E16, 
E18 
Spinal cord 1μM all-trans - 
Pombo et al. 
(1999)  
P7 Optic nerve 30 or 500nM 9-cis + 
 
Abbreviations: *: purified for OPCs; +: enhance; DIV: days in vitro; -: inhibit  
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6.3 Materials and Methods 
  6.3.1 CG4 cells 
The cells were first expanded in growth medium containing DMEM 
supplemented with 50 µg/ml apo-transferrin, 10 pg/ml D-biotin, 50 ng/ml sodium 
selenite, 5 µg/ml insulin, 1% antibiotic/antimycotic and 30% B104 conditioned medium.  
The cells were subcultured by rinsing them first with PUCKs [Section 5.3.3, pg. 82] and 
then incubating them for approximately 20 min in harvesting medium [EDTA and 
PUCKs (1:1) supplemented with 25 mM glucose, 2 mM sodium pyruvate, 10 mM 
HEPES, 1.25 μg/ml insulin, and 1% antibiotic/antimycotic].  Subsequently, the cells were 
collected and centrifuged at 800 rpm for 10 min, after which they were resuspended and 
plated in recovery medium [DMEM supplemented with 2 mM sodium pyruvate, 5% FBS, 
5 µg/ml insulin, and 1% antibiotic/antimycotic].  At the start of the trial, the cells, which 
were suspended in recovery medium, were plated at a density of 100,000 cells/well onto 
poly-D-lysine-coated wells or coverslips in 24-well plates.  Following cell attachment, 
the recovery medium was changed to a differentiation medium, which contained similar 
ingredients as the growth medium, except that it lacked B104 conditioned medium and, 
instead, contained 2% FBS.  Subsequently, after either 4 h or one day, individual wells 
were either treated with 10 nM or 1 μM all-trans RA or left untreated for control 
purposes.  (These RA concentrations were chosen based on previous studies [Table 6.1].)  
As RA is extremely light sensitive, cells were treated and maintained in the dark for this 
experiment.  (Note: All of the chemicals were obtained from Sigma-Aldrich except for 
FBS, which was obtained from Invitrogen.) 
  6.3.2 Immunocytochemistry 
Immunocytochemistry was conducted utilizing the following primary antibodies: 
A2B5 (1:100, hybridoma; ATCC), O4 (1:1000, Cedarlane Laboratories Ltd, Burlington, 
ON), anti-GalC (1:100, Ranscht et al., 1982), anti-myelin OG glycoprotein (MOG) 
(concentrate, kind gift of Dr. Minnetta Gardinier), anti-GFAP (1:800, Dako Canada Inc., 
Mississauga, ON), anti-PSA-NCAM (1:100, concentrate, Developmental Studies 
Hybridoma Bank), and anti-BrdU (1:400, Sigma-Aldrich, Oakville, ON).  The CG4 cells 
were double stained for either A2B5/GalC or O4/MOG using an identical protocol.  
These markers were used to identify cells at different stages of oligodendrogenesis 
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[Figure 2.4].  The monoclonal antibody A2B5 was used to recognize a complex 
ganglioside expressed on the OPC’s surface (Abney et al. 1983; Eisenbarth et al. 1979).  
The monoclonal antibody O4 recognized surface epitopes expressed by pro-OGs (Bansal 
et al. 1989).  GalC, the major galactosphingolipid of myelin, marked pre-myelinating 
OGs (Ranscht et al. 1982).  Finally, expression of myelin proteins, such as MOG, marked 
mature myelinating OGs.  The CG4 cells were fixed with 4% formaldehyde, which was 
made from paraformaldehyde, for 10 min after which they were washed twice for 5 min 
each with PBS.  This was followed by two 30-min incubations: first in the primary 
antibodies and then in the secondary antibodies [goat anti-mouse IgM μ-chain specific 
Alexa 594 (1:400, A2B5/O4; Invitrogen, Burlington, ON) and goat anti-mouse IgG γ-
chain specific FITC (1:50, GalC/MOG; BIO/CAN Scientific, Mississauga, ON)].  In 
addition, the nuclei of all cells were stained by a 10-min incubation in Hoechst dye 
(Sigma-Aldrich, Oakville, ON).  Two 5-min PBS washes followed each incubation.  The 
cells/coverslips were mounted in ProLong® Gold antifade reagent (Invitrogen, 
Burlington, ON).   
Double labeling of cultures for PSA-NCAM/GFAP was conducted as described 
above with minor alterations.  For instance, the cells were first stained for PSA-NCAM 
and then GFAP.  In addition, instead of PBS, the anti-GFAP antibody was diluted in 1% 
SM/0.03% TX.  Finally, the secondary antibodies utilized were goat anti-mouse IgM μ-
chain specific Alexa 594 (1:400, PSA-NCAM; Invitrogen, Burlington, ON) and goat anti-
rabbit IgG Alexa 488 (1:200, GFAP; Invitrogen, Burlington, ON).   
For staining proliferative cells, BrdU (Sigma-Aldrich, Oakville, ON) at a final 
concentration of 1 μM was added to the culture medium 1.5 h prior to processing.  
Subsequently, the CG4 cells were fixed for 10 min with 4% formaldehyde followed by 
two 5 min washes with PBS.  The cells were then incubated at 37ºC for 30 min in 2N 
HCl.  This was followed by two 5 min PBS washes and a 10 min block/permeablization 
in 3% SM/0.1% TX.  The cells were then incubated for 1 h, 30 min, and 20 min in 
primary antibody, secondary antibody (goat anti-mouse IgG γ-chain specific FITC [1:50, 
BIO/CAN, Mississauga, ON]), and Hoechst counterstain, respectively.  Two 5 min PBS 
washes were completed after each of these incubations.  The cells/coverslips were then 
mounted in ProLong® Gold antifade reagent. 
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The percentage of cells that were stained with A2B5, O4, GalC, PSA-NCAM or 
BrdU in each treatment group was calculated by counting the number of immunoreactive 
and Hoechst+ cells on micrographs taken from every third field at 20 X magnification for 
a total of 25 fields utilizing the ImagePro® Express 5.1 software (Olympus Canada Inc., 
Markham, ON).  Subsequently, the mean percentage of A2B5-, O4-, GalC-, or PSA-
NCAM-immunoreactive cells in the control group was determined from three coverslips.  
As there was only one untreated control group for the four RA treatment groups the data 
were calculated as percentage of the control.  In particular, the percentage of A2B5-, O4-, 
GalC-, or PSA-NCAM-immunoreactive cells from each individual RA-treated coverslip 
was divided by the mean percentage of the control cultures and multiplied by 100 in order 
to get a value which represented the percentage of the control.  The mean value of three 
identically treated coverslips was then determined.  These data were subsequently 
subjected to statistical analysis (two-way ANOVA and post hoc analysis conducted using 
Bonferroni’s).  For the BrdU incorporation experiment there were only 3 experimental 
groups.  Therefore, the RA treatment groups were not calculated as a percentage of the 
control.  Instead, the mean percentage of three coverslips from each experimental group 
was calculated in this case.  As a result, the statistical analysis utilized a one-way 
ANOVA. 
   6.3.3 Reverse transcriptase-polymerase chain reaction 
Samples were collected for RNA isolation by aspirating the medium and lysing 
the cells with 350 µl of Buffer RLT.  The lysed cells were then collected in Eppendorf 
tubes, vortexed for 1 min, and stored at -80ºC until they were processed.  The total RNA 
was extracted using the RNeasy® Mini kit (Qiagen Inc., Mississauga, ON) according to 
the manufacturer’s instructions.  cDNA was subsequently obtained using SuperScript™ 
Reverse Transcriptase (Invitrogen, Burlington, ON) as per the manufacturer’s instructions 
except for the following modification: after the addition and gentle mixing of 
SuperScript™ Reverse Transcriptase the tubes were incubated at 25ºC for 10 min, 37ºC 
for 1.5 h, and finally 70ºC for 15 min.  The EconoTAQ™ DNA Polymerase (VWR, West 
Chester, PA) kit was then used for PCR analysis.  The following chemicals were added to 
the PCR tube: 2 µl cDNA, 5 µl 10X Buffer, 1.5 µl primer 1 and 2 (10 µM), 1 µl of each 
dNTP, 1 µl TAQ polymerase, sterile distilled water to 50 µl.  The oligonucleotide DNA 
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primers utilized included:  
Gene Forward Primer  Reverse Primer 
β-actina 5′-ATTGTAACCAACTGGGACG-3′ 5′-TTGCCGATAGTGATGACCT-3′ 
MBPb 5′-CTATAAATCGGCTCACAAGG-3′ 5′-AGGCGGTTATATTAAGAAGC-3′ 
PSTc 5′-ACTGAGGAGCACCAAGAGACGC-3′ 5′-CCATGAAGGCAGGAATCCAAAGG-3′ 
a Hu et al (2004) 
b www.hcnr.med.harvard.edu/programs/atrc/reagent_details/MBP%20Rat.pdf 
c Soares et al. (2000); PST-Polysialyltransferase 
 
PCR was performed in a PTC-100™ thermal cycler.  After an initial denaturation step for 
1.5 min at 94°C, 30 cycles were carried out with each cycle consisting of a 45 s 
denaturation step at 94°C, a 1 min annealing step at 55°C and a 1 min elongation step at 
72°C.  This was followed by a further elongation step for 4 min at 72°C.  PCR products 
were analyzed by electrophoresis on 1% agarose gels using 1xTAE as the running buffer.  
The resulting bands, visualized with ethidium bromide, were photographed with the 
AlphaImager™ Gel Imaging System.  
6.4 Results  
6.4.1 Retionic acid’s effect on the differentiation of CG4 cells is 
impacted by concentration and treatment time 
RA was added to CG4 cells at two different concentrations (10 nM and 1 μM) at 
two distinct time points (4h and 1d) and left for a total of four days in culture.  At this 
time, the cells were processed via immunocytochemistry for the OG markers A2B5, O4, 
GalC and MOG.  As there was only a single untreated control group for this experiment 
the data were calculated as a percentage of control.  Statistical analysis was not conducted 
on the MOG data since the number of MOG+ cells was found to be minimal in all 
experimental groups at four days [Appendix B].  The remaining data sets were subjected 
to a two-way ANOVA with each OG marker being analyzed separately for statistical 
significance.  Multiple post hoc comparisons were then performed utilizing Bonferroni’s 
multiple comparison post-test.  The two-way ANOVA revealed a significant main effect 
of concentration [F(1,8)=23.93, p=0.0012] but not time [F(1,8)=0.040, p>0.05] or 
interaction [F(1,8)=0.829, p>0.05] on the percentage (treatment/control) of A2B5+ cells.  
In contrast, it failed to reveal any significant main effect on concentration [F(1,8)=5.084, 
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p>0.05], time [F(1,8)=0.721, p>0.05] or interaction [F(1,8)=1.174, p>0.05] in regards to 
the percentage (treatment/control) of O4+ cells.  The two-way ANOVA did, however, 
reveal a significant main effect of concentration [F(1,8)=9.444, p=0.0153] and time 
[F(1,8)=13.46, p=0.0063] but not interaction [F(1,8)=4.084, p>0.05] for GalC.  
Subsequently, Bonferroni’s post hoc tests revealed that the percentage (treatment/control) 
of A2B5+ cells is significantly lower in the 1 μM RA treatment groups in comparison to 
the 10 nM RA treatment groups regardless of the treatment time [Figure 6.1A].  It also 
revealed that the percentage (treatment/control) of GalC+ cells is significantly higher in 
cells treated with 1 μM RA at 1d than those treated with either 1 μM RA at 4h or 10 nM 
RA at 1d [Figure 6.1C]. 
6.4.2 The mRNA expression of MBP is similar in cultures at four days 
regardless of the experimental group. 
As all experimental groups contain only a few MOG-immunoreactive cells at four 
DIV, it was decided to examine the transcript expression of another myelin protein gene 
MBP utilizing RT-PCR.  The results of this analysis suggest that MBP expression is 
similar in cultures at four days regardless of the experimental group [Figure 6.2]. 
6.4.3 The percentage of BrdU+ cells present in cultures at one day is 
not affected by retinoic acid treatment.  
In order to determine if the concentration of RA could affect the proliferation of 
the CG4 cells, immunocytochemical analysis for BrdU was conducted at 1 DIV on 
control CG4 cells, as well as those treated with 10 nM or 1 μM RA at 4h.  The data were 
subjected to a one-way ANOVA, which failed to reveal a significant main effect of 
concentration [F(2,4)=1.6, p>0.05] [Figure 6.3].  
6.4.4 There are significantly more PSA-NCAM+ cells in cultures 
treated with 10nM retinoic acid at 4h than those treated with either 10 
nM at 1d or 1 μM retinoic acid at 4h.  
A potential downstream target of RA signaling in oligodendroglial cells is PSA-
NCAM.  Therefore, PSA-NCAM expression was examined in each of the experimental 
groups after 4 DIV utilizing immunocytochemistry.  The data obtained from this 
experiment were subjected to a two-way ANOVA, as well as Bonferroni’s post-test.  The 
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Figure 6.1 Retinoic acid’s effect on CG4 cell differentiation is impacted by time and 
concentration.  
 
CG4 cells, which were either left untreated or treated with 10 nM or 1 μM all-trans RA at 
4h and 1d in culture, were grown in vitro for a total of four days.  At this time three 
coverslips from each experimental group were stained for A2B5, O4 and GalC as 
described in Materials and Methods.  The percentage [treatment group (tx) /control (c)] of 
A2B5-, O4-, and GalC-immunoreactive cells was then calculated for each RA treatment 
group.  The black lines depict the control cultures, which were given a value of 100%.  
The histogram bars represent the mean of the percentages obtained from three individual 
coverslips, which were treated identically.  Error bars represent standard error of the 
mean.  Post hoc comparisons were performed with Bonferroni’s multiple comparison 
post-test.  This post-test revealed that the percentage of A2B5+ cells is significantly lower 
(p<0.05; brackets) when treated with 1 μM RA versus 10 nM RA regardless of the time it 
was added (A).  In comparison, the percentage of O4+ cells is found to be similar 
regardless of time and RA concentration (B).  The percentage of GalC+ cells is 
significantly lower (p<0.05; brackets) in the 1 μM 4h and 10 nM 1d treatment groups 
than the 1 μM 1d group (C).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 116
 
 117
 
 
 
 118
0 10nM 1μM0
10
20
30
40
50
RA Concentration
%
 B
rd
U
+
 
 
Figure 6.3 The percentage of BrdU+ cells is not significantly affected by retinoic acid 
treatment. 
 
CG4 cells, which were either left untreated or treated with 10 nM or 1 μM all-trans RA at 
4h and 1d in culture, were grown in vitro for a total of four days.  At this time three 
coverslips from each experimental group were stained for BrdU as described in Materials 
and Methods.  The histogram bars represent the mean of the percentages obtained from 
three individual coverslips, which were treated identically.  The error bars represent the 
standard error of the mean.  The data were analyzed utilizing a one-way ANOVA test and 
found to be not significant [F(2,4)=2, p>0.05]. 
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two-way ANOVA revealed a significant main effect of concentration [F(1,8)=55.56, 
p<0.0001] and interaction [F(1,8)=19.86, p=0.0021] but not treatment time 
[F(1,8)=1.641, p>0.05].  Subsequently, the post hoc test revealed that the percentage 
(treatment/control) of PSA-NCAM+ is significantly higher in cells treated with 10 nM 
RA at 4h than those treated with either 1 μM RA at 4h or 10 nM RA at 1d [Figure 6.4].  
As PSA-NCAM is a post-translational modification of the NCAM molecule, RT-PCR 
analysis was also conducted to determine whether the expression of PST, which is the 
enzyme responsible for adding polysialic acid units to the NCAM molecule in 
oligodendroglial cells (Stoykova et al. 2001), is affected by RA treatment.  The results of 
this analysis show that PST expression only appears to be reduced in the cells treated with 
1 μM RA regardless of the time [Figure 6.5].  
6.5 Discussion 
CG4 cells (Louis et al. 1992) were utilized instead of primary cultures to study the 
effect of RA on OG development because they exhibit several advantages over primary 
cultures, including accessibility and increased rate of differentiation.  These cells not only 
display numerous characteristics of normal oligodendroglial cells including 
morphological and antigenic phenotypes, but they also respond similarly to mitogens 
(Louis et al. 1992).   
In this study CG4 cells were treated with two concentrations of RA (10 nM and 1 
μM) at either 4h or 1d and then left for a total of 4 DIV.  RA’s effect on OG 
differentiation was then determined by conducting immunocytochemical analysis for the 
OG markers A2B5, O4, GalC, and MOG.  The results suggest that RA decreases A2B5 
expression in a concentration-dependent manner [Figure 6.1A].  Although this result is 
unexpected, there are several possible explanations that may account for this reduction.  
For instance, previous research has suggested that RA inhibits the progression of OPCs to 
pro-OGs (Noll and Miller 1994).  Although A2B5 is often utilized to identify OPCs, it 
also labels pro-OGs (Fok-Seang and Miller 1994).  Therefore, this reduction could reflect 
a decrease in the percentage of A2B5+O4+ CG4 cells with RA treatment.  In turn, a 
decrease in the percentage of A2B5,O4-double immunoreactive cells would indicate that 
the CG4 cells are not progressing through to later stages of development.  However, as  
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these monoclonal antibodies are of the same species and class, we were unable to address 
this issue directly.  However, analysis of the percentage (treatment/control) of O4+ cells 
suggests that this is unlikely since it is similar regardless of the concentration utilized 
[Figure 6.1B].   
Besides oligodendroglial cells, the A2B5 antibody also recognizes type 2 
astrocytes.  As CG4 cells can develop into either type 2 astrocytes or OGs (Louis et al. 
1992), the reduction in the percentage of A2B5+ cells could reflect a negative effect of 
RA on the development of type 2 astrocytes.  However, as the expression of GFAP was 
negligible in all cultures analyzed, this explanation is unlikely.   
As RA has been shown to inhibit proliferation in a concentration-dependent 
manner (Laeng et al. 1994), the reduction could reflect a decrease in the number of 
proliferative cells.  In order to address this possibility the cells were treated for one and a 
half hours with BrdU after one day in culture.  Cells were then processed and the 
percentage of BrdU-immunoreactive cells was determined.  Although the results of this 
experiment failed to reveal a significant difference between the RA-treated and control 
groups [Figure 6.2], the cells were not double-labeled with oligodendroglial markers and, 
hence, we are unable to comment on whether the proliferation at a particular stage of 
development was affected by RA. Furthermore, we cannot address whether the 
proliferation of the cells changed with more time in culture. 
RA’s effect on the percentage (treatment/control) of A2B5+ cells could also be 
due to a concentration-dependent effect on apoptosis.  Recent research has shown that 
RA can induce apoptosis in cells containing high concentrations of cellular RA-binding 
protein II (CRABPII), which shuttles RA to the RARs responsible for promoting 
apoptosis (Schug et al. 2007).  How it accomplishes this is unknown, but it may involve 
its ability to induce the expression of certain proapoptotic genes, including caspase 7 and 
caspase 9 (Donato and Noy 2005).  Although the total number of cells in the different 
experimental groups was found to be similar in our study, all cultures contained 
fragmented nuclei indicative of dead cells.  Further research will be needed to determine 
if RA enhances apoptosis in oligodendroglial cells.   
Analysis of the percentage of GalC+ cells revealed a time-dependent effect with 
respect to the 1 μM RA treatment group.    In particular, cultures treated with 1 μM RA at 
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either four hours or one day are found to contain 47.6% and 82.9% GalC+ cells, 
respectively, of the control cultures [Figure 6.1C].  Hence, this suggests that 1 μM RA is 
less effective at impairing CG4 cell differentiation when it is added after one day instead 
of four hours.  In comparison, treatment of CG4 cells with 10 nM RA resulted in a similar 
reduction in the percentage of GalC+ cells regardless of the time it was added.  One 
possible explanation for this time/concentration-dependent effect is that higher 
concentrations of RA at later stages of development may regulate additional effector 
genes that actually promote the differentiation of CG4 cells.  For example, RA has been 
shown to enhance MBP expression (Givogri et al. 2001).  Therefore, in order to see if 
RA’s effect on MBP mRNA expression could be impacted by concentration and/or 
treatment time, RT-PCR analysis was conducted.  Although the results imply that MBP 
expression is similar regardless of the experimental manipulation [Figure 6.3], subtle 
changes may have been missed due to the non-quantitative nature of our RT-PCR 
analysis.  Further research will be needed to determine the cause of the 
concentration/time-dependent effect.   
How RA can impair CG4 cell differentiation is unknown; however, it may involve 
its ability to augment the expression of PSA-NCAM (Husmann et al. 1989), which has 
been implicated in inhibiting OG differentiation (Decker et al. 2000).  However, contrary 
to our hypothesis we find that the percentage of PSA-NCAM+ cells is significantly higher 
in cells treated with 10 nM RA at 4h than those treated with either 1 μM RA at 4h or 10 
nM RA at 1d [Figure 6.4].  This was unexpected based on the findings of Decker et al. 
(2000), who report an increase in the percentage O4+ cells following endoN treatment.  
Closer examination of their data, however, reveals that this effect is only evident under 
certain in vitro conditions (Decker et al. 2000).  Furthermore, a similar experiment 
conducted by a different research group failed to reveal any differences in the percentage 
of GalC+ cells in endoN-treated and control cultures (Zhang et al. 2004).  Based on this 
information, as well as our results, it appears that RA’s effect on CG4 cell differentiation 
is independent of its effect on PSA-NCAM expression.  Although RA’s effect on PSA-
NCAM expression is opposite of what was expected, it may be due to the fact that 
Hussman et al. (1989) utilized a carcinoma cell line whereas we used CG4 cells.   
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Although RA’s effect on PSA-NCAM cannot account for its effect on 
differentiation, it suggests that it could also impact oligodendroglial cell migration.  This 
is due to the fact that PSA-NCAM is important in PDGF-directed OPC migration (Zhang 
et al. 2004).  In order to examine possible mechanisms by which RA could reduce PSA-
NCAM expression, the mRNA levels of PST, which is the main enzyme responsible for 
adding polysialic acid units to the NCAM molecule in oligodendroglial cells (Stoykova et 
al. 2001), was determined via RT-PCR.  In comparison to control cultures PST 
expression appeared to be reduced in cells treated with 1 μM RA but not 10 nM RA 
[Figure 6.5].  Hence, these results suggest that RA, at least at higher concentrations, may 
repress PSA-NCAM expression in CG4 cells, in part, by repressing PST expression.   
In conclusion, the results of this experiment highlight the complexity of RA’s 
effects on oligodendroglial cells.  In addition, they suggest that further research is needed 
to identify downstream effectors and targets of the RA signaling pathway active at 
various stages of OG development. 
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7.0 GENERAL DISCUSSION 
 
Hoxa2 is expressed in multiple CNS regions (Hao et al. 1999; Tan et al. 1992; 
Wolf et al. 2001) and cell types (Hao et al. 1999; Nicolay et al. 2004a).  However, our 
current understanding of its role in CNS development is limited to early stages of 
development, such as anterior-posterior (Gavalas et al. 1997) and dorsal-ventral  
(Davenne et al. 1999) patterning of the hindbrain, as well as neurogenesis (Gaufo et al. 
2004).  Although it is expressed by astrocytes and OGs (Hao et al. 1999), its role in the 
development of these cells is currently unknown.  Therefore, the main purpose of this 
thesis was to investigate the expression and function of Hoxa2 during 
oligodendrogenesis.  The research conducted is the first to show that Hoxa2 is expressed 
throughout OG development, diminishing only with the acquisition of a mature 
myelinating phenotype (Nicolay et al. 2004a) [Figure 3.3].  However, as this data was 
obtained prior to the identification of dorsal and ventral OPCs, further research is needed 
to determine if Hoxa2 expression is lineage specific.  In turn, this may explain why 
Hoxa2 expression is limited to a small subset of PDGFαR-immunoreactive cells in the 
telencephalon [Figure 5.3].   
Although Hoxa2 is expressed by A2B5+ OPCs [Figure 3.3] it does not appear to 
be required for OG specification in the pMN domain [Figure 3.5] or the telencephalon 
[Figure 5.2].  It should be kept in mind, however, that its role in these regions may have 
been overlooked due to the fact that we did not quantify the immunoreactive cells in the 
presence and absence of Hoxa2.  Furthermore, with the recent identification of ventral 
and dorsal OPCs arising from multiple CNS regions further research will be needed to 
determine whether Hoxa2 could be important for OG specification in specific CNS 
regions and/or OPC lineages.  In fact, circumstantial evidence suggests a role for Hoxa2 
in OG specification in the embryonic hindbrain.  In particular, researchers have found 
that Lbx1-expressing somatic sensory interneuron precursors, which arise from dp4-6 in 
the neural tube (Gross et al. 2002), are lost in r2 and dramatically reduced in r3 in Hoxa2 
mutant mice (Gaufo et al. 2004).  As dorsal OPCs appear to arise from dp3-5 in the 
neural tube (Cai et al. 2005), Hoxa2 may affect OG specification in this region.  In 
addition, expression of Pax3, which overlaps with that of Olig1 in the dorsal hindbrain 
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(Vallstedt et al. 2005), is expanded ventrally in r2 and r3 of Hoxa2 mutant mice (Davenne 
et al. 1999).   
At these rhombomeric levels OPCs also arise from the pMNv domain, which is 
defined by the TF Nkx2.2 (Vallstedt et al. 2005).  Although Davenne et al. (1999) 
reported that Nkx2.2’s expression profile displays a normal distribution in the hindbrain 
of Hoxa2-/- mice, they found that these mice exhibit a down-regulation of Pax6 
expression in r2 and r3.  As Pax6 and Nkx2.2 cross-repress one another in the neural tube 
(Briscoe et al. 2000), it is somewhat surprising, therefore, that Nkx2.2 expression was not 
altered in r2 and r3 of these mutant mice.  One drawback of this study, however, was the 
fact that the researchers examined expression profiles utilizing dorsal views of flat-
mounted hindbrains (Davenne et al. 1999).  This, in turn, could have made it difficult to 
identify subtle changes in expression profiles along the dorsal-ventral axis.  Support for 
this statement comes from the finding that Phox2b expression shows a dorsal expansion 
of its r2 ventral expression column in Hoxa2-/- versus WT mice (Davenne et al. 1999).  
Phox2b+ MNs arise from the Nkx2.2+ pMNv domain (Pattyn et al. 2003).  Furthermore, 
in ovo electroporation of chick embryos with a Nxk2.2-expressing vector results in 
ectopic expression of Phox2b (Pattyn et al. 2003).  Hence, this information suggests that 
there may be a change in Nkx2.2’s expression profile that has been overlooked.  Further 
research is needed in order to resolve this issue, as well as to examine Hoxa2’s role in 
OG specification in r2 and r3.  
In addition to Hoxa2, circumstantial evidence suggests that other Hox TFs could 
be important for OG specification in specific rhombomeres.  For example, Olig2 
expression, which specifically demarcates the pMN domain (Gaufo et al. 2003; Novitch 
et al. 2001), is absent in r5 in Hoxa3-/-;Hoxb3-/- mice (Gaufo et al. 2003).  Accordingly, 
these mice exhibit a loss of somatic MNs in this region (Gaufo et al. 2003).  As somatic 
MNs arise from the pMN domain prior to OGs (Fu et al. 2002), these results suggest that 
Hoxa3 and Hoxb3 could be important for OG specification in r5.   Interestingly, Olig2 
expression in the pMN domain is also dramatically decreased in Raldh2 mutant mice 
(Novitch et al. 2003).  Therefore, this suggests that Hox TFs could affect OG 
specification as downstream effectors in the RA signaling pathway.  Further research is 
needed to verify this.  In addition, further research is needed to examine the role of 
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Hoxa2 in different OPC lineages.  In order to determine its function(s) in a specific 
lineage, however, the elimination of the other OPC lineages may be required. 
In comparison to specification, the research conducted utilizing the CG4 cell line 
has demonstrated for the first time a role for Hoxa2 in OG differentiation [Figure 5.4].  
Although the mechanism by which it affects differentiation is unknown, we speculated 
that it may be mediated by PSA-NCAM.  Contrary to our hypothesis, however, we found 
that the percentage of PSA-NCAM+ cells is significantly lower in cells over-expressing 
Hoxa2 [Figure 5.5]. Therefore, it appears unlikely that Hoxa2’s effect on OG 
differentiation is mediated by PSA-NCAM. 
Due to the fact that Hox genes are regulated by RA (Simeone et al. 1990), we also 
examined the effect of RA treatment on CG4 cells.  The results of this experiment 
showed that the effect of RA on CG4 cell differentiation is affected by its concentration, 
as well as the treatment time [Figure 6.1].  Furthermore, the percentage of PSA-NCAM+ 
cells is significantly lower in the 1 μM RA 4h and 10 nM RA 1d treatment groups than 
the 10 nM RA 4h treatment group [Figure 6.4].  Although it was not directly 
demonstrated, the results suggest that RA’s effect on OG differentiation and PSA-NCAM 
expression may be mediated in part by Hoxa2.   
How RA could inhibit OG differentiation is unknown but it may involve its ability 
to enhance Sox9 and Sox6 expression.  In particular, RA enhances the mRNA expression 
of both Sox9 (Sekiya et al. 2000) and Sox6 (Hamada-Kanazawa et al. 2004a; Hamada-
Kanazawa et al. 2004b) in specific cell lines.  In addition, researchers have identified 
three potential RAREs upstream of the Sox9 promoter (Afonja et al. 2002).  As Sox9 
enhances Sox6 mRNA expression (Stolt et al. 2006), RA-induced expression of Sox9 
could indirectly enhance the expression of this SoxD TF.  Sox6 could then inhibit OG 
differentiation via interfering with the function of Sox10.  Interestingly, there is 
circumstantial evidence to suggest that Hox TFs could be involved in this signaling 
pathway since potential HBSs have been identified in putative regulatory elements of the 
Sox9 gene (Akiyama et al. 2007), therefore, suggesting that Sox9 could be a downstream 
target of Hox TFs. 
As RA also promotes OG differentiation (Barres et al. 1994; Pombo et al. 1999), 
the most obvious question that arises is whether Hox TFs could also act downstream of 
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RA in this process.  There are 39 mouse and human Hox/HOX genes (Akin and Nazarali 
2005; Favier and Dollé 1997; Santagati and Rijli 2003; Scott 1992); therefore, specific 
Hox TFs could either inhibit or promote OG differentiation.  Alternatively, evidence 
suggests that the role of Hox TFs, including Hoxa2, could be dependent on its 
surrounding environment.  Researchers have found that certain Smads (for Sma and 
Mad), which are downstream effectors in the BMP signaling pathway (Kloos et al. 2002), 
can modulate the DNA binding and transcriptional activities of Hox TFs (Li et al. 2006).  
Resolution of this issue will have to await further research. 
Although RA’s and Hoxa2’s effect on PSA-NCAM expression cannot account for 
their effect on OG differentiation, it suggests that Hoxa2 and RA could have additional 
roles in OG development.  In particular, PSA-NCAM is important for PDGF-directed 
OPC migration (Zhang et al. 2004).  Hence, based on the above results it could be 
hypothesized that RA and Hoxa2 could negatively impact OPC migration.   
PSA-NCAM is also expressed by neurons; however, its expression decreases with 
a time frame that corresponds with the onset of myelination (Charles et al. 2000).  
Researchers have found that removing the polysialic acid moiety from the NCAM 
molecule results in an increase in the number of myelinated internodes (Charles et al. 
2000).  As Hoxa2 is expressed by neurons (Nicolay et al. 2004a)[Figure 3.4] the above 
findings, along with our data, would suggest that over-expressing Hoxa2 in neurons could 
lead to an increase in the number of myelinated axons.  Interestingly, researchers have 
found that PSA-NCAM is re-expressed by demyelinated axons but not remyelinated 
axons in MS plaques (Charles et al. 2002).  Therefore, this suggests that PSA-NCAM 
does not favor myelination in both normal, as well as disease states.   
The findings described in this thesis not only represent the first step in the process 
of determining the function(s) of Hoxa2, but it also provides an indication of the role(s) 
of other Hox TFs in OG development.  In turn, the ultimate goal for elucidating the 
regulation of oligodendrogenesis is to be able to utilize the information to develop new 
therapeutic treatments for MS.  MS is an inflammatory disease of the CNS characterized 
by focal areas of demyelination that appear to be immune driven (Hemmer et al. 2006; 
Lucchinetti et al. 1999; Ozawa et al. 1994; Prineas et al. 1993a; Prineas et al. 1993b; 
Raine 1997a; Raine 1997b; Storch et al. 1998).  The resulting plaques, which can vary in 
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diameter from less than a millimeter to several centimeters (Al-Omaishi et al. 1999), can 
occur anywhere within the white matter but favor the periventricular regions, optic 
nerves, brainstem, cerebellum and spinal cord (Wingerchuk et al. 2001).  Early symptoms 
often include varying degrees of one or more of the following: weakness or reduced 
dexterity in one or more limbs, monocular vision loss, double vision, gait instability, and 
ataxia.  As the disease worsens, the majority of patients exhibit bladder dysfunction, 
fatigue, and heat sensitivity (Hauser and Oksenberg 2006).  Based on the frequency and 
duration of their symptoms MS patients can be divided into three groups.  Approximately 
85% of patients present with relapsing-remitting MS (RR-MS), which is characterized by 
acute attacks of worsening neurological function followed by a variable degree of 
recovery (Hauser and Oksenberg 2006; Lublin and Reingold 1996).  In many cases RR-
MS develops into progressive disability at which point the patients are diagnosed with 
secondary progressive MS.  In contrast, around 15% of patients display a relatively 
steady decline in neurological function and are, therefore, said to have primary 
progressive MS (PP-MS) (Hauser and Oksenberg 2006; Lublin and Reingold 1996).  
Interestingly, although the median age of onset of MS is approximately 28 (Wingerchuk 
et al. 2001),  patients presenting with PP-MS are usually older than those with RR-MS 
(Hauser and Oksenberg 2006).  
Currently most therapeutic treatments for MS are aimed at managing individual 
symptoms (Crayton et al. 2004) or the inflammatory/immune response (Hauser and 
Oksenberg 2006).  However, there is increasing attention being given to developing 
therapeutic treatments aimed at promoting remyelination of the demyelinated regions.  
Remyelination, which is characterized by axons exhibiting thin myelin sheaths, does 
occur to some extent in MS but fails with disease progression (Brück et al. 1994; Ozawa 
et al. 1994; Prineas et al. 1993a; Prineas et al. 1993b; Prineas et al. 1989; Raine and Wu 
1993).  Although there are two possible sources of remyelinating cells, adult OPCs or 
surviving OGs, current research supports the former (Chang et al. 2000; Gensert and 
Goldman 1997; Levine and Reynolds 1999).  Hence, remyelination would require these 
adult OPCs to proliferate, migrate, differentiate, and finally remyelinate the demyelinated 
axons.  Recent research has found that during remyelination the expression profiles of 
several TFs are reminiscent of those seen during normal development (Arnett et al. 2004; 
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Fancy et al. 2004; Sim et al. 2002; Watanabe et al. 2004).  Hence, it could be postulated 
that these TFs play similar roles in both instances.  Although the function of most TFs has 
not been analyzed in the context of remyelination, there is evidence supporting this 
statement for Olig1.  In particular, in the absence of Olig1, PLP/DM20 and MBP 
expression is markedly reduced in the P0 (Lu et al. 2002) and P14 (Xin et al. 2005) spinal 
cord and undetectable in the P14 corpus callosum, neocortex and striatum (Xin et al. 
2005).  Although the density of PLP/DM20-expressing cells is found to be similar in the 
adult unlesioned spinal cord of WT and Olig1-/- mice, it is significantly decreased in the 
mutant mice two weeks following lysolecithin-induced demyelination (Arnett et al. 
2004).  Hence, these results suggest that Olig1 is important for OG differentiation during 
normal development, as well as during remyelination.    
Knowledge regarding the role(s) of particular signaling pathways and TFs during 
normal oligodendrogenesis may be useful in identifying potential reasons for 
remyelination failure in MS.  For instance, researchers have found that Notch1 and its 
downstream effector, Hes5, are expressed by immature oligodendroglial cells within and 
around active MS lesions lacking remyelination.  The Notch ligand, Jagged1, is also 
expressed in these lesions but not in lesions exhibiting remyelination (John et al. 2002).  
As a result, it could be postulated that prolonged activation of the Notch signaling 
pathway by standard Notch ligands could inhibit OG differentiation and, hence, impair 
remyelination.  Initial support for this statement comes from the recent finding that 
inhibition of Notch signaling in mice with experimental autoimmune encephalomyelitis is 
associated with increased remyelination and decreased axonal damage in comparison to 
control (Jurynczyk et al. 2005).  Therefore, identifying transcriptional cascade anomalies 
within demyelinated lesions may lead to the development of therapeutic treatments aimed 
at enhancing endogenous remyelination. 
Furthermore, knowledge regarding the transcriptional regulation of normal OG 
development may also aid in establishing stem cell therapy as a feasible means of 
remyelinating MS lesions.  For instance, the success of this treatment depends upon the 
ability of directing these cells to become OGs.  As the TF Olig2 is important for OG 
specification in various regions of the embryonic CNS (Lu et al. 2002), it may be useful 
in this regard.  Indeed, researchers have found that transfecting NSCs obtained from 
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embryonic murine brains with Olig2 results in most cells becoming mature OGs.  
Furthermore, in contrast to control NSCs, these Olig2-transfected NSCs are found to 
actively participate in remyelinating cuprizone-induced demyelinated regions in the 
corpus callosum following transplantation (Copray et al. 2006).  Hence, understanding 
the transcriptional control of normal oligodendrogenesis will aid in the development of 
multiple therapeutic treatments aimed at promoting remyelination of MS lesions.  
It becomes evident from the above discussion, however, that researchers need to 
be aware of the fact that a specific treatment may affect more than the cell of interest.  
For example, whereas removal of the polysialic acid moiety from the NCAM molecule in 
neurons would likely aide in remyelination, its removal from OPCs may hinder 
remyelination by impairing the migration of these cells.  In addition, although 
information regarding the regulation of OG development will be extremely beneficial in 
determining mechanisms by which to promote remyelination in MS lesions, it has to be 
kept in mind that the demyelinating environment could potentially alter the function of 
particular TFs.    
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8.0 FUTURE DIRECTIONS  
 
8.1 Hoxa2 
Although the findings of this thesis primarily support a role for Hoxa2 in OG 
differentiation, there is reason to believe that it could also affect oligodendroglial 
specification, migration, and myelination.  For instance, TF patterning defects evident in 
r2 and r3 of Hoxa2-/- mice (Davenne et al. 1999) suggest that OG specification could be 
affected in these regions of the hindbrain.  In order to address this issue, 
immunohistochemical and/or in situ hybridization histochemical analysis should be 
conducted on transverse hindbrain sections of Hoxa2 transgenic mice at the levels of r2 
and r3 utilizing the following markers: Nkx2.2, Pax6, Olig2, Mash1, Ngn2, Pax3, Gsh1, 
and Dbx2.  Each of these TFs has been selected for specific reasons.  In particular, 
Nkx2.2 was chosen because it specifically demarcates the pMNv domain from which 
ventral OPCs arise in r2 and r3 (Pattyn et al. 2003).  Furthermore, Nkx2.2 appears to be 
important for OG specification in the anterior hindbrain since a dorsal expansion of its 
expression domain, as seen in Nkx6.1;Nkx6.2 double mutant mice, is associated with 
ectopic OG development (Vallstedt et al. 2005).  In turn, Pax6 was selected since it 
defines the dorsal boundary of the pMNv domain along with Nkx2.2 (Pattyn et al. 2003).  
In addition, its mRNA expression is reduced in r2 and r3 of Hoxa2-/- mice (Davenne et 
al. 1999).  Olig2 was chosen because it is expressed by OPCs in both ventral and dorsal 
regions of the hindbrain (Fu et al. 2002; Vallstedt et al. 2005).  Similarly, Pax3 was 
selected since dorsal OPCs have been shown to arise within its neuroepithelial expression 
domain (Vallstedt et al. 2005).  Furthermore, a ventral shift in Pax3’s expression profile 
has been found in r2 and r3 of Hoxa2-/- mice (Davenne et al. 1999).  Gsh1 and Dbx2 
were included because they define the ventral limit of the dorsal OPC domain (Vallstedt 
et al. 2005).  Finally, Mash1 and Ngn2 were selected since both factors exhibit expression 
anomalies in r2 and r3 of Hoxa2-/- mice (Davenne et al. 1999).  Furthermore, down-
regulation of these TFs appears to be important for the switch from neurogenesis to 
gliogenesis (Tomita et al. 2000; Zhou et al. 2001).  Due to the fact that the anomalies in 
gene patterning exhibited by Hoxa2-/- mice are seen at E10.5 (Davenne et al. 1999), 
histochemical analyses should first be conducted at this age in order to confirm these 
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findings, as well as look at other TFs.  Subsequently, it should also be conducted at E13.5 
since both dorsal and ventral OPCs are found in the hindbrain at this time (Vallstedt et al. 
2005).  Based on the initial findings it may be necessary to include an intermediary age, 
such as E12, in order to determine if there are any anomalies in the switch from 
neurogenesis to gliogenesis in these areas.  This would, in turn, require the inclusion of 
the neuronal marker Islet1, as well as the oligodendroglial marker PDGFαR.  Overall 
these experiments will enable the researcher to identify if there are any anomalies in 
temporal and/or spatial aspects of OG specification in both ventral and dorsal regions of 
r2 and r3. 
In comparison to OG specification, potential roles for Hoxa2 in migration and 
myelination are based on the finding that Hoxa2 over-expression results in significantly 
fewer PSA-NCAM+ cells.  As PSA-NCAM is important for PDGF-directed migration, it 
suggests that Hoxa2 could negatively impact this trait.  To test this directly, migration 
assays should be conducted utilizing WT and Hoxa2-S CG4 cells according to the 
protocols described in Zhang et al. (2004).  In turn, as PSA-NCAM axonal expression 
appears to negatively impact myelination (Charles et al. 2000), it suggests that Hoxa2 
could play a favorable role in this process.  As a result, it would be interesting to see if 
PSA-NCAM axonal expression is up-regulated in r2 and r3 of Hoxa2-/- mice and whether 
this up-regulation could negatively impact myelination.  However, as the Hoxa2 mutant 
mice die shortly after birth, r2/r3 explant cultures would have to be used in order to see if 
there are any anomalies in myelination.  
Further research is also needed in order to determine how Hoxa2 regulates PSA-
NCAM expression.  Although preliminary evidence suggests that it could involve 
multiple mechanisms, such as regulating NCAM and PST expression, it is currently 
unknown whether this regulation is direct or indirect.  In regards to NCAM expression, 
evidence suggests that Hoxa2’s effect could be direct since HBSs have been found in the 
NCAM promoter region (Hirsch et al. 1990).  However, in order to test this directly, CG4 
cells should be co-transfected with a Hoxa2-expressing plasmid, as well as a NCAM-
luciferase reporter construct utilizing the protocol described in Nielsen et al. (2004).  In 
comparison to NCAM, it is currently unknown whether HBSs are present in the promoter 
region of the PST gene.  Therefore, the first step would be to examine the PST promoter 
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region for potential Hoxa2-binding sites (Zeynep Akin’s PhD Thesis 2004).  If potential 
binding sites are identified, electrophoretic mobility shift assays should be conducted in 
order to show that Hoxa2 can indeed bind to these sites.  Luciferase assays should then be 
conducted if Hoxa2-binding sites are found in the promoter region.  
In addition to normal OG development, I believe it would be worthwhile to see if 
Hoxa2 could affect the ability of oligodendroglial cells to actively participate in the 
remyelination.  Previous research has shown that transplanted CG4 cells actively 
participate in repairing regions of persistent demyelination within the X-irradiated rat 
spinal cords (Franklin et al. 1996).  Therefore, I would suggest repeating this experiment 
utilizing WT and Hoxa2-S CG4 cells in order to determine if there are any discrepancies 
in the remyelination capabilities of these two cultures.   
Finally, research will need to be conducted in order to determine the mechanism 
by which Hoxa2 affects OG differentiation.  I would suggest utilizing RT-PCR and/or 
western blot analysis in order to determine if the expression of Sox9 and/or Sox6 is 
enhanced in the Hoxa2-S CG4 cultures in comparison to the WT.    
8.2 Retinoic acid 
Although there is much research supporting a role for RA in OG development, 
little is known regarding RA signaling in oligodendroglial cells.  For instance, 
information regarding the expression of Raldhs, CYPs, RARs, and RXRs during OG 
development is extremely limited.  Therefore, I would suggest conducting double 
immunofluorescent analysis in vitro and in vivo in order to determine if the expression of 
these factors changes as oligodendroglial cells progress from precursors to mature 
myelinating cells.  In turn, the information obtained from these studies could 
subsequently be utilized in the development of future experiments.  For example, if 
Raldhs are found to be expressed by differentiated OGs but not OPCs, this would suggest 
that only the former is capable of synthesizing RA.  This, in turn, could be subsequently 
tested in culture assays utilizing the protocol previously described by Mey and 
Hammelmann (2000).  Similarly, if OPCs express different RARs than OGs, this would 
suggest that these receptors are active at different stages of OG development.  This, then, 
could be tested in culture assays via activating specific RARs at different stages of OG 
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development utilizing retinoid specific agonists, such as those described in Goncalves et 
al. (2005).  
One interesting finding of this thesis was that both RA and Hoxa2 have similar 
effects on OG differentiation and PSA-NCAM expression.  As a result, it would be 
worthwhile to determine if Hoxa2 could act as a downstream effector of RA in 
oligodendroglial cells.  Hence, quantitative RT-PCR analysis should be conducted in 
order to examine the level of Hoxa2 mRNA expression in CG4 cells at 8, 16, and 36 
hours after RA exposure.  In addition, the expression of Sox9 and Sox6 should be 
analyzed as they may be involved in RA’s ability to inhibit OG differentiation.  As RA 
has been shown to induce the expression of multiple Hox genes in carcinoma cell lines 
(Simeone et al. 1990; Simeone et al. 1991), the mRNA levels of additional genes, such as 
Hoxb1, Hoxb2, and Hoxa1, should also be analyzed.  This is especially important since 
there is evidence suggesting that both auto- and cross-regulatory Hox TF loops could 
affect Hoxa2 expression (Lampe et al. 2004; Tümpel et al. 2007).  Furthermore, as genes 
located at the 3΄ end of the Hox clusters are more sensitive to RA than those located at the 
5΄ end (Simeone et al. 1990), I would suggest treating the CG4 cells after one day with 10 
nM RA.  This treatment regimen was chosen for two reasons.  First, treatment of 
carcinoma cells with 10 nM RA was found to induce primarily 3′ genes (Simeone et al. 
1990).  Secondly, treatment of CG4 cells with 10 nM RA after one day was found to not 
only impair OG differentiation but also reduce PSA-NCAM expression.  If RA is found 
to induce Hoxa2 expression, further research would then have to be conducted in order to 
establish a functional relationship between the two.    
8.3 Miscellaneous 
In addition to RA, several other factors affect Hoxa2 expression in the hindbrain.  
For example, FGF8 appears to repress Hoxa2 expression in r1 (Irving and Mason 2000).  
Based on this information, as well as our Hoxa2-S CG4 data, it would be expected that 
treating oligodendroglial cells with FGF8 would promote OG differentiation.  However, 
FGF8 treatment, similar to Hoxa2 over-expression, inhibits OG differentiation without 
affecting proliferation (Fortin et al. 2005).  In order to resolve this issue, further research 
is needed to determine if FGF8 treatment actually affects Hoxa2 expression in 
oligodendroglial cells.  In comparison to FGF8, Krox20 induces Hoxa2 expression in r3 
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and r5.  Although Krox20 is not expressed by oligodendroglial cells (Sock et al. 1997), 
they do express Krox24 (Sock et al. 1997), which appears to bind to a similar DNA target 
sequence as Krox20 (Lemaire et al. 1988).  Hence, further research, in the form of 
electrophoretic mobility shift assays and luciferase assays, should be conducted in order 
to determine if Krox24 could act upstream of Hoxa2 in oligodendroglial cells.  
Furthermore, as Krox24’s role in OG development is currently not known, this 
information could lead to the identification of potential functions which then could be 
tested.   
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9.0 CONCLUSION 
The data presented in this thesis is the first to show that Hoxa2 is expressed 
throughout OG development, diminishing only with the acquisition of a myelinating 
phenotype.  In addition, it is the first to demonstrate a role for Hoxa2 in OG 
differentiation.  Furthermore, it is also the first to identify PSA-NCAM as a downstream 
target of Hoxa2.  As PSA-NCAM affects oligodendroglial migration and myelination, 
this information suggests that Hoxa2 could also affect these processes.  Furthermore, the 
results suggest that over-expression of Hoxa2 exhibits similar effects on OG 
differentiation and PSA-NCAM expression as RA treatment.  Based on these findings, 
further research is needed in order to determine if Hoxa2 could affect migration and/or 
myelination, as well as whether it could act as a downstream effector of RA in 
oligodendroglial cells.  
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Appendix A. Carnegie/Theiler staging [Butler and Juurlink (1987) and Theiler (1972)] 
 
Carnegie 
Stage 
 
9 
 
10 
 
11 
 
12 
 
13 
 
14 
 
15 
Theiler Stage  1st  1/2  12 2nd 1/2 
12&13 
 
14 
 
15 
 
16 
 
17 
 
18 
E# 9 9.5 10 10.5 11 11.5 12 
# Somites (S) 1-3 4-12 13-20 21-29 30-34 35-39; cranial 
Ss become  
indistinct 
cranial Ss 
indistinct 
Length 
(mm) 
----- ----- 1.2-2.5 1.8-3.3 3.1-3.9 3.5-4.9 5-6 
CNS Open neural 
plate 
Neural folds 
begin to fuse in 
cerv.area (7S 
stage) 
Cranial 
neuropore (NP) 
closes 
Cranial NP 
closed; 
posterior NP 
constricted-still 
open 
Caudal NP 
closed 
Cerebral 
vesicles distinct 
Cerebral  
Vesicles 
 distinct 
Rotation Lordosis 
 
Early: lordosis;  
Turning begins 
(8S stage) 
Turning 
complete; 
Ventral 
curvature 
----- ----- ----- ----- 
Eyes ----- ----- Lens placode 
(LP) appears 
LP- distinct 
thickening  
Lens pit in 
older members 
Early: lens 
vesicle- deep 
pockets 
Older: pore like 
Pore like 
Ears ----- Otic placodes Otic placode 
invaginates 
Otic vesicle 
closed in older 
members 
Otic vesicle 
closed 
Otic vesicle 
closed; 
develops a 
short  
Endolymphatic 
Duct (ED) 
Otic vesicle 
closed;  
Elongated ED 
 
Nose  ----- ----- Olfactory 
placode (OP) 
appears 
OP- distinct 
thickening  
OP indents Lip around OP Deepened 
olfactory pit 
Branchial Bars  ----- ----- 1 & 2  3 present 1, 2, 3; 3rd & 4th 
concave 
1st bar- 
mandibular & 
maxillary 
1st bar- 
mandibular & 
maxillary 
Limb Buds 
(LB) 
----- ----- cranial LB @ 
S15 
indistinct 
Cranial LB 
distinct @ Ss 
8-12 
Caudal LB @ 
Ss 23-28 
Elongated LBs 
curve forward 
& medially  
Elongated  
LBs curve 
 forward & 
medially 
Tail ----- ----- ----- ----- Short stump Tail curves as 
well 
Tail lateral to 
head 
Hair ----- ----- ----- ----- ----- ----- ----- 
Other ----- ----- Spiral form-
caudal end 
lying on R head 
Narrow long 
vitelline duct 
 Cervical sinus 
appears 
----- Pontine  
flexure  
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Carnegie 
Stage 
 
16 
 
17 
 
18 
 
19 
 
20 
 
21 
 
22 
 
23 
Theiler 
Stage  
 
19 
 
20 
 
20 
 
21 
 
21 
 
22 
 
22 
 
23 
E# 12.5 13 13.5 14 14.5 15 15.5 16 
# Somites 
(S) 
Caudal Ss 
sharply  
defined 
Lumbosacral 
 Ss distinct 
; thoracic not 
Lumbosacral  
Ss indistinct 
Ss only  
visible  
in tail 
Ss only  
Visible 
 in tail 
Ss only  
Visible 
 in tail 
Ss only  
visible  
in tail 
Ss only  
Visible 
 in tail 
Length 
(mm) 
6-7 7-8 8-9 9-10 10-11 10.5-11.5 11-12 12-14 
CNS Cerebral 
vesicles 
 distinct 
Cerebral 
vesicles  
Distinct 
Cerebral 
Vesicles 
 distinct 
Cerebral 
 Vesicles 
 distinct 
Cerebral 
 Vesicles 
 distinct 
Cerebral 
 Vesicles 
 distinct 
Cerebral 
 Vesicles 
 Distinct 
Cerebral 
 Vesicles 
 Distinct 
Rotation ----- ----- ----- ------ ----- ---- ---- ---- 
Eyes Retinal 
 pigment 
appears;  
complete 
closure of 
LV 
Retinal 
 pigment 
Retinal 
 pigment 
Eyelids-sm 
 folds-not 
yet cover 
eyeball  
Lger eyelids 
Covering 
 most of  
eyeball 
Lger 
eyelids 
Eyelids Eyelids 
About 
 to 
 close 
Ears 6 auricular 
hillocks; 
ED longer 
6  
auricular 
 hillocks 
6  
auricular 
 hillocks 
Hillocks 
fuse=pinna 
pinna Pinna 
covers ~ ½  
of external 
auditory 
meatus 
(EAM) 
Pinna 
covers ~ ½  
of EAM 
Pinna 
 covers  
>1/2 EAM 
Nose  Nostrils 
narrowed to 
slits  
Nostrils Nostrils Nostrils Nostrils Nostrils Nostrils Nostrils 
Branchial 
Bars  
1st bar- 
mandibular 
& maxillary 
1st bar- 
 mandibular 
& maxillary 
1st bar- 
mandibular & 
maxillary 
1st bar- 
mandibular 
& maxillary 
1st bar- mandibular 
& maxillary 
1st bar-  
mandibular 
& maxillary 
1st bar- 
mandibular 
 &  
maxillary 
1st bar- 
mandibular 
 &  
maxillary 
Limb 
Buds 
(LB) 
Cranial LB- 
distal  
rounded 
footplate & 
proximal 
 region 
Forelimb:  
footplate  
has toe rays; 
hindlimb  
footplate 
distinct 
fFP:more  
pronounced  
toe rays,  
beginning to 
crenate; 
hFP: slight  
toe rays 
fFP-
crenated; 
hFP-toe 
rays 
Fingers  
separate;  
hFP- 
crenation 
Fingers 
distinct; 
 hFP= deep 
indents but 
not separate 
Distal  
phalanges  
separate 
of toes 
Complete 
Separation 
of toes;  
distinct  
flexures @  
elbow 
&knee 
Tail Longer Longer Longer Longer 
(curved to 
left) 
Longer 
Longer Longer Longer 
Hair ----- ----- ----- ----- 5 rows of 
whiskers,primordial  
hair follicle  
above ea eye  
&  in front  
of ea ear 
Numerous 
hair 
follicles 
recognized 
in the skin 
except head 
Numerous 
hair 
follicles 
recognized 
in the skin 
except head 
Hair  
Follicles 
cover entire 
 body 
Other ----- ----- ----- ----- ----- ----- ----- ----- 
 
 
Theiler 
Stage 
24 25 26 27 
E# 17 18 19 NB 
Length 14-18 16.5-20 18-23 23-27 
Eyes Eyelids fused Eyelids fused & 
thickened 
Eyes barely visible 
thru lids 
Eyes 
closed 
Ears EAM almost completely  
covered by pinna 
  Ears 
closed 
Limbs Fingers 2-5 parallel; toes still 
diverge 
Fingers & toes 
parallel 
  
Hair  Hair follicles over entire body Short Whiskers Longer whiskers  
Skin Becoming wrinkled Wrinkled & 
thickened 
Markedly wrinkled  
Other Anterior back almost straight    
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Appendix B. Supplemental Figures 
 
 Chapter 3 
 
 
 
Figure S3.1 Hoxa2 is expressed by some Nkx2.2-immunoreactive cells (arrow) in the 
mantle layer of the E12.5 spinal cord. [Scale bar = 100 μm] 
 
 
 
 
 
 
 
 
Figure S3.2 At E14.25 Olig2+ cells are occasionally seen in the marginal layer 
(arrows). [Scale bar = 100 μm] 
 
 
 161
 
Figure S3.3 There are few if any cells in the E14.25 spinal cord that co-express 
Nkx2.2 (red) and Olig2 (green). [Scale bar = 100 μm] 
 
 
 
 Chapter 4 
 
 
Figure S4.1 β-tubulin expression in the E12.5 spinal cord. [Scale bar = 100 μm] 
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 Chapter 5 
 
Figure S5.1 CG4 cells exhibit similar morphological and antigenic phenotypes as 
primary oligodendroglial cells. [Scale bar = 100 μm] 
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Figure S5.3 Hoxb3 was expressed throughout OG development. 
 
Primary mixed glial cell cultures from neonatal murine cerebral hemispheres were grown 
in culture for 18 days.  Double immunofluorescent staining was conducted with each of 
the four OG markers [A2B5 (A), O4 (D), GalC (G), and MBP (J)] and Hoxb3 (B, E, H, 
K).  Cells were visualized using nuclear fluorescent Hoechst counterstain (C, F, I, L). 
Each row illustrates micrographs obtained from individual filters [fluorescein (A, D, G, 
J), rhodamine (B, E, H, K), and DAPI (C, F, I, L)] of the same field.  Arrows demarcate 
representative Hoxb3 immunoreactive cells.  Scale bar = 100μm.   
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Chapter 6 
 
 
Figure S6.1 Regardless of the experimental condition there are only a few MOG+ 
cells. [Scale bar = 100 μm] 
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Hoxd1 is Expressed by Oligodendroglial Cells and Binds to a
Region of the Human Myelin Oligodendrocyte Glycoprotein
Promoter in vitro
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Abstract (1) Little information exists on the role of
clustered Hox genes in oligodendrocyte (OG) devel-
opment. This study examines the expression profile
of Hoxd1 and identifies a potential downstream target
in the OG lineage.(2) Immunocytochemical analysis
of primary mixed glial cultures demonstrated Hoxd1
was expressed throughout OG development. (3) A
human myelin protein gene, myelin oligodendrocyte
glycoprotein (MOG), was identified as a putative
downstream target of Hoxd1 through Genbank
searches utilizing the Hoxd1 homeodomain consen-
sus binding sequence. (4) The dissociation coefficient
constant (KD) and dissociation rate constant (kd) of
the Hoxd1–MOG complex, determined using elec-
trophoretic mobility shift assays (EMSAs), were
estimated to be 1.9 · 107 M and 1.3 · 103 s1,
respectively. The DNA–Hoxd1 homeodomain com-
plex had a half-life (t1/2) of 15 min. (5) Mutational
analysis of Hoxd1–MOG complexes revealed the
binding affinity of M1 (with mutation from 105450-
TAAT-301051 to TACT within the consensus binding
site) and M2 (with mutation from -105450-TAATTG-
30-1049 to TAATCC within the consensus binding site)
probes to the MOG promoter was severely affected.
Thus the TAATTG core of the binding sequence
appears important for Hoxd1 specificity. (6) Analysis
of the involvement of TAAT sites adjacent to the
consensus sequence in Hoxd1 binding showed the
binding affinity of the M3 probe was affected, but not
as severely as the M1 and M2 probes. These in vitro
results suggest the TTTAATTGTA sequence is
involved in Hoxd1 binding to the MOG promoter
but neighboring TAAT sites may also be needed.
Thus, MOG may be a target of Hoxd1.
Keywords Oligodendrocytes  Homeodomain 
Hoxd1  DNA-binding  MOG
Introduction
Oligodendrocytes (OGs) are the cells possessing the
ability to assemble a myelin sheath around axons in
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the central nervous system (CNS) (Southwood et al.
2004). In culture, OG development has been shown to
progress through a number of distinct stages charac-
terized by specific antigenic phenotypes. In particu-
lar, during early stages of oligodendrogenesis, A2B5+
oligodendrocyte precursor cells (OPCs) and O4+ pro-
OGs actively proliferate (Fok-Seang and Miller 1994)
and migrate (Noble et al. 1988). Subsequently, loss of
these traits and the emergence of galactocerebroside
(GalC) expression (Fok-Seang and Miller 1994;
Noble et al. 1988) signal terminal differentiation into
premyelinating OGs. Finally, progression to the
mature myelinating phenotype occurs when the cells
synthesize myelin proteins and elaborate sheet-like
membranes (Duchala et al. 1995).
Interestingly, as these cells progress from precur-
sors to mature myelinating OGs, they express a
dynamic combination of transcription factors (TFs),
which can be divided into specific families. In many
cases, multiple members of a particular TF family
have been shown to be expressed by oligodendroglial
cells. For example, two members of the Hox TF
family, Hoxa2, and Hoxb4, have been shown to be
expressed throughout oligodendrogenesis in vitro
(Nicolay et al. 2004a, b). This family consists of 39
mouse and human Hox genes organized into four
clusters (Hox A, B, C, D) and located on different
chromosomes (Scott 1992; Favier and Dolle´ 1997;
Santagati and Rijli 2003; Akin and Nazarali 2005).
These genes, in turn, are characterized by a 180-base
pair (bp) homeobox, which encodes a 60-amino acid
homeodomain (McGinnis et al. 1984a, b). Through
the homeodomain, Hox TFs can regulate the expres-
sion of downstream effector genes by binding to
specific nucleotide sequences (Hoey and Levine
1988).
In this study, we examined the expression of
another Hox TF, Hoxd1, in oligodendroglial cells. As
with Hoxa2 and Hoxb4, Hoxd1 expression was found
throughout OG development in vitro. Interestingly, a
Hoxd1 consensus binding sequence was subsequently
identified in the human myelin oligodendrocyte
glycoprotein (MOG) promoter. Equilibrium and
kinetics studies carried out with electrophoretic
mobility shift assays (EMSAs) showed specific
affinity (KD, 1.9 · 107 M; Kd, 1.3 · 103 s1; t1/2,
15 min) of the Hoxd1 homeodomain for the MOG
promoter region. Mutational analysis with EMSA
showed the proposed Hoxd1 binding site is important
for the binding affinity of the protein to the MOG
promoter region, but adjacent TAAT sites may also
be involved. Hence, these in vitro results suggest
Hoxd1 could play a role in OG differentiation and/or
maturation via affecting the expression of MOG.
Materials and Methods
Primary Glial Cultures
Cerebral hemispheres from newborn mice were
dissected in Dulbecco’s modified Eagle’s medium/
F12/10% fetal bovine serum (DMEM/F12/10% FBS).
Subsequently, single cell suspensions, obtained by
forcing diced tissue through a 75-mm Nitex mesh,
were plated in DMEM/F12/10% FBS for 4 days to
allow adherence of the cells. They were then cultured
for two sequential 1-week periods, first in a B104
conditioned medium, then in a low serum-containing
(0.3%) growth medium (GP medium) [described
previously by Gard and Pfeiffer (1990) and Doucette
and Devon (1994)] supplemented with 10 ng/ml basic
fibroblast growth factor (bFGF). Culture medium was
changed every 4 days.
Immunocytochemistry
Immunocytochemistry utilized the following primary
antibodies: anti-Hoxd1 (1:200), A2B5 (1:10, hybrid-
oma; American Type Cell Culture [ATCC]), O4
(1:10, hybridoma; Sommer and Schachner 1981),
anti-galactocerebroside (GalC) (1:20, hybridoma;
Ranscht et al. 1982), and anti-myelin basic protein
(MBP) (1:800; Sternberger Monoclonals, Lutherville,
MD). The secondary antibodies used included goat
anti-mouse IgM fluorescein isothiocyanate (FITC)
(1:100, A2B5/ O4; Sigma, Oakville, ON), donkey
anti-mouse IgG FITC (1:50, GalC; BIO/CAN Scien-
tific, Mississauga, ON), and goat anti-rabbit IgG CY3
(1:200, Hoxd1; BIO/CAN Scientific). Double label-
ing Hoxd1 with A2B5, O4, GalC, or MBP was
conducted using a procedure previously described in
Nicolay et al. (2004a, b) with the following modifi-
cations: cells were incubated for 4 h at room
temperature (RT) in anti-Hoxd1 diluted in 1% SM/
0.03% TX. The cells’ nuclei were stained using
Hoechst dye (Sigma, ON).
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Polymerase Chain Reaction (PCR)
All PCR amplifications, which utilized the Perkin
Elmer GeneAmpR PCR kit with AmpliTaqR poly-
merase, were conducted with a DNA thermal Cycler
(Perkin Elmer, Applied Biosystems, Mississauga,
ON).
Amplification of the Hoxd1 Gene Fragment
PCR was employed to clone a 327 bp sequence (696–
1023 bp) using the Hoxd1 gene as the DNA template
(Nazarali et al. 1992). The amplified gene fragment
consists of the N-terminal region just after the hexa-
peptide domain, the homeodomain, and the entire C-
terminal region of the Hoxd1 gene (Nazarali et al.
1992). Amplifications, performed using primer A and
primer B (listed in the Plasmid and oligonucleotides
section below), consisted of an initial denaturation at
948C for 3 min followed by 30 cycles of 1 min at 948C,
2 min at 588C, 1 min at 728C, and a final extension of
10 min at 728C. The PCR-amplified Hoxd1 DNA
fragment was digested with EcoRI and XhoI and
subcloned into the pFLAG-2 expression vector (Sigma,
St. Louis, MO) inframe with the methionine codon.
The Hoxd1 clone was sequenced using a T7 Sequenase
v2.0 kit (Amersham Pharmacia Biotech, Piscataway,
NJ) to confirm the sequence of PCR-amplified DNA.
Expression and Purification of the Hoxd1
Homeodomain Protein
Transformed E. coli XL1-Blue Supercompetent cells
(Stratagene, La Jolla, CA) containing the pFLAG-
Hoxd1 plasmid were grown in LB medium containing
ampicillin (5 mg/ml) at 378C. The Hoxd1 C-term
protein was then isolated using an established proto-
col (Hoey 1990) and purified as described by Kumar
and Nazarali (2001). The protein was quantified using
the Bio-Rad DC protein assay (Bio-Rad laboratories,
Hercules, CA), and the yield of purified Hoxd1
homeodomain protein was found to be approximately
100 mg/l of culture.
Electrophoretic Mobility Shift Assays (EMSA)
Protein–DNA complexes were resolved by EMSA as
described elsewhere (Ekker et al. 1991; Phelan et al.
1995; Kumar and Nazarali 2001) with the following
modifications: (a) Binding reactions were performed
in a total volume containing: Labeled probe
(50,000 cpm), purified Hoxd1 protein, 1· binding
buffer (10 mM HEPES, pH 7.9; 1 mM MgCl2;
60 mM KCl; 0.5 mM EDTA; 1 mM DTT; 10%
glycerol), and 1.0 mg poly dI-dC. (b) Samples were
incubated for 30 min at room temperature and then
separated on 8% non-denaturing polyacrylamide gel
(1.5 mm thickness) at 48C in 0.25· Tris–borate–
EDTA (TBE) buffer for 1.5 h at 140 V. (c) Gels were
fixed, dried, and visualized by autoradiography. The
complex protein–DNA was sliced out of the dry gel
and counts taken from the scintillation counter. In
experiments that contained competitor DNA, excess
unlabeled oligonucleotide over the labeled probe was
included. Nuclear extracts from embryonic mice at
12 days (E12) post coitum were prepared as described
by Lahiri and Ge (2000). Five mg of nuclear extracts
was used for each EMSA reaction. The anti-Hoxd1
antibody was added to specific reactions at a
concentration of 1:500 to the mixture of nuclear
extracts and DNA probe.
Competition Assay
Competition assays involved the use of cold probes
including the wild type probe (Normal), and M1 to
M3 mutant probes containing a specific change in the
41 bp region of the MOG promoter (see below).
Concentrations of 0, 5·, 50·, and 150· of cold probe
to hot normal probe were used individually and
EMSAs were performed.
Plasmid and Oligonucleotides
All oligonucleotides used in this study were pur-
chased from Invitrogen-GIBCO-BRL (Burlington,
Ontario, Canada). The target MOG oligonucleotide
encompassing the 1072 to 1032 region of the
promoter (N) and the mutated MOG probes (M1 to
M3) were as follows:
MOG (N) 50-CAAATTTTTAATTTTATTTAAT-
TGTAATTAATTTTAAGTGG-30
MOG (M1) 50-CAAATTTTTAATTTTATTTA-
CTTGTAATTAATTTTAAGTGG-30
MOG (M2) 50-CAAATTTTTAATTTTATTTAA-
TCCTAATTAATTTTAAGTGG-30
MOG (M3) 50-CAAATTTTTACTTTTATTTAA-
TTGTACTTACTTTTAAGTGG-30
Cell Mol Neurobiol
123
The primers used to amplify Hoxd1 were:
Primer A 50-TCGAATTCCTGTCCGAATATGG-
AGCC-30
Primer B 50-TGCTCGAGGGAAGGCTCTTGAG-
CCTG-30
Single-stranded oligonucleotides used in EMSA
were annealed by heating equal molar amounts of
oligonucleotides in STE buffer (10 mM Tris pH 8.0,
50 mM NaCl, 1 mM EDTA) above their denaturing
temperature (948C), followed by slow cooling to an
ambient temperature. The oligonucleotides were then
stored at 48C overnight before use in EMSA.
Results
Expression by Oligodendroglial Cells
Immunocytochemical analysis of primary mixed glial
cell cultures demonstrated Hoxd1 was expressed
throughout OG development (Fig. 1). In particular,
Hoxd1 expression was evident in A2B5, O4, GalC,
and MBP-immunoreactive oligodendroglial cells.
Although the location of immunoreactivity was
primarily nuclear, cytoplasmic staining was also
observed at later stages of oligodendrogenesis. In
addition, Hoxd1 expression did not appear to be
limited to OGs as demonstrated by the expression of
Hoxd1 in cells that were negative for the aforemen-
tioned oligodendroglial markers.
Hoxd1 Protein Interacts with the Human MOG
Promoter
Utilizing the recently characterized optimal DNA-
binding site sequence of the Hoxd1 homeodomain,
potential downstream targets were searched through
GenBank. One putative downstream target identified
by this search was the myelin protein, MOG. In
particular, the Hoxd1 consensus-binding site for
MOG was located in the promoter region of the gene
from 1047 bp to 1057 bp upstream of the start codon.
Subsequently, a double stranded oligonucleotide,
which represented the sequence from nucleotide
position 1072 to 1032 within the MOG promoter
and contained the putative Hoxd1 binding sequence,
ATTTAATTGTA (Kumar and Nazarali 2001), was
synthesized and used as a probe in EMSA to
determine its binding characteristics with purified
recombinant Hoxd1. As shown in Fig. 2, the presence
of a single DNA–protein complex was observed
when the probe was incubated with Hoxd1 (lane H),
but not with the control bovine serum albumin (lane
C). The presence of 10, 20, and 50-fold excess of
unlabeled wild type MOG promoter oligonucleotide
in the reaction competed efficiently for the formation
of the complex, as the intensity of the band decreased
with increasing fold of the unlabeled competitor and
was completely blocked after addition of 50-fold
excess cold probe (Fig. 2, lane 3, 4, 5).
Hoxd1 Protein Specificity for MOG Promoter
We conducted gel retardation assays (Ekker et al.
1991; Florence et al. 1991; Iler and Abate-Shen 1996)
to quantify the binding affinities of Hoxd1–MOG
complexes. The dissociation coefficient constant (KD)
of Hoxd1 was determined by using a fixed amount of
probe with increasing concentration of the protein.
We determined a KD in the order of 1.9 · 107 M for
the Hoxd1–MOG complexes from a plot of fraction
bound vs. Hoxd1 homeodomain concentration (nM)
(Fig. 3A, B); KD was estimated to be the protein
concentration that produced half maximal protection
(Ekker et al. 1991; Kumar and Nazarali 2001).
The dissociation rate constant (kd), a measure of
the stability of the complex between Hoxd1 and the
MOG promoter sequence, was calculated from
kinetic studies (Fig. 4A, B). Using the formula ln
(fraction DNA bound) = kdt (Ekker et al. 1991;
Kumar and Nazarali 2001), we determined a kd of
1.3 · 103 s1. The time required for half of the
DNA–protein complex to dissociate, defined as the
half-life (t1/2), was calculated using the formula t1/
2 = ln(0.5)/kd (Ekker et al. 1991; Kumar and
Nazarali 2001) and found to be 15 min.
Effect of MOG Promoter Mutation on Binding
Specificity of Hoxd1 Protein
To determine whether the core 105450-TAATTG-
301049 site within the Hoxd1 binding site on the
MOG promoter, as well as three other TAAT sites
flanking the putative binding site, were required for
binding Hoxd1, we synthesized probes M1 to M3 and
performed EMSAs with each probe. The M1 probe
contained a one-nucleotide change from normal
probe (105450-TAAT-301051 to TACT) within the
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putative Hoxd1 binding site. The EMSA results
(Fig. 5A, B) establish that Hoxd1 binds to the
MOG promoter with the intact TAAT site, but poorly
with the M1 probe (TACT). Thus, Hoxd1 protein
binding to the MOG promoter requires this
TAAT site. Similarly, the M2 probe, which contained
a two-nucleotide change from normal probe (105450-
TAATTG-301049 to TAATCC) within the consen-
sus-binding site, also bound poorly to Hoxd1 protein
(Fig. 5A, B). Therefore, the Hoxd1 protein appears to
require the TG nucleotide just after the TAAT site for
efficient binding to the MOG promoter sequence. The
M3 probe had a one-nucleotide change on three
TAAT sites (TAAT to TACT at positions 1041 to
1044, 1045 to 1048, and 1061 to 1064)
flanking the consensus-binding site. Results show the
binding of M3 to the Hoxd1 protein decreases, but
not as significantly as noted for M1 and M2. Thus,
these results suggest the ATTTAATTGTA binding
site is involved in the in vitro binding specificity of
Hoxd1 to MOG. However, one or more of the
flanking TAAT sites may also play a role in the
binding of Hoxd1.
EMSA was performed with different ratios of cold
to hot normal probe (0, 5·, 50·, 150·). Similarly,
each oligonucleotide (M1 to M3) was used as a cold
probe in EMSA. As shown in Fig. 6(A), the presence
of a single DNA–protein complex is observed when
the probe is incubated with the Hoxd1 protein (lane
2), but not with control bovine serum albumin (lane
1). The presence of 50-fold and 150-fold excess of
the unlabeled wild type (normal) MOG promoter
oligonucleotide (lane 8 and 9, respectively) in the
reaction competed efficiently for the formation of the
complex. Similarly, 50· or 150· excess cold probe
(M1, M2, M3) is sufficient to out-compete hot normal
probe in each assay. At 5· excess cold probe, N cold
competitor (Fig. 6A, lane 7), and M3 (Fig. 6B, lane 7)
have almost the same intensity band, although M3
appears slightly more intense. However, M1 (Fig. 6A,
Fig. 1 Hoxd1 is expressed
throughout oligodendrocyte
development. Primary
mixed glial cells were
grown in culture for a total
of 18 days. Double
immunofluorescent staining
was performed with Hoxd1
(B, E, H, K) and one of the
four OG markers [A2B5
(A), O4 (D), GalC (G),
MBP (J)]. The nuclei were
visualized utilizing
HOECHST fluorescent
counterstain. Each row
illustrates micrographs
obtained from individual
filters [fluorescein (A, D, G,
J), rhodamine (B, E, H, K),
and DAPI (C, F, I, L)] of
the same field. Arrows
identify representative
Hoxd1 immunoreactive
oligodendroglial cells.
Bar = 100 mm for
Fig. (A–L)
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lane 3) and M2 (Fig. 6B, lane 3) have more intense
bands than both M3 and N probes. This suggests M1
and M2 are unable to compete efficiently at this ratio
of cold probe to hot probe, and the core binding
sequence involved in Hoxd1 binding to the MOG
promoter is TAATTG.
Hoxd1 Protein Binds to MOG in Embryonic Mice
Cells
In addition to establishing that Hoxd1 recombinant
protein binds to MOG, we determined Hoxd1 binding
activity to MOG promoter in nuclear extract to
confirm our results. Nuclear extract from embryonic
mice at 12 days (E12) post coitum was used in EMSA
experiments. As shown in Fig. 7, a single large band
representing the MOG–protein complexes is formed
(lanes 3–6). Furthermore, increasing the protein
concentration in the nuclear extract results in an
increased intensity of the bands (lanes 3–6). These
results, therefore, suggest homeodomain proteins/
cofactors in nuclear extract bind to the MOG
promoter sequence.
In order to establish if Hoxd1 may be one of the
binding proteins in the nuclear extract, we performed
EMSA in the presence of antibodies directed against
Hoxd1 protein. The use of pre-immune serum and
labeled N probe did not result in a band shift or
formation of any specific complexes (Fig. 8, lane 1),
although the addition of the anti-Hoxd1 antibody
stopped the formation of specific complexes (Fig. 8;
lane 2 compared with lane 4).
Discussion
Hoxd1, a member of the labial subfamily of Hox TFs,
was recently shown to be expressed in the embryonic
murine telencephalon (Wolf et al. 2001), which is
Fig. 2 EMSA shows the Hoxd1 homeodomain can bind to the
MOG promoter region causing a shift. C = Control (BSA
protein in reaction mixture); H = Hoxd1 protein in reaction
mixture. The competition assay shows the probe is binding to
the protein. As the concentration of cold probe increases, the
shift band intensity decreases until it disappears. Lane 3 is 10·
the amount of cold probe to hot; Lane 4 is 20· the amount of
cold probe to hot; Lane 5 is 50· the amount of cold probe to hot
Fig. 3 (A) The affinity of the MOG promoter to the
homeodomain protein was measured by EMSA. Reactions
contained a fixed amount of labeled oligodeoxynucleotide and
increasing concentrations of Hoxd1 homeodomain. Bound and
free DNA were visualized by autoradiography. F, free probe.
(B) % fraction of bound DNA as a function of the log of the
Hoxd1 homeodomain protein concentration. The dissociation
coefficient constant (KD;1.9 · 107 M) was estimated as the
concentration of half-maximal binding under conditions of
excess protein when a plateau was reached and saturation of
DNA has occurred (Ekker et al. 1991)
Cell Mol Neurobiol
123
known to be populated by OPCs (Kessaris et al. 2006).
Therefore, in the present work, Hoxd1 expression was
analyzed in primary mixed glial cultures obtained
from the cerebral hemispheres of newborn mice.
These cultures consisted of oligodendroglial cells
grown on top of an astrocytic monolayer. The results
from this experiment show that although Hoxd1 is
expressed throughout OG development, the location
of immunoreactivity changed with differentiation. In
particular, cytoplasmic Hoxd1 expression was seen in
premyelinating and myelinating OGs. This cytoplas-
mic staining was not expected although it has also
been reported with other TFs (Armstrong et al. 1995;
Nicolay et al. 2004a, b; Wang et al. 2001).
Subsequently, an extensive search of Genbank
utilizing the Hoxd1 homeodomain consensus binding
site (Kumar and Nazarali 2001) identified the human
Fig. 4 (A) EMSA showing the decay of the homeodomain
Hoxd1–DNA complexes as a function of time. DNA–Hoxd1
complexes were incubated with cold probe in competition
reactions at time indicated. Lane 1–7= 0, 2.5, 5, 7.5, 10, 15 and
20 min. 0 min indicates binding reactions were loaded
immediately on gel after addition of cold competitor. F, free
probe with no protein. (B) Data were plotted as a function of ln
(fraction DNA bound) against various time (min) intervals. The
dissociation rate constant, kd, was calculated using the
equation: ln (fraction DNA bound) = kdt (Ekker et al. 1991)
Fig. 5 (A) EMSA was performed using normal (N) and
mutated (M1, M2, and M3) probes with the same molar
concentration of probe (50,000 cpm) and Hoxd1 protein
(400 nM). The N probe binds strongly to Hoxd1, whereas
M1 and M2 bind very weakly to the probe. M3 binds stronger
than M1 or M2. C = Bovine serum albumin protein + labeled
normal (N) MOG probe. (B) Comparison between normal and
three mutated MOG promoter elements for affinity of Hoxd1
binding. These results suggest TAAT and TG sites within the
consensus Hoxd1 binding site are involved significantly in the
specific binding of Hoxd1. Line connected by triangles (m)
represents the fraction of normal (N) probe bound to the Hoxd1
protein. Line connected by crosses (·) represents the fraction
of mutated (M3) probe bound to the Hoxd1 protein. Line
connected by circles (d) represents the fraction of mutated
(M1) probe bound to the Hoxd1 protein and line connected by
squares (j) represents the fraction of mutated (M2) probe
bound to the Hoxd1 protein. (See methods and materials for
details of probes used; N, M1 to M3)
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myelin protein gene, MOG, as a potential down-
stream target of Hoxd1. MOG, which is a component
of myelin protein in the CNS, is expressed on the
surface of oligodendroglial processes and myelin
sheaths (Brunner et al. 1989; reviewed in Johns and
Bernard 1999). Interestingly, reports indicate MOG is
alternatively spliced in humans (Ballenthin and
Gardinier 1996; Pham-Dinh et al. 1995) but not mice
(Ballenthin and Gardinier 1996).
The binding kinetics of the Hoxd1 protein to a 41
base pair region of the human MOG promoter
containing the Hoxd1 consensus sequence were
examined using EMSAs. From these mobility shift
experiments, the equilibrium dissociation coefficient
(KD) for Hoxd1 homeodomain at physiological ionic
strength was estimated to be 1.9 · 107 M. This KD
value for the recognition of the MOG promoter
containing the core TTTAATTGTA binding se-
quence indicates a relatively weak affinity as com-
pared to the KD reported for other homeodomains.
The absence of the N-terminal in our Hoxd1 protein
may have contributed to the low-binding affinity to
MOG. In particular, Gehring et al. (1994) suggest the
DNA binding constant of a truncated homeodomain
may be reduced about 10-fold relative to the intact
homeodomain. This reduced binding affinity can be
Fig. 6 (A, B) Competition assays were performed using
50,000 cpm of labeled MOG (N) promoter oligodeoxynucle-
otide and 400 nM of purified Hoxd1 homeodomain protein in
each reaction except for lanes containing 100 ng of BSA as
control (A: Lanes 1; B: Lane 1). Unlabelled competitor
oligodeoxynucleotides (N, M1, M2 or M3) were added in 5·,
50·, 150· excess to the hot probe (see text for details)
Fig. 7 EMSA was performed using E12 nuclear extract. A
single band was formed, representing the MOG–protein
complexes. With increasing concentration of E12 nuclear
extract (1·, 2·, 3·, 4·), the MOG-protein band increases in
intensity. Lane 1, F is free probe; Lane 2, Hoxd1 homeodomain
protein bound to N probe; Lane 3 is E12 nuclear extract
(3.5mg); Lane 4 is E12 nuclear extract (7 mg); Lane 5 is E12
nuclear extract (10.5 mg); Lane 6 is E12 nuclear extract
(14 mg). NE, nuclear extract. MOG–protein complexes
represent proteins in NE that bind to the MOG promoter
sequence (N)
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attributed to the absence of the DNA contacts formed
by the N-terminal arm of the intact homeodomain in
the minor groove.
The low affinity of the recombinant Hoxd1 for the
MOG promoter may also be due to its dependence on
cofactors not present in the EMSA reaction. Hoxd1
sequence contains an interaction motif (FEWMK)
that may allow it to interact with cofactors such as
Pbx in the same fashion as other members of the
family. In EMSA experiments where E12 nuclear
extract is used, the presence of cofactors and/or other
homeobox proteins may contribute to the affinity of
Hoxd1 to the MOG promoter. Interestingly, the KD
for Hoxd1 as determined by Kumar and Nazarali
(2001) was 8.6 · 109 M, which is higher than the KD
reported here. The use of a single Hoxd1 binding site
core as compared to multiple concatamer binding
sites in Kumar and Nazarali (2001) experiments may
have contributed to at least a 10-fold decrease in the
binding affinity of Hoxd1.
The MOG promoter sequence, which was used for
kinetic and equilibrium studies encompassing the
Hoxd1 consensus binding sequence TTTAATTGTA,
was subjected to one or two base alterations. The
results of the dissociation coefficient equilibrium
studies from mutant probes indicate oligonucleotides
containing the ATTTACTTGTA and ATT-
TAATCCTA core sequences exhibit very weak
affinities for Hoxd1 protein. A change in the binding
site by one base, from A to C in M1, and two bases,
from TG to CC in M2, significantly decreased the
affinity of Hoxd1 for the target sequence. Although
the change in the three other TAAT sites (TAAT to
TACT; M3 probe) flanking the core-binding site
resulted in a several fold decrease in binding affinity
compared to the normal probe, the M3 probe had a
higher affinity when compared to the mutational
change within the core binding site. Thus, the
TAATTG sequence seems to be important for Hoxd1
binding, but neighboring TAAT sites may also play a
role. Results of the competition assay suggest M1 and
M2 mutants are involved in Hoxd1 binding to the
MOG promoter region and, therefore, confirm the
equilibrium results. In contrast, the M3 probe com-
peted similarly to the normal probe, demonstrating
the TAAT sites adjacent to the core sequence in the
MOG promoter play a minimal role in Hoxd1 binding
in vitro.
In conclusion, Hoxd1 has been shown to be
expressed by oligodendroglial cells and binds to a
specific nucleotide sequence in the human MOG
promoter. These results suggest Hoxd1 may play a
role in OG differentiation and/or maturation. How-
ever, further research will be needed to determine
whether Hoxd1 inhibits or promotes this process in
oligodendroglial cells.
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Early Stages of Oligodendrocyte
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ABSTRACT Recent discoveries have enhanced our knowledge of the transcriptional
control of oligodendrocyte (OG) development. In particular, the transcription factors (TFs)
Olig2, Pax6, and Nkx2.2 have been shown to be important in the specification and/or
maturation of the OG lineage. Although numerous other TFs are expressed by OGs, little is
known regarding their role(s) in oligodendrogenesis. One such TF is the homeobox gene
Hoxa2, which was recently shown to be expressed by O4 pro-oligodendrocytes. The objec-
tives of this study were to examine the expression of Hoxa2 during the early stages of OG
development, as well as to determine whether Hoxa2 is required for specification and/or
early maturation of OGs. Immunocytochemical analysis of primary mixed glial cultures
demonstrated that Hoxa2 was expressed throughout oligodendrogenesis, diminishing only
with the acquisition of a myelinating phenotype. Serial transverse spinal cord sections from
embryonic days 12.5, 14.25, 16, and 18 Hoxa2/, Hoxa2/, and Hoxa2/ mice were
subjected to single and double immunohistochemical analysis in order to examine Hoxa2,
Olig2, Nkx2.2, and Pax6 expression profiles. Results obtained fromHoxa2/ andHoxa2/
mice suggested that Hoxa2 was expressed by migratory oligodendroglial cells. In addition,
comparison of spinal cord sections obtained from Hoxa2/, Hoxa2/, and Hoxa2/ mice
suggested that specification and earlymaturation of OGs proceeded normally in the absence
of Hoxa2, since there were no obvious alterations in the expression patterns of Olig2,
Nkx2.2, and/or Pax6. Hence, although Hoxa2 is expressed throughout OG development, it
does not appear to be critical for early stages of oligodendrogenesis in themurine spinal cord.
© 2004 Wiley-Liss, Inc.
INTRODUCTION
Oligodendrocyte precursor cells (OPCs), which are
characterized by platelet-derived growth factor--re-
ceptor (PDGFR) expression, first appear in the mu-
rine spinal cord at embryonic day 12.5 in a distinct
region of the ventral ventricular zone (vVZ) (Sun et al.,
1998). This region has been shown to correspond to the
motor neuron progenitor (pMN) domain, which is one
of five ventral progenitor domains formed in response
to graded Sonic hedgehog (Shh) concentrations (Eric-
son et al., 1997; Briscoe et al., 2000; Novitch et al.,
2001; Fu et al., 2002). In particular, Shh, which is
expressed and secreted by cells of the notochord and
floorplate, initially regulates the expression of the tran-
scription factors (TFs) that define the ventral (Nkx2.2/
Grant sponsor: Canadian Institutes of Health Research; Grant sponsor: Mul-
tiple Sclerosis Society of Canada; Grant sponsor: Rx&D/CIHR.
*Correspondence to: Adil J. Nazarali, Laboratory of Molecular Biology, College
of Pharmacy and Nutrition, University of Saskatchewan, 116 Thorvaldson
Building, 110 Science Place, Saskatoon, Saskatchewan.
E-mail: nazarali@duke.usask.ca
Received 23 August 2003; Accepted 18 December 2003
DOI 10.1002/glia.20028
Published online 30 April 2004 in Wiley InterScience (www.interscience.wiley.
com).
GLIA 48:14–26 (2004)
© 2004 Wiley-Liss, Inc.
Pax6) and dorsal (Olig2/Irx3) boundaries of the pMN
domain (Echelard et al., 1993; Bumcrot et al., 1995;
Marti et al., 1995; Ericson et al., 1997; Briscoe et al.,
2000; Novitch et al., 2001) (Fig. 1). Subsequently, re-
pressive interactions between these TFs maintain and
refine these boundaries (Briscoe et al., 2000; Novitch et
al., 2001).
Olig2, Pax6, and Nkx2.2 have been shown to be im-
portant in OPC specification and/or maturation, since
mutations of these genes lead to anomalies in these
processes (Sun et al., 1998; Qi et al., 2001; Lu et al.,
2002). Olig2, which specifically demarcates the pMN
domain and is expressed throughout oligodendrocyte
(OG) development, is critical for spinal cord oligoden-
drogenesis since, in its absence, expression of
PDGFR, Sox10, myelin basic protein (MBP), and pro-
teolipid protein (PLP)/DM20 are undetectable (Lu et
al., 2002). Mice deficient in Pax6 exhibit a delay of 1
day and a dorsalward shift in the appearance of
PDGFR cells (Sun et al., 1998). Nkx2.2 is important
in the spatial aspect of PDGFR OPC specification, as
demonstrated by a ventral expansion, as well as an
increased number of Olig2 cells (Qi et al., 2001). It has
also been hypothesized that a separate OPC lineage
arises from the Nkx2.2 V3 interneuron progenitor
(p3) domain. In addition, Nkx2.2 is important in OPC
maturation due to the fact that Nkx2.2 mutant mice
display not only a delay and reduction in MBP and
PLP/DM20 expression in the white matter but also an
absence of these markers in the gray matter (Qi et al.,
2001).
Although numerous other TFs are expressed by cells
of the OG lineage, researchers have been unable to
define where they ultimately lay in the transcriptional
control of oligodendrogenesis. One TF that has been
shown to be expressed by O4 pro-oligodendrocytes
(pro-OGs) is Hoxa2 (Hao et al., 1999). Hoxa2 is one of
39 mouse and human Hox genes that are organized
into four clusters (Hox A, B, C, D) located on different
chromosomes (Scott, 1992; Favier and Dolle´, 1997;
Santagafi and Rijla, 2003). These genes are character-
ized by a 180-base pair homeobox, which encodes a
60-amino acid homeodomain (McGinnis et al.,
1984a,b). Hox genes can regulate the expression of
downstream effector genes by binding to specific nucle-
otide sequences through the homeodomain (Hoey and
Levine, 1988; Hirsch et al., 1990; Jones et al., 1992,
1993). We have further investigated Hoxa2 expression,
as well as its potential role(s) in OG development. Our
results suggest that although Hoxa2 is expressed by
cells of the OG lineage, it does not appear to be critical
for the specification or early maturation of these cells
in the murine spinal cord.
Fig. 2. Oligodendrocytes (OGs) progress through four distinct
stages in vitro, characterized by unique morphological and antigenic
phenotypes (Sommer and Schachner, 1981; Abney et al., 1983; Raff et
al., 1983, 1985; Noble et al., 1988; Bansal et al., 1989; Fok-Seang and
Miller, 1994; Asou et al., 1995; Duchala et al., 1995; reviewed in
Miller, 1996).
Fig. 1. Platelet-derived growth factor--receptor (PDGFR) oligo-
dendrocyte precursor cells (OPCs) originate from the pMN domain.
Sonic hedgehog (Shh), which appears to exhibit a ventral to dorsal
decreasing concentration gradient, represses () and enhances (3)
the expression of class I (Pax6 and Irx3) and II (Nkx2.2 and Olig2)
transcription factors (TFs), respectively, that define the boundaries of
the pMN domain. These boundaries are further maintained and re-
fined by repressive interactions between these TFs (Echelard et al.,
1993; Marti et al., 1995; Ericson et al., 1997; Briscoe et al., 2000;
Novitch et al., 2001; Fu et al., 2002). N, notochord.
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MATERIALS AND METHODS
Primary Glial Cultures and
Immunocytochemistry
Cerebral hemispheres from newborn mice were dis-
sected in Dulbecco’s modified Eagle’s medium/ F12/10%
fetal bovine serum (DMEM/F12/10% FBS). Subse-
quently, single cell suspensions, obtained by forcing
diced tissue through a 75-m Nitex mesh, were plated
in DMEM/F12/10% FBS for 4 days to allow adherence
of the cells. They were then cultured for two 1-week
periods, respectively, in a B104 conditioned medium
Fig. 3. Hoxa2 was expressed throughout oligodendrocyte (OG) de-
velopment. Primary mixed glial cell cultures from neonatal murine
cerebral hemispheres were grown in culture for 18 days. Double
immunofluorescent staining was conducted with each of the four OG
markers [A2B5 (A), O4 (D), GalC (G), and MBP (J)] and Hoxa2
(B,E,H,K). Cells were visualized using nuclear fluorescent Hoechst
counterstain (C,F,I,L). Each row illustrates micrographs obtained
from individual filters [fluorescein (A,D,G,J), rhodamine (B,E,H,K),
and DAPI (C,F,I,L)] of the same field. Arrows demarcate representa-
tive Hoxa2 immunoreactive cells. Arrowheads demarcate a
Hoxa2MBP cell. The insets at the top right corner of the rhodamine
micrographs (E,H,K) show the percentage of O4, GalC, and MBP
cells that are immunoreactive for Hoxa2, respectively. [Percentages
depict averages calculated from two coverslips in which 100–200 OGs
were counted. The percentage of A2B5Hoxa2 cells was not deter-
mined because the monoclonal A2B5 antibody binds to cell-surface
antigens on oligodendrocyte type 2 astrocyte (O-2A) precursor cells,
which can give rise to either OGs or type 2 astrocytes depending on
culture conditions (Eisenbarth et al., 1979; Abney et al., 1983; Raff et
al., 1983), and therefore is not specific to the OG lineage.] Scale bar 
100 m.
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and a low serum-containing (0.3%) growth medium (GP
medium) [described previously by Gard and Pfeiffer
(1990) and Doucette and Devon (1994)] supplemented
with 10 ng/ml basic fibroblast growth factor (bFGF).
Culture medium was changed every 4 days.
Immunocytochemistry used the following primary
antibodies: anti-Hoxa2 (1:800; Hao et al., 1999), A2B5
(1:10, hybridoma; American Type Cell Culture
[ATCC]), O4 (1:10, hybridoma; Sommer and
Schachner, 1981), anti-galactocerebroside (GalC) (1:20,
hybridoma; Ranscht et al., 1982), and anti-MBP (1:800;
Sternberger Monoclonals, Lutherville, MD). A2B5, O4,
GalC, and MBP were used to mark cells at different
stages of OG development (Fig. 2). In particular, the
monoclonal antibody A2B5 was used to recognize a
complex ganglioside expressed on the surface of OPCs
(Eisenbarth et al., 1979; Abney et al., 1983). The mono-
clonal antibody O4 recognized surface epitopes ex-
pressed by pro-OGs (Bansal et al., 1989). GalC, the
major galactosphingolipid of myelin, marked pre-my-
elinating OGs (Ranscht et al., 1982). Finally, expres-
sion of myelin proteins, such as MBP, marked mature
myelinating OGs. Double labeling Hoxa2 with A2B5,
O4, or GalC was conducted using a procedure previ-
ously described by Doucette and Devon (1994) with the
following modifications: live cells were incubated for 30
min at 37°C in A2B5, O4, or anti-GalC monoclonal
antibodies diluted in phosphate-buffered saline (PBS);
the blocking and permeabilization steps were combined
with a 30-min incubation in 3% skim milk powder
solution containing 0.1% Triton X (3% SM/0.1% TX);
and cells were incubated for 4 h at room temperature
(RT) in anti-Hoxa2 diluted in 1% SM/0.03% TX. The
secondary antibodies used included goat anti-mouse
IgM fluorescein isothiocyanate (FITC) (1:100, A2B5/
O4; Sigma, Oakville, ON), donkey anti-mouse IgG
FITC (1:50, GalC; BIO/CAN Scientific, Mississauga,
ON), and goat anti-rabbit IgG CY3 (1:200, Hoxa2; BIO/
CAN Scientific). Between incubations, cultures were
washed twice for 5 min in PBS. Double immunostain-
ing Hoxa2 with MBP was done using a procedure pre-
viously described by Doucette and Devon (1994), with
two modifications: (1) cells were incubated in anti-MBP
and then anti-Hoxa2 for 30 min and 4 h, respectively;
(2) between anti-MBP and anti-Hoxa2 incubations,
cells were rinsed in PBS and were then incubated for
30 min in 3% SM/0.1% TX. The nuclei in all cell cul-
tures were stained using Hoechst dye (Sigma, ON). The
percentage of OGs (O4, GalC, and MBP cells) that
expressed Hoxa2 was calculated from 2 coverslips in
which 100–200 OGs were counted.
Hoxa2 Transgenic Mice and
Immunohistochemistry
Hoxa2/, Hoxa2/, and Hoxa2/ C57 black mice
(Gendron-Maguire et al., 1993) were obtained by timed
heterozygous matings. They were staged according to
the Carnegie (Butler and Juurlink, 1987) and Theiler
(1972) staging systems. The embryonic ages (E) and
corresponding Carnegie (C)/Theiler (T) stages used
were as follows: E12.5 (C16/T19), E14.25 (C19/T21),
E16 (C23/T23), and E18 (T25); the Carnegie staging
system does not go beyond stage 23. Although
Hoxa2/ mice could be identified by pinna deformities
at later stages of embryonic development (i.e., E14),
genotypes were confirmed by polymerase chain reac-
tion (PCR) analysis (Gendron-Maguire et al., 1993).
Mouse embryos were fixed by immersion in 4% para-
formaldehyde at 4°C for 24–48 h depending on their
age. Embryos were then rinsed and stored in 20% su-
crose until they were processed. Serial cryostat sec-
tions (8 m) were collected on gelatin-coated coverslips
and allowed to dry for 1 h prior to staining. The
following primary antibodies were used: anti-Olig2
[gift of Dr. Hirohide Takebayashi (Takebayashi et al.,
2000); E12.5, 1:4,000; rest, 1:2,000], anti-Nkx2.2 (hy-
bridoma; Developmental Studies Hybridoma Bank;
E12.5, 1:4; rest, 1:2), anti-Hoxa2 (Hao et al., 1999;
E12.5, 1:3,000; rest, 1:1,500), and anti-Pax6 (Develop-
mental Studies Hybridoma Bank; E12.5, 1:1,000; rest,
1:500). Immunohistochemical analysis of Hoxa2 and
Olig2 was performed with a procedure previously de-
scribed by Hao et al. (1999). The following modifica-
tions were made with regard to time intervals: PBS
washes were 8 min instead of 10 min; 3% SM/0.1% TX
blocks/permeabilizations were 20 min versus 30–60
min; and incubation in the secondary antibody was 30
min versus 45 min.
Immunohistochemical analysis of Nkx2.2 and Pax6
used a modified Mouse on Mouse (MOM)™ (Vector
Laboratories, Burlingame, CA) staining procedure.
Briefly, sections were washed twice in PBS for 8 min,
followed by a 20-min permeabilizing/blocking period in
Fig. 4. Transcription factor (TF) expression during oligodendrocyte
precursor cell (OPC) specification in the spinal cords of Hoxa2/,
Hoxa2/, and Hoxa2/ mice. Top two rows: Transverse thoracic
spinal cord sections from E12.5 (A–D) and E14.25 (E–H) Hoxa2/
and Hoxa2/ mice were immunolabeled with anti-Hoxa2 (A,E) anti-
Nkx2.2 (B,F), anti-Olig2 (C,G), and anti-Pax6 (D,H) as described in
Materials and Methods. Initially Hoxa2 expression was localized to
the ventral horns (vh) at E12.5 (A), after which it was expressed
throughout the mantle layer (ml) (E). Nkx2.2 and Olig2 cells, which
were initially localized to distinct domains in the vVZ at E12.5 (B,C),
had begun to migrate into theml by E14.25 (F,G). Pax6 was expressed
in the ventricular zone (vz) at both stages (D,H), with occasional
immunoreactive cells found in the ml by E14.25 (H). Middle row:
Transverse thoracic spinal cord sections from E12.5 (I,J) and E14.25
(K,L) Hoxa2/ and Hoxa2/ mice were double immunolabeled with
anti-Hoxa2 (I,K) and anti-Islet1(Isl1)(J) or anti-Nkx2.2(L), respec-
tively. Each fluorescent image illustrates micrographs obtained from
individual filters [fluorescein (I,K) and rhodamine (J,L)] of the same
field. Hoxa2 was co-expressed by Isl1 motor neurons at E12.5 (I,J).
At E14.25 Hoxa2Nkx2.2 cells were demonstrated in the mantle
layer (K,L). Bottom two rows: Transverse thoracic spinal cord sections
from E12.5 (M–O) and E14.25 (P–R) Hoxa2/ mice were immunola-
beled with anti-Nkx2.2 (M,P), anti-Olig2 (N,Q), and anti-Pax6 (O,R).
Expression profiles of Nkx2.2, Olig2, and Pax6 were similar in the
presence (B–D,F–H) and absence (M–R) of Hoxa2. Analyses were
conducted with at least three spinal cord sections at each stage of
development in both the presence and the absence of Hoxa2. Signifi-
cant discrepancies were not observed and any inconsistencies were
primarily due to the way the sections were cut, in particular, the
location (G,Q) and shape (H,R) of the central canal varied between
some sections. Scale bars  100 m.
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3% SM/0.1% TX. After two 2-min washes in PBS, sec-
tions were incubated for 1 h in MOM Mouse Ig blocking
solution. Following a 5-min block in MOM diluent,
sections were incubated at RT for 30 min and 10 min in
primary and secondary antibodies, respectively. Two
2-min PBS washes were done between incubations.
Endogenous peroxidase activity was then blocked by an
8-min incubation in a 0.3% hydrogen peroxide solution.
After two 4-min PBS washes, sections were incubated
in avidin-biotin complex (Vectastain Elite ABC; Vec-
tor) for 20 min at RT. The sections were subsequently
washed for 8 min in PBS and then 0.175 M sodium
acetate, respectively. For diaminobenzidine tetrahy-
drochloride (DAB) staining, a 2-min incubation was
performed as described previously by Hao et al. (1999).
Sections were then washed in PBS, dehydrated, and
mounted in Permount (Fisher Scientific, Nepean, ON).
For immunofluorescent double labeling, sections
were washed twice in PBS for 8 min, followed by a
20-min block/permeabilization in 3% SM/0.1% TX.
They were then incubated overnight in primary anti-
bodies [anti-Hoxa2 (1:200), anti-Olig2 (1:2,000), anti-
Pax6 (1:100), anti-Nkx2.2 (concentrate), anti-Islet1
(Developmental Studies Hybridoma Bank, 1:3,000),
and anti--tubulin (1:8,000)] diluted in 1% SM/0.03%
TX. After two 8-min PBS washes, sections were incu-
bated for 3 h in Alexa 594 and 488 secondary antibodies
(Molecular Probes, Eugene, OR). Finally, sections were
rinsed in PBS and were mounted in Citifluor (Merivac,
Montreal, QC). (When sections were stained for -tu-
bulin an additional 8-min incubation in Hoechst dye
was performed to identify nuclei.)
RESULTS
Hoxa2 Is Expressed Throughout OG
Development In Vitro
Immunocytochemical analysis of primary mixed neo-
pallial glial cell cultures demonstrated that Hoxa2 was
expressed throughout OG development, diminishing
only with the acquisition of a myelinating phenotype
(Fig. 3). In particular, greater than 95% of O4 pro-
OGs and GalC pre-myelinating OGs expressed Hoxa2
(Fig. 3E,H). As OGs matured to the MBP myelinating
phenotype, the percentage of Hoxa2-expressing cells
dropped to 56% (Fig. 3K). The location of immunoreac-
tivity was primarily nuclear; however, at the pre-my-
elinating stage cytoplasmic staining was also observed.
Although Hoxa2 was expressed in most cells in the OG
lineage, its expression in these mixed glial cell cultures
was not limited to OGs. This was demonstrated by the
expression of Hoxa2 in cells that were A2B5, O4, GalC,
and MBP-negative (Fig. 3B,E,H,K).
Hoxa2 Expression Is Not Required for OPC
Specification in the Murine Spinal Cord
At E12.5 (C16/T19) Hoxa2 was expressed predomi-
nantly in the ventral horns (Fig. 4A). In contrast,
Nkx2.2 and Olig2, which may mark separate OPC lin-
eages, were expressed in distinct regions of the vVZ in
Hoxa2/ and Hoxa2/ mice (Fig. 4B,C; data not
shown). In particular, Nkx2.2 was expressed in the p3
domain, which is adjacent to the floorplate. Olig2 was
expressed just dorsal to the Nkx2.2 p3 domain in the
pMN domain. Although Olig2 expression was re-
stricted to the vVZ, some Nkx2.2 cells were found in
the adjacent mantle layer (Fig. 4B). Double immuno-
fluorescent staining demonstrated that some of the
Nkx2.2 cells located in the mantle layer co-expressed
Hoxa2 (data not shown). Many Islet1 motor neurons
in the mantle layer also co-expressed Hoxa2 (Fig. 4I,J).
At E14.25 (C19/T21), Hoxa2 was expressed
throughout the mantle layer (Fig. 4E). Although at
E14.25, Nkx2.2 and Olig2 continued to be expressed in
the vVZ, Nkx2.2 and Olig2 cells were also found in
the mantle layer (Fig. 4F,G). Occasionally, Olig2-im-
munoreactive cells were observed in the marginal layer
at this stage of development (data not shown). Double
immunofluorescent staining demonstrated that few if
any cells exhibited co-expression of Nkx2.2 and Olig2
at E14.25 (C19/T21) (data not shown). However, most
Nkx2.2 cells located in the mantle layer expressed
Hoxa2 (Fig. 4K,L).
The absence of Hoxa2 expression in the vVZ during
OPC specification would suggest that it may not be
critical for this process in the spinal cord. To test this
directly, immunohistochemical analysis of Hoxa2/,
Hoxa2/, andHoxa2/ spinal cord sections were con-
ducted to determine whether Nkx2.2, Pax6, and/or
Olig2 expression profiles were altered in the absence of
Hoxa2. Hoxa2/ and Hoxa2/ mice were used inter-
changeably to represent the presence of Hoxa2, since
expression profiles were similar in both genotypes. Sin-
gle immunohistochemical analysis of Hoxa2/ mice
demonstrated that at E12.5 (C16/T19) Olig2 was ex-
pressed in an adjacent nonoverlapping domain with
Nkx2.2, whereas Pax6 was expressed dorsal to the
Nkx2.2 domain (Fig. 4B–D). Comparison of these ex-
pression profiles with those obtained from Hoxa2/
mice demonstrated that they were maintained in the
absence of Hoxa2 (4M-O). At E14.25 (C19/T21), when
immunoreactive cells were still evident in the vVZ,
expression profiles of Nkx2.2, Olig2, and Pax6 were
similar regardless of genotype (Fig. 4F–H,P–R). Double
immunofluorescent staining of Nkx2.2 and Olig2 or
Pax6 at E12.5 (C16/T19) confirmed that the expression
profiles were maintained in the absence of Hoxa2 (Fig.
5).
Hoxa2 Is Not Required for Early Maturation of
OGs in the Murine Spinal Cord
At E16 (C23/T23) and E18 (T25), Hoxa2 was ex-
pressed throughout the mantle layer, with occasional
immunoreactive cells also observed in the marginal
layer (Fig. 6A,E,I–K). Nkx2.2 and Olig2 cells contin-
ued to migrate into the mantle layer, and eventually
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these cells began to accumulate in the marginal layer
of Hoxa2/ and Hoxa2/ mice. This migration was
accompanied by a reduction and the eventual disap-
pearance of Nkx2.2 and Olig2 immunoreactive cells
in the vVZ at E16 (C23/T23) and E18 (T25), respec-
tively (Fig. 6B,C,F,G). Comparisons of Nkx2.2 and
Olig2 expression profiles from Hoxa2/ and Hoxa2/
mice with that of Hoxa2/ mice failed to reveal any
consistent changes in expression profiles (Fig. 6B–D,F–
H,L–Q).
Double labeling immunohistochemical analysis of
Olig2 and Nkx2.2 expression in Hoxa2/ and
Hoxa2/ mice demonstrated that with continued mat-
uration co-expression of these TFs became evident, es-
pecially in the marginal layer (Fig. 7A,B). Comparison
of these co-expression profiles with those obtained from
Hoxa2/ mice showed no detectable alterations (Fig.
7C,D). In addition, comparisons of Hoxa2/,
Hoxa2/, and Hoxa2/ mice demonstrated that the
accumulation of Olig2 cells in the marginal layer of
the developing spinal cord proceeded similarly regard-
less of genotype (Fig. 7E–H). Thus, the early matura-
tion of OGs proceeded normally in the absence of the
Hoxa2 gene.
Fig. 5. Oligodendrocyte precursor cell
(OPC) specification occurred normally in
the absence ofHoxa2. Transverse thoracic
E12.5 Hoxa2/ and Hoxa2/ spinal cord
sections were subjected to double immu-
nofluorescent labeling with anti-Nkx2.2
and anti-Olig2 (A–D) or anti-Nkx2.2 and
anti-Pax6 (E–H) antibodies as described
in Materials and Methods. Each row illus-
trates micrographs obtained from individ-
ual filters [fluorescein (A,C,E,G) and rho-
damine (B,D,F,H)] of the same field.
Nkx2.2 and Olig2 exhibit adjacent non-
overlapping expression domains in both
wild-type (A,B) and mutant (C,D) mice.
Nkx2.2 and Pax6 exhibit similar expres-
sion domains in both wild-type (E,F) and
mutant (G,H) mice. Scale bar  100 m.
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Figure 6.
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DISCUSSION
OG development in vitro progresses through a num-
ber of distinct stages, which are characterized by spe-
cific antigenic phenotypes (Fig. 2). During the early
stages of oligodendrogenesis, OPCs and pro-OGs,
which are characterized by A2B5 and/or O4 staining,
actively proliferate and migrate. Subsequently, loss of
these traits and the emergence of GalC expression sig-
nal terminal differentiation into pre-myelinating OGs.
Finally, progression to the mature myelinating pheno-
type occurs with the production of myelin proteins and
the elaboration of sheet-like membranes (Abney et al.,
1983; Fok-Seang andMiller, 1994; Duchala et al., 1995;
reviewed in Raff et al., 1985; Noble et al., 1988; Miller,
1996).
Although in situ hybridization and immunohisto-
chemical analysis have shown that Hoxa2 is expressed
in regions of the central nervous system (CNS), includ-
ing the myelencephalon, diencephalon, and spinal cord
(Tan et al., 1992; Wolf et al., 2001), Hao et al. (1999)
were the first to demonstrate the expression of Hoxa2
by cells of the OG lineage. In particular, Hao et al.
(1999) demonstrated that O4 pro-OGs, obtained from
E15 murine cerebral hemispheres, expressed Hoxa2.
To confirm these findings, as well as further investi-
gate Hoxa2 expression in cells of the OG lineage, an
immunocytochemical analysis was performed on pri-
mary mixed glial cultures obtained from the cerebral
hemispheres of newborn mice. These cultures consisted
of oligodendroglia that developed on top of an astrocytic
monolayer. The results showed that although Hoxa2
was expressed throughout OG development (Fig. 3),
the location of immunoreactivity, as well as the num-
ber of Hoxa2 OGs changed with maturation. In par-
ticular, Hoxa2 expression by OGs was primarily nu-
clear (Fig. 3B,E), however, cytoplasmic staining was
also observed at the pre-myelinating stage (Fig. 3H).
The reason for this cytoplasmic staining is unknown,
but it has been demonstrated with several other TFs
(Armstrong et al., 1995; Wang et al., 2001). Subse-
quently, there was a reduction in the number of
Hoxa2 myelinating OGs in comparison to Hoxa2
pre-myelinating OGs (Fig. 3H,K).
Researchers recently identified a subfamily of basic
helix-loop-helix (bHLH) TFs known as the Olig genes,
whose members include Olig1, Olig2, and Olig3 (Lu et
al., 2000; Takebayashi et al., 2000; Zhou et al., 2000).
Olig1 and Olig2 are co-expressed by cells in the pMN
domain of the developing spinal cord prior to PDGFR
(Lu et al., 2000; Zhou et al., 2000). In contrast, Olig3,
which is transiently expressed in the embryonic CNS,
is not co-expressed with Olig2 (Takebayashi et al.,
2002). Olig1 and Olig2 cells disperse throughout the
spinal cord in a ventral to dorsal manner similar to
that of PDGFR cells (Zhou et al., 2000). Further-
more, double in situ hybridization histochemical anal-
ysis has also demonstrated that PDGFR cells co-
express Olig1 and Olig2 (Lu et al., 2000; Zhou et al.,
2000). Hence they are believed to be the earliest known
markers of the OG lineage. In addition, Olig1 and Olig2
continue to be expressed in OGs into adulthood (Lu et
al., 2000; Takebayashi et al., 2000).
In the present study, Olig2 was used to identify cells
of the PDGFR OPC lineage. Although Olig2 initially
specifies motor neuron precursors at the early stages of
spinal cord development, it is downregulated as the
cells differentiate (Novitch et al., 2001). In addition, it
is not expressed by glial fibrillary acidic protein
(GFAP) astrocytes (Takebayashi et al., 2000), which
are also found in the CNS. These findings suggest that
during periods of oligodendrogenesis in the spinal cord,
Olig2 is specific to the OG lineage. Olig2 was used as
our OG marker instead of Olig1 for two reasons. First,
whereas the number of Olig2 cells has been shown to
be similar to that of PDGFR cells, Olig1 cells ap-
peared to outnumber PDGFR cells (Zhou et al.,
2000). Second, Olig2 has been shown to be critical for
OG development in the spinal cord since OPCs and
mature OGs failed to develop in its absence. In con-
trast, PDGFR cells appeared on schedule in the ab-
sence of Olig1; however, there was a delay in the ap-
pearance of Sox10, MBP, and PLP/DM20 expression in
the white matter of the spinal cord (Lu et al., 2002).
Research on OG development in the chick has led to
the hypothesis that a separate OPC lineage may also
arise from the Nkx2.2 p3 domain. Although all migra-
tor Olig2 cells co-express Nkx2.2 in the chick spinal
cord, Nkx2.2 cells that are weak or negative for Olig2
expression were found, and a portion of these cells
expressed O4 (Zhou et al., 2001; Fu et al., 2002). In
addition, 33% of A2B5 glial restricted precursor
cells, which were immunopurified from E13.5 rat spi-
nal cord, have been shown to be immunoreactive for
Nkx2.2. These Nkx2.2 cells were believed to be OGs
because few -tubulin neurons and GFAP astrocytes
expressed Nkx2.2 (Qi et al., 2001).
In our study, immunohistochemical analyses were
initiated at E12.5 (C16/T19) since Olig2 expression
Fig. 6. Transcription factor (TF) expression during oligodendrocyte
precursor cell (OPC) maturation in the spinal cords of Hoxa2/,
Hoxa2/, and Hoxa2/ mice. Top two rows: Transverse thoracic
spinal cord sections from E16 (A–D) and E18 (E–H) Hoxa2/ and
Hoxa2/ mice were immunolabeled with anti-Hoxa2 (A,E) anti-
Nkx2.2 (B,F), anti-Olig2 (C,G), and anti-Pax6 (D,H) as described in
Materials and Methods. At these stages Hoxa2 was expressed pre-
dominantly in the mantle layer (ml) (A,E). Nkx2.2 and Olig2 cells
continued to migrate into the ml and eventually accumulated in the
marginal layer (mal) (B,C,F,G). Pax6 expression was concentrated in
the ventricular zone at these stages, with occasional immunoreactive
cells found in the ml (D,H). Middle row: Transverse thoracic spinal
cord section from an E16 (I–K) Hoxa2/ mouse was double immuno-
labeled with anti-Hoxa2 (I) and anti-tubulin (J). -Tubulin staining
was used to demarcate the mal, which is populated primarily by glial
cells. Cells were visualized using nuclear fluorescent Hoechst coun-
terstain (K). Each fluorescent image illustrates micrographs obtained
from individual filters [fluorescein (I), rhodamine (J), and DAPI (K)] of
the same field. At later stages of development occasional Hoxa2 cells
(arrows) were found in the glial-rich mal. Bottom two rows: Trans-
verse thoracic spinal cord sections from E16 (L–N) and E18 (O–Q)
Hoxa2/ mice were immunolabeled with anti-Nkx2.2 (L,O), anti-
Olig2 (M,P), and anti-Pax6 (N,Q). Expression profiles of Nkx2.2,
Olig2, and Pax6 were similar in both the presence (B–D,F–H) and
absence (L–Q) of Hoxa2. Scale bars  100 m.
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would be downregulated in postmitotic motor neurons
at this time. In addition it corresponds to the emer-
gence of PDGFR expression in the vVZ (Sun et al.,
1998). At this stage, Hoxa2 was expressed predomi-
nantly in the ventral horns (Fig. 4A), which was in
direct contrast to Nkx2.2 and Olig2, which were ex-
pressed in the vVZ (Fig. 4B,C) of Hoxa2/ and
Hoxa2/ mice. Hence, our results suggest that Hoxa2
expression in OPCs occurs following specification. At
later stages, overlapping expression profiles of Hoxa2
with Nkx2.2 and Olig2 in the mantle layer suggest that
Hoxa2 is expressed by migratory OG cells. Unfortu-
nately, we were unable to conclusively show double
labeling of Hoxa2 and Olig2 because both antibodies
Fig. 7. Early oligodendrocyte
(OG) maturation proceeded nor-
mally in the absence of Hoxa2.
Transverse thoracic E16 Hoxa2/
and Hoxa2/ spinal cord sections
were subjected to double immuno-
fluorescent labeling with anti-
Nkx2.2 and anti-Olig2 (A–D) or
anti-Olig2 and anti--tubulin
(E–H) as described in Materials
and Methods. Each row illustrates
micrographs obtained from indi-
vidual filters [fluorescein (A,C,E,G),
rhodamine (B,D,F,H )] of the same
field. With continued maturation,
cells began to co-express Olig2 and
Nkx2.2 (arrows) in both heterozy-
gous (A,B) and mutant (C,D) mice.
Furthermore, the migratory pat-
tern of Olig2 cells was similar in
both heterozygous (E,F) and mu-
tant (G,H) mice, as demonstrated
by the accumulation of immunore-
active cells in the marginal layer
(mal). Scale bar  100 m.
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were rabbit polyclonals. However, we were able to dem-
onstrate co-expression of Hoxa2 by Nkx2.2 cells (Fig.
4K,L), which have been hypothesized to represent a
separate population of OPCs (Fu et al., 2002) as well as
co-expression of Nkx2.2 and Olig2 (Fig. 7A–D).
With continued maturation Hoxa2 expression in OGs
appeared to diminish as suggested by the finding that
Nkx2.2 and Olig2 cells greatly outnumbered Hoxa2
cells in the marginal layer (Fig. 6A–C,E–G). In con-
trast, Hoxa2 cells outnumbered Nkx2.2 and Olig2
cells in the mantle layer, which supported the in vitro
finding that cells in addition to OGs also express Hoxa2
(Fig. 6A–C,E–G). For example, Hoxa2 has been shown
to be expressed by Islet1 motor neurons and GFAP
astrocytes (Hao et al., 1999) (Fig. 4I,J). Although
Hoxa2 is not specific to the OG lineage, no TFs have
been shown to be expressed exclusively by OGs.
As most research regarding OG development has
involved the analysis of the rodent spinal cord, we
decided to focus our study on this area of the CNS.
Although Shh dependence and the ventral origin of
OPCs are similar in the spinal cord and brain (Pringle
and Richardson, 1993; Ono et al., 1995; Hall et al.,
1996; Orentas et al., 1999; Tekki-Kessaris et al., 2001;
Alberta et al., 2001; reviewed in Woodruff et al., 2001),
differences in OG development in these regions have
emerged. For example, Nkx2.2Olig2 cells are found
in the vVZ of the chick spinal cord prior to emigration
(Zhou et al., 2001; Fu et al., 2002). In contrast, in the
chick hindbrain only Nkx2.2 cells are found in the
vVZ at the onset of oligodendrogenesis with Olig2 ex-
pression only evident in migratory cells (Fu et al.,
2002). Takebayashi et al. (2000) have also shown dis-
crepancies in Olig1 and Olig2 expression in the murine
embryonic brain versus spinal cord. In particular, in
the murine embryonic brain Olig2 displayed a broader
expression domain than Olig1. In addition it was
shown that in certain brain regions numerous Olig2
cells were found, few of which co-expressed Olig1 or
2-3 cyclic nucleotide-3-phosphohydrolase (CNP)
(Takebayashi et al., 2000), the latter being a myelinat-
ing glial cell specific enzyme. Takebayashi et al. (2000)
concluded that Olig2 may not be limited to OGs in the
brain and hence may play a role in this region distinct
from Olig1. This conclusion is supported by the study of
Lu et al. (2002), who found that in the hindbrain and
areas of the forebrain, the early stages of OG develop-
ment proceeded largely unaltered in the absence of
Olig2. Hence, Olig2 does not appear to play a critical
role in OG development in certain brain regions. These
discrepancies may be partially due to differing expres-
sion profiles of regulatory TFs by cells of the OG lin-
eage along the anterior-posterior axis, such as the Hox
genes.
One potential role forHoxa2 in OG development may
be via its transcriptional regulation of neural cell ad-
hesion molecule (NCAM). NCAM, a cell surface glyco-
protein, exists as three prominent protein isoforms
(120,140,180 kD), which are encoded by four predomi-
nant transcripts arising from alternative splicing and
polyadenylation sites of a single gene (Barbas et al.,
1988). Examination of the 5 end of the NCAM gene has
revealed homeodomain binding sites (HBSs) that have
the potential to be regulated by homeobox genes (Hir-
sch et al., 1990; Jones et al., 1992, 1993). Hoxc6
(Hox3.3) and Hoxb9 (Hox2.5) have previously been
shown to enhance chloramphenicol acetyltransferase
(CAT) activity significantly via NCAM HBS (Jones et
al., 1992, 1993). In contrast, Hoxb8 (Hox2.4) decreased
HBS-I/ HBS-II- directed CAT activity, as well as
Hoxb9-enhanced activity (Jones et al., 1992). Hence
NCAM promoter activity may be the result of the com-
bined actions of numerous Hox genes. Furthermore,
mutations in NCAM HBSs resulted in alterations in
-galactosidase reporter gene expression patterns in
the embryonic spinal cord in vivo (Wang et al., 1996).
NCAMs undergo a variety of posttranslational mod-
ifications, including glycosylation by enzymes such as
sialyltransferase (Rothbard et al., 1982; Finne et al.,
1983; Breen et al., 1987; Breen and Regan, 1988); the
activity of this enzyme is developmentally regulated
(Breen et al., 1987; Breen and Regan, 1988). As a
result, NCAMs vary in their sialic acid content, with
the highest evident in the embryonic polysialylated
form of NCAM (PSA-NCAM) (Breen et al., 1987; Breen
and Regan, 1988; Rothbard et al., 1982; Finne et al.,
1983). Sialic acid content has been demonstrated to be
inversely related to NCAM homophilic binding proper-
ties, such as adhesion and rate of aggregation (Hoff-
man and Edelman, 1983; Sadoul et al., 1983). Hence
Hoxa2 could potentially enhance or repress transcrip-
tion of the NCAM gene, which would subsequently give
rise to embryonic or adult forms, depending on the
activity of sialyltransferase. The expression of either
the embryonic or adult form of NCAM by oligodendro-
glial cells may affect their motility and maturation
(Wang et al., 1994; Gard et al., 1996).
Comparison of Nkx2.2, Olig2, and Pax6 expression
profiles obtained from at least three spinal cord sec-
tions of E12.5, E14.25, E16, and E18 mice in both the
presence (Hoxa2/ and Hoxa2/), and the absence of
Hoxa2 (Hoxa2/) failed to reveal major differences.
These results suggest that Hoxa2 does not appear to be
critical for the OPC specification and early maturation
in the murine spinal cord. One potential reason for this
could be that other Hox genes may compensate for the
loss of Hoxa2 in the developing spinal cord. Analyzing
OG development in the more anterior regions of the
CNS in Hoxa2/ mice, where Hox gene compensation
is less likely, should demonstrate whether discrepan-
cies in early stages of OG development exist in the
absence of the Hoxa2 gene.
The regulatory mechanisms controlling oligodendro-
genesis, once elucidated, will guide the development of
therapeutic approaches to treating demyelinating dis-
eases such as multiple sclerosis (MS). MS is an inflam-
matory disease of the CNS characterized by focal areas
of demyelination that appear to be immune driven
(Prineas et al., 1993a,b; Ozawa et al., 1994; Raine,
1997a,b; Storch et al., 1998; Lucchinetti et al., 1999).
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The OG progenitors are the most motile of the OG
lineage cells (Gansmuller et al., 1991), which are re-
cruited to areas of demyelination over only a very lim-
ited area (Franklin and Blakemore, 1997). There are
three potential sources of remyelinating OGs: adult
progenitors endogenous to or adjacent to the lesion, or
mature OGs that have survived the demyelinating
event (Levine et al., 2001). Remyelination, which is
characterized by axons exhibiting thin myelin sheaths,
fails with disease progression (Prineas et al., 1989,
1993a,1993b; Raine and Wu, 1993; Bru¨ck et al., 1994;
Ozawa et al., 1994). The reason that remyelination
fails remains unknown, but it may include errors in
migration or maturation. PSA-NCAM is one of several
molecules that appear to be important for the migra-
tory ability of OG progenitor cells (Barral-Moran et al.,
2003). Hence, elucidation of the transcriptional control
by Hox genes of molecules involved in these processes,
such as NCAMs, will help determine ways to enhance
remyelination.
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SUMMARY
1. Although recent advances have provided insight into the transcriptional control of
oligodendrocyte (OG) development, little information exists on the role of clustered Hox
genes in this process. The aim of this study was to examine the expression profile of Hoxb4
in the oligodendroglial lineage.
2. Immunocytochemical analysis of primary mixed glial cultures demonstrated that
Hoxb4 was expressed throughout OG development, being coexpressed with oligoden-
droglial markers, A2B5, O4 (97%), GalC (91%), and MBP (93%).
3. Immunohistochemical analysis of transverse spinal cord sections demonstrated dif-
fuse expression of Hoxb4 throughout the spinal cord at E12.5 (C16/T19), after which ex-
pression was confined primarily to the presumptive gray matter.
4. At E14.25 (C19C/T21), Olig2C cells had begun to migrate out from the ventral
ventricular zone into the presumptive gray matter. These results suggest that Olig2C cells
could coexpress Hoxb4 since it is expressed throughout this region.
5. The expression of Hoxb4 by cells of the OG lineage indicates that it could play a
role in OG maturation.
KEY WORDS: oligodendrocyte development; Hoxb4; Olig2; primary glial cultures; spinal
cord.
INTRODUCTION
Oligodendrocytes (OGs) are myelinating cells of the central nervous system (CNS).
In the murine spinal cord platelet-derived growth factor alpha receptor (PDGFfiR)C
OG precursor cells (OPCs) first appear at approximately embryonic day (E) 12.5 in
a distinct region of the ventral ventricular zone (vVZ) (Sun et al., 1998). This region
has been shown to correspond to the progenitor motor neuron domain (pMN), which
is defined by the expression of the basic helix-loop-helix transcription factor Olig2
(Novitch et al., 2001; Zhou et al., 2000). Although Olig2 initially specifies motor
neuron precursors at early stages of spinal cord development, it is downregulated as
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Fig. 1. Illustration depicting OG development. OGs progress through four dis-
tinct stages which are characterized by unique morphological and antigenic pheno-
types (Abney et al., 1983; Asou et al., 1995; Bansal et al., 1989; Duchala et al., 1995;
Fok-Seang and Miller, 1994; reviewed in Miller, 1996; Noble et al., 1988; Raff et al.,
1983, 1985; Sommer and Schachner, 1981).
these precursor cells differentiate into motor neurons (Mizuguchi et al., 2001; Novitch
et al., 2001; Zhou et al., 2000). Olig2 expression that persists in the pMN domain after
motor neurons are generated specifies cells of the OG lineage (Lu et al., 2000; Zhou
et al., 2000). Initially only a few OPCs are found on each side of the central canal
but these cells subsequently proliferate and migrate first laterally then dorsally to
populate the entire cross-sectional area of the spinal cord (Lu et al., 2000; Zhou et al.,
2000).
Analysis of glial cell differentiation in vitro has shown that OG development
progresses through a number of distinct stages, which are characterized by the expres-
sion of specific cell surface markers (Fig. 1). During early stages of differentiation,
characterized by A2B5 and/or O4 staining, cells are actively proliferating and mi-
gratory. Loss of these traits signals terminal differentiation of the OG lineage, which
is characterized by the expression of galactocerebroside (GalC) and subsequently
the expression of myelin proteins (Abney et al., 1983; Asou et al., 1995; Bansal et al.,
1989; Duchala et al., 1995; Fok-Seang and Miller, 1994; reviewed in Miller, 1996;
Noble et al., 1988; Raff et al., 1983, 1985; Sommer and Schachner, 1981).
The timing of OG differentiation is believed to be dependent on an intrinsic clock
that counts cell divisions driven by mitogens, such as platelet-derived growth factor
(PDGF) (Raff et al., 1985, 1988). Differentiation is further modified by hydrophobic
signals, such as retinoic acid (RA) or thyroid hormone (Barres et al., 1994; Ibarrola
et al., 1996; Noll and Miller, 1994). Potential downstream targets of RA signaling
are the Hox genes, which are characterized by a 180-bp homeobox (Gould et al.,
1998; McGinnis et al., 1984a,b). This nucleotide sequence encodes a 60 amino acid
homeodomain that contains a helix-turn-helix motif (Kissinger et al., 1990; McGinnis
et al., 1984a,b). Hence Hox genes can regulate the expression of downstream effector
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genes by binding to specific nucleotide sequences through the homeodomain (Han
et al., 1989; Hoey and Levine, 1988; Kissinger et al., 1990). Hoxb4 is one of 39 mouse
and human Hox genes that are organized into four clusters (Hox A, B, C, D) lo-
cated on different chromosomes (Favier and Dolle´, 1997; Graham et al., 1989; Scott,
1992). In situ hybridization histochemistry conducted by Gaunt et al. (1989) and
Graham et al. (1988, 1989) demonstrated that Hoxb4 mRNA is expressed in numer-
ous tissues, including the CNS with the anterior limit of expression extending into
the myelencephalon. We have analysed Hoxb4 expression patterns during murine
OG development in cell cultures and in spinal cord sections. Our results demonstrate
that Hoxb4 is expressed by cells of the OG lineage.
MATERIALS AND METHODS
Primary Glial Cultures
Cerebral hemispheres from newborn mice were dissected in DMEM/F12/10%
FBS. Single cell suspensions, obtained by forcing diced tissue through a 75 „m Nitex
mesh, were plated in DMEM/F12/10% FBS for 4 days to allow adherence of the cells.
They were then cultured for two 1-week periods, respectively in a B104 conditioned
medium and a low serum-containing (0.3% FBS) growth medium (GP medium)
used previously by Gard and Pfeiffer (1990) and by Doucette and Devon (1994); this
OG growth medium was supplemented with 10 ng/mL basic fibroblast growth factor
(bFGF). The growth medium was changed every 4 days.
Immunocytochemistry
Immunocytochemistry utilized the following primary antibodies: anti-Hoxb4
(BabCO, CA; 1:500), A2B5 (ATCC; 1:10), O4 (hybridoma; Sommer and Schachner,
1981; 1:10), anti-galactocerebroside (GalC) (BRD1 hybridoma; Ranscht et al., 1982;
1:20), and anti-myelin basic protein (MBP) (Sternberger Monoclonals; 1:800). The
cell cultures were double immunostained with Hoxb4 and A2B5, O4, or GalC using
the live staining method described by Doucette and Devon (1994) and Hao et al.
(1999) but with an incubation period of 30 min at 37–C for A2B5, O4, and anti-GalC.
The secondary antibodies used included a goat anti-mouse IgM FITC (Sigma, ON;
1:100); a donkey anti-mouse IgG FITC (BIO/CAN Scientific, ON; 1:50); and a goat
anti-rabbit IgG CY3 (BIO/CAN Scientific, ON; 1:200). Between incubations cultures
were washed two times for 5 min each in PBS. Double immunostaining for Hoxb4
and MBP was done using the procedure described in Doucette and Devon (1994)
with two modifications: (1) permeabilization and blocking were combined with a
30 min incubation in 3% skim milk/0.1% Triton-X; (2) the primary antibodies were
diluted in 1% skim milk/0.03% Triton-X. The nuclei in all cell cultures were stained
using HOECHST dye.
Immunohistochemistry
C57 black mouse embryos were staged according to the Carnegie (Butler and
Juurlink, 1987) and Theiler (1972) staging systems. The embryonic ages (E) and
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corresponding Carnegie(C)/Theiler (T) stages utilized were E12.5 [C16/T19], E14.25
[C19C/T21], E16 [C23/T23], and E18 [T25]; the Carnegie staging system does not
go higher than stage 23. Once the embryos were staged, they were fixed by im-
mersion in 4% paraformaldehyde at 4–C for 24–48 h depending on their age, and
cryostat sections (8 „m) were cut through the upper thoracic level as described by
Hao et al. (1999). The following primary antibodies were used: polyclonal anti-Olig2
(E12.5, 1:4000; rest of stages, 1:2000, gift of Dr Hirohide Takebayashi) and anti-
Hoxb4 (E12.5, 1:3000; rest of the stages, 1:2000). Immunohistochemical staining was
performed using the procedure described by Hao et al. (1999), with the following
modifications: PBS washes were 8 min instead of 10 min; 3% skim milk/0.1%Triton-
X block/permeabilizations were 20 min versus 30–60 min; and incubation in the
secondary antibody was 30 min versus 45 min.
RESULTS AND DISCUSSION
Immunocytochemistry was conducted in this study as it allowed for a thorough
investigation of Hoxb4 expression throughout OG development. The cerebral hemi-
sphere cultures analyzed consisted of oligodendroglia that developed on top of an
astrocytic monolayer. Although the anterior limit of Hoxb4 expression had been
shown to be the mid-myelencephalon (Gaunt et al., 1989; Graham et al., 1988, 1989),
Hoxb4 was expressed by cells obtained from murine cerebral hemispheres. Similar
findings have been observed with Hoxa2 where its expression was subsequently
shown to extend to the forebrain (Hao et al., 1999; Tan et al., 1992; Wolf et al., 2001).
Furthermore our laboratory had previously demonstrated that Hoxa2 was expressed
by O4C pro-OGs obtained from E15 mouse cerebral hemispheres (Hao et al., 1999).
Hoxb4 was expressed by the majority of cells throughout OG development.
Greater than 90% of the cells that expressed O4 (97%), GalC (91%), and MBP
(93%) also coexpressed Hoxb4 (Fig. 2). The percentage of A2B5C/Hoxb4C cells
was not determined because A2B5 labels oligodendrocyte type 2 astrocyte (O-2A)
precursor cells, which can give rise to either OGs or type 2 astrocytes depending
on culture conditions (Raff et al., 1983), and therefore is not specific to the OG
lineage. Expression of Hoxb4, which is a transcription factor, was primarily nuclear
(Fig. 2(B, E, K)), however weak cytoplasmic staining was observed occasionally in
GalCC cells (Fig. 2(H)). The reason for this is unknown but similar observations have
been reported with several other transcription factors (Armstrong et al., 1995; Wang
et al., 2001).
Although Hoxb4 was expressed throughout OG development, it was not specific
to the OG lineage. This was demonstrated by the fact that the number of Hoxb4C
cells was greater than that of OG markers in primary mixed glial cultures (Fig. 2).
Furthermore Hoxb4 RNA has been shown to be expressed in various embryonic
tissues, including hindbrain, spinal cord, stomach, lung, kidneys, and prevertebra
(Gaunt et al., 1989; Graham et al., 1988).
Hoxb4 expression was investigated in transverse spinal cord sections at stages
E12.5 [C16/T19] to E18 [T25]. At E12.5 [C16/T19] expression was diffuse being
slightly more intense in the ventral horns (Fig. 3(A)). At later stages of development
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Fig. 2. Hoxb4 expression pattern throughout OG development. Primary glial cell cultures from neonatal
murine brain were grown in culture for 18 days. Double immunofluorescent staining was conducted with
each of the four OG markers [A2B5 (A), O4 (D), GalC (G), and MBP (J)] and Hoxb4 (B, E, H, K). Cells
were visualized utilizing nuclear fluorescent HOESCHT counterstain. Each row illustrates micrographs
obtained from individual filters [fluorescein (A, D, G, J), rhodamine (B, E, H, K), and DAPI (C, F, I, L)]
of the same field. Arrows demarcate representative Hoxb4 immunoreactive cells. The insets at the top
right corner of the rhodamine micrographs (E, H, L) show the percentage of O4C, GalCC, and MBPC
cells that are immunoreactive for Hoxb4, respectively. [Percentages depict averages calculated from 2 to
3 coverslips in which 100–150 OGs were counted.] Bar D 100 „m for Fig. (A)–(L).
(E14.25–E18) Hoxb4 was expressed primarily in the presumptive gray matter
(Fig. 3(C, E, G)). Previously, Graham et al. (1988, 1991) and Gaunt et al. (1989), had
determined by in situ hybridization histochemistry the expression patterns of Hoxb4.
Although only one micrograph of a»12.5 day postcoital (d.p.c) transverse spinal cord
section illustrated Hoxb4 expression, it had been stated to exhibit a dorsoventral ex-
pression pattern similar to that of the other Hoxb genes (Graham et al., 1988, 1991). At
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Fig. 3. Expression of Hoxb4 in the embryonic spinal cord in relation to the OG marker Olig2.
Transverse sections of the thoracic spinal cord at E12.5 [C16/T19], E14.25 [C19C/T21], E16
[C23/T23], and E18 [T25] were immunolabeled with Hoxb4 (A, C, E, G) and Olig2 (B, D, F, H).
At E12.5 when Olig2C OPCs (B) were localized to the vVZ Hoxb4 (A) was diffusely expressed
throughout the spinal cord, being slightly more intense in the ventral horns. Also at later stages of
embryonic development Hoxb4’s expression pattern (C, E, G) displayed domains of overlap with
Olig2 (D, F, H). The micrographs are representative of sections obtained from approximately four
embryos from at least two different litters. Bar D 100 „m for Fig. (A)–(H).
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10.5 d.p.c., the expression of Hoxb genes was dispersed throughout the entire spinal
cord (Graham et al., 1988, 1991). In our immunohistochemical analysis, immunore-
activity appeared to be slightly greater in the ventral horns (Fig. 3(A)). In situ hy-
bridization histochemistry has also shown that Hoxb genes exhibit strong expression
in the dorsal spinal cord at 12.5 d.p.c. after which expression appeared in the ventral
spinal cord at 14.5 d.p.c. (Graham et al., 1991). In our study, Hoxb4 was found to be
expressed throughout the presumptive gray matter at E14.25 [C19C/T21] (Fig. 3(C)).
The Hoxb4 gene has been shown to give rise to multiple transcripts (Graham et al.,
1988); it is not known if all yield a translated product. The probe utilized by Graham
et al. (1991) did not distinguish between them; therefore, differences in expression
patterns may exist for the individual transcripts.
There are currently very few immunohistochemical markers available for study-
ing OG development in vivo. Therefore, OG development in the spinal cord was
followed by analyzing Hoxb4 expression in relation to that of Olig2. Evidence that
supports the use of Olig2 as an OG marker is threefold. First, Olig2C cells, which
are initially found in pMN domain, disperse throughout the spinal cord as previously
described for PDGFfiR (Lu et al., 2000; Zhou et al., 2000). Furthermore, it has been
shown that the number of Olig2C cells is similar to that of PDGFfiRC cells (Zhou
et al., 2000). Second, Olig2 is not coexpressed with the astrocytic marker glial fib-
rillary acidic protein (GFAP) (Takebayashi et al., 2000). Finally, Olig2 appears to
be critical for OG development since in its absence OPCs and differentiated OGs
fail to develop in the spinal cord (Lu et al., 2002). Therefore, Olig2 is the earliest
known marker of OG development since its expression precedes that of PDGFfiR
by approximately 1–1.5 days (Zhou et al., 2000). Immunohistochemical analysis in
this report has focused primarily on the ventral spinal cord due to the predominant
expression of Olig2 in this region during embryonic development. We were unable
to demonstrate coexpression of Hoxb4 with Olig2 since both antibodies were rabbit
polyclonals.
Immunohistochemical analyses were initiated at E12.5 [C16/T19] since at this
stage Olig2 expression has been downregulated in differentiated motor neurons and
PDGFfiRC OPCs have arisen in the vVZ. Unlike Olig2, which was localized to the
vVZ (Fig. 3(B)), Hoxb4 stained nuclei were diffusely distributed at this stage, with
immunoreactivity slightly more intense in ventral horns (Fig. 3(A)). The Hoxb4C cells
in the ventral horns were most likely neurons because neuron-specific fl-tubulin was
also expressed in these areas (data not shown). However, the results suggest that
Hoxb4 may be expressed by OPCs in vivo since Hoxb4 stained nuclei are diffusely
distributed throughout the ventricular zone. From E14.25 [C19C/T21] onward Hoxb4
was expressed throughout the presumptive gray matter (Fig. 3(C, E, G)). Beginning
at E16 [C23/T23], some Hoxb4C cells were also observed in the presumptive white
matter, increasing somewhat in numbers at E18 [T25] (Fig. 3(E, G)). Olig2C cells
began to accumulate in the presumptive gray matter at »E14.25 [C19C/T21] with
occasional immunoreactive cells found in the presumptive white matter (Fig. 3(D)).
This migratory pattern continued at later stages with an increasing number of im-
munoreactive cells accumulating in the presumptive white matter (Fig. 3(F, H)).
Therefore, these results suggest that a population of Olig2C cells may coexpress
Hoxb4. However, the Olig2C cells outnumbered Hoxb4C in the presumptive white
P1: IZO
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matter (Fig. 3(G, H)). In addition, the number of Hoxb4C cells in transverse spinal
cord sections was greater than that of the Olig2C cells, which lends support to our
cell culture findings of cells other than OG expressing this Hox protein.
One potential role of Hoxb4 in OG development may be as a downstream ef-
fector in RA pathway. The role of RA in OG development has previously been
described. In particular, Noll and Miller (1994), utilizing E14–18 rat spinal cord cul-
tures, found that RA (1 „M) inhibits maturation of OPCs. Interestingly, Barres et al.
(1994) showed that low concentrations of RA (10 nm) applied to postnatal day 8
rat optic nerve cultures promoted differentiation. Although these results initially
appear to be contradictory it could be hypothesized that they represent ends of the
same developmental pattern. Hence high concentrations of RA early on in devel-
opment could inhibit OG differentiation, allowing OPC distribution throughout the
spinal cord (Noll and Miller, 1994). Then as OG development proceeds and RA lev-
els diminish, cells could be facilitated to differentiate. Since RA has been shown to
regulate Hoxb4 expression in hindbrain (Gould et al., 1998), it has the potential to
affect expression in OGs. Now that it has been demonstrated that Hoxb4 is expressed
by cells of the OG lineage it will be interesting to determine whether RA exerts its
effects on OG development via Hox genes, such as Hoxb4.
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ABSTRACT
Oligodendrocytes (OGs) assemble the myelin sheath around
axons in the central nervous system. Specification of cells
into the OG lineage is largely the result of interplay
between bone morphogenetic protein, sonic hedgehog and
Notch signaling pathways, which regulate expression of
transcription factors (TFs) dictating spatial and temporal
aspects of oligodendrogenesis. Many of these TFs and
others then direct OG development through to a mature
myelinating OG. Here we describe signaling pathways and
TFs that are inductive, inhibitory, and/or permissive to OG
specification and maturation. We develop a basic transcrip-
tional network and identify similarities and differences
between regulation of oligodendrogenesis in the spinal cord
and brain. VC 2007 Wiley-Liss, Inc.
INTRODUCTION
In the central nervous system (CNS), oligodendrocytes
(OGs) assemble the myelin sheath around axons (South-
wood et al., 2004). OG development in vitro progresses
through distinct stages characterized by specific anti-
genic phenotypes (Fig.F1 1). During early stages of oligo-
dendrogenesis, A2B5þ oligodendrocyte precursor cells
(OPCs) and O4þ pro-OGs actively proliferate (Fok-Seang
and Miller, 1994) and migrate (Noble et al., 1998). Sub-
sequently, loss of these traits and the emergence of gal-
actocerebroside (GalC) expression (Fok-Seang and
Miller, 1994; Noble et al., 1998) signal terminal differen-
tiation into premyelinating OGs. Progression to the
mature myelinating phenotype occurs when cells synthe-
size myelin proteins and elaborate sheet-like membranes
(Duchala et al., 1995).
In developing vertebrate embryos, OPCs arise in mul-
tiple distinct foci located in various regions of the CNS
(Cai et al., 2005; Kessaris et al., 2006; Perez Villegas
et al., 1999; Pringle and Richardson, 1993; Spassky
et al., 1998). Subsequently, oligodendroglial cells from
these foci migrate out to populate specific regions of the
CNS (Kessaris et al., 2006; Ono et al., 1997; Pringle and
Richardson, 1993; Spassky et al., 1998; Tekki-Kessaris
et al., 2001). Interestingly, OG development and ulti-
mately myelination progress at different rates depend-
ent upon the CNS region examined (Fok-Seang and
Miller, 1994; Foran and Peterson, 1992; Hamano et al.,
1998; LeVine and Goldman, 1988; Reynolds and Wilkin,
1988).
A very dynamic combination of transcription factors
(TFs) are expressed by OGs as they progress from pre-
cursor to mature myelinating cells (Fig. 1). Whereas
some TFs, such as Sox10 (Stolt et al., 2002), are
expressed throughout OG development, expression of
many TFs, such as SCIP (Collarini et al., 1992) and
Krox24 (Sock et al., 1997), is transient. In most cases
expression decreases with differentiation (Collarini
et al., 1992; Schreiber et al., 1997); however, for Nkx6.2,
expression increases in time with that of myelin proteins
(Awatramani et al., 1997). Role(s) of some TFs have
been elucidated utilizing transgenic knockout mice and
transfection assays (Table T11). In some cases TF function
is consistent with its expression profile as is the case
with Olig2, which is expressed throughout OG develop-
ment (Lu et al., 2000) and is important in OG specifica-
tion (Lu et al., 2002) and maturation (Fu et al., 2002).
However, in other cases the expression profile may not
easily suggest the TF function. For example, Sox10 is
expressed throughout OG development but is only criti-
cal in OG maturation (Stolt et al., 2002). Interestingly,
most of these TFs are downstream targets or effectors in
signaling pathways, such as sonic hedgehog (Shh)
(Ericson et al., 1997; Lu et al., 2000), bone morphoge-
netic protein (BMP) (Samanta and Kessler, 2004), and
Notch (Wang et al., 1998).
This review describes transcriptional control of oligo-
dendrogenesis by examining TFs not in isolation but in
the context of a transcriptional network. Although one
can make fairly confident statements about roles of sev-
eral TFs in oligodendrogenesis, functional linkages
between TFs and/or signaling pathways require more
conjecture. Our approach to this complex problem is to
discuss TFs and signaling pathways in the context of
their roles as inductive, inhibitory and/or permissive
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agents to OG specification and maturation. In doing so,
the review points out known, unknown and unresolved
issues in the transcriptional control of oligodendrogene-
sis and hypothesizes potential roles or connections of the
TFs and signaling pathways in question. The synthesis
of information regarding these TFs and signaling path-
ways into a transcriptional network serves as a template
to be modified as new information is obtained and as a
resource to researchers in formulating pertinent hypoth-
eses and designing appropriate experimental protocols.
OG SPECIFICATION
Inductive Factors
In the embryonic spinal cord, platelet-derived growth
factor a-receptor (PDGFaR)þ OPCs initially arise from a
distinct region of the ventral ventricular zone (vVZ)
called the motor neuron progenitor (pMN) domain (Fu
et al., 2002) (Fig. F22). The pMN domain is specifically
demarcated by the basic helix-loop-helix (bHLH) TF
Olig2 (Fu et al., 2002; Novitch et al., 2001). Olig2 is crit-
ical to OG specification in the spinal cord since PDGFaR
expression is lost in its absence (Lu et al., 2002). Fur-
thermore, Nkx6.1 (Liu et al., 2003) and Gli2 (Qi et al.,
2003) mutant mice, which display a dramatic transient
decrease in Olig2 expression, correspondingly exhibit a
delay and transient reduction in PDGFaR expression
(Liu et al., 2003; Qi et al., 2003). Olig1 is also expressed
in the pMN domain of rodents (Zhou et al., 2000) but is
not critical to OG specification in the spinal cord since
PDGFaR expression appears on schedule in its absence
(Lu et al., 2002).
Expression of Olig1 and Olig2 is induced by Shh in a
concentration-dependent manner (Lu et al., 2000). In
the early embryonic spinal cord Shh exhibits a ventral
to dorsal decreasing expression gradient (Gritli-Linde
et al., 2001) (Fig. 2) that directs formation of five ventral
progenitor domains, including the pMN domain, by reg-
ulating expression of TFs in the vVZ (Briscoe et al.,
2000; Ericson et al., 1997; Lu et al., 2000). Hence Shh is
important to OG specification in the spinal cord since it
regulates Olig2 expression. Indeed, Wnt-1/Shh trans-
genic mice, which ectopically express Shh in the dorsal
midline of the spinal cord under the control of the Wnt-1
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Fig. 1. Expression profiles of various TFs during OG development.
(top) OGs progress through four distinct stages characterized by unique
morphological and antigenic phenotypes. (myelin.: myelinating).
(bottom) Speculated expression profiles of TFs expressed by cells of the
oligodendroglial lineage (see Table 1 for references). If not stated other-
wise, expression was assumed to be nuclear. In cases where overall
expression profiles of two or more TFs appeared similar, TFs were
grouped together (e.g., Hes5 and Id4). Variations in line thickness illus-
trate either changes in the percentage of cells expressing the TF(s) or
the intensity of the TF(s) expression. (—), nuclear expression; (—), cyto-
plasmic expression; POU III, Brn-1,2 and SCIP; *, later stages of OG
development were not analyzed; #, expression profile may vary depend-
ing upon the CNS region and/or cell line.
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Abbreviations
bHLH Basic helix-loop-helix
BMP Bone morphogenetic protein
Brn Brain
CBF1 C promoter binding factor 1
CNP 20,30-cyclic nucleotide 30-phosphodiesterase
CNS Central nervous system
COUP-TFI Chicken ovalbumin upstream promoter-transcription
factor I
Dpc Days postcoitum
E Embryonic age
E2F-1 E2F transcription factor 1
FGF Fibroblast growth factor
GalC Galactocerebroside
GABA Gamma-aminobutyric acid
GFP Green fluorescent protein
Gli2 GLI-Kru†ppel family member Gli2
Hes5 Mammalian homolog of hairy and Enhancer of split
Hox Homeobox
Id Inhibitor of DNA binding
Irx Iroquois
Krox24 Kr€uppel box
MAG Myelin associated glycoprotein
Mash1 Mammalian achaete-scute homolog 1
MBP Myelin basic protein
MN Motor neuron
MyTI Myelin transcription factor I
NFIA Nuclear factor I A
Ngn Neurogenin
Nkx2.1/Nkx2.2 NK2 transcription factor related, locus 1 or 2
Nkx6.1/Nkx6.2 NK6 transcription factor related, locus 1 or 2
OG(s) Oligodendrocyte(s)
Olig Oligodendrocyte transcription factor
OPC(s) Oligodendrocyte precursor cell(s)
P Postnatal day
Pax6 Paired box gene 6
PDGFaR Platelet-derived growth factor alpha receptor
PLP Proteolipid protein
pMN Motor neuron progenitor domain
POU Pit-1, OTF1 & 2, UNC86 family of genes
PSA-NCAM Polysialylated neural cell adhesion molecule
RA Retinoic acid
RAR Retinoic acid receptor
RXR Retinoid X receptor
SCIP Suppressed cAMP inducible POU
Shh Sonic hedgehog
siRNA Short interfering RNA
Sox SRY-box containing gene
TF(s) Transcription factor(s)
TH Thyroid hormone
T3 triiodothyronine
T4 Thyroxine
vVZ Ventral ventricular zone
Wnt-1 Wingless-typeMMTVintegration site family, member 1
Zfp488 Zinc finger protein for OG differentiation.
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regulatory element, exhibit ectopic Olig2 and PDGFaR
expression in this region (Lu et al., 2000).
Recent research shows the role of Shh is consistent
throughout most of the CNS. In particular, injection of a
Shh-expressing retrovirus into embryonic day (E) 9.5
murine telencephalic vesicles results in ectopic Olig2
and PDGFaR expression (Nery et al., 2001). Conversely,
Shh mutant mice lack Olig1, Olig2 (Alberta et al., 2001;
Lu et al., 2000), and PDGFaR (Alberta et al., 2001)
expression throughout the brain. Furthermore, in
Nkx2.1 mutant mice, which lack Shh expression in the
medial ganglionic eminence and the hypothalamus at
E11.5 (Sussel et al., 1999), telencephalic expression of
PDGFaR is absent at E14.5 (Nery et al., 2001; Tekki-
Kessaris et al., 2001).
Although Shh is crucial to OG specification through-
out much of the CNS by regulating expression of Olig
TFs, the function(s) of these TFs vary by region. Unlike
the spinal cord, PDGFaR expression is evident in the
hindbrain and in focal regions of the ventral forebrain
in the absence of Olig2 (Lu et al., 2002). However, in
Olig1/2 double knockout mice, PDGFaR expression is
absent in all examined brain regions (Zhou and Ander-
son, 2002). Therefore, Olig1 is important in OG specifi-
cation in certain brain regions. Accordingly, infection of
cortical cultures with an Olig1-containing adenovirus
greatly increases the percentage of infected cells that
are OPCs (Alberta et al., 2001; Lu et al., 2000). As
researchers have yet to identify the chick ortholog of
Olig1 (Zhou et al., 2001), the TF Nkx2.2, whose expres-
sion is also induced by Shh in a concentration-dependent
manner (Ericson et al., 1997), may play an important
role in OG specification in certain chick brain regions. A
supportive finding is that in the embryonic chick hind-
brain only Nkx2.2 is expressed in the vVZ during OG
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TABLE 1. TFs Expressed by Cells of the OG Lineage
Family Class/group
Transciption
factor
Role in OG
specification Role in OG maturation Additional CNS expressing cells
HLH I E2A36 AQ3
HEB36
II Mash112,39 Neural precursor18
Ngn317 Sp (SC)17 þ17 Neural precursor17
Olig14,21 þ (B)20,21,41 þ20,40 Neural precursor21
Olig24,8 þ20# þ8 Neural precursor21,26
V Id239 13,39 Neural precursor, neuron11,22, astrocyte37
Id413 Neural precursor, neuron11
VI Hes512 12 Neural precursor, neuron1
Hox A Hoxa29,23 Neuron9,23, astrocyte9
B Hoxb424 Neuron24
Nkx Nkx2.2*27 Sp (SC)27 þ27 Neural precursor27
Nkx6.2*5 Myelin (u)31 Neural precursor, neuron31
POU III Brn-128 Neural precursor2, neuron10
Brn-228 Neural precursor2, neuron10
SCIP7,28 Neural precursor, neuron2
Sox C Sox415 Neural precursor, neuron6
Sox1115 Neural precursor, neuron6,15
D Sox532 Tp (SC)32 32 Neural precursor, neuron, radial glia32
Sox632 Tp (SC)32 32 Neural precursor, neuron, radial glia32
E Sox8*33 þ33
Sox934a þs (SC)34 Neural precursor, radial glia, astrocyte34, bergmann glia14
Sox1016*35 þ35
F Sox1730 þ30 Neuron, astrocyte30
Zinc finger Krox2429
MyTI3*25 þ25 Neural precursor, neuron3
Zfp48838 þ38
Kr€uppel rKr219 Neural precursor, neuron19
HLH, helix-loop-helix; þ, promote; , inhibit; Sp, spatial; B, brain specific effect; SC, spinal cord; #, specific brain regions not affected; *, TF binding sites found in the
promoters of myelin protein genes; Tp, temporal; (u), ultrastructure; þs, promotes neural to glial switch.
References: 1Akazawa et al. (1992), 2Alvarez-Bolado et al. (1995), 3Armstrong et al. (1995), 4Arnett et al. (2004), 5Awatramani et al. (1997), 6Cheung et al. (2000), 7Collarini
et al. (1992), 8Fu et al. (2002), 9Hao et al. (1999), 10He et al. (1989), 11Jen et al. (1996), 12Kondo and Raff (2000a), 13Kondo and Raff (2000b), 14Kordes et al. (2005), 15Kuhlbrodt
et al. (1998a), 16Kuhlbrodt et al. (1998b), 17Lee et al. (2003), 18Lo et al. (1991), 19Lovas et al. (2001), 20Lu et al. (2002), 21Lu et al. (2000), 22Neuman et al. (1993), 23Nicolay et al.
(2004a), 24Nicolay et al. (2004b), 25Nielsen et al. (2004), 26Novitch et al. (2001), 27Qi et al. (2001), 28Schreiber et al. (1997), 29Sock et al. (1997), 30Sohn et al. (2006), 31Southwood
et al. (2004), 32Stolt et al. (2006), 33Stolt et al. (2004), 34Stolt et al. (2003), 35Stolt et al. (2002), 36Sussman et al. (2002), 37Tzeng and De Vellis (1998), 38Wang et al. (2006),
39Wang et al. (2001), 40Xin et al. (2005), 41Zhou and Anderson (2002).
Fig. 2. Shh signaling directs the formation of ventral progenitor (p)
domains, such as the pMN domain, which gives rise to motor neurons
(MNs) and subsequently oligodendroctyes (OGs). Shh, which exhibits a
ventral to dorsal decreasing expression gradient in the spinal cord,
enhances (fi) or represses (^) the expression of the TFs defining the
boundaries of the pMN domain. These boundaries are further main-
tained and refined by repressive interactions between these TFs.
(*, effect is only evident during early stages of development). NB:
Whether MNs and OGs arise from a common precursor or separate
neural- and glial-restricted precursors remains unresolved.
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specification whereas Olig2 is expressed by groups of
Nkx2.2þ cells in the subventricular zone and in individ-
ual migrating cells (Fu et al., 2002). Also, recent
research suggests that Mash1 is important for the speci-
fication of a particular population of OPCs in the ventral
forebrain since in its absence a dramatic transient
decrease in PDGFaR expression occurs in this area at
E12.5 and E13.5 (Parras et al., 2007).
Spatial and Temporal Modulating Factors
Although Olig1 and Olig2 specifically demarcate the
pMN domain (Fu et al., 2002; Zhou et al., 2000), three
additional TFs—Nkx2.2, Pax6, and Irx3—define its
boundaries (Briscoe et al., 2000) (Fig. 2). In particular,
the ventral boundary of the pMN domain is defined by
Pax6 and Nkx2.2 (Briscoe et al., 2000), whereas the dor-
sal boundary is defined by Irx3 and Olig2 (Fu et al.,
2002). Subsequently cross-repressive interactions
between these TFs maintain and refine these boundaries
(Briscoe et al., 2000; Novitch et al., 2001). In addition,
at early stages of spinal cord development, Nkx2.2 also
represses Olig2 expression (Novitch et al., 2001; Zhou
et al., 2001).
Therefore, Nkx2.2, Pax6, and Irx3 should be impor-
tant in spatial aspects of OG specification since they
determine the boundaries of the Olig2þ pMN domain.
Furthermore, as early development appears to proceed
from ventral to dorsal in the spinal cord (Altman and
Bayer, 1984), these TFs could also be important in tem-
poral aspects of OG specification. Indeed, Pax6-deficient
mice exhibit a dorsal-ward shift and a delay of 1 day in
the appearance of PDGFaRþ cells (Sun et al., 1998).
These anomalies likely occur since Pax6-deficient mice
display a dorsal expansion in the expression domain of
Nkx2.2 (Ericson et al., 1997) that represses Olig2
expression at early stages of development (Novitch
et al., 2001; Zhou et al., 2001). Correspondingly, in the
absence of Nkx2.2 a ventral expansion occurs in the
Olig2þ pMN domain (Qi et al., 2001). This ventral
expansion also occurs in Ngn3 mutant mice, which lack
Nkx2.2 expression in the spinal cord at E13.5 (Lee
et al., 2003). Whether ventral expansion in the Olig2þ
domain results in premature OG specification in these
mutant mice has yet to be determined. Interestingly, in
the absence of both Nkx6.1 and Nkx6.2 TFs, a dorsal
expansion of the Nkx2.2þ domain occurs (Vallstedt et al.,
2005), which may be responsible for the lack of PDGFaR
expression in the pMN domain (Cai et al., 2005; Vallstedt
et al., 2005) in these mutant mice. Although the reason
for the dorsal expansion of the Nkx2.2þ domain is
unknown, it is likely indirect since Nkx2.2 and Nkx6.1/
6.2 TFs exhibit overlapping expression domains in the
vVZ during early stages of spinal cord development
(Briscoe et al., 2000; Vallstedt et al., 2001).
The function of Irx3 in OG development has not been
investigated but is likely important in temporal and spa-
tial aspects of OG specification since Irx3 represses
Olig2 expression (Novitch et al., 2001). In particular, the
absence of Irx3 could result in a dorsal expansion in the
Olig2þPDGFaRþ domain as well as prolonged OG speci-
fication. Whether Irx3, as well as Nkx2.2 and Pax6,
could play similar roles in the brain, or whether addi-
tional TFs are involved has not been determined.
Inhibitory Factors
Unlike Shh signaling, BMP signaling patterns the in-
termediate and dorsal embryonic spinal cord by regulat-
ing expression of TFs in these regions (Timmer et al.,
2002). BMP signaling represses Olig2 expression
(Mekki-Dauriac et al., 2002); how it accomplishes this is
unknown, but indirect enhancement of Irx3 expression
may be involved (Meyer and Roelink, 2003), which in
turn represses Olig2 expression (Novitch et al., 2001).
As BMP signaling represses Olig2 expression, it should
inhibit OG specification. Indeed, grafting BMP2-produc-
ing cells in ovo alongside ventral aspects of chick E3
trunk neural tubes strongly inhibits development of O4þ
cells (Mekki-Dauriac et al., 2002). In contrast, blocking
BMP signaling by grafting noggin-producing cells in ovo
alongside dorsal aspects of chick E3 trunk neural tubes
results in a dorsal expansion of O4þ cells in the vVZ on
the grafted side (Mekki-Dauriac et al., 2002). Further-
more, BMP signaling plays a similar role in the brain
since treatment of E16 rat cortical cultures with BMP2
or noggin significantly decreases or increases, respec-
tively, the number of O4þ cells (Mabie et al., 1999).
Hence, BMP signaling negatively regulates OG specifica-
tion; however, whether downstream effectors in the
pathway vary depending on the region has yet to be
determined.
Recent research shows that OPCs in the murine em-
bryonic spinal cord can also arise from a dorsal region of
the ventricular zone at later stages of development (Bat-
tiste et al., 2007; Cai et al., 2005; Vallstedt et al., 2005).
Unlike the pMN domain, OG specification in this region
occurs independently of Shh signaling (Cai et al., 2005).
Instead, late dorsal appearance of OPCs in the spinal
cord may be due to a reduction in BMP signaling with
continued embryonic development (Vallstedt et al.,
2005). Dorsally-derived OPCs are also seen in the hind-
brain (Vallstedt et al., 2005) and telencephalon (Kessaris
et al., 2006); however, whether BMP affects OG specifi-
cation in these regions will require further research.
Neural-Glial Switch: Permissive Factors
In the developing spinal cord gliogenesis is preceded
by neurogenesis (Zhou and Anderson 2002). For exam-
ple, the pMN domain gives rise to motor neurons prior
to OGs (Fu et al., 2002) (Fig. 2). During neurogenesis,
Olig2 is co-expressed with the TFs Ngn1 (Zhou et al.,
2001) and Ngn2 (Novitch et al., 2001; Zhou et al., 2001).
Downregulation of Ngn1/2 in the pMN domain is critical
to OG specification, since electroporation of chick embry-
onic spinal cords with Olig2 fails to promote ectopic OG
J_ID: Z76 A_ID: 00015-2007.R2 Art: GLIA20540 Date: 21-JUNE-07 Stage: I Page: 4
ID: vijayk Date: 21/6/07 Time: 21:55 Path: J:/Production/GLIA/Vol00000/070057/3B2/C2GLIA070057
4 NICOLAY ET AL.
GLIA DOI 10.1002/glia
specification unless Ngn1/2 expression is repressed, such
as via Notch signaling (Zhou et al., 2001). Although elec-
troporation with a constitutively active form of Notch
and its downstream effector Suppressor of Hairless
repressed Ngn1/2 expression, it did not promote ectopic
OG specification unless electroporated with Olig2 (Zhou
et al., 2001). Hence Notch signaling provides an environ-
ment that favors OG specification. Accordingly, when
Notch signaling activity is reduced, OPCs fail to appear
on schedule in zebrafish spinal cords (Park and Appel,
2003); associated changes include an excess of neurons
and a loss of olig2 expression at 1 day postfertilization
(Park and Appel, 2003). A similar phenotype is seen in
the spinal cords of chick embryos that undergo in ovo
electroporation with short interfering RNAs (siRNAs)
directed against the TF NFIA (Deneen et al., 2006).
NFIA is required to maintain expression of Hes5
(Deneen et al., 2006), which is a downstream target in
the Notch signaling pathway (Wang et al., 1998).
As Notch ligands and receptors are expressed in dis-
tinct and overlapping neuroepithelial domains in the
embryonic spinal cord (Lindsell et al., 1995, 1996),
Notch signaling may also play a permissive role in dor-
sal OG specification at later stages of development.
Although multiple Notch receptors are expressed in the
embryonic CNS (Lindsell et al., 1995, 1996), research
examining the role of Notch signaling in OG develop-
ment has primarily focused on Notch1 (Genoud et al.,
2002; Givogri et al., 2002), which also inhibits neuronal
differentiation (Park and Appel, 2003). How Notch1 ful-
fills its functions in both motor neuron and OG develop-
ment is unknown but may involve Notch3, which
represses Notch1-mediated transcriptional activation of
Hes TFs in a concentration-dependent manner (Beatus
et al., 1999). Interestingly, in the lumbar region of the
E13.5 rat spinal cord Notch3 expression appears greater
than Notch1 in the pMN domain (Lindsell et al., 1996),
whereas the opposite appears true at E14.5 (Lindsell et
al., 1995). Hence Notch3 signaling during late neurogen-
esis could inhibit Notch1 activity and hence allow neuro-
nal differentiation. Prior to oligodendrogenesis a
decrease of Notch3 expression in the pMN domain could
restore Notch1 activity and provide an environment
favoring OG specification.
Notch ligands and receptors are expressed in neuroe-
pithelial regions of the E13.5 rat brain (Lindsell et al.,
1996), supporting the view that Notch signaling may
play a similar role in oligodendrogenesis throughout the
CNS; however, further research is needed to verify this.
Another potential factor involved in the switch from
neurogenesis to gliogenesis is the TF Sox9. Although
specific ablation of Sox9 expression in nestin-positive
neural stem cells does not alter Olig2, Nkx2.2, Nkx6.1,
and Irx3 expression domains, there is an initial signifi-
cant reduction in OPCs that recovers partially with con-
tinued embryonic development (Stolt et al., 2003). These
mice also exhibit a significant transient increase in
motor neurons (Stolt et al., 2003). The incomplete na-
ture of these effects is most likely due to the presence of
two additional class E Sox TFs—Sox10 and Sox8—which
appear to compensate for the loss of Sox9 (Stolt et al.,
2003). Therefore, Sox9, as well as potentially Sox8 and
Sox10, appear to favor the switch from neurogenesis to
oligodendrogenesis in the spinal cord. However, further
research must determine how this is accomplished, as
well as whether any links to Notch signaling exist. In
addition, whether Sox9’s role is similar throughout the
CNS is not known.
Recent research suggests the SoxD TFs, Sox5 and
Sox6, may interfere with SoxE function in the spinal
cord by competing for binding sites and/or interaction
partners (Stolt et al., 2006). This may explain why
OPCs arise earlier and are transiently increased in the
spinal cords of Sox5/Sox6 double-deficient mice. How-
ever, as the number of motor neurons in these mutant
mice is not altered (Stolt et al., 2006), further research
will need to clarify the exact roles of the SoxE and SoxD
TFs in OG specification as well as how they relate to
one another.
MATURATION OF OGs
Inhibitory Factors
Following specification, Notch signaling inhibits pre-
mature OG differentiation in the embryonic spinal cord.
In particular, heat shock induced ubiquitous expression
of a constitutively active form of zebrafish Notch1a fol-
lowing OG specification greatly reduces proteolipid pro-
tein 1 (plp1)/dm20þ cells (Park and Appel, 2003). Con-
versely, ablation of Notch1 in oligodendroglial cells
results in a dramatic increase in cells expressing high
levels of PLP/DM20 mRNA in the E17.5 murine spinal
cord (Genoud et al., 2002).
Notch signaling is also important in preventing pre-
mature OG maturation in the brain. In particular, acti-
vation of the Notch pathway in purified OPC cultures
results in a large proportion of OPCs failing to differen-
tiate into GalCþ OGs (Wang et al., 1998). In contrast,
heterozygous mice deficient in Notch1 display a tran-
sient increase in myelin basic protein (MBP) and PLP
expression in numerous brain regions (Givogri et al.,
2002). Furthermore, ablation of Notch1 in oligodendro-
glial cells results in a significant increase of perinuclear
myelin-associated glycoprotein (MAG)þ cells in the new-
born cerebrum (Genoud et al., 2002).
Additionally, overexpression in purified OPCs of the
TF Hes5, a downstream target of Notch signaling (Wang
et al., 1998), results in most cells failing to differentiate
(Kondo and Raff, 2000a). Hes5 appears to inhibit OG
maturation via multiple mechanisms. In particular, it
can directly repress Sox10 expression, which is impor-
tant for OG maturation. In addition, it can repress MBP
promoter activity in Oli-neu cells. Although Hes5 can
bind to the MBP promoter, this binding is not required
for its repression of promoter activity. Therefore, this
suggests Hes5 indirectly represses MBP expression. One
mechanism by which Hes5 may accomplish this is via
binding to Sox10 and/or Mash1 (Liu et al., 2006). As
both these TFs activate the MBP promoter in Oli-neu
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cells (Gokhan et al., 2005), Hes5 could repress MBP
transcription by interfering with their function. Corre-
spondingly, Hes5 is only able to repress MBP promoter
activity when Sox10 is expressed at low levels (Liu
et al., 2006). Sox10 expression levels appear to increase
after primary oligodendroglial cells are induced to differ-
entiate in vitro (Dugas et al., 2006; Wei et al., 2004).
Retinoic acid (RA) also inhibits premature maturation
since treatment of spinal cord cultures with RA results in
a substantially reduced number of O4þ and GalCþ cells
(Noll and Miller, 1994). Furthermore, differentiation of
purified cerebral OPCs into GalCþ OGs is attenuated by
treatment with a high concentration of RA (Laeng et al.,
1994). How RA accomplishes this is unknown, but it may
involve its ability to enhance expression of polysialylated
neural cell adhesion molecule (PSA-NCAM) (Husmann
et al., 1989), which is implicated in inhibiting OG differ-
entiation (Decker et al., 2000). In particular, RA enhances
activity of sialyltransferase, which adds sialic acid resi-
dues to the NCAM protein, in a concentration-dependent
manner (Deutsch and Lotan, 1983). As this effect is first
evident 1 day after RA treatment (Deutsch and Lotan
1983), downstream targets of RA, such as Hox and Krox
TFs (Conlon and Rossant, 1992), may be involved. Hox
TFs are indeed implicated in the regulation of NCAM
expression (Jones et al., 1992). Furthermore, Hoxa2 (Hao
et al., 1999; Nicolay et al., 2004a) and Hoxb4 (Nicolay
et al., 2004b) are expressed by cells of the OG lineage.
Therefore, RA may inhibit OG maturation by enhancing
expression of PSA-NCAM, potentially with the aid of
downstream effectors such as Hox genes.
BMP signaling, which initially inhibits OG specifica-
tion, subsequently inhibits OG maturation. In particu-
lar, placement of BMP4-soaked beads at the ventral
midline of murine cervical spinal cord/hindbrain
explants results in a dramatic decrease in PLPþ and
MAGþ cells in the area around the beads (See et al.,
2004). In addition, treatment of immunopurified cerebral
OPCs, which were first allowed to mature to the GalCþ
stage in differentiation medium, with BMP4 severely
reduces MBP and PLP expression (See et al., 2004).
BMP signaling may inhibit OG maturation by induc-
ing expression of the TFs Id2 and Id4 (Samanta and
Kessler, 2004). Indeed, overexpression of Id2 (Wang
et al., 2001) or Id4 (Kondo and Raff, 2000b) in purified
OPCs cultured in differentiation medium results in most
cells failing to mature into GalCþ OGs. One way in
which Id2 and Id4 may inhibit OG maturation is by neg-
atively regulating the function of Olig1 and Olig2, which
are believed to promote maturation (Fu et al., 2002; Lu
et al., 2002). In particular, Olig1 and Olig2 interact with
E2A TFs (Samanta and Kessler, 2004), which are
expressed by oligodendroglial cells and are believed to
mediate effects of Olig TFs (Sussman et al., 2002). Id2
and Id4 are believed to interfere with Olig/E protein het-
erodimerization since they interact with both Olig1 and
Olig2 (Samanta and Kessler, 2004) as well as E2A pro-
teins (Sun et al., 1991). Hence, BMP signaling may in-
hibit OG maturation by enhancing Id TF expression,
which blocks Olig1 and Olig2 function.
Sox5 and Sox6 are also important for inhibiting OG
maturation since a significant increase in MBP- and
PLP-immunoreactive cells is apparent in the spinal
cords of 18.5 days post coitum (dpc) Sox5/Sox6 condi-
tional-double deficient mice (Stolt et al., 2006). These
TFs appear to inhibit OG maturation by interfering
with Sox10 function. In particular, Sox5 and Sox6 can
block Sox10-directed activation of the MBP promoter in
oligodendroglial cell lines. These TFs may block Sox10
function via multiple mechanisms as they can recognize
Sox10-binding sites and interaction partners (Stolt
et al., 2006).
Promoting Factors
Once OPCs reach their final destination, maturation
ensues. Various TFs, including Olig1, Olig2, Nkx2.2,
Nkx6.2, and MyTI, favor OG maturation. For example,
in Olig1 mutant mice, PLP/DM20 and MBP expression
is markedly reduced in postnatal day 0 (P0) (Lu et al.,
2002) and P14 (Xin et al., 2005) spinal cord and unde-
tectable in the P14 corpus callosum, neocortex, and
striatum (Xin et al., 2005). Similarly, the number of
GalCþ and PLPþ OGs is significantly reduced in spinal
cord cultures following Olig2 antisense treatment (Fu
et al., 2002). How Olig1 and Olig2 promote maturation
is unknown but may involve their regulation of specific
TFs. One such TF is Zfp488, which is a potential down-
stream target of Olig1; Zfp488 expression is lost in the
spinal cord, optic nerves, cerebellum, and corpus cal-
losum of Olig1 mutant mice (Wang et al., 2006). Down-
regulating Zfp488 expression in an oligodendroglial cell
line results in a reduction in MBP and 20,30-cyclic nucle-
otide 30-phosphodiesterase (CNP) expression. Interest-
ingly, Zfp488’s transcription appears to be specifically
regulated by Olig1 since only Olig1, but not Olig2, can
significantly enhance luciferase reporter activity driven
by its putative promoter. Olig2 appears to interact with
Zfp488 at the protein level (Wang et al., 2006); however,
further research must determine if this interaction is
required for their function.
Ectopic expression of Olig2 in chick embryonic spinal
cords via in ovo electroporation induces Sox10 expres-
sion (Liu et al., 2007). Furthermore, Sox10 expression is
undetectable throughout the spinal cord in the absence
of Olig2 (Lu et al., 2002). Olig1, whose expression reap-
pears after Sox10 in the rodent embryonic spinal cord
(Zhou et al., 2000), may be important in maintenance of
Sox10 expression since Olig1 mutant mice exhibit a
decrease in Sox10þ cells (Lu et al., 2002; Xin et al.,
2005). As researchers have yet to find a chick Olig1
ortholog (Zhou et al., 2001), this may explain why strong
expression of Sox10 is seen much earlier in rodents
(Zhou et al., 2000) than in the chick (Zhou et al., 2001).
Sox10 is important in OG maturation since a delay
and a dramatic decrease in the expression of PLP and
MBP occurs in the spinal cords of Sox10-deficient mice
(Stolt et al., 2002). Furthermore, transplantation of
Sox10-deficient neural stem cells into 3–9 day old mouse
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retinas failed to myelinate the host nerve fiber layer
(Stolt et al., 2002). More recently, Dugas et al. (2006)
used siRNA to prevent normal induction of Sox10
expression in OPCs in vitro and found a significant
reduction in cells differentiating into MBP-expressing
cells. In addition, overexpressing Sox10 in embryonic
chick spinal cords via in ovo electroporation induces
expression of Nkx2.2, Olig2, MBP, PLP, and MAG (Liu
et al., 2007). Some MAGþ cells co-express Nkx2.2 or
Olig2 (Liu et al., 2007), which suggests Sox10 may indi-
rectly enhance myelin protein gene expression through
these TFs. However, as a proportion of the MAGþ cells
do not express Nkx2.2 or Olig2 (Liu et al., 2007), Sox10
may also directly induce myelin protein gene expression.
Indeed, Sox10 appears to directly regulate MBP expres-
sion since it can bind to three distinct sites in MBP’s
proximal promoter. Accordingly, Sox10-directed activa-
tion of the MBP proximal promoter is reduced or almost
completely blocked by mutating the three sites individu-
ally or all together, respectively (Stolt et al., 2002).
Sox10 also appears to regulate transcription of two
gap junction proteins—connexin47 (Schlierf et al., 2006)
and connexin32 (Bondurand et al., 2001; Schlierf et al.,
2006)—which are important for normal CNS myelina-
tion (Menichella et al., 2003). In particular, Sox10 acti-
vates the connexin32 promoter (Bondurand et al., 2001;
Schlierf et al., 2006) as well as the connexin47 promoter
1b (Schlierf et al., 2006) in luciferase reporter gene
assays. This activation appears to be direct since it is
dramatically reduced by mutations in either the Sox10
DNA-binding domain or binding sites (Bondurand et al.,
2001; Schlierf et al., 2006). These connexin proteins are
important for normal CNS myelination since con-
nexin32/connexin47 double knockout mice exhibit pro-
found CNS myelin abnormalities, such as thin, vacuo-
lated, or absent myelin sheaths (Menichella et al., 2003).
Since Sox10 is a poor transcriptional effector on its
own (Kuhlbrodt et al., 1998b), other TFs are likely
implicated in this process. One potential TF is SCIP,
which is expressed by oligodendroglial cells (Collarini
et al., 1992) and functions synergistically with Sox10
(Kuhlbrodt et al., 1998b). Surprisingly, myelination
occurs normally in the spinal cords of SCIP mutant mice
(Bermingham et al., 1996). In contrast, mice lacking the
ligand-dependent TF COUP-TFI, which is a potential
upstream regulator of SCIP, exhibit CNS hypomyelina-
tion and dysmyelination (Yamaguchi et al., 2004). The
reason for the discrepancy in mutant phenotypes is
unknown but may be due expression of two additional
class III POU TFs, Brn-1 and Brn-2, which could poten-
tially be regulated by COUP-TFI in oligodendroglial
cells (Schreiber et al., 1997) and hence could compensate
for SCIP in its absence. Also, oligodendroglial cells
express two additional Sox proteins, Sox4 and Sox11,
which function synergistically with Brn-1 and/or Brn-2
(Kuhlbrodt et al., 1998a).
Other TFs that function synergistically with Sox10
are Olig2 and Sp1. In particular, when Olig2 and its het-
erodimerization partner E47 are co-transfected with
Sox10 in Oli-neu cells, a synergistic increase in MBP
promoter activity occurs (Gokhan et al., 2005). As Sox10
can interact with Olig2 (Stolt et al., 2006), this synergis-
tic activation may be dependent upon formation of a
transcriptional complex. Like Olig2, a synergistic activa-
tion of the MBP promoter is also seen when a mouse
embryonic fibroblast cell line NIH 3T3 is co-transfected
with Sox10 and the TF Sp1 (Wei et al., 2004); however,
whether these TFs interact at the protein level has yet
to be determined.
Sox8, another group E Sox TF, also plays a role in OG
maturation since a transient reduction occurs in the
number of MBPþ and PLPþ cells in the spinal cords of
Sox8-deficient mice (Stolt et al., 2004). Hence myelin
protein expression seen in Sox10-deficient mice may be
due to compensatory effects of Sox8 and vice versa. In
fact, Sox8 has a limited ability to compensate for Sox10
since a dramatic decrease in MBP and PLP expression
occurs in the spinal cords of P7 transgenic mice, in
which Sox10 is replaced by Sox8 (Kellerer et al., 2006).
In addition to Sox10, Olig2 also appears to regulate
expression of Nkx2.2. In particular, ectopic Nkx2.2
expression is found 5 days following in ovo electropora-
tion of E2 chick spinal cords with an Olig2-expressing
vector (Liu et al., 2007). Evidence supporting Nkx2.2’s
role in promoting OG maturation is the finding that in
its absence, a delay and a dramatic decrease in PLP/
DM20 and MBP expression occurs in the spinal cord (Qi
et al., 2001). Furthermore, in Nkx2.2 mutant mice MBP
expression is reduced or lost in the E17.5 medulla and
P7 forebrain, respectively (Qi et al., 2001). Correspond-
ingly, Ngn3 mutant mice, which lack Nkx2.2 expression
in the E13.5 spinal cord, display a dramatic reduction in
PLP and MBP expression at P0 (Lee et al., 2003).
How Nkx2.2 promotes OG maturation is uncertain,
but it appears to involve its ability to regulate expres-
sion of certain myelin protein genes. In particular, over-
expressing Nkx2.2 in NIH 3T3 cells can induce green
fluorescent protein (GFP) expression driven by a portion
of the PLP promoter (Qi et al., 2001). This induction
may be direct since consensus Nkx2.2-binding sites are
found in the PLP promoter (Qi et al., 2001). Interest-
ingly, MBP promoter also contains Nkx2.2-binding sites
(Qi et al., 2001). In contrast to PLP, however, Nkx2.2
represses MBP promoter activity either on its own (Wei
et al., 2005) or directed by certain other TFs (Gokhan
et al., 2005). Although these results appear to contradict
the transgenic knockout data, they may reflect a cell
line- or CNS region-specific effect. In particular, these
transient transfection assays were conducted utilizing
two oligodendroglial cell lines—CG4 and Oli-neu
(Gokhan et al., 2005)—established from primary oligo-
dendroglial cultures from either perinatal rat cerebral
cortex (Louis et al., 1992) or E15 murine brains (Jung
et al., 1995), respectively. Interestingly, Nkx2.2’s expres-
sion profile during OG development varies not only
between these two cell lines, but also with primary cul-
tures obtained from the embryonic murine spinal cord
(Fu et al., 2002; Gokhan et al., 2005; Qi et al., 2001; Wei
et al., 2005). Hence, further research is needed to
resolve this issue.
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Another Nkx TF, Nkx6.2, exhibits an expression pro-
file similar to MBP and PLP (Awatramani et al., 1997).
Although Nkx6.2 has multiple binding sites within the
PLP and MBP promoters (Awatramani et al., 1997),
MBP is similarly expressed in the spinal cord, forebrain,
and cerebellum of wild-type and Nkx6.2 mutant mice
(Cai et al., 2001). However, Nkx6.2 is required for nor-
mal myelin ultrastructure (Southwood et al., 2004).
The TF MyTI may also promote OG maturation since
co-transfection of oligodendroglial cells with a plasmid
expressing the seven zinc-finger isoform of MyTI and a
CNP-luciferase reporter results in a 6.7-fold induction in
reporter activity when compared with the empty vector
(Nielsen et al., 2004). Furthermore, infection of rat OPC
cultures with a retrovirus containing a truncated MyTI,
which is expected to interfere with endogeneous MyTI
function, results in a significant reduction in the differ-
entiation of oligodendroglial cells (Nielsen et al., 2004).
Sox17, a Sox F TF, also appears important in OG mat-
uration (Sohn et al., 2006). In particular, down-regula-
tion of Sox17 expression in purified OPCs with siRNAs
results in a significant increase or decrease in the per-
centage of A2B5þ and O4þ cells, respectively. Not only
are these findings reversed in OPCs, which overexpress
Sox17, but these cells also display increased RNA levels
of MBP, MAG, and CNP. Sox17 may promote maturation
via several mechanisms. For instance, overexpression of
Sox17 in purified OPCs results in a significant decrease
in the percentage of proliferative cells, which suggests it
could promote cell cycle exit. In addition, Sox17 may
regulate transcription of particular myelin protein
genes; for instance, it can enhance luciferase activity
driven by the MBP promoter (Sohn et al., 2006). How-
ever, whether this effect is direct or indirect is not
known and will require further research. Surprisingly,
Notch signaling also promotes OG maturation (Cui
et al., 2004; Hu et al., 2003). Although unexpected given
the previous information, this could reflect a ligand-, re-
ceptor-, and/or downstream effector-dependent event.
Indeed, evidence suggests it could be ligand-dependent;
whereas activation of Notch signaling via the standard
Notch ligands, Jagged1 or Delta1, results in most OPCs
failing to differentiate (Hu et al., 2003; Wang et al.,
1998), treatment of purified OPCs with the novel Notch
ligands, F3 or NB-3, promotes their maturation into
CNPþ OGs (Cui et al., 2004; Hu et al., 2003). In con-
trast, current data do not support a receptor-dependent
effect since Notch1 appears important for inhibiting
(Genoud et al., 2002; Givogri et al., 2002) as well as pro-
moting (Cui et al., 2004; Hu et al., 2003) OG matura-
tion. However, as Notch2 and/or Notch3 are expressed
in similar areas as Notch1 in the embryonic and post-
natal CNS (Irvin et al., 2001; Lindsell et al., 1996), fur-
ther research must clarify which receptors are involved
in each process. In comparison, some evidence supports
a downstream effector-dependent event. In particular,
the Delta1/Notch signaling pathway in OPCs appears to
utilize CBF1 (Wang et al., 1998), whereas the F3,NB-3/
Notch signaling pathway in the same cells requires Del-
tex1 (Cui et al., 2004; Hu et al., 2003). Interestingly,
these Notch signaling pathways also appear to activate
distinct target genes since exposing oligodendroglial
cells to Delta1 or F3/NB-3 enhances mRNA expression
of Hes5 (Wang et al., 1998) or MAG (Cui et al., 2004; Hu
et al., 2003), respectively. Hence, various factors may
dictate the effect of Notch signaling on OG maturation.
Researchers have also found treatment of either pri-
mary mixed glial cultures or purified OPCs with RA pro-
motes OG maturation (Barres et al., 1994; Givogri et al.,
2001; Pombo et al., 1999). The obvious disparity between
these findings and those in the previous section is likely
due to discrepancies in experimental protocols utilized
by individual research groups. In particular, although
all conducted in vitro culture assays, each research
group utilized different ages, CNS regions, and/or RA
concentrations (Barres et al., 1994; Givogri et al., 2001;
Laeng et al., 1994; Noll and Miller, 1994; Pombo et al.,
1999). As such, the contradictory results may be due to
a stage- and/or concentration-dependent effect(s). Cur-
rent research favors the former since treatment of new-
born cerebral cultures with micromolar concentrations
of RA impairs OG maturation if they are first purified
for OPCs (Laeng et al., 1994), whereas it promotes this
process if the cells are grown in culture for 1 week prior
to treatment (Givogri et al., 2001). In contrast, current
data do not support a concentration-dependent effect
since both micromolar and nanomolar concentrations of
RA promote OG maturation in vitro (Barres et al., 1994;
Givogri et al., 2001; Pombo et al., 1999). However, as
these data were obtained using different experimental
protocols, further research must also resolve this issue.
RA exists as two distinct isomers—all-trans and 9-
cis—which can differentially bind to specific receptors.
In particular, 9-cis RA can bind to both retinoic acid
receptors (RARs) and retinoid X receptors (RXRs),
whereas all-trans RA can only bind to the former
(Allenby et al., 1993). These receptors, which exist as
multiple isoforms, bind primarily as heterodimers to RA
response elements found in the regulatory regions of
various genes (Maden, 2002). Intriguingly, evidence sug-
gests RA’s effect on OG maturation could be receptor-de-
pendent. In particular, although all-trans RA enhances
MBP expression (Givogri et al., 2001), it is unable to
activate the MBP promoter when RARa is transfected
alone or in combination with RXRa (Pombo et al., 1999).
Since the isomer dictates which receptors are bound, it
may also affect the outcome. Although most groups uti-
lized all-trans RA (Barres et al., 1994; Givogri et al.,
2001; Laeng et al., 1994; Noll and Miller, 1994), the
extent of isomerization in the cultures, as well as any
stage-dependence, is unknown; further research is
required to resolve this issue.
RA may promote OG maturation via several mecha-
nisms. For instance, RAR can repress the promoter ac-
tivity of the TF E2F-1, which induces expression of
genes involved in DNA replication or mitosis (Polager
et al., 2002) in the presence of RA (Nyg€ard et al., 2003).
This repression, in turn, could lead to cell cycle with-
drawal and subsequent OG maturation. In addition,
RA’s ability to promote maturation depends upon mem-
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bers of the p53 TF family since RA-induced maturation
is blocked when purified OPCs are infected with domi-
nant-negative forms of p53 or p73 (Billon et al., 2004).
How p53 and p73 promote OG maturation is uncertain,
but it may involve their ability to induce gene expres-
sion of two cyclin-dependent kinase inhibitors—p21 and
p27 (Fontemaggi et al., 2002). Overexpressing p27 in
CG4 cells enhances MBP promoter activity (Wei et al.,
2003, 2004) by increasing Sp1 binding to the MBP pro-
moter (Wei et al., 2003). Accordingly, a dramatic
decrease in MBP expression is seen in the cerebellum of
p21/ mice at P4 and P6 (Zezula et al., 2001).
Thyroid hormone (TH) also promotes OG differentia-
tion; treatment of E14.5 murine spinal cord explants
with the TH triiodothyronine (T3) increases both MBP
þ
cells and the formation of structures resembling myelin
internodes (Park et al., 2001). T3 has multiple stimula-
tory effects on the expression of several myelin protein
genes in aggregating telencephalic cultures (Tosic et al.,
1992). The importance of TH in OG maturation in the
brain is evident from studies utilizing hypothyroid and
hyperthyroid animals. In particular, hypothyroid rats
exhibit a transient reduction in expression levels of vari-
ous myelin protein genes (Ibarrola and Rodrıguez-
Pe~na, 1997). Conversely, rats treated with the TH thy-
roxine (T4) exhibit higher MBP and PLP mRNA levels
(Ibarrola and Rodrıguez-Pe~na, 1997). The effects of TH
on OG maturation appear to be mediated by the TH re-
ceptor alpha 1, which acts as a ligand-dependent TF,
since in its absence a significant decrease in the percent-
age of GalCþ OGs in TH-treated optic nerve cultures is
found (Billon et al., 2002). The mechanisms by which
TH promotes maturation appear similar to those of RA
(Billon et al., 2004; Nygard et al., 2003).
CONCLUSIONS
Over the past decade enormous strides have been
made in our understanding of the transcriptional control
of OG specification, particularly in the pMN domain. In
this region OG specification is largely the result of inter-
play between Shh, BMP, and Notch signaling pathways,
which regulate expression of TFs dictating spatial and/
or temporal aspects of oligodendrogenesis (Fig. F33).
Although much less is known regarding regulation of
this process in other regions, several similarities and dif-
ferences have been identified. However, as most of this
information was obtained prior to the discovery of dis-
tinct ventral and dorsal OPC progenitor domains in the
spinal cord (Cai et al., 2005; Vallstedt et al., 2005), hind-
brain (Vallstedt et al., 2005), and telencephalon (Kes-
saris et al., 2006), it must be re-examined with this in
mind. Complicating this research is the expression of
similar oligodendroglial markers by both dorsal and ven-
tral progenitors, making it difficult to distinguish
between the two (Cai et al., 2005; Kessaris et al., 2006;
Vallstedt et al., 2005). This will be particularly problem-
atic with respect to dorsal OPCs since they often arise
after their ventral counterparts (Cai et al., 2005; Kessa-
ris et al., 2006). A redeeming fact, evident from knowl-
edge of transcriptional control of OG specification in the
pMN domain, is that signaling pathways and TFs
involved in dorsoventral patterning of a particular pro-
genitor domain will likely affect OG specification in that
region. As information regarding this process is avail-
able for many CNS areas, it will greatly expedite
research into transcriptional control of OG specification
in distinct progenitor domains.
In addition to specification, researchers have made
huge contributions to understanding transcriptional con-
trol of OG maturation. In most cases, TFs and signaling
pathways identified either inhibit or promote this pro-
cess; however, instances exist where the effect of a par-
ticular signaling pathway appears dependent upon such
factors as ligand, receptor, and/or stage of oligodendro-
genesis. Intriguingly, many signaling pathways and TFs
appear to act, in part, by affecting expression and/or
function of other TFs (Fig. 3). In addition, many TFs
and signaling pathways appear to play similar roles
throughout the CNS. However, since some of this infor-
mation was obtained utilizing in vitro assays (Barres
et al., 1994; Cui et al., 2004; Hu et al., 2003; Laeng
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Fig. 3. Basic transcriptional network of OG development. For sim-
plicity reasons the figure depicts transcriptional control of oligodendro-
glial cells arising from the pMN domain in the rodent embryonic spinal
cord. Specification: Many TFs (e.g., Olig2, Nkx2.2, Pax6) and signaling
pathways (BMP, Notch, Shh) are important for OG specification in the
pMN domain. Many of these factors are involved in the dorsoventral
patterning of the spinal cord (upper left). For instance, Shh directs for-
mation of five ventral progenitor domains, including the pMN domain,
by regulating expression of TFs in the vVZ. This includes regulating
expression of Nkx2.2 and Pax6, as well as Olig2 and Irx3, which define
the ventral and dorsal boundaries, respectively, of the pMN domain.
Subsequently, cross-repressive interactions between these TFs maintain
and refine these boundaries. Of these TFs, only Olig2 is critical for OG
specification in this region; however, it cannot promote OG development
unless Ngn1/2 expression is downregulated such as via Notch signaling
(bottom left). Maturation: Several TFs (e.g., Olig2, Sox10, Olig1, Hes5)
and signaling pathways (BMP, Notch) affect OG maturation. Most of
these factors appear to act, in part, by modulating expression and/or
function of other factors. For example, Olig1 may promote OG matura-
tion by maintaining or inducing expression of Sox10 and Zfp488,
respectively. In contrast, Hes5 may impair this process by inhibiting
expression and/or function of Sox10, which promotes OG maturation.
For more information on individual factors please refer to the text. (^),
inhibit/repress; (fi), promote/induce; (fi), maintain; (—), heterodimers;
(dotted line), indirect effect; Id, Id2/Id4; Nkx6, Nkx6.1/6.2; TH, thyroid
hormone; *,effect is only evident during early stages of development.
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et al., 1994; Nielsen et al., 2004; Noll and Miller, 1994;
See et al., 2004; Sohn et al., 2006), in vivo verification is
needed. In addition, further research must clarify where
particular TFs play a role in maturation since in most
cases researchers have only examined expression of
myelin proteins. Furthermore, how transcriptional con-
trol of OG maturation compares between ventral and
dorsal progenitors remains to be determined. Although
this is a huge undertaking, it will be aided by the vast
knowledge already accumulated regarding expression of
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TABLE 2. Expression profiles of PDGFaR (§), PLP/DM20 (¤), and TFs implicated in OG development in the CNS
Age
Telencephalon Diencephalon
Mesen-
cephalon
Rhombencephalon
Spinal cord
Cortex/fiber
tracts
Ganglionic
eminences/basal
ganglia Thalamus Hypothalamus Cerebellum Medulla/pons
E12-12.5 Id220,49 Mash16 Mash115 Ngn327 Id220,49 Id220 Brn-18 Hoxa221,b422
POU8 Olig233 Nkx2.223 Nkx2.223 POU8 Id220,49 Id49
SoxC6 POU2 §24 §24 Sox1112 Ngn327 Mash115,Ngn327
Sox116 POU2 POU2 Nkx2.223 Nkx2.221
Olig237 Olig1,241
§24 §24
Sox1112 POU8
SoxC12,6,D29,E41,30,31
E13-13.5 Hes55 Hes55 Hoxa239 Hoxa239 Hes55 Hes55 Hes55 Hes55
Hoxa239 Hoxa239 Mash133 Mash133 Mash133 SCIP32 Ngn327 Hoxa27
SCIP32 Mash133 Nkx2.223 Ngn327 SCIP32 Nkx2.237 Ngn314,27
Olig1,219,33 Olig1,241 Nkx2.223 Sox1112 Olig1,241 Nkx2.226
§34,¤35 ¤19,35 Olig1,233 §24,¤35 Olig1,218,41
POU2 POU2 ¤19,35 SCIP32 Sox1013,1112 §18,41,24
POU2 Sox931,1041,1112
Sox1728
E14-14.5 Hes51 Olig1,234 Hes51 Hes51 Hes51 Hes51 Hes51 Hes51
SoxC6 §34 Hoxa239 Ngn327 Sox1112 Ngn327 Hoxa221,b422
POU2 Olig1,241 Olig1,234 Olig1,241 Ngn327,14
Sox1034 §24 §34,¤35 Sox1112 Nkx2.218,21
POU2 POU2 Olig1,241
SoxC6 Sox1034 §18,41, ¤38
SoxC12,6,D29,E41,30,31
Zfp48838
E15-15.5 Id220 Olig219 Nkx2.223 Ngn327 §24 Ngn327 Brn-1,28
POU8 §19 ¤35 Nkx2.223 POU8,32 §24,¤35 Hoxa27
Sox1112 Sox1112 Sox1112 ¤35 Sox1112 POU8,32 Ngn327
Sox1112 Sox1013,1112 Nkx2.226
Olig1,218,33
§18,41,24,¤18,35
SoxE41,30,31,1112
E16-16.5 §25 POU2 §25 Ngn327 §25,¤35 Hoxa221,b422
POU2 §25,¤35 Sox1040 Nkx2.221
POU2 Olig221
¤35
Sox830,931,1728, D29
E17-17.5 Brn-28,SCIP32 Brn-28 Hes51 Brn-28 SCIP32 Id220 Hes51 Hes51
Hes51 §34 SoxC12,6 Ngn327 Sox1112 Olig226 Olig226 Hoxa27
Id220 ¤35 §26 §26,¤35 §24,¤35
§34 Sox1112 Sox1112 Sox1112 Sox932,C6
Sox1013,C12,6
E18-18.5 Olig1,234 Nkx6.210 Nkx6.210 Nkx6.210 Hoxa221,b422
§34 ¤35 SCIP32 ¤35 Nkx2.221,6.210
rKr216 Olig221
SCIP32 §26,¤26,35
Sox1034 SoxD29,E4,30,31
Zfp48838
E19-19.5 Sox1112 ¤35 Sox1112 Sox1112 ¤35 Hoxa27
¤35
PN Brn-2,SCIP8 §25 §25 §25,¤35 §25 Id220,36 §25,¤35 Nkx2.226
Id220,36 Nkx6.210 §17,¤26,35
MyTI3, rKr216 Olig1,233 SoxD29,830,1017, 1728
Olig1,233 §25,¤35 Zfp48838
§25,¤26,35 SoxC6,E11
SoxE13,C6, 1728 Zfp48838
Zfp48838
POU, Brn-1,2 and SCIP; SoxC, Sox4 and 11; SoxE, Sox8, 9, and 10; PN, postnatal day (primarily P0-14).
Although TFs and/or OG markers are expressed in the same CNS region, the expression profiles may or may not overlap. For the purpose of this table information was
standardized utilizing the Carnegie/Theiler staging system. Utilizing this staging system the day of vaginal plug is considered E1; therefore, the days were adjusted
accordingly so as to have consistent expression data. In cases where the staging information was not given1,4,10,16,17,20,25,26,29-31,37,38,41 the indicated age in the manuscript was
utilized. The embryonic age listed is for mice; the corresponding rat embryonic age is 1.5 days older. Most references utilized in situ hybridization, whereas some references
also utilized immunohistochemistry3,4,7,14,15,16,21,22,28-31,33,37,39.
References: 1Akazawa et al. (1992), 2Alvarez-Bolado et al. (1995), 3Armstrong et al. (1995), 4Cai et al. (2005), 5Casarosa et al. (1999), 6Cheung et al. (2000), 7Hao et al. (1999),
8He et al. (1989), 9Jen et al. (1996), 10Komuro et al. (1993), 11Kordes et al. (2005), 12Kuhlbrodt et al. (1998a), 13Kuhlbrodt et al. (1998b), 14Lee et al. (2003), 15Lo et al. (1991),
16Lovas et al. (2001), 17Lu et al. (2002), 18Lu et al. (2000), 19Nery et al. (2001), 20Neuman et al. (1993), 21Nicolay et al. (2004a), 22Nicolay et al. (2004b), 23Price et al. (1992),
24Pringle & Richardson (1993), 25Pringle et al. (1992), 26Qi et al. (2001), 27Ravassard et al. (1997), 28Sohn et al. (2006), 29Stolt et al. (2006), 30Stolt et al. (2004), 31Stolt et al.
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TFs in the CNS (TableT2 2). The importance of obtaining
this information is evident from the findings that
although ventral and dorsal OPCs appear able to com-
pensate for each other if one progenitor type is ablated
(Cai et al., 2005; Kessaris et al., 2006), the compensation
appears limited if OPCs are present but their matura-
tion is defective (Yue et al., 2006). Ultimately, identify-
ing molecular mechanisms regulating OG development
will be critical to establishing therapeutic strategies for
demyelinating diseases, such as multiple sclerosis.
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SUMMARY
1. The olfactory epithelium (OE) is a simple structure that gives rise to olfactory sen-
sory neurons (OSNs) throughout life.
2. Numerous transcription factors (TFs) are expressed in regions of the OE which
contain progenitor cells and OSNs. The function of some of these TFs in OSN development
has been elucidated with the aide of transgenic knockout mice.
3. We review here the current state of knowledge on the role of TFs in OE neuro-
genesis and relate the expression of these TFs, where possible, to the well-documented
phenotype of the cells as they progress through the OSN lineage from progenitor cells to
mature neurons.
KEY WORDS: Dlx5; Hes; KLF7; Lhx2; Mash1; Mecp2; NeuroD; Ngn; Olig2; O/E; Runx1;
Wt1.
INTRODUCTION
The olfactory epithelium (OE) and its underlying lamina propria comprise the ol-
factory mucosa, which lines the posterior/superior region of the nasal cavity (Frisch,
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homolog of hairy and Enhancer of split; HLH, helix–loop–helix; Id, inhibitor of DNA binding; INPs,
immediate neuronal precursors; KLF7, Kru¨ppel-like factor 7; Lhx2, LIM homeobox protein 2; Mash1,
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Fig. 1. Neurogenesis in the OE (A). Three distinct cell types (HBCs, GBCs, and OSNs) are believed
to comprise the OSN cell lineage. These cell types can be distinguished based on morphological and anti-
genic phenotypes, as well as, on their location in the OE with respect to the basal lamina. Currently, there
are only three TFs (Mash1, Ngn1, NeuroD; mauve-colored font) that have been studied well enough to
state which cells in the OSN lineage express each TF. (B) model of transcriptional regulation of neuro-
genesis in the OE. See text for discussion. →: enhance/promote; ⊥: repress/inhibit; ?: uncertain. Abbrevi-
ations: ACIII—adenylyl cyclase type III; BrdU—bromodeoxyuridine; DSL—Delta, Serrate, and LAG-2
family of Notch ligands; GAP43—43 kDa growth associated protein; GBCs—stem cell globose basal cell;
GBCt—transit amplifying globose basal cell; GBCinp—immediate neuronal precursor globose basal cell;
Golf—olfactory G protein; HBC—horizontal basal cell; NCAM-neural cell adhesion molecule; OcNc—
olfactory cyclic nucleotide gated channel; OE—Olfactory Epithelium; OMP-olfactory marker protein;
ORs—odorant receptors; OSNi—immature olfactory sensory neuron; OSNm—mature olfactory sensory
neuron.
1967; Morrison and Costanzo, 1992; reviewed in Schwob, 2002). The olfactory sen-
sory neurons (OSNs), which detect odors in the air we breathe, are located within
this epithelium (Fig. 1(A)) and continue to be generated throughout life (Graziadei
and Monti Graziadei, 1979; Caggiano et al., 1994; reviewed in Schwob, 2002). This
lifelong neurogenesis occurs as a result of the continual proliferation and differen-
tiation of stem/progenitor cells located near the base of the epithelium. Although
some of these precursor cells seem fated to the neuronal lineage, others are mul-
tipotent and can differentiate into neuronal as well as non-neuronal cells (Schwob
et al., 1994; reviewed in Schwob, 2002). In addition to playing a role in neurogenesis
that occurs on a daily basis, the stem/progenitor cells of the OE are also responsi-
ble for replacing OSNs that are invariably lost when the olfactory axons are injured
(reviewed in Schwob, 2002).
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The OE arises from a thickening of the surface ectoderm called the olfactory
placode (OP), which is first evident in the mouse at embryonic day 9 (E9) and which
subsequently invaginates to form the olfactory pit (Cuschieri and Bannister, 1975).
The lining of the OP thickens and subsequently gives rise to three layers character-
istic of the adult OE (Fig. 1(A)) (Graziadei and Monti Graziadei, 1979). The inner
basal layer, which is adjacent to the basal lamina, is composed of two cell types, the
horizontal (HBC) and globose (GBC) basal cells (Graziadei and Monti Graziadei,
1979). The intermediate layer contains neurons exhibiting a basal to apical matu-
ration gradient such that mature OSNs are found closer to the outer apical layer.
The apical layer also contains the nuclei and bulk of the soma of the supportive
sustentacular cells (Graziadei and Monti Graziadei, 1979). At E11 in the mouse,
over 95% of mitotic cells are found apically in the developing OE whereas postna-
tally cell proliferation and thus the generation of neuronal progenitor cells is found
predominantly near the base of the OE (Smart, 1971).
Over the past decade knowledge regarding the transcriptional control of neu-
rogenesis in the OE has increased significantly (Fig. 1 and Table 1). Although there
are a large number of transcription factors (TFs) that are expressed in the OE
(Table 1), expression profiles during OSN development have only been determined
for a few TFs. (Fig. 1(A)). The onset of expression of helix–loop–helix (HLH) TFs
during rodent OE neurogenesis appears to be similar during embryonic and neona-
tal development, as well as, during regeneration following methyl bromide-induced
lesions in the OE of adult rats (Cau et al., 1997, 2002; Manglapus et al., 2004). This
suggests that the transcriptional control of OE neurogenesis is consistent through-
out life. Hence the OE is an excellent model from studying neurogenesis because
it produces neurons throughout life and exhibits an enormous regenerative capac-
ity (Schwartz Levey et al., 1991; Caggiano et al., 1994; Schwob et al., 1994, 1995).
Furthermore, since neurological diseases, such as Alzheimer’s disease and Rett’s
syndrome, exhibit abnormalities in the OE (Ronnett et al., 2003; Ghanbari et al.,
2004), analysis and culturing of OE biopsy specimens from these patients may be
very useful in determining the etiology, pathogenesis, and treatment of these dis-
eases.
This review describes what is known about the transcriptional control of neu-
rogenesis in the OE and relates the expression of these TFs, where possible, to the
well-documented phenotype of the cells as they progress through the OSN lineage
from progenitor cells to mature neurons (Fig. 1, Table 1).
OSN LINEAGE: FROM PROGENITOR CELL TO MATURE NEURON
Postnatally and continuing into adulthood, three cell types (HBCs, GBCs, and
OSNs) comprise the OSN lineage within the pseudostratified OE (Fig. 1(A)). HBCs
and GBCs are located in the inner basal OE layer, which is adjacent to the basal
lamina (Graziadei and Monti Graziadei, 1979). The HBCs, which lie directly against
the basal lamina, are morphologically flat cells that express cytokeratin 5/6 and 14
(Fig. 1(A)) (Graziadei and Monti Graziadei, 1979; Holbrook et al., 1995). In
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contrast, GBCs, which are primarily situated immediately apical to the HBCs
(Fig. 1(A)), are morphologically round cells (Graziadei and Monti Graziadei, 1979;
Holbrook et al., 1995).
With the aide of lineage tracers, such as replication-incompetent retroviruses,
researchers have identified cells in the basal region of the OE that appear to give
rise to neuronal and non-neuronal cells in rats exposed to methyl bromide (Schwob
et al., 1994). Whether these cells are GBCs or HBCs is still debatable, since both cell
types display increased BrdU expression in response to methyl bromide exposure
(Schwob et al., 1995). Interestingly, a recent study suggests that HBCs may be the
multipotent progenitor cells of the OE since they display characteristics exhibited
by stem cells in other regions of the body (Carter et al., 2004). However, further
research is needed to substantiate this finding.
Similar studies utilizing tritiated thymidine and replication-incompetent retro-
viruses in normal, bulbectomized, or transected mice have also identified cells in
the basal region of the OE that appear to give rise to neurons. Based on their mor-
phological and antigenic phenotype these cells appear to be GBCs (Schwartz Levey
et al., 1991; Caggiano et al., 1994; Schwob et al., 1994). Interestingly, researchers
have found through tissue culture experiments that GBCs appear to be a heteroge-
neous population of cells consisting of early transit amplifying cells and late imme-
diate neuronal precursors (INPs) (Calof and Chikaraishi, 1989; Gordon et al., 1995).
Transit amplifying cells, which are believed to be the direct progeny of stem cells,
comprise an intermediate population of committed progenitors that have a lower
capacity for self-renewal than do stem cells but a higher probability of initiating ter-
minal differentiation after several cell divisions. Thus, transit amplifying cells serve
to increase the number of differentiated cells produced by each stem cell division.
In the olfactory epithelium they are involved in tissue repair after injury as well as
playing a role in the regular renewal of OSNs.
Following one or more divisions, the INPs exit the cell cycle and differenti-
ate into immature OSNs, which are located immediately apical to the GBCs in the
intermediate region of the OE (Graziadei and Monti Graziadei, 1979; Calof and
Chikaraishi, 1989). Immature OSNs are bipolar cells that express β-tubulin, GAP43,
SCG10, and NCAM (Fig. 1(A)) (Calof and Chikaraishi, 1989; Roskams et al., 1998;
Verhaagen et al., 1989; Pellier-Monnin et al., 2001). Development of these cells into
mature OSNs involves the elaboration of a dendrite and axon, which project to the
apical or basal surfaces, respectively. The dendrite is characterized by the presence
of a dendritic knob, which extends beyond the apical surface of the OE and bears
numerous cilia (de Lorenzo, 1957; Frisch, 1967). The cilia express many proteins
that are important in odorant signal transduction, including Golf, adenylyl cyclase
III (ACIII), olfactory cyclic nucleotide-gated channel (OcNc), and odorant recep-
tors (ORs) (Jones and Reed, 1989; Bakalyar and Reed, 1990; Brunet et al., 1996;
Belluscio et al., 1998; Matsuzaki et al., 1999; Wong et al., 2000; reviewed in Ronnett
and Moon, 2002). Interestingly, each murine OSN expresses only one of approxi-
mately 1000 OR genes (Malnic et al., 1999; Zhang and Firestein, 2002) which has led
to the suggestion that it is the unique combination of OSNs responding to each odor
that allows for the discrimination of a wide variety of odors (Malnic et al., 1999).
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The OSN axons upon exiting the basal side of the OE fasciculate and traverse
the cribiform plate to form the outer layer of the OBs. Upon reaching the OBs the
axons defasciculate and target different regions (Whitesides and LaMantia, 1996),
terminating in structures called glomeruli (Graziadei and Monti Graziadei, 1979).
Interestingly, all sensory neurons terminating on a particular glomerulus have been
shown to express the same odorant receptor (OR) (Mombaerts et al., 1996).
TRANSCRIPTIONAL REGULATION: OSN PROGENITORS
Neurogenesis in the OE has been very well characterized in terms of the pheno-
type of cells as they progress through the lineage (Fig. 1(A)). Thus, the expression
profile of a particular TF can be very useful in predicting its role in OSN devel-
opment. For example, since Mash1 is expressed in apical, intermediate, and basal
regions of the murine embryonic OE (Cau et al., 1997; 2002; Theriault et al., 2005), it
could function at various stages of OSN development. However, as it is expressed by
mitotic transit amplifying progenitor cells and not differentiated OSNs (Fig. 1(A))
(Gordon et al., 1995; Cau et al., 1997), it must act early in the OSN lineage. In-
deed, in the absence of Mash1 there is a drastic reduction in mitotic basal progeni-
tors, as well as, in β-tubulin+ and SCG10+ neurons in the OE (Table 2) (Guillemot
et al., 1993; Cau et al., 1997; 2002). This, in turn, corresponds with a dramatic in-
crease in the expression of Steel, which marks sustentacular cells, in the mutant OE
(Murray et al., 2003). Therefore, these findings suggest that Mash1 could be critical
for neuronal determination in the OE. As Mash1 is not expressed in the ventrocau-
dal region of the OE, it is not surprising that OSN development proceeds normally
in this region in the absence of Mash1 (Cau et al., 1997).
Two TFs that have been shown to affect Mash1 expression in the olfactory
placode or OE during embryonic development are Hes1 (mammalian homolog of
Drosophila Hairy and Enhancer of split; Cau et al., 2000) and Wt1( + KTS) (Wilms’
tumor zinc-finger protein; Wagner et al., 2005) (Fig. 1(B) and Table 2). Hes1 is ex-
pressed on the apical side of the embryonic OE (Table 1) (Cau et al., 2000; 2002),
which contains a large number of mitotic cells (Smart, 1971). Therefore, based on its
expression profile Hes1 could play a role very early in OSN development. However,
Hes1 is a downstream effector in the Notch signaling pathway (Nishimura et al.,
1998), which is dependent on Mash1 for the correct expression of the Notch ligands
(Cau et al., 2002). Therefore, Hes1 would be expected to act downstream of Mash1.
Surprisingly, although Hes1 expression is drastically downregulated at E12.5 in the
Mash1 murine mutant OE, its expression at E10.5 is largely unaffected by the ab-
sence of Mash1 (Cau et al., 2000, 2002). This suggests that Hes1 plays an early role
independent of Mash1 expression. Indeed, Hes1 appears to be a limiting factor of
neurogenesis since there is a dramatic increase in the number of Mash1+ cells at
E10.5 in its absence. In addition, there is a significant increase in the number of
SCG10+ OSNs at E12.5 (Table 2) (Cau et al., 2000). The delayed increase in neu-
ronal numbers may be due to the presence of an additional Hes TF, Hes5, which is
also a downstream effector of the Notch-signaling pathway (Nishimura et al., 1998)
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and, hence, could prevent premature differentiation in the absence of Hes1. Indeed,
Hes1/Hes5 double mutant mice exhibit a large increase in the number of SCG10+
neurons at E10.5 (Cau et al., 2000). Cau et al. (2000) proposed a model in which Hes1
initially limits the extent of neurogenesis in the embryonic OE, whereas both Hes1
and Hes5 function synergistically to prevent premature differentiation of OSNs by
acting as downstream effectors in the Notch signaling pathway (Fig. 1(B)). Whether
Hes1 and Hes5 play similar roles in the adult OE remains to be determined.
Unlike Hes1, Wt1 is expressed predominantly in the basal region of the em-
bryonic OE (Table 1). Wt1 and Mash1 have been shown to be co-expressed in a
proportion of cells in the OE (Wagner et al., 2005). There are several lines of ev-
idence that support the role of Wt1 as an upstream effector of Mash1. Firstly, se-
lective ablation of the alternatively spliced Wt1( + KTS) isoform results in a dra-
matic decrease in the expression of Mash1 in the developing OE (Wagner et al.,
2005). Transfection of HEK293 cells with Wt1( + KTS) results in an upregulation of
Mash1 mRNA and protein expression. However, co-transfection of HEK293 cells
with a Mash1 promoter construct and Wt1( + KTS) is unable to significantly en-
hance the activity of the Mash1 promoter even though it contains two predicted
Wt1( + KTS) binding sites (Wagner et al., 2005). Hence, further research is needed
to determine if additional factors are required for Wt1( + KTS) to activate Mash1
expression or whether Wt1( + KTS) could act post-transcriptionally, as suggested
by Wagner et al. (2005). In addition, analysis of Mash1 expression in Wt1( + KTS)
wild-type and mutant mice at earlier stages of embryonic development may deter-
mine whether Wt1( + KTS) truly induces Mash1 expression or merely maintains it.
TRANSCRIPTIONAL REGULATION: OSN DIFFERENTIATION
Multiple TFs have been suggested or shown to act downstream of Mash1, in-
cluding Runx1 and Ngn1, respectively (Table 2) (Cau et al., 2002; Theriault et al.,
2005). Runx1 appears to be expressed predominantly in the basal region of the OE
where it exhibits overlapping expression with Mash1 and NeuroD. In addition, a
small number of Runx1-expressing cells appear to co-express β-tubulin (Table 1).
Runx1 appears to act downstream of Mash1 since Mash1 expression is unaltered in
Runx1-deficient mice (Table 2) (Theriault et al., 2005). In fact, Runx1 is important
in preventing premature differentiation of OSN progenitors since Runx1-deficient
mice exhibit a significant decrease in the number of NeuroD+ cells, as well as, an
increased number of β-tubulin+ OSNs (Table 2). How Runx1 prevents premature
differentiation is unknown but may involve its ability to repress the expression of
the cyclin dependent kinase inhibitor, p21 (Theriault et al., 2005), which is involved
in cell cycle exit (Luo et al., 1995).
As early OSN progenitors are present in Runx1-deficient mice (Theriault et al.,
2005), other TFs must compensate for Runx1 in its deficiency. Possible candidates
include Atf5 and Id4 TFs, which have been shown to inhibit neuronal differentia-
tion in the brain (Lyden et al., 1999; Angelastro et al., 2003) and are expressed in
the OE (Table 1) (Jen et al., 1996; Hansen et al., 2002). Unlike the brain, however,
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Atf5 and Id4 do not appear to be expressed by progenitor cells (Jen et al., 1996;
Hansen et al., 2002; Angelastro et al., 2003) and, therefore, may have divergent roles
depending upon the tissue in which they are expressed. Thus, further research is
needed to decipher the role of Atf5, Id4 and other TFs in the correct timing of OSN
differentiation.
Although Ngn1 is expressed by basal progenitor cells, some of which also ex-
press Mash1 (Fig. 1(A) and Table 1), it likely plays a role in OSN differentiation
since it acts downstream of Mash1 in most of the OE (Cau et al., 1997; 2002). In-
deed, there is a delay and a transient dramatic decrease in SCG10 expression in the
absence of Ngn1 (Table 2), which is more severe in the caudal region of the mutant
OE (Cau et al., 2002). Mash1 is not normally expressed in the ventrocaudal region
of the OE (Cau et al., 1997), so Ngn1 may have an earlier function in this region. In
support of this, SCG10 expression is absent in the embryonic OE of Mash1/Ngn1
double mutant mice (Cau et al., 2002). In addition, another Ngn TF, namely Ngn2,
is also expressed in the ventrocaudal region of the OE (Cau et al., 1997) and hence
could account for the transient nature of the Ngn1 mutation in this region. Since
Ngn2 expression is limited to the ventrocaudal region (Cau et al., 1997), additional
TFs must compensate for Ngn1 in other regions of the OE. One potential candidate
is the HLH TF Olig2, which is expressed by OSNs (Table 1) (Takebayashi et al.,
2000) and has been shown to be important in motor neuron development in the
spinal cord (Lu et al., 2002).
As Ngn1 has been shown to regulate the expression of Hes6 and NeuroD
(Koyano-Nakagawa et al., 2000; Cau et al., 2002), OSN differentiation may also
be regulated by these TFs. Although their roles in OSN differentiation have not
been elucidated, evidence exists in other neuronal lineages in support of this.
In particular, researchers have found that overexpression of NeuroD in E20 rat
retinal explants results in premature differentiation of late-born retinal neurons
(Ahmad et al., 1998). Similarly, Hes6 has been shown to promote neuronal differ-
entiation in the retina and neural plate (Bae et al., 2000; Koyano-Nakagawa et al.,
2000). As both of these TFs exhibit overlapping expression profiles with Ngn1 in
the OE (Cau et al., 1997; Suzuki et al., 2003a), they are ideally positioned to act
downstream of Ngn1 in promoting OSN differentiation (Fig. 1(B)). Interestingly,
Hes6 has been shown to abolish Hes1-induced transcriptional repression (Bae et al.,
2000). Koyano-Nakagawa et al. (2000) have proposed that one way in which Hes6
may promote neuronal differentiation is by means of a positive feedback loop in
which Hes6 inhibits the expression/activity of HLH repressors (e.g. Hes1; Bae et al.,
2000) and therefore indirectly enhances Ngn1 expression.
Although the OE expression of the LIM homeobox TF, Lhx2, appears to be
only slightly reduced in Ngn1 mutant mice, it is strongly reduced in the absence of
Mash1 (Cau et al., 2002). Therefore, Lhx2 must act downstream of Mash1 in the
regulation of neurogenesis in the OE. As Lhx2 is expressed in the basal and inter-
mediate regions of the OE (Cau et al., 2002; Hirota and Mombaerts, 2004; Kolterud
et al., 2004), it may play a role in OSN differentiation (Table 1). Numerous OR
genes, which are expressed by immature and mature OSNs (Iwema and Schwob,
2003), are absent in Lhx2 mutant mice (Hirota and Mombaerts, 2004; Kolterud et al.,
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2004). Unfortunately, it is difficult to identify the exact function of Lhx2 due to dis-
crepancies in reported effects on OSN differentiation in mutant mice. In particular,
Hirota and Mombaerts (2004) found that SCG10, GAP43 and OMP expression is
reduced, severely reduced or absent, respectively, in Lhx2 mutant mice. In contrast,
Kolterud et al. (2004) found expression of SCG10, GAP43 and OMP in the Lhx2
mutant OE. As both groups utilized the same mutant mouse line, these discrepan-
cies cannot be explained by different mutant phenotypes. Instead, the discrepancies
may be due to selection of different regions of the OE for study since Kolterud et al.
(2004) found OMP+ OSNs were selectively situated in the dorsomedial region of
the nasal cavity of the mutant OE mice. Interestingly, both research groups found
that the Lhx2 mutant mice exhibit an increase in the number of NeuroD+ cells in
the OE (Table 2) (Hirota and Mombaerts, 2004; Kolterud et al., 2004). As NeuroD
is expressed by mitotic cells, as well as, some β-tubulin+ OSNs (Cau et al., 1997),
Lhx2 could either inhibit the progression of neurogenesis at the level of the pro-
genitor or early differentiated neuron. Current evidence supports the latter, since
there is an increased number of NeuroD+/β-tubulin+ cells in the Lhx2 mutant OE
(Kolterud et al., 2004). Further research is needed to decipher the role of Lhx2 in
OSN differentiation.
TRANSCRIPTIONAL REGULATION: OSN MATURATION
There are a number of TFs that are not critical for OSN differentiation but
instead appear to be important in OSN maturation and function. For example,
Olf-1 binding sites, to which all O/E TFs have been shown to bind (Malgaretti et al.,
1997; Wang et al., 1997; 2002), have been identified in the promoter regions of sev-
eral markers expressed by mature OSNs including OMP, Golf, OcNc, and ACIII
(Kudrycki et al., 1993; Wang et al., 1993). Furthermore, co-transfection experiments
have shown that O/E TFs can induce reporter gene expression driven by the OMP
and ACIII promoters (Wang et al., 1997).
As O/E TFs are expressed in basal and intermediate regions of the OE
(Table 1) (Wang et al., 1997; 2002; Cau et al., 2002), which contain progenitors and
OSNs, respectively, additional factors must interfere with their ability to enhance
OMP, Golf, OcNc and/or ACIII expression at early stages of OSN development. In
fact, there appear to be numerous factors that could determine their functional ac-
tivity. For example, a zinc finger protein, Roaz, interacts with O/E TFs and inhibits
their transactivation of OSN specific genes in vitro (Tsai and Reed, 1997). As Roaz
exhibits an overlapping expression profile with the O/E TFs in the basal and lower
intermediate regions of the OE (Tsai and Reed, 1997; Wang et al., 1997; 2002), it
may inhibit their function during early stages of OSN development. In addition,
NFI TFs, which also have binding sites in the promoters of OMP, OcNc and ACIII
(Baumeister et al., 1999), appear to interfere with O/E activity since co-transfection
of HEK293 cells with O/E-1 and an OMP promoter construct containing a mutated
NFI binding site results in an increase in the activation of the OMP promoter by
O/E-1 (Behrens et al., 2000). As NFI-A and NFI-C appear to exhibit overlapping
Transcription Factors and Olfactory Sensory Neurons 815
expression domains with the O/E TFs (Table 1) (Behrens et al., 2000; Wang et al.,
1997; 2002), they could interfere with O/E function in vivo. Furthermore, the TF
O/E-4 appears to be a much weaker transcriptional activator than the other mem-
bers of the O/E family (Wang et al., 2002) and, therefore, may interfere with their
function.
OMP expression is, however, detected in O/E-1-, O/E-2-, and O/E-3-deficient
mice (Wang et al., 2004; Lin and Grosschedl, 1995). Although other family members
may compensate for these O/E TFs in their absence, the findings of Kudrycki et al.
(1998) suggest this is not the case since reporter gene expression is seen in the OSNs
of transgenic mice in which the OMP reporter construct contains a mutated Olf-1
binding site. As a result additional TFs may play a more important role than O/E
TFs in regulating OMP expression. Alternatively, O/E TFs may be more critical for
the expression of Golf, ACIII and/or OcNc. Hence, further research is needed to
determine if O/E TFs regulate the expression of Golf, ACIII, and/or OcNc, as well
as, whether olfaction is impaired in these mutant mice.
Interestingly, olfactory axons fail to innervate the lateral and/or dorsal regions
of the OBs in O/E-2 and O/E-3 deficient mice (Wang et al., 2004). As O/E-2 and
O/E-3 are expressed in the OE, but not in the nasal mesenchyme or the OB, the
aberrant innervation of target tissue by olfactory axons is most likely a direct effect
of the absence of O/E-2 and O/E-3. Hence, further research is needed to clarify
the role of O/E TFs in the maturation of OSNs and in the ability of their axons to
innervate the OB.
One TF that appears to be important in the maturation of OSNs is the
methylated-CpG binding domain protein Mecp2. As the majority of Mecp2+ cells
co-express OMP in the postnatal OE with very few co-expressing β-tubulin (Cohen
et al., 2003), it is ideally positioned to act in OSN maturation. Interestingly, Rett’s
syndrome patients, who have been shown to exhibit mutations in the MECP2 gene
(Amir et al., 1999; Lee et al., 2001), exhibit an increased ratio of β-tubulin to OMP
expression in OE biopsy specimens (Ronnett et al., 2003) as well there is an impair-
ment of OSN maturation in the OE of Rett’s Syndrome patients (Ronnett et al.,
2003). Similarly, Mecp2 mutant mice exhibit a transient delay in the transition of
OSNs from immature GAP43+ cells to mature OMP+ cells. These mutant mice
also exhibit transient abnormalities in olfactory axon projections in the glomeruli
(Matarazzo et al., 2004).
Interestingly, Mecp2 has been shown to be involved in the imprinting of home-
obox TF Dlx5 (Horike et al., 2005), which is also expressed in the OE (Depew et al.,
1999; Levi et al., 2003). In particular, Mecp2 mutants exhibit an increase in Dlx5
expression, which appears to be due to an increase in the paternal allele expression
(Horike et al., 2005). Although the effects seen in Mecp2 mutant mice could be due
to an increased Dlx5 expression, there are several findings that do not support this.
There is a transient delay in the onset of OMP expression in the absence of Dlx5
(Levi et al., 2003) which is accompanied by the disruption of OB axonal innervation
in these mutant mice (Levi et al., 2003; Long et al., 2003). One complicating factor in
determining Dlx5’s role in OSN maturation and its potential connection to Mecp2
is that Dlx5 mutant mice exhibit abnormalities in the OBs, as well as, the nasal
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mesenchyme that could indirectly affect neurogenesis in the OE (Depew et al., 1999;
Levi et al., 2003; Long et al., 2003). A further complication is the fact that there are
two Dlx5 mutant mouse strains that vary in the severity of olfactory placode/OE
anomalies (Depew et al., 1999; Levi et al., 2003; Long et al., 2003). Hence, further
research is needed to decipher the role of Dlx5, as well as, its regulation by Mecp2
in OSN development.
Another TF that appears to be important in OSN maturation is the Kruppel-
like TF KLF7 (Laub et al., 2001). Although there are no significant changes in OE
thickness, cell density, proliferation, or apoptosis in KLF7 mutant mice, there is a re-
duced number of NCAM+ OSNs that also exhibit reduced axon growth in these mu-
tant mice at E11.5. Subsequently, olfactory axons fail to innervate the OBs at later
stages of development in KLF7 mutant mice. Interestingly, the mutant OE exhibits
a dramatic decrease in the expression of p21, which has been shown to promote cell
cycle exit, as well as, neurite outgrowth (Luo et al., 1995; Tanaka et al., 2002). Hence,
further research is needed to determine whether the mutant’s anomalies are due to
reduced p21 expression or whether other factors are involved.
CONCLUSION
Over the past decade there have been significant advances in our understand-
ing of the transcriptional control of neurogenesis in the OE. Although numerous
TFs are expressed in regions of the OE containing cells of the OSN lineage, thus
far only a handful have been identified with the aide of transgenic knockout mice
as playing roles in OE neurogenesis (Table 1). Mash1 has emerged as an important
proneural gene in olfactory neurogenesis, with the transient expression of this TF
by the transit amplifying GBCs appearing to be a critical step in their progression
to a neuronal fate (Guillemot et al., 1993; Gordon et al., 1995; Cau et al., 1997; 2002;
Murray et al., 2003). Accordingly TFs shown to regulate Mash1 expression, such as
Hes1 and Wt1( + KTS), exhibit abnormalities in OE neurogenesis. Numerous TFs
have also been identified that act downstream of Mash1, including Ngn1, NeuroD,
Hes TFs, and Lhx2 (Fig. 1(B)) that appear to be important in OSN differentiation.
In addition, a handful of TFs, such as Mecp2, Dlx5, and KLF7, appear to be impor-
tant in OSN maturation and functional innervation of the OBs.
Unfortunately, there are limitations to the usefulness of transgenic knockout
mice in elucidating the function of TFs in OE neurogenesis. For example, in some
cases multiple members of the same TF family, such as the O/E TFs, are expressed
by OSNs (Table 1) and, hence, could play redundant roles. As a result, a mutation
in only one member of the TF family may not uncover function due to the compen-
satory effects of the other members. In addition, for TFs that play key roles very
early in embryonic development the ability to determine their role in later devel-
opmental events such as OSN differentiation or maturation may be severely ham-
pered when using the transgenic knockout approach. For example, Pax6 and Otx2
are important in patterning the head since in their absence several sensory struc-
tures, including the olfactory placodes, are absent (Acampora et al., 1995; Grindley
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et al., 1995). Thus, it remains to be determined if their effects on olfactory placode
development are direct or whether they arise as a consequence of abnormal pat-
terning of a number of structures in the head. Thus experimental models involving
gain-of-function, as well as, conditional or multiple gene ablations may be required
to determine the function of some of the TFs in OE neurogenesis.
In addition, there are many aspects of the regulation of OE neurogenesis that
remain to be elucidated. For instance, a clear sense of how the transcriptional cas-
cade (Fig. 1(B)) interacts with the positive and negative microenvironmental signals
(Calof et al., 2002, 1996; Schwob, 2002) that regulate the state of dynamic equilib-
rium of neurogenesis in the OE is lacking. Furthermore, there is a major gap in our
knowledge of OE neurogenesis in regards to the transcriptional control of OR gene
selection by individual OSNs. Researchers have found that OSNs expressing the
same OR are randomly distributed in one of four zones in the OE (Sullivan et al.,
1995). The only TFs that have been shown to exhibit expression patterns reflec-
tive of a particular OR zone(s) are Msx1 (Norlin et al., 2001), Id2, and Id3 (Tietjen
et al., 2003); however, whether they are important for OR expression is currently un-
known. Finally, the transcriptional control of neurogenesis in the human OE needs
to be examined in order to determine if similarities and differences exist between
rodents and humans. Recent research has shown that many similarities, as well as,
differences are seen in the cellular architecture of human and rodent OE (Hahn
et al., 2005), which may be reflected in their regulation.
The importance of elucidating the transcriptional control of OE neurogenesis
is that it has the potential of providing a tool with which to explore the pathophys-
iology of developmental and age-related diseases in humans. In particular, findings
in laboratory animals can be readily tested in human biopsy tissue obtained from
donors as young as 2 years of age (Ronnett et al., 2003) when the pathophysiol-
ogy of Rett’s Syndrome, for example, is actively progressing, or as old as elderly
Alzheimer’s disease patients to study the pathophysiology of age-related diseases.
It also provides an opportunity to study single-cell transcriptomes in neuronal pro-
genitor cells and in mature neurons obtained from an easily accessible human tissue
source (Tietjen et al., 2003).
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